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Glucocorticoids (GCs) are synthesised endogenously in mammals by the 
hypothalamic pituitary adrenal (HPA) axis in response to stress. These hormones can 
elicit a number of physiological roles by binding to and activating specific receptors 
(glucocorticoid or mineralocorticoid receptors- GR or MR). GCs are important in 
tissue development and maturation and commonly used therapeutically. Mammalian 
animal studies have suggested that over-exposure to GCs, whether 
pharmacologically or through induction of maternal stress, is associated with 
increased cardiovascular disease risk in adult life. The underlying mechanisms 
underpinning this early life programming are poorly understood, however GC 
exposure during development may have direct and indirect effects on the structure 
and function of developing tissues and organs which may predispose to disease in 
later life. Current mammalian models of programming do not lend themselves well to 
studying organ development during embryogenesis. The zebrafish provides an ideal 
model to study this phenomenon due to the transparent nature of developing larvae 
and the availability of transgenic lines expressing fluorescent markers.  
Methods 
GC pathways were comprehensively characterised during zebrafish embryo 
development using qRT-PCR and steroid ELISAs. The physiological roles of GCs 
were assessed during early zebrafish development (first 120 hours post fertilisation 
(hpf)) assessing stress response, swim activity and global development following 
various genetic and pharmacological manipulations of the GC system. The impact 
that GC manipulation had on the cardiovascular system was also investigated. 
Embryos which had been exposed to GC manipulation during early development 
were then allowed to develop to adulthood in order to assess the long term impact. 
The same parameters were investigated in the adult as in the embryo.  
Results 
The key components of the GC system are present and functional in the developing 
embryo with de novo cortisol biosynthesis evident from 48hpf. A functioning 
hypothalamic pituitary inter-renal (HPI) axis is demonstrable from 72hpf. 
Manipulation of specific components of the GC pathway during early embryonic 
development influences growth-rate, head-trunk angle, chorion hatch-rate and swim 
behaviour. Manipulation of GCs during embryogenesis resulted in altered body 
weight, length and girth in adulthood, with altered stress response and swim 
behaviour also detected. Embryonic heart development was also affected with a 
reduction in ventricle cardiomyocyte number, cardiac gene abundance (vhmc) and 
cardiac function during embryogenesis resulting in structural abnormalities such as 
fewer trabeculae and increased intra-ventricular space. Embryonic GC manipulation 
also alters the formation and patterning of intersegmental blood vessels by 120hpf. In 
adulthood this manifests as a reduced angiogenic capacity.  
Conclusion 
The zebrafish embryo represents a valid and physiologically relevant model for GC 
research. Manipulation of GCs during early development results in altered growth, 
gene abundance and cardiovascular structure. These findings have significant 
implications for on-going research addressing GC mediated programming and 
suggest that the zebrafish is a highly suitable model for GC research   
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EDTA ethylenediaminetetraacetic acid 
EF ejection fraction 
ef1α elongation factor 1 alpha 
EGFP enhanced green fluorescent protein 
ELISA enzyme-linked immunosorbent assay  
eNOS endothelial nitric oxide synthase 
ERK extracellular-regulated kinase 





FLi1 friend leukaemia integration 1 transcription factor 
GAPDH glyceraldehyde 2-phosphate dehydrogenase 
GC(s) glucocorticoid(s) 
GFP green fluorescent protein 
GR glucocorticoid receptor 
h hour 
H&E haematoxylin and eosin  
H2O water 
HPA hypothalamic-pituitary-adrenal 
hpf hours post fertilisation 
HPI hypothalamic-pituitary-interrenal 
HR heart rate 
HRP horse radish peroxidase 
hsp heat shock protein 
in utero  in the womb 
in vitro studies out with organism 
in vivo  studies in whole living organism 
IP intraperitoneal 
ISV inter segmental vessels 
L litre 
LBD ligand binding domain  
m milli 
M moles 
MAPK mitogen-activated protein kinase 
MC(s) mineralocorticoid(s) 
MC2R melanocortin 2 receptor 
Met metyrapone 
min minute 
mm-Mo 5-mispair mo  
mmp matrix metalloprotease  
Mo antisense morpholino  
MR mineralocorticoid receptor 
mRNA messenger ribonucleic acid  
NF-kB nuclear factor kappa-light-chain-enhancer of activated b cells 
NO nitric oxide 
NOS nitric oxide synthase  
PBS phosphate buffered saline 
PBST phosphate buffered saline tween-20  
PCR polymerase chain reaction 
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qRT-PCR quantitative real time polymerase chain reaction 
RIPA radioimmunoprecipitation assay  
RNA ribonucleic acid 
Rnase ribonuclease 
rpm rotations per minute 
RT-PCR real-time polymerase chain reaction  
RU486 mifepristone (gr and pr antagonist) 
SEM standard error of mean 
ss-Mo splice site specific mo  
star steriodogenic acute regulatory protein 
SV sinus venosus  
TALENs transcriptor activator-like effector nucleases 
tg transgenic 
TNFα tumour necrosis factor alpha  
UPL universal probe library 
VEGF vascular endothelial growth factor  
VI vascularisation index 
VSMC vascular smooth muscle cells  
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1.1 Introduction  
Mothers at risk of pre-term delivery are often prescribed glucocorticoids (GCs) in 
order to promote maturation of the lung and reduce infant morbidity and mortality. In 
their role as mediators of the stress response, GCs may rise as a direct result of 
maternal stress or indirectly through alterations in maternal diet or environment. 
Concerns remain that this early exposure of the foetus to high GCs could result in 
reprogramming of cellular and molecular mechanisms which could in turn lead to 
increased susceptibility to disease later in life. Current animal models are not ideally 
suited to assess the developmental impact of both excess and low levels of GC 
during critical developmental time points. In contrast, the zebrafish embryo allows 
ready access to this developmental window. This thesis will investigate the 
suitability of the zebrafish as a model of embryonic GC manipulation and its impact 
on subsequent structure and function in the adult cardiovascular system. 
1.2 Steroid hormones 
Steroids are a family of endocrine hormones derived from the same common 
precursor, cholesterol and thus have closely related structures. There are two main 
sub-categories; sex hormones (androgens, oestrogens and progestins) and 
corticosteroids. Steroid biosynthesis or steroidogenesis occurs throughout the body 
but the main sites are the adrenal cortex, placenta, the testes and ovaries. Although 
steroidogenesis is often thought of as separate processes with distinct gland 
dependent roles, e.g. oestrogen and the ovaries, steroid generation is often through 
common pathways. There are numerous mutual features amongst the different steroid 
sub-categories with enzymes, reactions and regulatory processes often common 
(Miller & Auchus, 2011) with termination reactions being the obvious difference 
(Davies & MacKenzie, 2003). Thus alteration in the expression of these features may 
ultimately alter the levels of many different types of steroid hormone. The work 





Corticosteroid hormones are a family comprising two subcategories, GCs and 
mineralocorticoids (MCs) (Payne & Hales, 2004). In mammals, corticosteroids play 
important roles in response to stressful stimuli such as trauma, starvation, sepsis 
(Nakano et al, 1987) and tissue ischemia (Sapolsky et al, 2000; Sellevold & Jynge, 
1988) and are also involved in a range of physiological activities. MCs (for example 
aldosterone) regulate sodium and potassium levels in extracellular fluids (Hu et al, 
2001), thus making an important contribution to regulation of electrolyte balance and 
blood pressure (Davies & MacKenzie, 2003; Sanderson, 2006). GCs, such as 
cortisol, are important for neural processes, carbohydrate, protein and fat metabolism 
as well as inflammation regulation and other immune responses (Moritz et al, 2005). 
Although both corticosteroid families play important roles, the focus for this work 
will be GCs as GC exposure during development has been shown to influence later 
adult health (Seckl & Meaney, 2004). 
1.3  Glucocorticoid hormones 
1.3.1 Glucocorticoid function 
Normal mammalian GC physiology can be broadly categorised into three main roles, 
(1) maintenance, with respect to metabolic, autonomic, psychological, haemostatic 
and cardiovascular functions (2) suppressive, by keeping in check pathways involved 
in cellular proliferation, differentiation, tissue maturation and death, and infection or 
inflammation mechanisms; and (3) partitioning of body components to maximise 
efficiency, through processes such as proteolysis and insulin resistance in muscle and 
increased insulin sensitivity and lipidogenesis in fat depots (Chapman & Seckl, 2008; 
Fowden & Forhead, 2004; Girod & Brotman, 2004; Moritz et al, 2005). 
GCs are administered therapeutically to regain/replace physiological concentrations 
in deficiencies and, at higher doses, are frequently prescribed for their anti-
inflammatory or immunosuppressive roles in the treatment of such conditions as 
asthma, rheumatoid arthritis (Bello & Garett, 1999), transplant rejection and lympho-
proliferative disease (Almawi et al, 2002). Therapeutic GCs are one of the most 
commonly prescribed drugs worldwide (Bello & Garett, 1999). 
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1.3.2 Glucocorticoid biosynthesis 
GCs are produced endogenously under the control of the neuroendocrine system, the 
hypothalamic pituitary adrenal (HPA) axis (Walker, 2007). Briefly, upon stimulation 
by stressor (immune, physical, metabolic, emotional) or circadian (a diurnal pattern 
with evening troughs and early morning peaks) cues, the hypothalamus releases 
corticotrophin-releasing hormone (CRH) stimulating the pituitary to produce and 
release adrenocorticotrophic hormone (ACTH). ACTH binds to the melanocortin 2 
receptor (MC2R) on the surface of the adrenal cortex activating signal transduction 
pathways and resulting in GC biosynthesis in the zona fasciculata region of the 
adrenal cortex (Sanderson, 2006). Steroidogenesis from cholesterol is through a 
series of mostly hydroxylation reactions catalysed by various members of the 
cytochrome P450 enzyme family. The main features will briefly be highlighted. 
Cholesterol is transported into the mitochondria, via steroidogenic acute regulatory 
protein (StAR), where side-chain cleavage of cholesterol is catalysed by 
monooxygenase P450scc (Cyp11a1). Afterwards, 17α-hydroxylation (Cyp17), 3β-
hydroxysteroid dehydrogenation (Hsd3b), and 21-hydroxylation (Cyp21a1) occur 
prior to the last step in cortisol biosynthesis, which is 11-hydroxylation mediated by 
11β-hydroxylase (Cyp11b1) (Tokarz et al, 2013b). The structural organisation and 






Figure 1.1 Hypothalamic-pituitary-adrenal (HPA) axis. 
A schematic highlighting the key structures of the mammalian hypothalamic pituitary 
adrenal (HPA) axis along with the main signal transduction features in the production of 
the glucocorticoid hormone cortisol in response to stress or stimulus. Figure reproduced 
with consent from Hiller-Sturmhöfel S, Bartke A (1998) The endocrine system: an 
overview. Alcohol health and research world 22: 153-164. 
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1.3.3 Glucocorticoid action 
GCs predominately produce their central and peripheral effects through activation of 
the relative low affinity but ubiquitously expressed GC receptors (GR). In some 
instances however actions are mediated through the higher affinity MC receptors 
(MR) which are found less ubiquitously expressed in a tissue specific manner 
(Chapman & Seckl, 2008; Walker, 2007). While this may imply that GC action is 
regulated by the receptor expression in particular tissue types it should be noted, that 
GC action in a particular tissue is not governed solely by the level of receptor 
expression but is also governed by ligand availability. As the circulating level of the 
main GC cortisol (corticosterone in rodents) generally outweighs that of the main 
mammalian MC, aldosterone, it may be perceived that cortisol always occupies MR, 
if this ligand is present in MR rich tissue. To prevent this unnecessary activation of 
MR in most tissues these receptors are co-expressed with 11β hydroxysteroid 
dehydrogenase type 2 (11βHSD2) which acts as a barrier to MR activation by GCs 
by converting them into their inactive form (this will be discussed in more detail 
later).  
1.3.4 Glucocorticoid receptor 
As mentioned above, many of the effects mediated by GCs are via the GR. The 
human form of this receptor is a protein member of the superfamily of ligand 
regulated nuclear receptors, known as the nuclear receptor 3 subfamily (Hollenberg 
et al, 1985). Cloning of human GR in the 1980s led to the discovery of two 
functional isoforms referred to as alpha (α) and beta (β). These isoforms have 
identical N-terminal regions (encoded by exons 2-8) and differing C-terminal regions 
(encoded by exons 9α and 9β respectively). The α-isoform is 777 amino acids in 
length, is expressed in virtually all cell types, and is responsible for mediating most 
GC effects. The shorter β-isoform is 742 amino acid residues in length and only 
accounts for less than 1% of GR found in the body. While the β-isoform is present in 
the cytoplasm like the α-isoform it is incapable of hormone binding due to alterations 
in the ligand binding domain (LBD); a proposed role for GR-β is in inhibitory action 
on GR-α but this is un-confirmed. Further sub-types of GR (mainly GR-α subtypes) 
have been discovered more recently, the purpose of which is hypothesised to confer 
cellular heterogeneity. As the physiological and pharmacological actions of GC are 
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primarily mediated through the activation of the GR-α LBD, GR herein will refer to 
all functional α-isoforms. 
GR are expressed in almost every cell in the body, where activation by GCs can have 
pleiotropic effects. The unbound form of the receptor is present within the cytoplasm 
in an inactive oligomeric complex with some regulatory proteins such as the Heat 
Shock Protein (HSP) 90 and 70 KD forms, the p59 immunophilin, FKBP52 and the 
small p23 phosphoprotein (Davies et al, 2005). The presence of these compounds is 
thought to maintain the C-terminal domain in a favourable conformation for ligand 
binding. As GCs are lipid soluble they are able to diffuse easily through the plasma 
membrane and bind to the specific, high-affinity GR within the cytoplasm. The 
resulting complex, the GR-GC complex, releases the GR from its interactions with 
the inhibitory complex, resulting in a conformational change, unmasking of the 
receptor nuclear localization signal (Figure 1.2). Upon activation, GR-GC translocate 
to the nucleus and binds as a dimer to DNA through its central domain. GR can 
interact either with DNA by targeting specific nucleotide palindromic sequences 
termed Glucocorticoid Response Elements (GRE) or Negative GRE (nGRE) (Ruegg 
et al, 2004). Depending on the nature of the GRE, the overall process of GR binding 
can result in activation or repression of genes which contain these GR-binding sites 
(Davies et al, 2005). 
Receptor activation can, therefore, alter gene expression in target tissues through the 
processes of transactivation and transrepression (Spokoini et al, 2010). GCs have 
also been shown to exert a number of rapid actions which are independent of gene 
transcription, such as the production of endothelial nitric oxide (eNO) by eNO 
synthase (eNOS) (Hafezi-Moghadam et al, 2002; Lowenberg et al, 2006). 
As for many ligand-regulated nuclear receptors, transgenic mice have allowed the 
specific roles of GR to be investigated. Homozygous disruption of GR (GR (-/-) 
highlights the multiple roles of this receptor as knockdown results in reduction of 
gluconeogenic enzymes and amino acid catabolising gene expression and infant 
mortality shortly after birth (Cole et al, 1995). Furthermore dysregulation of the HPA 
axis components, such as raised ACTH, has also been observed (Newton, 2000) 









1.3.5 Glucocorticoid regulation 
As in the case of many other endocrine hormones, GC biosynthesis is controlled by a 
negative feedback inhibition loop (Figure 1.1). This is a GR-mediated method of 
regulation is where the final product of the cascade, cortisol in humans, 
corticosterone in rodents, feeds back on both the hypothalamus and pituitary gland 
suppressing ACTH stimulation of the adrenal cortex and, thus, inhibiting the release 
of hormones in the signalling cascade. 
Another way of keeping in check GR activity is through local pre-receptor 
metabolism by the 11βHSD isoenzymes (Nagalski & Kiersztan, 2010) which 
regulate tissue GC exposure through alterations in enzyme activity. This family 
catalyses the inter-conversion of cortisol and corticosterone (in rodents) with their 
inert 11-keto forms (cortisone and 11-dehydrocorticosterone respectively). There are 
two isozymes of 11βHSD. Type 2 (11βHSD2) is a dehydrogenase which is 
Figure 1.2 Glucocorticoid receptor (GR) interactions with DNA. 
The inactive GR is found in the cellular cytoplasm and is bound to heat shock proteins (hsps) such as the 
hsp90 shown here. Association with hsps prevents the movement of the GR into the cell nucleus. Once 
glucocorticoid (GC) crosses the cell membrane and binds to the GR, the hsps then disassociate allowing 
the GR-GC complex to translocate from the cytoplasm into the nucleus where it undergoes dimerization. 
The zinc finger domains of the GR are then free to bind specific DNA sequences, the Glucocorticoid 
Response Elements (GRE), found within the 5′ promoter region of the target gene. GR are able to 
activate gene transcription, or repress transcription if the region contains a negative GRE (nGRE). This 
figure was reproduced with consent from “Umland SP, Schleimer RP, Johnston SL (2002) Review of 
the molecular and cellular mechanisms of action of glucocorticoids for use in asthma. Pulmonary 
Pharmacology and Therapeutics 15: 35-50. 
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responsible for the conversion of corticosterone or cortisol to their biologically 
inactive 11-keto derivatives. This has a key role in preventing GC from binding to 
the non-selective MR in MC target tissues. In contrast, the type 1 isozyme 
(11βHSD1) functions as an 11β-reductase. It is responsible for local regeneration of 
active GCs from circulating inert 11-keto forms in specific tissues (eg liver, lung and 
adipose tissue). These tissues have been shown to express GR but not MR, 
suggesting that 11β-HSD1 is important for amplifying GC-dependent activation of 
GR in target tissues (Klusonova et al, 2009; Kotelevtsev et al, 1997). 
The importance of these enzymes in GC regulation has been described elsewhere 
(Ferrari, 2010; Morton, 2010; Seckl et al, 2004). However, some observations will be 
summarised here. Human 11βHSD2 gene mutations result in apparent MC excess, 
which is characterized by activation of renal MR by GC resulting in sodium 
retention, severe hypertension, and hypokalaemia (Wilson et al, 1995). Furthermore 
deregulated HPA axis activity has been observed in 11βHSD2 -/- mice (Kotelevtsev 
et al, 1997). Exposure of mice to raised levels of 11-dehydrocorticosterone, the 
substrate for 11βHSD1, has been shown to result in increased circulating GCs, and 
down-regulation of HPA activity axis. As the 11βHSD1 enzyme is highly expressed 
in metabolically active tissues (such as liver and adipose tissue), impairment of local 
GC regeneration in 11βHSD1 -/- mice results in fat accumulation and hepatic insulin 
resistance (Harno et al, 2013). 
1.3.6 Glucocorticoid dysregulation  
Although short-term elevations in GC levels can be beneficial (for survival in 
severely stressful conditions or when administered as therapy for inflammatory or 
malignant disease) chronic elevation of GCs is detrimental (Chapman & Seckl, 2008; 
Stumpf, 1990). Constant activation of the HPA axis, whether this is as a result of 
defective control mechanisms/biosynthesis pathways or pharmacotherapy, can 
threaten the dynamic equilibrium and unless allostasis (adaptive changes) occurs, 
system defects such as adrenal hyperplasia can result and if left untreated survival 
can be impaired (O'Connor et al, 2000).  
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Cushing’s disease is a well-documented condition of prolonged high circulating 
cortisol levels, commonly as a result of a pituitary adenoma (pituitary tumour) and/or 
uncontrolled ACTH production (Stewart & Petersenn, 2009). This condition is 
characterised by increased cardiovascular disease risk factors, including elevated 
systolic blood pressure, central obesity (Girod & Brotman, 2004; Ng & Celermajer, 
2004), dyslipidaemia, insulin resistance (Trayhurn & Beattie, 2001) and 
hyperglycaemia (Stewart & Petersenn, 2009). Prior to advanced medical treatment it 
was not uncommon for those suffering from Cushing’s disease to die prematurely of 
myocardial infarction or stroke (Colao et al, 1999). GR genetic variants, such as the 
common haplotype 3, have been associated with Cushing-like symptoms such as 
hypertension, visceral obesity and hyperinsulinaemia. This genetically determined 
cortisol sensitivity is involved in the pathogenesis of cardiovascular disease (van den 
Akker et al, 2008). Many of the cardiovascular risk factors associated with raised GC 
levels are summarised in Figure 1.3. 
In contrast people with chronic GC insufficiency in a group of autosomal recessive 
disorders characterised by defective steroidogenesis enzymes, referred to as 
congenital adrenal hyperplasia (CAH) (Mullins et al, 2009), or with Addison’s 
disease, (an insufficient production of adrenal steroids) exhibit chronically low blood 
pressure, hypoglycaemia, fatigue and weight loss. 
It is not uncommon for those receiving GC pharmacologically to experience a 
number of side-effects, including osteoporosis, delayed wound healing, glaucoma, 
diabetes, vasculitis, ulceration, pancreatitis and increased risk of infection (Schacke 
et al, 2002) and increased cardiovascular risk (Souverein et al, 2004). Many side-
effects of GC therapy can be attributed to the non-selective nature of these 
compounds with the treatment of particular conditions leading to disruption of 
healthy anabolic processes. In some cases at extreme doses, MC side effects, such as 
water retention, may also be observed; however, generally this would only occur 




Figure 1.3 Impact of raised glucocorticoid levels on cardiovascular risk factors. 
The above schematic summarises some of the risk factors associated with chronically raised 
glucocorticoid (GC) levels. Features highlighted are those which are known cardiovascular 
risk factors. This Figure has been adapted from Girod JP, Brotman DJ (2004) Does altered 
glucocorticoid homeostasis increase cardiovascular risk? Cardiovascular Research 64: 217– 
226. 
1.4 Glucocorticoids and the stress response 
Stress is an evolutionary conserved mechanism which enables fast carefully 
orchestrated physiological responses to cope with life-threatening dangers such as 
predation, trauma, noxious stimuli or environmental stressors. The perception of 
stress in vertebrates is through the hypothalamus and subsequent activation of the 
sympathetic nervous system. GCs play an important role in this stress response along 
with catecholamine production. Catecholamines such as epinephrine initiate the rapid 
fight or flight response to stress, while GC produce a more moderate slower 
physiological response to sustained or prolonged stressor. The roles of GCs in the 
stress response include an increase in the mobilisation of energy from storage 
locations throughout the body into the bloodstream (for mitochondrial energy 
requirements), an increase of cardiovascular tone (increasing cardiovascular 
efficiency) and a delay in the non-essential processes within the body such as 
feeding, digestion, growth, and reproduction. Stress induced GC production also 
enhances the body’s immune system to allow better protection from harmful 
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pathogens, thus reducing the risk of infection (Sapolsky et al, 2000). When the 
stressor has been removed the negative action of GC feeds back on the HPA axis to 
prevent chronic pathological activation (Sapolsky et al, 2000) (Figure 1.1). Further 
post-stressor roles of GC include returning energy homeostasis through 
replenishment of energy stores. As mentioned previously chronic unregulated stress 
response can have serious pathophysiological effects. 
1.5 Glucocorticoids and the cardiovascular system 
During the stress response short-term alterations in GC levels act to maintain 
vascular tone and modify cardiovascular inflammatory, proliferative and remodelling 
responses to injury (Walker, 2007). As highlighted in section 1.3.5 instances of GC 
dysregulation have been associated with numerous direct and indirect actions on the 
cardiovascular system (Stumpf, 1990) with prolonged effects maladaptive, resulting 
in severe metabolic and cardiovascular consequences (summarised in Figure 1.3). 
The pathology of conditions such as Cushing’s disease, Addison’s disease and CAH 
further highlight the role of GC the cardiovascular system. Complete cardiovascular 
collapse and death can occur with the absence or very low levels of adrenal steroid 
biosynthesis (Grunfeld & Eloy, 1987; Hammer & Stewart, 2006) and in instances of 
chronic steroid biosynthesis (Cushing’s disease) premature atherosclerosis, 
hypertension, cardiac myopathy, reduced ejection fraction, congestive heart failure 
and ischaemic heart disease have been documented (De Leo et al, 2010). Chronic 
therapeutic use of GCs is also known to result in several adverse cardiovascular 
complications including hypertension, atherosclerosis, and heart failure (Grunfeld & 
Eloy, 1987; Saruta, 1996). Although there is strong evidence to allow us to describe 
an association between GCs and the cardiovascular system, little is known on 
specific GC (exogenous and/or endogenous)-mediated cardiovascular responses and 
their mechanisms (Sainte-Marie et al, 2007) and whether the observations are a 
direct GC mediated effect on the cardiovascular tissues or indirect effect, such as 




1.5.1 Glucocorticoid signalling on the cardiovascular system 
The possibility of direct actions on the cardiovascular system (blood vessels and the 
heart itself) has been suggested through the finding of widespread expression of both 
MR and GR in on the myocardium (Katz et al, 1988), blood vessel walls (Christy et 
al, 2003), cultured vascular smooth muscle cells (VSMC) (Scott et al, 1987) and 
isolated endothelial cells (EC) (Yang & Zhang, 2004). Further support is provided by 
evidence indicating that manipulation of GCs results in altered cardiac and vascular 
cell structure and function. Altered cardiac morphology and function (in the form of 
decreased heart rate and cardiac output (Roy et al, 2009)) has been observed in rats 
following exposure to GC, with vascular collapse observed in the complete absence 
of adrenal GC steroidogenesis (Hammer & Stewart, 2006).  
Indirect actions of GCs on the cardiovascular system may be due to interaction with 
other organ systems such as the liver, kidney, central nervous system and adipose 
tissue (Ferrari, 2003). It is thought that cardiovascular dysfunction then results as a 
consequence of increased cardiovascular risk factors such as insulin resistance, 
hyperglycaemia, hypertension (in a dose-dependent fashion), dyslipidaemia, 
cholesterolaemia, and central obesity (Girod & Brotman, 2004; Ng & Celermajer, 
2004; Trayhurn & Beattie, 2001). These risk factors are often associated with 
Cushing’s disease supporting an indirect role of GC (Figure 1.3 highlights these risk 
factors).  
1.5.2 Glucocorticoids and the vasculature- human and animal studies  
GC have been shown to be essential in the modulation of peripheral vascular tone, 
with raised blood pressure observed in dogs and rats treated with non-physiological 
concentrations of the GC deoxycorticosterone (Ullian, 1999). Clinical observations 
of Cushing’s and Addison’s sufferers or those who have side-effects from therapeutic 
application also highlight a link between vascular tone and GC exposure, with 
hypertension observed in instances of raised GC. It remains unclear as to whether 
alterations observed in the vasculature are as a result of direct effects on the vascular 




1.5.2.1 Glucocorticoids and vascular endothelial function 
GR has been detected in both VSMC and EC, and GC have been shown regulate 
vascular reactivity on both cell types (Yang & Zhang, 2004). The importance of GR 
in endothelial function was demonstrated in vascular-endothelium-specific GR 
knockout mice where animals were found to be resistant to dexamethasone (Dex-a 
synthetic GC/GR selective agonist)-induced hypertension and showed a decreased 
contractile response to Dex (Goodwin et al, 2011).  
In humans, endothelial cell dysfunction has been noted following GC administration 
and is thought to contribute to the increased incidence of stroke and heart attack 
observed in this setting (Ullian, 1999). Endothelial cell dysfunction is associated with 
impaired nitric oxide (NO) production, perturbed interactions between platelets, 
leukocytes and the vessel wall, and alterations in thrombosis and thrombolysis 
(Girod & Brotman, 2004). While it has been shown that endothelial cell dysfunction 
can be caused by hyperglycaemia, hypertension and dyslipidaemia, all of which are 
well-known effects of chronic GC exposure (Jensen-Urstad et al, 1997), direct 
actions on the vasculature have been shown when cortisol administered to healthy 
normotensive individuals was found to impair cholinergic vasodilation (Mangos et 
al, 2000). Furthermore organ bath assessments have also shown to GC suppress the 
synthesis of potent vasodilators such as prostaglandin 2 (PG2) and NO in healthy 
tissue.  
NO is a potent endothelium derived vasodilator; imbalance of this compound has 
been associated with many cardiovascular disorders. GC overexposure has been 
shown to reduce NO levels, which may play a key role in GC mediated hypertension 
observed in Cushing’s for example. A number of possible mechanisms by which GC 
inhibit NO synthesis (mainly by interactions with endothelial nitric oxide synthase 
(eNOS)) and have been reviewed comprehensively elsewhere (Ullian, 1999) these 
include 1) reduction in transcription of the gene encoding eNOS, 2) increased rate of 
eNOS messenger ribonucleic acid (mRNA) degradation, 3) reduced stability of the 
eNOS protein stability, 4) impaired agonist induced calcium mobilisation from 
intracellular stores (eNOS requires the binding of a calmodulin/calcium complex) 
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and finally 5) a reduction in the availability of eNOS cofactor (GC are thought to 
reduce the synthesis of tetrahydrobiopterin an important cofactor of eNOS). 
Rodent studies have documented a decrease in the levels of the inflammatory 
mediator PG2 following Dex induced hypertension. Further studies using isolated 
endothelial cells confirm the role of GR in GC mediated inhibition of PG2 by 
demonstrating the ability of GR antagonists to prevent the GC induced effects 
(Ullian, 1999). While it unclear how GC inhibit the synthesis of PG2, GC have been 
shown to suppress the transcription of 2 cyclooxygenase (COX-2) in bovine arterial 
endothelial cells suggesting a possible mechanism for the suppression of PG2 by GC 
(Inoue et al, 1999). It has also been suggested that a decrease in PG2 is as a result of 
inhibition of phospholipase A2 and arachidonic acid (Lewis et al, 1986). The 
regulation of peripheral vascular tone is balance between the effect of 
vasoconstrictors and vasodilators, as highlighted above vasodilation is regulated by 
GC. It has also been shown that GC can influence vascular resistance by regulation 
of vasoconstriction too. 
1.5.2.2 Non-endothelial effects of glucocorticoids 
GC administration to healthy adults increases the vessel total peripheral resistance 
(Pirpiris et al, 1992). It may be that GC modulate vascular tone by endothelium-
independent mechanisms such as the enhancement of response to vasoconstrictor 
hormones such as norepinephrine, angiotensin II, arginine vasopressin, endothelin I 
and thromboxanes (Girod & Brotman, 2004; Ullian, 1999) an example of this using 
ex vivo rabbit aortic strips showed increased contractile sensitivity to norepinephrine 
vasoconstriction when co-treated with corticosterone (Fowler & Chou, 1961). 
Further support for a non-endothelial effect was observed in rat VSMC where GC 
exposure was found to up-regulate the expression of alpha-1 adrenergic and 
angiotensin II receptors and display a potentiation of the vasoconstrictive actions of 
these factors (Ullian, 1999).  
It has also been documented that GC increase the expression of ACE and the 
production of angiotensinogen (Aubert et al, 1997) and that GC alter vascular tone 
by activation of the renin-angiotensin system (Suzuki et al, 1982). The influence of 
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GC on VSMC hypertrophy has been investigated; however the data thus far suggest 
that this is not the causative mechanism of altered vascular tone. 
1.5.2.3 Glucocorticoids and angiogenesis 
Although high blood pressure is a common feature of Cushing’s disease, vascular 
remodelling may develop independently of raised blood pressure. As alluded to 
earlier GC are important for proliferative and remodelling responses to injury 
(Walker, 2007) with sufferers of Cushing’s disease often displaying vascular 
contusion (bruising to artery wall), impaired wound healing atherosclerosis and 
vascular remodelling (Rizzoni et al, 2009). GC, through the action of GR, have been 
shown to alter vascular remodelling by inhibiting endothelial cell tube formation 
(Logie et al, 2010) and the migration and proliferation of human (Goncharova et al, 
2003) and animal (Pross et al, 2002) VSMC in culture. 
The ability of GCs to inhibit the process of angiogenesis is well-documented, with 
cortisol often used as a positive control substance (inhibitor) in many investigations 
of angiogenesis. GC suppression of angiogenesis is thought to contribute to impaired 
wound healing in Cushing’s disease, furthermore cutaneous wound healing and 
myocardial infarction recovery have been shown to be inhibited by local generation 
of GC by 11βHSD1 (Small et al, 2005). There is also an increasing body of evidence 
which suggests that endogenous GC contribute to regulation of new vessel formation 
(Hadoke et al 2009).  
A great deal of interest has focused on the anti-angiogenic properties of GC, with the 
suggestion of possible therapeutic applications. GC are used therapeutically in the 
inhibition of angiogenesis in capillary haemangioma and certain cancers (Yano et al, 
2006a; Yano et al, 2006b) and also in the inhibition of neointimal proliferation 
following intra-vascular injury (Hadoke et al, 2006).  
While it is clear that GC have a role in angiogenesis it remains unclear as to the 
mechanisms by which GCs inhibit blood vessel formation. It has been suggested that 
GC-mediated anti-angiogenesis activity is linked to their anti-inflammatory roles but 
in cultured human cells, endothelial cell tube formation is inhibited even in the 
absence of an immune or anti-inflammatory response (Logie et al, 2010). Exposure 
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of GC to cultured human cells was found to impair cell to cell contacts and 
morphology rather than impairing the proliferative, migratory or viability of the cells 
(Logie et al, 2010). It, therefore, may be that GCs provide their anti-angiogenic 
action through alterations in the cytoskeletal structure. While this suggests a possible 
mechanism for GC reduction in angiogenesis it is unlikely that this is the only 
mechanism involved as GC administration has also been shown to decrease the 
expression of crucial regulatory component of angiogenesis (Logie et al, 2010). 
As mentioned previously GC administration impairs the activity of PG2 which is also 
important in angiogenesis. It has been suggested that GC inhibit angiogenesis by 
inhibiting production of PG2, as GC have been shown to decrease endothelial cell 
PG2 this may be possible. Vascular endothelial growth factor (VEGF), another key 
mediator of angiogenesis, has been reduced in several cell types (Koedam et al, 
2002) including VSMC following exposure to GCs. VEGF, has a number of 
specialised effects on vascular EC such as the increase of proliferation, migration and 
vascular permeability (Iwai et al, 2004). VEGF production and activity increases 
during hypoxia (Tintu et al, 2009) or instances where increased blood flow is 
desirable (e.g. the placenta), and has been shown to be prevented by GC exposure in 
those instances (Hewitt et al, 2006). 
GC have been shown to play an important role in the vascular response to injury in 
vivo (Fishel et al, 1995). The mechanical removal of vascular occlusion can result in 
fibroproliferative vascular response (restenosis). The use of GC in the prevention of 
neointimal lesion formation or restenosis was suggested in part due to their 
antiproliferative and anti-inflammatory properties. GC administration has been 
shown to successfully reduce post angioplasty neointimal proliferation in rats, 
rabbits, and dogs, and with mixed success in humans (Hadoke et al 2009: Hadoke et 
al 2013). It is unclear mechanistically how GCs prevent restenosis. However, it may 
be due to suppression of pro-inflammatory pathways such as the nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-kB) pathway, the reduced 
production of inflammatory cytokines, or tumour necrosis factor alpha (TNF-α) 
release (Pesarini et al, 2010). GCs have also been shown to reduce matrix 
metalloprotease (MMP) activity and secretion suggesting that prevention of 
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neointimal lesion formation may be due to the inhibition of smooth muscle cell 
migration (Fishel et al, 1995).  
While the data summarised here may suggest that GCs act as potent anti-
inflammatory agents or by the prevention of tissue remodelling inhibit atherogenesis 
and thus offer therapeutic application it should also be considered that GC excess, 
such as Cushing’s disease, is associated with increased atherosclerosis (Hadoke et al, 
2013). While it may be that atherosclerosis in these instances is due to increased 
cardiovascular risk factors such as dyslipidaemia it should also be considered that 
GC have complex, and often contradictory, influences on cardiovascular disease and 
cardiovascular risk (Walker, 2007). 
1.5.3 Glucocorticoids and the heart 
As highlighted above excess levels of GC have been associated with numerous 
cardiovascular disease risk factors and adverse cardiac events such as left ventricular 
hypertrophy and cardiac failure. The elucidation of tissue-specific effects of GR 
action can often be difficult, since the GR overlaps functionally MR and most 
metabolically active organs, including the heart, express substantial levels of both 
GR and MR (Tokudome et al, 2009).  
Much of the role of GC modulation on the heart has been gathered using genetic 
manipulation techniques of these receptors in rodent models. GR knockdown mice 
die shortly after birth with multiple organ defects and widespread somatic oedema. 
This suggest the importance of these receptors in early development but makes 
investigation of specific roles problematic, often investigation occurs in late gestation 
however notably the heart is smaller, with abnormal cellular and ultra-structural 
architecture (Rog-Zielinska et al, 2012). Over-expression of GR in mice has been 
shown to induce atrio-ventricular (AV) block (Sainte-Marie et al, 2007). Conditional 
knock down of the other GC receptor MR has been shown to produce severe heart 
failure and cardiac fibrosis, which is fully reversible with the addition of MR 
antisense mRNA (Beggah et al, 2002). Conditional over-expression of MR in mice 
triggers cardiac arrhythmias resulting in excess mortality which can be reduced with 
the addition of MR antagonist (Ouvrard-Pascaud et al, 2005). These GR and MR 
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manipulation studies highlight novel effects of GR and MR activation in the heart, 
suggesting that both receptors have direct and specific cardiac effects in rodent 
models (Wintour, 2006), with important roles in development of this systems (Rog-
Zielinska et al, 2012). While both GR and MR have been found to be expressed in 
the heart (Brown et al 2005), the influence which these receptors play in cardiac 
development are poorly characterised, with much of published data thus far focusing 
on the role of endogenous and exogenous GC on the developed heart. 
As with the vasculature, GCs have also been shown to have a direct and short term 
effect on contractile function in the heart. Dex treatment enhances the development 
of contractile tension and increases contraction and relaxation velocities in cardiac 
muscles (Katz et al, 1988; Penefsky & Kahn, 1971; Sainte-Marie et al, 2007), similar 
observations were noted following exposure to cortisol (Rossier et al, 2008). Further 
support for a more chronic or longer term GC-mediated role on the myocardium was 
observed in adrenalectomised rats, thus unable to produce corticosterone, 
demonstrating decreased cardiac contractile force, which is was rescued upon Dex 
treatment (Rao & Narayanan, 2000). A number of rodent and cell culture studies 
have also demonstrated GC-induced cardiac hypertrophy (Ohtani et al, 2009). 
However, cardiac hypertrophy, which develops with MR over-expression, has not 
been documented in mouse hearts with over-expression of GR, suggesting that 
cardiac hypertrophy is predominantly MR-mediated. Cardiac MR have been shown 
to play a key role in cardiac remodelling, with the MR antagonists spironolactone 
and eplerenone shown to reduce mortality in patients with heart failure and either 
impaired systolic function (Stevenson, 2006) or diabetes following acute myocardial 
infarction. 
1.5.3.1 Glucocorticoids in heart protection 
GCs have also been shown to elicit a cardio-protective effect in the acute setting of 
myocardial ischemia reperfusion in both animals (Sapolsky & Meaney, 1986; 
Sapolsky et al, 2000; Tokudome et al, 2009) and humans (Giugliano et al, 2003). In 
accordance, blockade of the GR has been shown to increase infarct size (Hafezi-
Moghadam et al, 2002). However, as highlighted previously prolonged exposure to 
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high systemic levels of GC can be detrimental following myocardial infarction, due 
to suppression inflammatory processes critical for infarct healing. 
1.5.4 Problems with glucocorticoid cardiovascular research 
There are substantial weaknesses in this field, since very few experiments have 
dissected systemic (e.g. actions in liver or kidney) from local (intravascular) effects 
of either GC or MC. It has also been difficult to recapitulate in vivo findings in 
experiments in isolated vessels or cardiomyocytes in vitro. The potential for 
occupancy of MR as well as GR by cortisol has not always been taken into account 
in interpretation of results, with the potential effects of aldosterone often ignored. 
Furthermore the concentrations and time-course of GC exposure has often not 
reflected normal physiological relevance suggesting that while indicative of the role 
that GC may play in cardiovascular pathophysiology it is unclear what their activity 
is in normal physiology. 
1.6 Glucocorticoids during development 
GCs have also been shown to be critical during development, where they are thought 
to regulate tissue and organ development, maturation and morphology by promoting 
cellular differentiation (Fowden & Forhead, 2004). Towards the end of gestation GC 
levels rise rapidly, preparing the foetus for the extra-uterine environment, resulting in 
maturational changes in organ systems such as the heart, gut, kidneys and, 
importantly, stimulating surfactant production by the lung (Cottrell & Seckl, 2009). 
It is thought these effects result from a shift from cellular proliferation to 
differentiation events. Furthermore, it has been shown that maturation can be induced 
prematurely through exogenous GC administration (Ballard, 1979; Ballard et al, 
1975; Fowden & Forhead, 2004) and it is due to this well-known effect that GCs are 
often used in the treatment of mothers at risk of preterm delivery to promote infant 
lung maturation (Bolt et al 2001: Seckl & Meaney 2004). The importance of these 
hormones in organ maturation is highlighted in GR -/- mice which die within min of 
birth as a result of retarded lung development (Cole et al, 1995), and kidney and 




1.6.1 Glucocorticoids in cardiac maturation 
Numerous mechanical and hormonal factors, such as GCs, are thought to play 
important roles in the maturation of the mammalian heart. While the expression of 
GR and MR in the developing heart is indicative of a role it is difficult to investigate 
the actions specifically in organ development. However it has been shown in global 
GR -/- mice that disruption of GR signalling results in immature late gestation hearts 
with tissue specific cardiomyocyte GR -/- mice displaying impaired contractile 
function and altered compact myocardium structure (Rog-Zielinska et al, 2012). 
Infants which are born prematurely have an increased risk of cardiovascular disorder, 
it has been hypothesised by Rog-Zielinska and colleges (Rog-Zielinska et al, 2012) 
that since premature births occur before the surge in GC in late gestation, that organs 
are immature for the extra-uterine environment and thus disorder risk increases. 
While this hypothesis may be possible, in humans it is particularly difficult to dissect 
out the long-term effects of premature birth from the long-term effects of therapeutic 
GC administration in maturation of pre-term foetus. 
1.6.2 Glucocorticoid treatment of pre-term infants 
Although GC treatment results in an overall reduction in neonatal death and cerebro-
ventricular haemorrhage (Roberts & Dalziel, 2006) in certain circumstances the 
benefit of accelerated lung maturity may be associated with detrimental 
consequences of GC excess since GR are found in most tissues (Harris & Seckl, 
2011). Short-term side effects include hypertension, hyperglycaemia, infections, 
intestinal perforations, gastrointestinal bleeding, inhibition of somatic growth and 
hypertrophic cardiomyopathy (Bolt et al, 2001). The putative long-term effect on the 
foetus of antenatal GC administration remains a point of much debate with 
uncertainty about the optimal number and timing of doses of GC administered to 
mothers (Newnham & Moss, 2001). Concerns remain with regard to the longer term 
consequences which may include inhibition of lung growth and neurodevelopmental 
abnormalities in later life (Bolt et al, 2001; Phillips et al, 2005). 
Numerous studies both in humans and in animal models have shown that prenatal 
exposure to GCs can influence environment significantly enough to alter growth and 
increase the likelihood of cardio-metabolic disease, HPA axis perturbations and 
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affective disorders in later life (Cottrell & Seckl, 2009; Phillips et al, 2005; Seckl & 
Meaney, 2004). Furthermore other factors of pre-natal programming such as 
maternal diet, drug use or stress are thought to be mediated by alterations in GC 
levels. As a result GC administration is the second most common model of in utero 
early-life programming of adult disease after diet restriction (Moritz et al, 2005). 
1.7 Early life programming 
During intrauterine development, every organism has a critical window of organ and 
system developmental plasticity. This key window provides the animal or organism 
with the ability to phenotypically alter or adapt in response to environmental 
conditions to maximise the chances of survival (Gluckman et al, 2005; Hochberg et 
al, 2011; Moczek et al, 2011). When this change or adaptation is permanent, it is 
termed a “early-life programming” (referred to herein as programming) change and 
is associated with long-lasting effects on tissue structure and/or function (Brenseke et 
al, 2013). A number of epidemiological studies have suggested that intrauterine 
environment influences development and risk of disease in later life (Barker & 
Osmond, 1988; Barker, 1998; Barker et al, 1993; De Blasio et al, 2007). This 
suggests that an adverse environment (De Blasio et al, 2007), during sensitive 
periods or windows of tissue morphological/physiological development and 
organisation, can result in compensatory or adaptive cellular processes 
(morphological remodelling by disruption or activation of cellular proliferative or 
differentiation events (Langley-Evans, 1997) and alteration in gene abundance to 
name a few), resulting in altered growth and long-term disturbances in the structure 
and function of tissues, (De Blasio et al, 2007; Stocker et al, 2005; Wintour et al, 
2003). This concept of early-life-programming is displayed well in the so called 
“thrifty phenotype” (Barker et al, 1989; Hales & Barker, 1992) where maternal 
starvation and thus reduction in nutrient and oxygen supply, correlates with adaptive 
changes in the foetus to maximise metabolic efficiency and reduce growth. 
While this adaption ordinarily is beneficial, at least in the short term, for the health 
and survival of the organism, a “mismatch” has been described where adapted 
individuals are subsequently exposed to a persistent environmental condition unlike 
those originally adapted to (Bateson et al, 2004; Byrne & Phillips, 2000; Godfrey et 
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al, 2007). The degree of disparity between the plasticity-induced environment and 
the adult environment can have a profound effect on the risk of developing disorder 
in later life. Barker et al (Barker et al 1993) found in the “thrifty phenotype” group 
that the offspring of starved mothers had an increased incidence of metabolic 
disorders in later life when the nutritional status was markedly different to that 
experienced during early development. 
A plethora of processes and systems have been highlighted as programmable through 
alteration of uterine environment with a number of diseases or disorders being 
attributed to early-life programming such as cardiovascular disorders, 
neuropsychiatric disorders (Bale et al, 2010), obesity (Cottrell & Ozanne, 2008) 
metabolic syndrome (Wang, 2013) and chronic kidney disease (Kett & Denton, 
2011; Vehaskari, 2010) to name a few.  
1.7.1 Possible mechanisms of cardiovascular early-life programming 
A number of mechanisms have been proposed to explain the effects of early-life 
alterations in adult cardiovascular health, such as epigenetic, morphological, 
physiological and metabolic changes. 
1.7.1.1 Epigenetic modifications 
Epigenetic modifications are alterations in gene expression or cellular phenotypes 
which are as a result of mechanisms other than changes in the underlying DNA 
sequence (no alterations in nucleotide sequence); occasionally these alterations are 
found to be heritable. There are three main forms of epigenetic modifications I) 
Histone modifications ii) MicroRNAs and iii) DNA methylation (Santos & Joles, 
2012). Several studies have shown that programming effects lead to alterations in the 
epigenetic pattern of crucial genes involved in growth, metabolism and 
cardiovascular development, with experimental rodent models demonstrating that 
DNA methylation has a role in atherosclerotic and cardiovascular disease 




1.7.1.2 Structural and physiological changes 
Numerous animal studies have suggested that alterations in morphology and 
physiology of the cardiovascular and renal systems have been associated with the 
adverse long-term early-life programming effects (Santos & Joles, 2012). 
Direct cardiovascular programming has been associated with altered vasoconstrictor 
responses with VSMCs displaying increased superoxide production and some 
arteries (e.g. carotid, mesenteric) showing impaired endothelium-dependent 
vasodilation. Rat offspring of food-restricted (protein and/or calorific) mothers have 
aortic and mesenteric artery remodelling and also display reduced levels of elastin in 
their aorta accompanied with persistent abnormalities in arterial stiffness. Although 
unclear in these rat models, abnormalities in arterial stiffness in adult humans 
increases systolic and pulse pressure. This is particularly interesting as hypertension 
is a common phenotype associated with programming (Alexander, 2006; Ojeda et al, 
2008). Alterations in composition and structure of extracellular matrix of the vessels 
has also been observed in rats which has been found to impair angiogenesis and 
reduce capillary density (Nuyt & Alexander, 2009; Struijker Boudier, 1999). 
It has been proposed that adaptations associated with early-life programming can 
alter mechanisms of cardiac growth, resulting in permanent changes to cardiac 
structure and function (Wang et al, 2012). However, this hypothesis is based on 
known features of heart growth but little work has been carried out to ascertain 
whether it is correct. In many mammals, heart growth in early gestation is 
predominantly due to the proliferation of mono-nucleated cardiomyocytes. As 
gestation progresses there is a shift from hyperplastic to hypertrophic growth and 
these mono-nucleated cardiomyocytes differentiate into a bi-nucleated form. Post 
natal heart growth, therefore, is thought to be a result of hypertrophy of these bi-
nucleated cardiomyocytes rather than the process of proliferation (Mollova et al, 
2013). During development mechanisms are in place to regulate cardiomyocyte 
proliferation, apoptosis and the timing of terminal differentiation. However, 
numerous models of early-life programming have suggested a reduction in cellular 
proliferation and an increase in apoptosis as central adaptive changes in other organ 
types (Botting et al, 2012). If this was to occur in the heart it may result in reduced 
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cardiomyocyte number, increasing the vulnerability of the heart in situations of 
increased demand, of particular significance given the importance of cardiac 
hypertrophy as a cardiovascular mortality and morbidity indicator (Porrello et al, 
2008). Although the number of studies investigating the cellular basis of 
programming of cardiovascular disease is limited there is some indication that a 
reduction in cardiomyocyte number may be a central feature (Porrello et al, 2011; 
Porrello et al, 2008).  
Although physical/structural alterations in the cardiovascular system itself may be 
causative in the development of cardiovascular disorder in later life, the 
physiological changes in other tissues should also be taken into consideration after 
all the likelihood of developing cardiovascular disease or disorder is increased by the 
presence of risk factors. With structural and functional alterations in the kidney, 
pancreas and liver observed in programming models, an increase of cardiovascular 
risk factors such as hypertension, glucose intolerance and insulin resistance (Santos 
& Joles, 2012) may occur indirectly. 
1.7.2 Contributors to early-life programming 
A number of possible in utero insults to the foetus have been associated with the 
concept of programming, including maternal nutrition (both starvation and more 
recently increased food consumption as a result of the “obesity epidemic”), 
malnutrition (leading to iron or vitamin deficiency)(Wu et al, 2004), narcotic drug 
use, alcohol consumption (Minnes et al, 2011), intrauterine exposure to therapeutic 
drugs (reviewed by Fowden & Forhead, 2004) to environmental factors such as 
pollution (Hong et al, 2013) and tobacco smoke (Suter et al, 2013) or physical and 
psychological stressors (Davis & Sandman, 2010). A commonly studied and well-
documented model of altered environment and disease programming is early-life 
overexposure to GCs. This concept has been reviewed extensively (Dotsch et al, 
2012; Khulan & Drake, 2012; Raikkonen et al, 2009; Raikkonen et al, 2011; 





1.8 Glucocorticoid-induced early-life programming 
1.8.1 Animal studies 
Numerous animal (mostly rodent) models have been used to study GC modulation. 
There is considerable evidence to suggest that foetuses exposed to increased levels of 
GCs (Dex or cortisol) in the womb have intrauterine growth retardation (IUGR) as 
observed both in sheep (Ikegami et al, 1997; Jobe et al, 1998; Nyirenda et al, 1998) 
and in rats (Langdown & Sugden, 2001; Nyirenda et al, 2006; Nyirenda et al, 1998). 
In rats, an increased heart weight/body weight ratio has also been noted; upon closer 
inspection of these hearts a number of features were observed. These included altered 
actin and total protein levels, disrupted protein/DNA ratio and larger cardiomyocyte 
volume, length and width 5 and 7 days after birth. These data are indicative of 
myocardial hypertrophy (Rademaker & de Vries, 2009). Furthermore these rat 
offspring also show increased premature mortality compared to control littermates in 
adulthood which was attributed to end stage cardiac and renal failure. Cardiac failure 
could be explained as a result of reduced cardiomyocyte proliferation, and thus 
reduced cardiomyocytes in hearts which could in turn impair normal contractile and 
functional activity of the heart (Rademaker & de Vries, 2009).  
Further studies in rats and sheep have shown increased neonatal systolic blood 
pressure (Dodic et al, 2002; Langley-Evans et al, 1996; Oritz et al, 2003) following 
excess intrauterine Dex or cortisol exposure. The alteration in blood pressure has 
been shown to persist into adulthood in sheep (Dodic et al, 2002). However 
comparable findings were not observed in a similar model in the guinea pig 
suggesting this may be a species-dependant observation (Rademaker & de Vries, 
2009). Findings in animal models have also shown that the time-point of GC 
treatment may be crucial, with hypertension noted in sheep treated in the first month 
of gestation but not in those treated in the third (Dodic et al, 2002). In contrast, 
IUGR is most notable when GCs are administered towards the end of gestation, 
specifically in the third trimester, in rats (Nyirenda et al, 1998; Seckl, 2004) although 
effects are still evident if exposure is continued throughout pregnancy. The 
mechanisms by which GC can programme adult hypertension are unknown but a 
variety of explanations have been suggested. These include reduction in nephron 
number (Oritz et al, 2003; Wintour et al, 2003), altered response to vasoactive 
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substances (Derks et al, 1997; Nuyt & Alexander, 2009), influence on altered 
function of the renin-angiotensin system (Dodic et al, 2002) and altered post natal 
HPA axis activity (Marciniak et al, 2011). In instances of IUGR not only is vascular 
dysfunction observed, but altered vascular structure is also noted, such as mesenteric 
artery and aorta remodelling in rats (Khorram et al, 2007a; Khorram et al, 2007b) 
It is not only cardio-metabolic features which can be programmed by GC exposure. 
GCs are essential for many aspects of normal brain development; exposure of the 
brain to raised levels of GC whether through maternal stress or therapeutically has 
been shown to result in life-long alterations in neuroendocrine function and 
behaviour. Male rat models of GC overexposure display anxiety-related behaviours 
and by non-human primate maternal stress studies, where there is an association with 
attention deficits in offspring (Cottrell et al 2009). Animal studies have also shown 
that GC exposure during development does not only affect behaviour but can also 
reprogram the function of the HPA axis in the offspring as evident by long-term 
effects on basal GC levels in the offspring (Seckl et al 2004).  
1.8.2 Human studies 
The effects of GC treatment in humans have been studied with findings suggesting 
that children of mothers treated antenatally, even with short term Dex, suffer from 
IUGR (Bloom et al, 2001; French et al, 1999). A number of human studies looking 
at IUGR have shown an increased risk of cardiovascular death in adult life, it is 
unclear whether this is due to programming or confounding health feature of being 
born with IUGR.  
The longer-term, life-time consequences of excess GC exposure during development 
in the human remain poorly documented. This can be in part attributed to the fact 
that preterm administration of GC only emerged as a recognised and widely used 
treatment in the 1980s and so the oldest of these offspring are now in their third or 
fourth decade. Hypertension, hypertrophic cardiomyopathy and left ventricular 
outflow tract obstruction have been described in association with Dex treatment in 
some young neonatal humans (Rademaker & de Vries, 2009). These observations 
may be due to a direct effect of GCs on the heart, as noradrenergic and autonomic 
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processes have been found to be altered following GC overexposure in human (Bian 
et al, 1993).  
Epidemiological evidence suggests that an adverse environment also programs 
increased risk of neuroendocrine and cognitive disorders in adulthood. Very little is 
known about the mechanisms by which GC influence neurodevelopment in the 
human, however a common behavioural outcome of pregnancies affected by prenatal 
stress is an increased incidence of attention deficit hyperactivity disorder (O’Connor 
et al 2002). Further features which have been thought to be influenced by GC 
exposure include cognitive development (impaired language development) and 
psychoactive disorders such as schizophrenia; however supporting data are limited. 
Not only is there limited evidence of long-term effects published findings are often 
contradictory which may be due to difficulties in separating the detrimental effects of 
GC treatment with the detrimental effects of pre-term birth. 
1.9 Developmental programming models 
Various models have been used to study the developing foetus and the influence of 
which subtle alterations during early vertebrate developmental stages may produce 
on organogenesis and function. Despite this the precise roles of GCs in the embryo 
and the impact that manipulation during early development remains unclear. A 
particular gap in our knowledge lies in the actions of GCs in the developing foetus 
and the importance of GC regulation in normal organ development. It is also unclear 
as to what the underlying molecular mechanisms linking impaired development and 
adult disease or disorder are (Alsop & Vijayan, 2008) and whether there are 
particular windows in embryogenesis where alterations have a more profound and 
specific effect. In understanding these better it may be possible to intervene early in 
life of those susceptible to reduce the incidence and severity of the disease or 
disorder in later life. 
1.9.1 Human studies 
Whilst developmental programming is a well-established observational theory, there 
remains a deficit in our knowledge with regard to the underlying cellular and 
molecular mechanisms occurring in the embryo that lead to this phenomenon. 
48 
 
Human epidemiological studies have provided much of the support for Barker et al’s 
work but numerous caveats and confounding features should be considered.  
At a maternal/ level, for example, maternal age, parity, multiple foetuses (twins are 
generally smaller at birth - Multiple Births in England and Wales for 2011 obtained 
from the Office of National Statistics: twin average weight 2.5kg vs singletons 
3.5kg- and according to Barker’s hypothesis should have greater morbidity and 
mortality. However further complexity in data analysis is shorter gestational length- 
37 weeks for twin vs 40 weeks for singletons (thus prematurity may be a factor)) and 
/placental relationship to name but a few. At a juvenile level, catch-up growth and 
discrepancies in displaying body weight/mass and body composition can skew data.  
At adult level socio-economic factors, lifestyle choices, and environment should all 
be taken into consideration when interpreting results. Human studies have 
exclusively used retrospective data which rely on health professionals recording the 
appropriate information and for the health of the children to be accurately monitored 
throughout life, in many instances for 80+ years (the mean life expectancy in the UK 
is 80yrs). Often the initial study cohort decreases with time and cases lost to follow 
up for various reasons may further confound key findings. Furthermore, there have 
been marked improvements in sanitation, housing, education and health-care 
(particularly pre, post and neonatal) in the last 50 years alone, resulting in improved 
infant survival (especially in those with additional -environmental complications 
such as preeclampsia for which historically mortality was high) resulting in a trend 
for increasing life expectancy. A further confounding factor is the potential time-
frame for a person to experience adverse health; when does the disease or disorder 
manifest, and does the increasing life-span of humans alter the risk of “mis-match” 
and disease? With an aging population it may be that we are not seeing the true 
extent of programming yet. 
In summary, human studies are complicated by a number of variables coupled with 
challenges of accurate and comprehensive follow up which means that very large 
cohorts are required to see both cross sectional and longitudinal effects over time. 
Despite modern data systems and information technology, studies of this scale are 
increasingly difficult and expensive. 
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1.9.2 Animal studies 
Animal models have been proposed as a means to address the gap in understanding 
of the cellular and molecular mechanisms underlying programming by allowing 
accurate measurements, follow-up and documentation of phenotype in a more 
controlled way. A further advantage of animal models is the relative homogeneity of 
animal cohorts which reduces the confounding effects of genetic variation, typical of 
human studies (Drake and Walker 2004). Numerous animal models have been used 
to explore the cellular and molecular mechanisms of programming and have revealed 
an association with growth, metabolic status and cardiovascular risk. However, none 
of these models achieve the gold standard as a clinically-relevant model.  
One difficulty is variations between species; for example, mouse models of maternal 
hyperglycaemia result in normal or small-sized pups whereas human offspring 
exposed to hyperglycaemia develop macrosomia (larger than normal birth weight) 
(Brenseke et al, 2013). Furthermore, particularly relevant to tissue plasticity 
programming is that rodent species are altricial with organ maturation largely 
occurring after birth, thus the influence of postnatal factors may be highly relevant in 
these rodent models. This may explain why pre- and peri-natal conditions have a 
more profound effect in human, primate or ovine models of programming (Brenseke 
et al, 2013). 
A number of approaches used to monitor development in vertebrate model systems 
are invasive for both mother and foetus and can be associated with high morbidity, 
furthermore confounding factors such as activation and induction of the maternal 
HPA axis, make monitoring GC activity problematic. A further feature of current 
models which makes investigation and subsequent findings difficult to interpret is the 
influence of the placental barrier. It is known that the placenta offers a controlling 
mechanism for perturbed GC levels as it contains both 11βHSD1 and 11βHSD2 
regulating the trans-placental transfer of cortisol and cortisone in many mammals 
(Burton & Waddell, 1999; Waddell et al, 2005). The placenta is also susceptible to 
excess levels of GC, with a reduction in placental weight, accompanied by reduced 
vascularity and increased apoptosis (Hewitt et al, 2006; Waddell et al, 2005). Thus, it 
is hard to determine whether the effects induced by prenatal exposure to GCs 
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occurred secondary to placental changes, direct effects on the foetus or a 
combination of both. Although work carried out by Holmes and colleagues does 
suggest a key role of feto-placental 11βHSD2 in prenatal GC programming (Holmes 
et al, 2006). 
1.9.3 The placental influence 
The mammalian placenta possesses a number of protective mechanisms which help 
to prevent potentially harmful compounds from entering the environment. Placental 
11βHSD2 expression regulates over-exposure to cortisol by converting large 
amounts into the inactive metabolite cortisone (Yang, 1997). Suppression of 
placental 11βHSD2 activity either genetically (heredity disorder) or by maternal 
liquorice consumption allows greater levels of maternal GCs to cross the placenta, 
resulting in a physiologically-relevant model replicating Dex treatment (Holmes et 
al, 2006). In humans, a reduction in placental 11βHSD2 correlates with lower birth 
weight and higher blood pressure in later life (Cottrell & Seckl, 2009). Mice 
displaying global 11βHSD2 knockout also exhibit reduced birth weight along with 
heightened anxiety in adulthood (Holmes et al, 2006). Furthermore placental 
11βHSD2 expression is altered by maternal environment, with maternal starvation or 
stress resulting in reduced 11βHSD2 expression and activity (Langley-Evans, 1997; 
Langley-Evans et al, 1996; Mairesse et al, 2007). In addition, mammalian growth is 
directly related to placental growth and development, with a number of placental 
abnormalities (such as decreased placental blood flow, placental abruption or previa, 
and infection) associated with small-for-gestational-age offspring. Growth is also 
dependent on adequate placental nutrient transfer. As embryos exposed to GCs in 
utero display IUGR, it is possible that the effects of GCs on development are due to 
direct effects on the placenta with reduction in placental weight (Korgun et al, 2012), 
altered vascularisation (dilation of the -placental circulation (Clifton et al, 2002)), 
suppression of extracellular matrix (e.g. fibronectin and laminin expression (Yoon et 
al, 1998)) and up-regulation of placental glucose transporters (Korgun et al, 2012) all 
reported. 
While it is apparent that the models currently in use have allowed progress in 
understanding programming, this section highlights the requirement for alternative 
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and complementary models in which we can further improve our understanding and 
knowledge by diminishing the effects of confounding factors such as the placenta 
and in utero development; one such model is the zebrafish (Figure 1.4). 
1.10 The zebrafish as a research model 
There are a number of benefits of the zebrafish as a vertebrate model system for the 
study of development and organ system dysfunction (Ackermann & Paw, 2003; 
Dodd et al, 2000; Hu et al, 2001). These benefits include external fertilisation, 
embryonic transparency (Glickman & Yelon, 2002) (Figure 1.4) and rapid 
embryogenesis (Lieschke & Currie, 2007). Contrary to their appearance, zebrafish 
have many similarities to humans at a molecular and cellular level, with greater 
genetic similarities than many invertebrates (Veldman & Lin, 2008). Like humans, 
zebrafish possess immune, digestive, nervous and cardiovascular systems with many 
of these organs systems analogous to their human counterparts at anatomical and 
physiological levels. 
A number of distinct phenotypes, many which are consistent with human disorders, 
have been produced in zebrafish (Barrett et al, 2006; Veldman & Lin, 2008). In 
addition, Zebrafish are amenable to generating transgenic lines (Udvadia & Linney, 
2003), many with tissue specific expression resulting in fluorescence in various 
organs and tissue systems, thus allowing enhancement of in vivo imaging capabilities 
(Veldman & Lin, 2008). Antisense morpholino (Mo) (Ackermann & Paw, 2003; 
Veldman & Lin, 2008) zinc finger nucleases (Zfns) (Meng et al, 2008) and 
transcriptor activator-like effector nucleases (TALENs)(Dahem et al, 2013) offer the 
opportunity to knockdown or modify gene expression. 
Another important feature of zebrafish is the ability to regenerate a number of organ 
systems and structures. For example the complete regeneration of the caudal fin 
(Mathew et al, 2007), heart (Poss et al, 2002) and spinal cord have been reported. 
Ordinarily following injury or damage scar tissue forms in mammalian hearts. In 
zebrafish, however, up to 20% of the heart ventricle can be removed with complete 
regeneration within 60 days (Poss et al, 2002). Caudal tail fin regeneration has been 
shown to be inhibited by incubation with a number of pharmacological agents 
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(Mathew et al, 2007). The zebrafish (Figure 1.4) therefore provides a unique model 
to test the impact of interventions on tissue regeneration pathways. 
 
Figure 1.4 Image of a 120 hour post fertilisation zebrafish embryo. 
Image is of a wild-type embryo, embedded in agar. At this time point all major organ 
systems are developed, swim bladder is inflated and embryos are free swimming. Important 
features are highlighted. 
1.11 Zebrafish glucocorticoid system 
1.11.1 Teleost steroidogenesis 
In teleost fish such as the zebrafish the process of steroidogenesis is very similar to 
mammalian steroid biosynthesis, with many of the steroids and enzymes present in 
humans being found in zebrafish (Hsu et al, 2009). Like humans the predominant 
circulating corticosteroid is cortisol. This is produced from the piscine stress axis 
analogous to the HPA axis, the hypothalamus-pituitary-interrenal (HPI) axis in which 
cortisol is produced by the inter-renal gland, a homologue to the mammalian adrenal 
gland (Schoonheim et al, 2010; Ziv et al, 2013). The inter-renal gland is a cluster of 
specialised cells embedded within the head kidney, the formation of this gland has 
been comprehensively reviewed elsewhere (Liu, 2007). The proposed pathway of 
zebrafish steroidogenesis is highlighted in Figure 1.5. To date most of the 
highlighted enzymes have been cloned in the adult zebrafish and their expression has 
been confirmed using polymerase chain reaction (PCR) or in situ hybridisation 
(Tokarz et al, 2013a; Tokarz et al, 2013b). Although the numerous studies carried 
out would suggest a well-characterised steroidogenic system, the putative 
physiological significance of these findings is unclear. Consequently, more work is 





1.11.2 Zebrafish glucocorticoid receptors 
There has been great debate in recent years as to whether teleost fish produce 
aldosterone, with the current consensus being that they lack the capacity to 
synthesise aldosterone (Alsop & Vijayan, 2008; Colombe et al, 2000; Jiang et al, 
1998; Strum et al, 2005). Despite the absence of aldosterone, zebrafish possess both 
GR and MR and cortisol has been shown to have both MC and GC activity, 
controlling both metabolic and electrolyte processes (McGonnell & Fowkes, 2006). 
This has important roles in seawater and freshwater adaption (Strum et al, 2005); 
however in freshwater fish such as zebrafish the specific roles are unclear. 11-
Deoxycorticosterone has also been shown to exhibit strong MR affinity, but there is a 
lack in evidence to suggest that this is of physiological significance (Lohr & 
Hammerschmidt, 2011). 
The role of steroids in zebrafish is similar to that observed in terrestrial vertebrates 
with most of the cellular responses associated with cortisol in the zebrafish thought 
to be facilitated by GR activation. Cortisol has been shown to be involved in the 
zebrafish for the regulation of metabolism, immune response, osmoregulation, along 
with reproductive influences and circadian cell-cycle rhythmicity (Tokarz et al 
2013a). Similarities between the zebrafish and mammalian systems are highlighted in 
the increase of phosphoenolpyruvate carboxykinase (PEPCK) activity following 
cortisol administration with inhibition observed in response to the GR (and PR) 
antagonist RU486 (Aluru & Vijayan, 2009). 
Despite the teleost genome wide duplication event (an evolutionary multiplication of 
some genes), unlike most teleost fish, zebrafish only have one GR type which has a 
high level of similarity with the human GRα form (Schoonheim et al, 2010), with 
splice variant isoforms being almost identical between the two (Schaff et al, 2008). 
This again supports the zebrafish as an appropriate and relevant model for 
comparative functional and genomic studies of the GC system (Aluru & Vijayan, 
2009). 
While the role of steroids in the adult zebrafish is reasonably well-characterised 
comparatively little is known about the role of steroids such as GC during 
development. A limited number of studies have been carried out in zebrafish and 
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other teleost species concerning corticosteroid biosynthesis (Alsop & Vijayan, 2008; 
Alsop & Vijayan, 2009), and steroid activity during development (Pikulkaew et al, 
2010). The expression of some steroid biosynthesis genes, such as cyp11a1 and 
hsd3b has been detected during early stages in zebrafish embryogenesis (Hsu et al, 
2009). However, the physiological role of steroids in the developing zebrafish are 
poorly characterised (Pikulkaew et al, 2011). Experimental alterations in steroids 
during development in other species of teleost have been shown to cause distinct 
changes in offspring, such as growth delay following cortisol incubation (Brooks et 
al, 1997). This suggests that these compounds are biologically active throughout the 
early embryonic stages (Pikulkaew et al, 2010). These data support the role of GCs 




Figure 1.5 The proposed steriodogenic pathway in the zebrafish 
Features highlighted are genes encoding suggested enzymes, those marked in grey have confirmed catalytic activity. Major circulating steroids are 
highlighted by boxes, with the dashed box highlighting a proposed mineralocorticoid receptor (MR) ligand. This figure has been reproduced with 
consent from Tokarz J, Möller G, Hrabe de Angelis M, Adamski J (2013a) Zebrafish and steroids: What do we know and what do we need to know? 




1.12 The zebrafish as a model of cardiovascular development 
Zebrafish are now widely used for the study of cardiovascular disorders. Zebrafish 
do not spontaneously develop cardiovascular disorders analogous to humans (Chico 
et al, 2010) but a number of conditions can be readily modelled and many gene 
specific transgenic strains have been generated. There are numerous features in the 
zebrafish which make them a desirable cardiovascular model.  
The heart is the first functioning organ to be formed during vertebrate embryogenesis 
(Stainier, 2001). The morphological processes of heart formation and development 
have been shown to occur in a similar way in many vertebrate species (Schwerte & 
Fritsche, 2003; Schwerte & Pelster, 2000). The embryonic heart is best described as 
a tube like structure, contracting and moving blood in a peristaltic fashion which 
undergoes morphogenetic movements leading to the formation of a looped, multi-
chambered organ (Glickman & Yelon, 2002) consisting of 2 chambers, an atrium 
where the blood flows into the heart and a ventricle where the blood flows out. A 2 
day old zebrafish heart is comparable to a 12 day mouse or 35 day human embryonic 
heart (Stainier, 2001). The genetic processes which regulate cardiac development in 
these early vertebrate stages thought to be highly conserved between vertebrates, and 
so the zebrafish offers an ideal model for early mammalian cardiovascular 
development (Glickman & Yelon, 2002). Furthermore the adult zebrafish heart is 
anatomically similar to the embryonic mammalian heart prior to septation (the 
formation of the septum); unlike in mammalian hearts, however, adult zebrafish 
cardiomyocytes are mono-nucleated, small in size and retain proliferative capacity 
(Porrello et al, 2011; Poss et al, 2002). It has been shown that these mature zebrafish 
cardiomyocytes can proliferate to help regenerate following injury (Jopling et al, 
2010) a feature which has also been shown in the early postnatal mammalian 
ventricle (Poss et al, 2002). 
In the zebrafish embryonic heart, cardiomyocyte contractions are first detected as 
uncoordinated irregular contractions in the linear heart tube. However, as formation 
of the heart progresses cardiac contractility become more coordinated (Bakkers, 
2011). In addition to the cellular composition and the similarities in contractile 
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machinery, the processes which regulate cardiac rhythmicity such as ion flux and 
thus cardiac contraction being remarkably similar in fish to those observed in 
mammals (Nguyen et al, 2008). 
Various cardiovascular parameters can be assessed easily in the developing 
zebrafish, due to embryonic transparency, allowing in vivo observation using bright 
field microscopy without invasive techniques; it is even possible to track individual 
erythrocytes using image analysis software (Chico et al, 2010). A number of other 
technologies also allow determination of heart rate, cardiac wall motion amplitude, 
and systolic/diastolic wall velocity (Denvir et al, 2008). 
Through the use of endothelial transgenic fish and other technologies it has been 
possible to increase our knowledge of the zebrafish vascular system, allowing 
investigation of the mechanisms underlying early embryonic blood vessels formation 
and the signals and factors which are responsible for arterial and venous 
differentiation (Glickman & Yelon, 2002). The complex circulatory system found in 
zebrafish is, in most respects, very similar to that of other vertebrates, including 
humans however an added advantage of the zebrafish embryo for cardiovascular 
research is the non-reliance of a functional cardiovascular system over the first few 
days of development (Pelster & Burggren, 1996). The zebrafish embryo can survive 
without circulating blood and only by oxygen passive diffusion for several days 
allowing the study of dysfunctional hearts (Glickman & Yelon, 2002; Pelster & 
Burggren, 1996), in contrast to rodent and avian models in where similar mutations 
would result in mortality.  
1.13 Experimental rationale 
The data presented here display a clear correlation between environmental alterations 
and disease progression in later adult life, with cardiovascular disease and alteration 
in HPA axis function often displayed. It is believed that this alteration in adult 
phenotype is as a result of adaptive changes at an organ level occurring in the 
developing foetus. These adaptive changes may not manifest as disease in adulthood 
unless further confounding features are also displayed, these may be in the form of 
environmental alterations or further disease risk factors. 
58 
 
Current models of programming do not allow us to understand better whether 
environmental alterations can have a direct and subtle effect on the system of 
interest, for example the cardiovascular system. The zebrafish has many desirable 
features which allow assessment of the organ development, providing a possible 
model of programming. As GC modulation is one of the most well characterised 
models of programming, this approach will be used to test the zebrafish as a 
programming model 
1.14 PhD hypothesis  
Modulation of embryonic GC function will result in direct effects on the structure 
and function of the developing cardiovascular system leading to long-lasting 
structural, functional and molecular changes in the adult.  
1.15 PhD aims 
 To characterise the GC system in the embryonic and adult zebrafish to 
confirm the suitability of this species as a model of GC modulation. 
 To investigate classical mammalian programmable features (development, 
stress response and behaviour) in the zebrafish embryo (up to 120 hpf) and 
adult (up to 120 days post fertilisation (dpf)) after GC manipulation. 
 To investigate programmable features of the cardiovascular system in the 
zebrafish embryo and adult after GC manipulation. 
1.16  Experimental plan 
The experimental work described in this thesis was designed to determine the 
suitability of the zebrafish as a programming model, by manipulating the embryonic 
environment (either by pharmacological or molecular means) during early stages of 
development (from fertilisation up to 120 hpf) and then assessing the long-term 
impact of this early-life environmental change in adulthood (120 dpf). At both 
embryonic and adult phases a number of parameters were assessed such as growth 
and development, HPI axis function, gene expression, behaviour and cardiovascular 
structure and function. More detail about specific assays will be given in the relevant 




Chapter 2 Materials and methods 
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2 Materials and methods 
2.1 Materials  
Unless stated otherwise all solvents were purchased from BDH (VWR, 
Leicestershire, UK) and were of analytical reagent grade. All pharmacological agents 
were purchased from Sigma Aldrich Company Ltd (Dorset, UK). 
2.2 Zebrafish maintenance  
Zebrafish of the wild type (WIK) (obtained from University College London, UK), 
transgenic cardiac myosin light chain 2: green fluorescent protein 
tg(CMLC2:GFP)(Burns et al 2005)(obtained from Harvard University, Boston, 
USA) and the transgenic friend leukaemia integration 1 transcription factor 
(FLi1):enhanced green fluorescent protein tg(FLi1:EGFP) (Lawson & Weinstein, 
2002) (obtained from University of Sheffield, UK) lines were housed in the QMRI 
(BRR) zebrafish facility and maintained under standard culture conditions, with a 
14h light and 10h dark cycle, at 28.5
o
C, as recommended by (Lawrence, 2007). 
2.2.1 Embryo maintenance 
All procedures for embryos were carried out on eggs and larvae up to a maximum of 
120hpf, in accordance with Home Office regulations. Age of embryos was 
determined according to the commonly accepted staging protocol of Kimmel et al. 
(Kimmel et al, 1995). Embryos were stored in 30 mL Petri dishes at a density of <50 
embryos (~1.5 embryos/ mL) and housed in an incubator at 28.5
o
C. All embryos 
used in this current work were on a no feeding regimen as nutrient supply before this 
age is reliant on yolk sac reserve. For “grow-up” experiments and for general 
breeding of lines, the feeding regimen began at 5 dpf (according to Home Office 
guidelines) when embryos were transferred to 1 L larval raising tanks. 
2.2.2 Adult maintenance 
All procedures on adult zebrafish were carried out in accordance to Home Office 
regulations, following approval by the local Ethical Review Committee. Adult fish 
were staged according to Parichy et al (Parichy et al, 2009). Health screens were 
carried out according to BRR guidelines and animals which were deemed unwell or 
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of detrimental health (impaired swimming, emaciated, egg associated oedema) were 
disposed of humanely. Adult zebrafish were housed in 10 L tanks at a density of 2-3 
fish per L (maximum of 30 fish per tank). 
2.3 Light microscopy 
All visual observations were carried out using a Leica Stereomicroscope MZ16F 
dissecting microscope. All light microscopy images were obtained using standard 
white light, whilst fluorescent (GFP, EGFP, DAPI, Texas red and mCherry) images 
were produced by using UV mercury bulb with an appropriate filter. Photographic 
images were collected using an attached Leica Camera (DFC320FX). 
2.4 Zebrafish embryo studies 
2.4.1 Embryo collection  
Following onset of light cycle, adult (sexually mature) zebrafish initiate spawning 
and fertilisation of eggs in desirable environmental conditions (Westerfield, 2000). 
Containers with marbles were placed into the bottom of tanks prior to onset of the 
light cycle to encourage spawning and prevent predation/cannibalism by adult fish 
(Lawrence, 2007), whilst also allowing ease of egg removal. Collected eggs were 
stored in systems water (6g salt, Tropic Marin® Wartenberg, Germany) in 20 L of 
in-house deionised H2O) with 0.5 mg/L of the antiseptic methylthioninium chloride 
(methylene blue). All unfertilised eggs were discarded and the remaining healthy 
fertilised eggs were scored according to Kimmel et al (Kimmel et al, 1995). Embryos 
> 8 cell stage (~2 hpf) were also discarded. 
2.4.2 De-chorionation of embryos 
Although spontaneous hatch-rate was monitored for developmental assessment in a 
number of cases manual de-chorionation was required. This is a simple procedure 
consisting of gently teasing apart the chorion, using fine Dumont 5# forceps, and 




2.4.3 Scoring of embryonic phenotypic characteristics  
To assess the influence of environmental, pharmacological or molecular 
manipulation on the developing zebrafish embryos, gross morphology was observed 
under a dissecting light microscope (x10 (Section 2.3)). For each manipulation used 
in this study, determination of suitable non-teratogenic concentrations was achieved 
by embryonic exposure from 2 hpf to a dilution series of the drug, the vehicle and a 
negative control, or in the case of molecular manipulation; Mo and their relevant 
controls. 
Mortality and the presence of malformations were assessed for each concentration 
and time point of development, in incidences where high drug or Mo concentrations 
were used this has been determined as a concentration for which no malformations or 
lethality were observed in the first 24 hpf in at least 90% of the individuals in three 
consecutive experiments. 
A scoring system was devised where a number of abnormal physical characteristics 
were assessed: pulmonary and pericardial swelling/ballooning, tail deformities such 
as truncated coiled or bending; blood pooling, altered heart rate and small /deformed 
heads. Normal embryos were determined subjectively compared to controls, head 
size and body axis were assessed according to the Kimmel paper (Kimmel et al, 
1995) with normal heart rate of around 150bpm and no detectable blood pooling 
(Figure 2.1). The number of normal factors was determined for embryos; a score was 
assigned with regard to severity of phenotype, with 6 representing normal and 1 a 
severe phenotype as detailed in table 2.1 (examples are shown in Figure 2.1). 
Table 2.1 Classification of zebrafish embryo morphological characteristics 
Embryos were scored according to a number of normal factors. Normal factors were 
as follows, normal head size, straight body axis, normal heart rate (HR), blood 
present within the heart, no pooling of red blood cells and normal tail circulation. 
 









Figure 2.1 Normal and abnormal zebrafish larvae appearance 
Normal appearance 96 hours post fertilisation (hpf) embryo shown in the upper panel with 
some of the abnormal features shown in the bottom panel. Normal features highlighted 
include eye size (E), location of heart (H), typical appearance of yolk sac (YS) at 96hpf, 
inflated and detectable swim bladder (SB) and the straight tail (T). Features highlighted as 
abnormal are pin head (PH), small eyes (SE), pericardial oedema (PO), yolk sac oedema 
(YSO), yolk sac extension oedema (YSEO), tail axis abnormalities (TA). Scale bars 
represent 0.5mm. 
 
2.4.4 Embryonic manipulation 
2.4.4.1 Embryonic pharmacological manipulation 
Embryos from the 2 cell stage to 120 hpf were exposed to a number of 
pharmacological agents at varying concentrations. Drugs of interest which were 
investigated were as follows: the GR agonist Dex, the GR (and progesterone receptor 
(PR)) antagonist RU486 (also known as mifepristone), the 11β-hydroxylase inhibitor 
metyrapone (Met) the 11β-hydroxylase substrates 11-deoxycorticosterone (Doc) and 
11-deoxycortisol (Doxy), and the zebrafish MR agonist spironolactone (Scott et al, 
2005). All drug optimisation is described in Appendix 1. Unless stated otherwise a 
standard drug exposure protocol was used for each drug of interest. Groups of 30 
embryos were placed in Petri dishes containing 30 mL of systems water. Embryos 
64 
 
were exposed to the drug solution continuously up to 120 hpf and drugs were 
replaced daily. 
2.4.4.2  Embryonic genetic manipulation  
Genetic manipulation of embryos was carried out by Mo antisense gene knock-down 
(Heasman, 2002; Summerton, 1999) targeted towards the genes encoding cyp11b1 
and gr. Mo were purchased from GeneTools (Philomath, Oregon, USA) 
(http://www.gene-tools.com) designed specifically to the zebrafish cyp11b1 and gr 
gene sequence. Mo design and region targeting is explained in more detail elsewhere 
(Moulton & Yan, 2008). For each gene three 25mer Mo sequences were produced: 
1) Translational blocking Mo, which is targeted to the ATG start codon, 
preventing ribosomal assembly and mRNA production (referred herein as 
atg-Mo). 
2) Splice site specific Mo which is targeted to pre-mRNA across or near exon-
intron boundaries inhibiting splicing, resulting in exon excision and shortened 
or truncated mRNA (referred to herein as ss-Mo). 
3)  5-Mispair Mo with an almost identical sequence to the ss-Mo but with a 
number of mismatched base pairs throughout the course of the sequence. This 
oligo sequence controls against off-target effects which may be introduced by 
high concentrations of antisense molecules (referred to herein as mm-Mo). 
 
The sequences of all Mo are shown (Appendix 1). For cyp11b1 Mo all sequences 
designed have 3’ modifications of carboxyfluorescein, a green emitting fluorescent 
tag; for GR Mo all sequences designed have a 3’ modification of lissamine, a red 
emitting fluorescent tag. These 3’ modifications allow visualisation of morpholino 
uptake following microinjection  
2.4.4.2.1 Morpholino microinjection 
Microinjection is a fast, high throughput technique for injection of synthetic 
oligonucleotide sequences into newly fertilised eggs at the 2-8 cell stage. 
Microinjection was carried out as described by Nusslein-Volhard et al. (Nusslein-
Volhard & Dahm, 2002). To summarise, injection needles with an inner diameter of 
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0.1mm were pulled from glass capillary tubes (borosilicate glass 1.0mm O.D x 0.78 
mm I.D from Harvard Apparatus, Kent, UK) with care using a micropipette puller 
(P-97 Flaming/Brown Micropipette Puller from Sutter Instruments (Novato, CA, 
USA)). For needles used here the following ramp features were deemed optimum, 
heat 450, pull 85, velocity 55 and time 150. Due to the buoyant nature of the 
embryos, 2% agar (melted in H2O) microinjection plates were used to line up and 
hold embryos in an appropriate injection position with sufficient water surrounding 
the embryos to prevent dehydration and to provide surface tension. 
The Narishige IM-300 programmable micro-injector was set up and the needle was 
loaded with approximately 3 µL of morpholino (diluted to appropriate concentration 
as shown in Appendix 1). A calibration injection onto mineral oil over a graticule 
slide was carried out, which allowed the measurement of bolus sphere diameter. 
From the radius (r) of this bolus, the volume of injection was calculated as below so 
that the amount of morpholino to be injected could be accurately determined (normal 
injection volume was 5 nL). When injector pressure and bolus size were optimal the 
needle was inserted through the chorion into the yolk sac of the embryo below the 
cell mass, where, if accurately injected, the morpholino was taken up into the 
cytoplasm of the newly forming cells through a process known as cytoplasmic 
streaming. Optimisation of morpholino dosage is shown in Appendix 1.  




2.4.5 Embryonic developmental assessments 
A number of assessments were carried out through the course of 120 hpf to 
determine whether manipulation had any impact on development. 
2.4.5.1 Hatch rate, embryogenesis, body length and growth rate 
The normal window of spontaneous chorion hatching occurs between 48 and 72 hpf, 
the rate of which embryos hatched in embryos manipulated pharmacologically or 
genetically was monitored at 24h intervals over 120 hpf to determine whether 
treatment increased or decreased the rate at which hatching occurs. The total number 
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of embryos hatched was expressed as percentage of the surviving population at a 
given time point. 
Body length, growth rate and embryogenesis at a given time were determined on 
embryos which had been manually de-chorionated (as described in section 2.4.2) and 
imaged. All images were captured using a Leica Stereomicroscope MZ16F dissecting 
microscope with a Leica camera (DFC320FX), as described in section 2.3, then 
quantitatively analysed using ImageJ software. 
2.4.5.1.1 Head-trunk angle 
Head-trunk angle was used as a marker of global developmental during normal 
zebrafish embryogenesis from 20 to 70 hpf. The head-trunk angle (in degrees) 
increases uniformly as a result of the body straightening shown in technique 
optimisation (Figure 2.2) and as previously described (Kimmel et al, 1995). Using 
still images obtained at 10X magnification the head trunk angle is the angle obtained 
by drawing a line through the middle of the head connecting the eye and ear, a 
parallel line is then drawn through the notochord; the angle is obtained at the point 
which these lines cross (as shown in Figure 2.2). 
 
Figure 2.2 Assessment of embryonic head-trunk angle 
A) A) Head trunk angle measurement example. B) Head trunk-angle throughout the first 72 
hours post fertilisation (hpf) of zebrafish development; data are mean ± SEM for control 
embryos throughout development (n=4; (10 embryos per experiment)). 
  


































2.4.5.1.2 Total body length 
Total body length was also determined from still images at x20 magnification. 
Images were analysed using a method previously described (Kimmel et al, 
1995)(Figure 2.3). For each length measurement time was also recorded allowing 










2.4.5.2 Eye length and area 
Further developmental assessment and determination of craniofacial abnormalities 
following manipulation was carried out by determining eye length relative to body 
length. For this 30x magnification images were captured as in section 2.3, and the 
length (b) and width (a) of the eye was determined using ImageJ software. From this, 
eye area was determined using the following formula. 
Equation 2.2 Eye area 
 
2.4.5.3 Embryo swim activity 
Embryonic swim activity was observed at 72 and 120 hpf through open-field 
observations as previously described (Levin & Cerutti, 2009). Briefly, a single 
embryo was placed in a 5cm Petri dish delineated into three evenly spaced concentric 
rings, described as inner, mid and outer regions. Each embryo was introduced into 
















Figure 2.3 Assessment of embryonic length with time 
Total body length (mm) throughout the first 120 hours post fertilisation (hpf). 
Data are mean ± SEM for control embryos throughout development (n=4; 10 
embryos per experiment)). 
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the mid region of a marked dish containing 3 mL of fresh systems water. Embryo 
movements were recorded from above using a digital CCTV camera (Baxall, AD 
group, UK). Data were analysed by commercially available software (Limelight Ltd, 
UK) to determine total distance travelled, percentage of time spent in each region of 
the Petri dish and average speed of movement for each embryo (n=12 embryos per 
group). 
2.4.5.4 Embryo movement 
At 48 hpf all movements produced by the embryo are in the form of random 
twitching rather than coordinated locomotor activity. The influence of 
pharmacological or genetic manipulation on this phenomenon was determined by 
placing 20 embryos into a 5cm Petri dish. The embryos were then filmed at 10x 
magnification for 5 min using a digital CCTV camera (Baxall, AD group, UK). The 
mean number of twitches recorded for the group in the footage was counted using 
slow speed play back. 
At 96 hpf coordinated muscular movement is usually present in response to touch 
stimulus. Here embryos were touched gently with Dumont #5 forceps; if embryos 
swim to remove themselves from the stimulus this was scored as a swim=1, if no 
movement was detected this was recorded as a no swim=0. A group cumulative score 
was produced. N=5 experiments (10 embryos per experiment). 
2.4.6 Vascular formation analysis 
tg(FLi1: EGFP) embryos were used to determine the influence of GC on vascular 
formation. In this transgenic line enhanced green fluorescent protein (EGFP) is 
expressed by the fli1 transcription factor, this is expressed in cells of presumptive 
haemangioblast lineage and allows vascular visualisation (Lawson & Weinstein, 
2002b)(Figure 2.4). 
2.4.6.1 Intersegmental vessel number 
Normal intersegmental vessels (ISV) were considered to be vessels which expressed 
GFP, joined the aorta to the dorsal longitudinal anastomotic vessel (DLAV) and were 
not branched in appearance (Figure 2.4). Under a fluorescent microscope (40 x) 
normal ISV were counted dorsally from the yolk sac throughout the length of the tail, 
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within a similar focal plane. The number of complete ISV crossing completely 
between the two primary vessels un-branched was determined at 48, 72, 96 and 
120hpf. Embryos were maintained in 24 well plates with 2 mL of incubation 
solution, to allow observation throughout development. 
2.4.6.2 Vascularisation index 
On images obtained at 40 x magnification a region of 5 somites was selected in the 
tail dorsally from the yolk sac. Here 3 parallel lines were drawn using ImageJ 
software. The number of vessel intersections were then counted and the sum of these 
counts was then plotted to produce the vascularisation index of the embryos as 
described elsewhere (Pelster et al, 2003)(Figure 2.4).  
  
 
Figure 2.4 Representative image of tg (FLi1: EGFP) zebrafish embryo.  
Vasculature in a 96 hour post fertilisation (hpf) zebrafish embryo, visible as a result of 
enhanced green fluorescent protein (EGFP) expressed under the control of the fli1 
transcription factor. Intersegmental vessels (ISV) can be observed between dorsal 
longitudinal anastomotic vessels (DLAV) and aorta. High magnification of the region 
highlighted with a red dashed square shows the distance between vessels (yellow lines), 





2.4.7 Cardiac assessment 
tg(CMLC2: GFP) embryos were used to determine the influence of GC on cardiac 
formation. In this transgenic line green fluorescent protein (GFP) is expressed under 
the control of the CMLC2 promoter resulting in green hearts when observed under 
fluorescent microscope (Figure 2.5) 
2.4.7.1 Heart removal from tg (cmcl2: GFP) embryos 
tg(CMLC2:GFP) (Figure 2.5), embryos at 120 hpf were euthanized by anaesthetic 
overdose (neat MS-222) and then fixed in 4% paraformaldehyde (PFA) overnight at 
4
o
C, washed 3 times with 1x Phosphate Buffered Saline Tween-20 (PBST) and then 
stored in absolute methanol at -80
o
C until required. Following storage, methanol was 
removed from embryos which were then washed 3 times with Phosphate Buffered 
Saline (PBS) in preparation for heart removal. 
Hearts were removed either manually by pinching the heart (under a fluorescence 
microscope) above the yolk sac using fine forceps (Dumont #5) and gently teasing it 
out, or using a mechanical disruption procedure. The mechanical procedure was 
adapted from a previously published protocol (Burns & MacRae, 2006). Briefly, 
embryos were pooled in a 1.5 mL Eppendorf tube and a 19 gauge needle with regular 
bevel attached to a 5 mL syringe was inserted and repeatedly plunged (30-40 times) 
to homogenise the embryos. The resulting homogenate was filtered through a 105µm 
nylon mesh, the perfusate was collected and GFP positive hearts were selected under 
fluorescent microscope (Figure 2.5). Isolated hearts were stored in RNAlater (Life 
Technologies, Paisley, UK) for PCR (see gene analysis section 2.6), fixed again in 
4% PFA for histology (see histology section 2.8) or quickly frozen by placing on dry 
ice. 
2.4.7.2 Assessment of cardiomyocyte number 
PFA-fixed isolated hearts were incubated in 200 µL DAPI (1/1000 with PBS) for 1h 
at room temperature then washed in PBS for 1h at room temperature under gentle 
agitation. The hearts were then mounted on microscope slides in Flouromount-G 
(Southern Biotech, Birmingham, USA) and imaged using confocal microscopy 
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(Leica SP5 confocal). Z stacks were produced at intervals of 2-5μM, and collected 
using the supplied Leica software.  
Tiff images were analysed using ImageJ software and the number of DAPI positive 
cells (those DAPI marked cells within the GFP area) were counted using a cell 
counter plugin. This software allows analysis of Z-stack images while tracking 
previously-counted cells, thus preventing duplication. To eliminate the possibility of 
erythrocyte, atrial or bulbus arteriosus cell staining only cells which were double 
stained (green and blue) were considered. To accurately count cells, intra and inter 
operator counts were analysed (see statistical section 2.10). Each heart was counted 3 
times on separate days and a mean was taken. 
 
Figure 2.5 Representative image of tg (CMLC2:GFP) zebrafish embryo 
A) 96 hours post fertilisation (hpf) zebrafish embryo under UV light; fluorescence is due to 
GFP expression under the cardiomyocyte light chain 2 (CMLC2) promoter which is highly 
expressed in the heart of the zebrafish. Some key structures have been highlighted: eye (E), 
bulbus arteriosus (BA), ventricle (V), atrium (A) and the yolk sack (YS). A) image of 
ventricle in zebrafish embryo. B) isolated 120 hpf zebrafish embryonic hearts with 
fluorescent ventricles the bulbus arteriosus (BA) is highlighted for orientation. (Scale bar is 
50µm). 
2.4.7.3 Cardiac functional assessment 
tg(CMLC2:GFP) embryos (Figure 2.5) were used to determine the influence of 
manipulation on heart structure and function. Hearts were visualised under 
fluorescence using an Axioskop II MOT compound microscope with a (X40) dipper 
objective lens. Images were captured throughout the course of the cardiac cycle using 
a black and white camera connected to a computer. Videos were processed using 




files into a number of frames. These still images were opened in ImageJ software for 
further assessment.  
The ventricle was assessed for diastole and systole throughout three cardiac cycles. 
The outer side of the ventricle was outlined using the draw ellipse feature at the 
maximum during the cardiac cycle -the end diastolic area (EDA) and the minimum-
end systolic area (ESA). These data were used to calculate the ejection fraction using 
an area subtraction method. 
Equation 2.3 Ejection fraction 
 
Further measurements were obtained using the images. The ventricular width (a) and 
length (b) were determined using the line utility. These data were then input into the 
formula for prolate spheroid to calculate ventricle volume (µl
3
) during systole and 
diastole. 
Equation 2.4 Ventricle volume 
 
The difference between diastolic and systolic volume enables calculation of stroke 
volume (the volume of blood pumped by the ventricle per cardiac cycle). 
Equation 2.5 Stroke volume 
 
Heart rate was measured by timing 15 heart beats and then calculating the number of 
beats per minute (bpm). Bpm were then combined with the stroke volume to 
calculate cardiac output. 





2.4.7.4 Assessment of cardiac morphology 
Alterations in cardiac morphology as a consequence of manipulation were measured 
by determining the distance between two regions of the heart -the sinus venosus 
(SV), the region of blood inflow to the heart, and the bulbus arteriosus (BA) the 
outflow from the ventricle by using the straight line function in ImageJ software. The 
measured length (µm) was then normalised by body length (mm)(Antkiewicz et al, 
2005). 
2.4.7.5 Assessment of pericardial oedema 
As oedema is often a feature of cardiac morphological or functional defects, the area 
of oedema was also determined. Here the area between the yolk sac and the jaw and 
the outer pericardial tissue was traced using lateral images and ImageJ software, and 
the freehand trace tool. The area contained within this freehand trace was calculated. 
For each fish three traces were determined on separate occasions, a mean of the three 
measurements was then produced for each embryo. 
2.5 Adult zebrafish studies 
2.5.1 Adult fish anaesthesia 
Fish were moved from 10 L holding tanks to small 1 L tanks containing 4.2% v/v 
MS-222 and left until equilibrium was lost (fish float on side), operculum movement 
slowed and fish did not respond to touch stimuli. When satisfactory anaesthesia was 
achieved fish were removed from water and placed in a moistened sponge for either 
visual observation under dissecting microscope, tail resection or morphometric 
analysis. Period and frequency of anaesthesia was kept to a minimum in accordance 
with Home Office guidelines. After procedure fish were placed in a recovery tank of 
systems water at 28.5ºC. Fish were monitored during recovery and when satisfactory 
operculum movement and swim activity were observed fish were returned to holding 
tank. 
2.5.2 Adult fish culling 
Adult fish were culled according to Home Office guidelines for Schedule 1B. Adult 
fish were added to an appropriated volume of neat MS-222 to give anaesthetic 
overdose. Fish were left until equilibrium was lost, operculum movement had 
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completely ceased and no response to touch was noted. From here Home Office 
schedule 1 culling procedures were followed to destroy brain function: decapitation 
anterior to the gills using a sharp scalpel blade. 
2.5.3 Adult morphometric assessments 
Adult fish were weighed as follows. A 500 mL beaker of systems water was placed 
on a balance, the balance was then set to zero. Fish were individually collected from 
10 L holding tank using a net, excess water was removed by briefly dabbing the net 
on a paper towel. The fish was then gently transferred to the weighing balance 
beaker. Measurements for all fish were taken in triplicate, and results displayed as a 
mean per fish. 
Adult fish length was determined from anaesthetised fish (to prevent undue stress). 
When suitable anaesthesia was achieved, fish were placed laterally on a moistened 
sponge. Digital callipers (Digital Electronic Vernier Calliper (0-150 mm) Sealey) 
were then used to measure the total body length anterior to posterior (not including 
tail fin rays). After satisfactory measurements fish were transferred to the recovery 
tank. The fish length and weight data were then used to calculate the condition factor 
(Siccardi et al, 2009). 
Equation 2.7 Condition factor 
 
2.5.4 Adult fish dissection and tissue harvesting 
Adult fish were culled as in section 2.5.2 and placed, ventral side up, on a moistened 
sponge, adult tissue was removed in an adapted protocol (Gupta & Mullins, 2010) . 
2.5.4.1 Heart removal 
As head was removed by decapitation, gills were pulled aside to expose the heart, 
using fine forceps; the heart (ventricle, atrium and the BA) was removed by gently 
pinching above the BA. For RNA extraction beating hearts were transferred to ice 
cold PBS to remove some of the blood which is known to be protease rich. For 
histology hearts were fixed in neutral buffered formalin overnight at 4
o
C then rinsed 
3 times in PBS. After this they were stored in methanol until required. Hearts were 
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weighed on a microbalance (analytical semi-micro balance, Denver) by adding the 
tissue to an Eppendorf of known weight. Heart lengths were determined by placing 
them on an agar lined Petri dish and capturing images using a Leica 
Stereomicroscope MZ16F dissecting microscope with a Leica camera (DFC320FX). 
Heart length was determined using ImageJ software. 
2.5.4.2 Liver and gut removal 
After heart removal, a cut was made ventrally from cloaca to gills. The skin of the 
peritoneal cavity was then removed to expose liver and gut. Due to the lobular nature 
of the liver, some liver tissue may be entwined with the gut; when this occurred the 
gut tissue was teased out to clearly display the tan coloured vascularised tissue of the 
liver. Great care was taken to not puncture the gut which contains numerous RNases. 
Liver tissues were collected and stored in 1 mL of RNAlater to stabilise tissue, this 
was left at room temperature overnight and then stored at -20
o
C until RNA 
extraction. 
2.5.4.3 Kidney removal 
After gut removal, ovaries or testes were then removed from female and male fish, 
respectively. The swim bladder was then removed, by pinching the inflated region 
just posterior to head with forceps and gently pulling towards the tail. Removal of the 
swim bladder exposes the kidney (including head kidney and interrenal gland) which 
is located along the dorsal body wall and can be removed. The translucent, faintly 
pink coloured kidney structure is teased away gently from the vertebrate of the spine.  
2.5.4.4 Smooth muscle removal 
Smooth muscle was dissected by de-scaling a region of the tail and removing bones 
to expose pink coloured muscle tissue. 
2.5.4.5 Brain removal 
The brain was removed by breaking open the skull and simply teasing out the lobed 
milky white tissue within. Due to the site of decapitation, the cerebellum and medulla 
were often found in the body section and were teased out using fine forceps (Dumont 
#5). Isolated brain tissue was stored in RNAlater for PCR investigation.  
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2.5.5 Adult blood glucose measurements 
Blood glucose was determined using a commercial blood glucose meter (Freestyle 
freedom lite blood glucose monitoring system) with Freestyle lite blood glucose test 
strips, as directed by manufacturer’s instructions. To acquire sufficient blood, this 
was a terminal procedure and blood was removed from fish which had been culled, 
blood collection was by exsanguination and blood placed directly on the blood 
glucose strips. 
2.5.6 Adult behavioural assessments 
Of the numerous zebrafish behavioural assays described (Levin & Cerutti, 2009) 
three were used in the current work (schematics shown in Figure 2.6). These were 
open-field, forced swim and novel object assays. For each assay fish were transferred 
from the 10 L holding tank into the observation tank by netting. The test tank 
contained fresh, temperature-controlled water which was replaced for each fish 
monitored. After the assay the fish were netted from the observation tank and 
transferred to a new 10 L tank (post observation tank). Room temperature was 
monitored throughout the assay, with light and ambient noise controlled. 
2.5.6.1 Forced dive swim assay 
Zebrafish were placed individually in a 1.5 L trapezoidal tank (15.2 height × 27.9 top 
× 22.5 bottom × 7.1 width (cm).) The tank was filled ¾ with fresh 28.5ºC systems 
water. This tank was illuminated from above using a standard angle poise desk lamp 
and from below by placing the tank on a light-box (X-Ray MG-7 Standard 17'' X 14'' 
Illuminater Light Box, Wolf). The CCTV camera was mounted laterally to capture a 
side view of this tank (as indicated in Figure 2.6). Limelight software was used to 
divide the tank into two equal horizontal portions. The fish was then placed in the 
tank and the behaviour was recorded over a 5 min period. Total distance, zone 
crossing, time spent in each region and the average velocity were recorded to 
determine the boldness of fish. Generally fish will spend longer at the bottom of a 




2.5.6.2 Open-field assay 
The open field test consisted of transferring a single fish from the holding tank to the 
centre of a square tank (15x15cm) the tank contained 28.5ºC systems water to a 
depth of 3 cm ~ 1.5 L. The tank was lit from below using a light box, light from 
above was provided by a desk lamp. To minimize interference or disturbance a 20cm 
box surrounded the edges of the tank. A CCTV camera was suspended above the 
tank for recording movement within the test area. Limelight software was used to 
record and analyse behaviour. The software delineates a 3x3 (21 cm
2
) square grid 
arena and over the course of 5 min records the movement within the tank. For each 
fish introduced to the observation tank the total distance travelled, number of grid 
crossings, time spent in each area and the average velocity were calculated.  
2.5.6.3 Novel object assay 
The same tank and camera set up as for the open-field assay was used for novel 
object assay. However, in this assay a novel object (aquarium enrichment ornament, 
Pets at home, UK wide) was used to represent a predator. The novel object was 
placed in the centre of the tank and Limelight software was then used to delineate the 
tank into two regions, the central region (predation area) containing the novel object 
(plus a 2 cm border) and the rest of the tank (avoidance area). The time spent in 
either the predation or the avoidance area was recorded over a 5 min period. This test 
is another method for determination of the boldness of a fish, with the longer spent in 













Figure 2.6 Schematic representation of experimental set up for behavioural assays 
Shown are dive, open-field and novel object behavioural assays. For each assay, dorsal and 
lateral views are shown to illustrate the experimental set-up. For dive and open-field assays 
typical zebrafish software traces are shown. For the novel object assay, the predator/novel 
object (aquarium enrichment ornament) is shown. 
2.5.7 Tail fin regeneration 
To determine whether there was any difference in regenerative capabilities between 
embryonically-manipulated adult groups, a tail fin regeneration assay was carried 
out. To visualise and image blood vessels, adults of the tg(FLi1: EGFP) line were 
used and anaesthetised as described (section 2.5.1). Fish were placed, lateral side up, 
on a Petri dish, tails fin rays were gently spread out and images of tails pre 
amputation were recorded using light microscopy. Using dissection scissors and fine 
forceps, tails were lifted from the Petri dish surface and a single vertical cut was 
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made perpendicular to the fin rays. Dissected tail sections were retained for further 
analysis. Images of the tail were then recorded post-amputation. Fish were placed in 
a recovery beaker post amputation and, following recovery, were housed singularly 
and tail regrowth monitored over 30 days. Regrowth was calculated relative to total 
body length. 
2.5.7.1 Assessment of tail-fin vascular patterning  
Determination of tail vascularisation in adult zebrafish was carried out as previously 
described (Pugach et al, 2009) and the fish were euthanized (section 2.5.2) at the end 
of the procedure. Briefly, following administration of anaesthetic overdose fish were 
placed dorsal side upwards and facing to the right on a slotted sponge. A Hamilton 
syringe was filled with 4 µL of 10 mg/mL 70kDa dextran, Texas Red ® dissolved in 
PBS. With the bevel facing upwards the needle was positioned such that if the fish 
eye were a clock the needle would be pointing at the 7 o’clock position at a 45-65 
degree angle to the fish. The needle was gently inserted and the plunger was 
gradually depressed. After around 5 min, the dye can be discerned in the tail 
vasculature of the fish (Figure 2.7). 
  
Figure 2.7 Assessment of tail-fin vascular patterning.  
Shown are white light and fluorescent 10X magnification images of the tail fin region 
of adult tg (FLi1: GFP) fish. Higher magnification images are shown of the GFP 
expression in tail ray fins, with 70kDa dextran injections and a merge of the two 
images to show blood flow within ray fins of the tail. 
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2.6 Gene abundance study 
Gene nomenclature used throughout will be as follows (unless highlighted in text),  
Example, glucocorticoid receptor  
GR, human (Homo sapiens) GR gene isoform, protein designation GR 
Gr, rodent (Mus musculus, Rattus norvegicus) GR isoform; protein designation GR 
gr zebrafish (Danio rerio) GR gene isoform, protein designation Gr 
2.6.1 Ribonucleic acid (RNA) extraction 
Multiple methods for total RNA extraction were used as some methods were found 
to yield higher mRNA concentrations in a tissue specific manner. 
2.6.1.1 Whole embryo ribonucleic acid (RNA) extraction 
In whole embryos the RNeasy Mini Kit (Qiagen, Crawley, West Sussex, UK) was 
used to extract RNA from pooled embryos (<48hpf, 20 embryos; >48hpf, 10 
embryos). Tissue was homogenised in Buffer RLT (provided with kit) using a bead 
mixer mill (3 min at 15Hz) immediately prior to RNA extraction according to the 
provided manufacturer’s protocol for RNA extraction from animal cells. 
2.6.1.2 Embryonic heart ribonucleic acid (RNA) extraction 
Total RNA was extracted from isolated embryo hearts (see heart isolation protocol 
section 2.4.9.1). 100 hearts from 120 hpf embryos were pooled. Here an RNeasy 
Micro Kit (Qiagen, Crawley, West Sussex, UK) was used as per manufacturer’s 
protocol for RNA extraction for cultured cells. 
2.6.1.3 Adult tissue ribonucleic acid (RNA) extraction 
Total RNA was isolated from adult organ tissue (see section on adult organ 
dissection section 2.5.4) by addition of TRIzol ® reagent (Invitrogen Ltd, Paisley 
UK) and subsequent homogenisation in a bead mixer mill. RNA was then extracted 
from the resultant homogenate according to manufacturer’s directions. 
2.6.2 Ribonucleic acid (RNA) quantity 
RNA quantity was determined using a Nano-drop ® spectrophotometer ND-1000 
(Fisher Scientific, Loughborough, UK) to determine extracted RNA concentration at 
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260nm (molar extinction coefficient 40ng-cm/µL). RNA integrity was verified by a 
260/280 nm absorbance ratio of ~2. 
2.6.3 Ribonucleic acid (RNA) quality 
To further determine the quality of RNA a 1 % agarose gel was produced using 0.5X 
Tris/Borate/ethylenediaminetetraacetic acid (EDTA) (TBE) solution (5 x solution 
54g Tris base, 27.5 g boric acid, 20 mL of 0.5 M (pH 8) u to 1 L with distilled water 
(ddH20)) and GelRED reagent (Invitrogen, Paisley, UK). The gel was then run in a 
standard horizontal gel electrophoresis tank at 80 volts for 1 h using molecular 
weight ladders (18S and 28S Ribosomal RNA from calf liver, Sigma Aldrich, Poole, 
UK) for identification of 18S and 28S RNA Bands under a UV light transilluminator 
in the GelDoc gel imaging system (BioRad, Hertfordshire) using associated software 
(Image Lab™ Software, BioRad, Hertfordshire). These bands correspond to the 28S 
and 18S ribosomal subunits and are found in a ratio of 2:1 (28S:18S) in eukaryote 
samples, such as zebrafish (Peterson & Freeman, 2009). 
2.6.4 Ribonucleic acid (RNA) clean-up 
Samples which were found to have gDNA contamination (appearing as a smear on 
the RNA gel) were treated with DNA-free ™ kit (Applied Biosystems, Warrington, 
UK) to eliminate possible DNA presence. The protocol was followed as per 
manufacturer’s instructions using 40 µL RNA, 4µL 10x DNase buffer-1 and 4µL 
DNase inactivation Reagent. RNA was re-analysed as before (sections 2.6.2 and 
2.6.3) to determine successful DNA removal. 
2.6.5 Ribonucleic acid (RNA) reverse transcription 
RNA (0.5µg) was reverse transcribed into cDNA using the High capacity cDNA 
Reverse Transcription Kit (Applied Biosystems, Warrington, UK) according to 
manufacturer’s guidelines using 10 µL 2x RT Master Mix (provided with the kit) and 
10 µL RNA (0.5 µg total RNA). A no enzyme control was also included to assess 
reverse transcription activity and demonstrate that there is no genomic DNA (gDNA) 
contamination within the sample. The following reverse transcription conditions 
were used, 25
o
C for 10 min, 37
 o
C for 120min, 85
 o






2.6.6 Polymerase chain reaction (PCR) primer design 
Gene of interest nucleotide sequences were obtained by searching Ensembl Genome 
Browser, zebrafish database. Here transcript sequence and accession number were 
obtained. This gene information was then used to design appropriate oligonucleotide 
primer pairs. Primer design is a key determinant of PCR success, without a 
successful primer set PCR products are not produced. Real-time PCR primers were 
designed using free online Primer3 software through insertion of gene of interest 
nucleotide sequence or accession number. This software takes into consideration 
three main criteria 1) primers should contain between 40-60% of the nucleotide bases 
guanine (G) or cytosine (C), with minimal clusters of the two bases together 2) 
primers should be 20-40 base pairs in length and not self-complimentary 3) primer 
melting temperatures (Tm) should be no more than 5
o
C different and around 65-70
 
o
C. For qRT-PCR, primers were designed using the Universal Probe Library Assay 
design online software (Roche Diagnostics) by insertion of the gene name or 
accession number into the zebrafish database. Here primer pair sequences were 
produced along with the complimentary UPL probe, with multiple assays described 
ranked in order of criteria success. After primers (either RT-PCR or qRT-PCR) were 
designed the sequences were then checked using BLAST software, which checks the 
alignment of a nucleotide sequence against all sequenced zebrafish genes. All primer 
pairs were purchased as lyophilised powders from Sigma-Aldrich and were 
reconstituted in TE Buffer (10 mM Tris at pH 8.0 with HCl 1 mM EDTA). Assay 
success was determined by using high quality cDNA pooled from either a range of 
aged embryos or from various adult tissues. 
2.6.7 Real time polymerase chain reaction (RT-PCR) 
Real time PCR (RT-PCR) reactions were carried out using PCR Master Mix 
(Promega (www.promega.com)) according to manufacturer’s instructions. For a 20µl 
reaction volume, 10 µL 2x PCR Master Mix, 1 µL of each primer (forward and 
reverse) 6 µL dH2O and 2 µL cDNA were used. The following PCR parameters were 
used for all genes initially: an initial 5min denaturation at 94
o
C followed by 30 
annealing cycles of 94
 o
C for 15 sec, 55
 o
C for 1 min and 72
 o
C for 10 sec and then a 
final extension at 72
 o
C for 5 min. PCR products were run out on a 1.5% TBE 
agarose gel containing 1/10000 (v/v) Gelred ™ Nucleic acid stain (Cambridge 
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Bioscience, Cambridge, UK). The gel was then run in a standard horizontal gel 
electrophoresis tank at 100 volts for 1.5 h using molecular weight ladders 
(QuickLoad © PCR Marker, New England Biolabs) for transcript identification. The 
gel was then observed under a UV light transilluminator in the GelDoc gel imaging 
system (BioRad, Hertfordshire) using associated software Image Lab™ Software, 
BioRad, Hertfordshire, UK). If the assay was unsuccessful (no detectable bands), the 
annealing and denaturing parameters were altered or a small amount of MgCl2 was 
added to the reaction mixture. If these alterations still did not produce bands or bands 
were detected faintly or at the wrong band size, further PCR troubleshooting was 
carried out using the online resource https://www.neb.com/tools-and-
resources/troubleshooting-guides/pcr-troubleshooting-guide 
 
2.6.8 Quantitative real time polymerase chain reaction (qRT-PCR) 
The following procedure was used to quantify numerous genes of interest using the 
LightCycler 480 system (Roche, Hertfordshire, UK). To determine the concentration 
of a given gene in a sample a standard curve was produced. Initial investigation of 
primer success and determination of sample dilution factor was carried out, this 
allows sample amplification to occur within the standard curve, and a dilution factor 
of 1:40 was selected for all tissue samples. As genes are expressed in varying levels 
in early development, a pooled time-course was used to determine the suitability of 
an assay (primer pairs and probe) for detection of the gene of interest. Those deemed 
successful were linear and had an efficiency of between 1.7 and 2.1. The error should 
be as close to 0 as possible, with slight increases allowed, an error greater than 0 is 
likely to be as a result of poor pipetting or problems mixing cDNA and master mix.  
All standards and samples (including controls) were run in triplicate for each gene of 
interest. Probes used were from the Universal Probe Library (UPL) (Roche 
Diagnostics Ltd, UK). To each well 8µl of master mix containing probe and primer 
combination for each gene of interest (recipe for master mix is shown in table 2) was 
added. The plates were thoroughly sealed and centrifuged at 4
o
C for 3 min at 8,000g. 
The LightCycler system was used at the following operating conditions 95
o
C for 5 
min, 50 cycles (95
o
C 10 sec, 60
o
C 30 sec, 72
o
C 1 sec), 40
o
C 30 sec. All 
quantification analysis was carried out using the LightCycler software provided by 
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manufacturer, data produced were through the maximum second derivative method, 
whereby the entire amplification curve is considered rather than just the threshold 
point. For each experiment an appropriate housekeeping gene was run concurrently. 
For each assay, samples were quantified relative to the standard curve to produce a 
concentration in arbitrary units (AU). From here the mRNA concentration for the 
gene of interest was then corrected by the mean of two appropriate housekeeping 
genes. 
A number of housekeeping genes were assessed for suitability and it was found that, 
particularly in developmental studies, the abundance of genes can alter with time. 
For all developmental studies, the housekeeping genes of choice were elongation 
factor 1α (ef1α) and 18s (Figure 2.8). For all studies which included only samples of 
the same developmental stage, the house keeping genes used were ef1α and, on 
occasion, gapdh. For adult tissue ef1α, gapdh and beta actin βactin were used. 


























































































































Figure 2.8 Relative abundance of housekeeping genes 
Determination of suitability of housekeeping genes for developmental studies. Concentration 
is determined through the standard curve of pooled samples and thus expressed as a relative 
concentration (AU). Data shown are for determination of suitable housekeeping gene for the 
developmental study (24-240hpf). A) Elongation factor 1 alpha (ef1α) B) 18s and C) β actin 






2.7 Protein study 
2.7.1 Radioimmunoprecipitation assay (RIPA) extraction 
Tissue was incubated for 3 min in radioimmunoprecipitation assay (RIPA) buffer on 
ice (6 embryos in 50 μL) containing phenylmethylsulfonyl fluoride (1 mM) and 
protease inhibitors [1:100] (Sigma-Aldrich protease inhibitor cocktail P2714: 
AEBSF 2 mM, E-64 14 µM, Bestatin 130 μM, Leupeptin 0.9 µM, Aprotinin 0.3 μM, 
EDTA 1 mM). Tissue was then homogenised in a Soniprep Ultrasonic Homogenizer 
(Sonciator - Model 3000MP Ultrasonic Homogenizer, BioLogics). Following 
sonication, tissues were centrifuged at 12,000 g for 5 min at 4
o
C. The subsequent 




2.7.2 Protein quantification 
Protein concentration was determined using a Bradford Assay. Standards of bovine 
serum albumin (BSA) in RIPA buffer were produced in the range of 0.05 - 1.0 
mg/mL. 5 µL of standards, samples or blank (RIPA alone) were added in triplicate to 
a 96 well plate followed by 25 µL of Reagent A (BioRad, Hertfordshire, UK) and 
200 µL of Reagent B (BioRad), and incubated for 15 min at room temperature 
(approximately 20
o
C). The absorbance was measured at 750 nm and the 
concentrations of the samples were calculated using MRX microplate plate reader 
(Dynex Laboratories Ltd, West Sussex, UK) software and interpolation from the 
standard curve. 
2.7.3 Western blotting 
2.7.3.1 Sample preparation and gel loading 
Protein samples were diluted to give the desired amount of protein (10µg), using 
Laemmli 2x buffer (4% SDS, 10% 2-mercaptoethanol, 20% glycerol, 0.004% 
bromophenol blue and 0.125 M Tris HCl (pH 6.8). 
Prior to loading onto the gel, protein samples were incubated at 95
o
C for 5 min, 20µl 
of sample was then loaded per well of a 2% Bis-Tris gel (Fisher Scientific UK Ltd, 
Loughborough, UK). Samples were run as per manufacturer’s instructions, with SDS 
Bis-Tris buffer at 100V for 45 min. The gel was then transferred to nitrocellulose 
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membrane by a semi-dry transfer method (200mA for 120 min) using transfer buffer 
(Tris base, pH 8.3, 25 mM, glycine 192mM, methanol 20%). 
2.7.3.2 Membrane blocking 
The nitrocellulose membrane was blocked using 5% dried milk powder (Tesco, UK) 
in TBST (NaCl 137 mM, Tris base pH 7.5 20 mM, 0.1% Tween 20) for 1 h at room 
temperature under gentle agitation. 
2.7.3.3 Primary and secondary antibody incubation 
Following blocking, the membrane underwent an overnight incubation at 4
o
C with 
gentle agitation with the primary antibody (goat anti-trout GR a GR antibody which 
was a kind gift from Dr M Vijayan, University of Waterloo, Canada) diluted in 
TBST with 5% dried milk powder (1:250). After the overnight incubation the 
membrane was washed with TBST 3 x 5min then incubated with TBST containing 
secondary antibody, a rabbit anti goat antibody conjugated to horse radish peroxidase 
(HRP) (1:1000) (Santa Cruz Biotechnology, Heidelberg, Germany, Cat no sc-2768) 
for 2 h at room temperature with gentle agitation. After this a final 3 x 5 min washes 
were performed with TBST to remove any unbound secondary antibody. 
2.7.3.4 Protein detection  
Enhanced chemiluminescence (ECL) reagent (GE Healthcare, Buckinghamshire, 
UK) was applied to the washed membrane as per manufacturer’s instructions. In a 
dark room, the ECL loaded membrane was exposed to photographic film for 5 min to 
visualise the protein bands. The film was then developed. 
2.7.3.5 Membrane stripping and re-probing 
To quantify the band and thus the protein content the membrane was stripped of the 
ECL reagent and the bound GR primary and secondary antibodies and re-probed 
with the house keeping protein α-tubulin. The membrane was placed in stripping 
buffer (20 mL 10% sodium dodecyl sulphate (SDS), 12.5 mL Tris HCl (pH 6.8), 67.5 
mL H2O and 0.8 mL β-mercaptoethanol) for 30 min at 50
o
C. After incubation the 
membrane was rinsed 3x 5 min with TBST at room temperature. After washing, the 
membrane was then re-blocked. The membrane was then incubated in primary and 
secondary antibodies as previously carried out, however for α-tubulin a concentration 
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of 1:500 (in TBST) of the primary antibody (rabbit host catalogue number AB4074, 
Abcam, Cambridge, UK) was used with 1:1000 anti-rabbit secondary antibody (Goat 
anti rabbit, Santa Cruz Biotechnology, Heidelberg, Germany, Cat no sc-2030). After 
this detection and film exposure were carried out as in section 2.7.3.4. However, in 
this instance membrane film exposure was for 30 sec and not 5 min as for the GR 
antibody. 
2.7.3.6 Protein density quantification 
Protein bands were quantified to determine changes throughout development. To do 
this densitometry of Western blots was carried out. The films from GR antibody and 
α tubulin exposure were scanned into a computer using a standard office scanner. 
The images were then saved as Tiff files; this format of image can then be opened 
using ImageJ software where the band densitometry plug-in tool was used to subtract 
the bands obtained from the GR antibody from the α-tubulin band. Each membrane 
was measured 3 times and the Western blot protocol was carried out 3 times to 
accurately quantify GR protein abundance. 
2.7.3.7 Zebrafish antibody problems  
Unlike rodent species, a limited number of antibodies have been produced 
specifically for the zebrafish. Although the number of proteins which have 
complementary antibodies in the zebrafish is increasing rapidly there is still a short-
fall. A number of papers have reported success in using different antibodies specific 
for other species. For this work a number of GR-related antibodies were used. 
However, even with optimisation few were successful. Antibodies which did not 
work were anti-GR antibody catalogue number Ab3578 (Abcam, Cambridge, UK) 
and anti-GR antibody catalogue number SC-1004 (Santa Cruz Biotechnology, 
Heidelberg, Germany). There are many possible factors why these antibodies did not 
work, including isotope or epitope location. 
2.8 Histology  
Whole embryos or isolated adult hearts were used for histological examination using 
a protocol previously published (Sabaliauskas et al, 2006) with mounting in a precast 
agarose mould. Agarose blocks were paraffin embedded by the SuRF@ QMRI 
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facility (http://www.surf.ed.ac.uk/histology) and paraffin blocks were sectioned, 
using a microtome, to give 5µm thin sections which were mounted onto microscope 
slides. After slides were dried overnight, haematoxylin and eosin (H&E) staining was 
performed using a standard protocol. Masson’s trichrome collagen staining was 
performed by SuRF@QMRI facility staff using a standard protocol. Embryos were 
sectioned laterally to give full body sections and hearts were sectioned longitudinally 
through the ventricle. 
2.9 Steroid quantification 
2.9.1 Steroid extraction-embryonic whole body cortisol 
The cortisol content of fish at different stages of development and in response to 
various GR and pathway manipulations was determined. Groups of 15 embryos from 
each time point (8-120hpf) or treatment group (pharmacologically or genetically 
manipulated) of interest were homogenised in 1 mL of systems water using a mixer 
mill (MM301, Retsch® Leeds, UK) and metal beads. This homogenate was added to 
7 volumes of 100% methanol and the mixture was left at 4
o
C for 24h to remove 
insoluble matter. 1 mL of this supernatant was dried down under nitrogen then 
reconstituted with 500 µL of cortisol ELISA assay buffer (0.05 mol/L PBS (pH 7.4) 
containing 0.1% BSA).  
2.9.2 Steroid extraction-adult swim water 
An advantage of using adult zebrafish was the possibility to detect cortisol in the 
swim water- the water surrounding the fish in the tank. Here static stand-alone (those 
not on the system) tanks were used. Pilot studies were carried out to optimise the 
experimental set-up.  
2.9.2.1 Water volume and stocking density 
The volume of water which was found to yield the greatest cortisol levels without 
compromising animal welfare was found to be 1L. Unsurprisingly it was determined 
that cortisol expression increased linearly with fish number in tank (Figure 2.9), with 























2.9.2.2 Sample time 
Although levels of cortisol were detectable after only 1 h in the tank, to eliminate for 
circadian influence, fish were held within test tanks for a 24 h period (to control for 
diurnal cortisol flux). All stressor experiments, tank transfers, feeding were also 
carried out at the same time of day (2pm). 
2.9.2.3 Experimental considerations 
Detectable levels of cortisol were observed in the flow systems water (data not 
shown). This water flows through all tanks which are present in a system so 
detectable levels of cortisol would not be surprising. To control for this, enough fresh 
systems water was made for all tanks investigated at a given time (Section 2.2). The 
feeding regimen was also found to interfere with cortisol levels, as the SDS feeds 
(Section 2.2) show minor but detectable levels of cortisol (data not shown). 
However, as control fish and treatment fish were treated identically this was found 
not to affect the data, but may influence investigation of food restriction as a stressor; 
for the latter a fed-water control would be used. To eliminate any food-related 








2.9.2.4 Swim water cortisol extraction 
To concentrate the steroids within 500 mL of the holding water, samples were 
filtered through Sep-Pak®Classic C18 Cartridges-360 mg Sorbent per Cartridge, 55-
Figure 2.9 Optimisation of quantification of cortisol release by adult zebrafish. 
An increasing linear relationship can be seen between the number of adult fish (2, 5, 10 fish 
in duplicate) per tank (litre volume) and cortisol detected in swim water after 24 hours. Every 




105 µm Particle Size (Waters, Hertfordshire, UK) connected to a vacuum system 
(Waters, Hertfordshire, UK). Prior to sample filtration, cartridges were primed as per 
manufacturer’s instructions with 5 mL methanol, followed by 5 mL of ddH2O. 
Samples were fed through the cartridges by a syphon approach, whereby glass bottles 
containing fish swim water were placed on an elevated platform above the Sep-Pak 
cartridges with a narrow hose with one end submerged in the water. The other end of 
the hose was attached to the Sep-Pak cartridge and, when the vacuum system was 
started, the swim water was syphoned through the cartridge. The flow rate from the 
hose was regulated by the presence of small taps prior to the cartridge. 
When sufficient sample had been filtered through the cartridge the steroids were 
eluted, using 2 mL of methanol, into glass tubes and stored. Pilot studies with 
radioactive steroid showed that approximately 100% of steroid was recovered from 1 
L of water in this way. The methanol eluent was evaporated to dryness under a 
stream of nitrogen and was reconstituted in 0.5 mL ELISA assay buffer. 
2.9.3 Cortisol enzyme-linked immunosorbent assay (ELISA) 
Total cortisol was measured using a sensitive and specific in-house ELISA modified 
from methods previously described (Al-Dujaili et al, 2009).  
2.9.3.1 Assay sensitivity 
Assay sensitivity is 0.025 ng/mL (0.06 nmol) with extraction recoveries ranging from 
94.8-106.7 % for cortisol levels in the range of 2.6-140.8 ng/mL. Cross reactivity of 
the anti-sheep cortisol antibody were 0.68% for cortisone, 1.12% for deoxycortisol, 
0.4% for testosterone,0.01% for progesterone and other interfering steroids <0.01%. 
Intra- and inter- assay precision values were 3.2% and 5.7% respectively. 
2.9.3.2 Enzyme-linked immunosorbent assay (ELISA) methodology 
Briefly a 96-well plate (Griener Bio-One, Germany) was coated overnight at 4oC 
with coating buffer (0.25 mol/L PBS (pH 7.4)) containing 200 ng/mL Cortisol-CMO-
BSA conjugate: plates were then (0.02 mol/L PBS (pH 7.4) containing 0.05% Tween 
20) and blocked (0.025 mol/L PBS (pH 7.4) containing 0.1% BSA) at 37oC for 2 h. 
Cortisol standards (0-1000 ng/mL) and samples were added to wells, along with 
antibody solution (1:20,000 sheep anti-cortisol antibody (Micropharm, London, UK)) 
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and incubated at room temperature for 1 h. Samples were then washed and treated 
with enzyme solution (1:20,000 horseradish peroxidase-donkey-anti-sheep IgG 
Sigma Chemical Company, Poole, UK) for 1h. After washing, peroxidase substrate 
solution (0.33 mg/mL Tetramethylbenzidine (TMB) and 30% H2O2 in 0.2M acetate 
citrate buffer) was added. The reaction was stopped after 15 min incubation at room 
temperature by the addition of 5 µL 1M H2SO4 to each well. Absorbance at 450 nm 
was measured in an MRX Microplate reader (Dynatech Laboratories). 
2.9.4 Deoxycortisol enzyme-linked immunosorbent assay (ELISA) 
Total Doxy was measured with a specific in-house ELISA adapted from the above 
cortisol ELISA protocol. For Doxy ELISA, however, standards were in the range of 
(0-50 ng/mL). The primary antibody was used at the concentration of 1:10,000 
(rabbit anti-deoxycortisol antibody, Micropharm, London, UK). The enzyme solution 
was used at 1:10,000 (horseradish peroxidase-goat anti rabbit IgG, Sigma Chemical 
Company, Poole, UK). 
2.9.5 Enzyme-linked immunosorbent assay (ELISA) quantification 
The readings obtained from the microplate reader were analysed using AssayZap 
software (Biosoft ® Cambridge) where the standard solutions were used to produce a 
standard curve and the sample concentrations were interpolated. The concentrations 
produced by software were given in nmol/L from this a concentration of ng/fish 
could then be calculated. 
2.10 Statistical analysis 
Data are presented as mean ± standard error of the mean (SEM) unless stated 
otherwise. Statistical analysis was carried using GraphPad Prism 5.0, as follows, 
unless stated otherwise in the relevant text. Comparison of two matched groups was 
carried out as follows, parametric un-paired data by (Welch) unpaired t-test, 
parametric paired data by paired t-test, non-parametric and unpaired data by The 
Mann-Whitney test and non-parametric and paired data by the Wilcoxon matched 
pairs test. Comparison of three or more groups at one sample point was carried out 
by one-way analysis of variance (ANOVA) followed by appropriate post-hoc tests 
(e.g. comparison of every mean to a control mean, by Dunnett's post hoc test or 
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comparison of every mean with every other mean by Tukey's post hoc test). For 
studies where groups were affected by two factors (for example time and drug 
treatment) a two-way (not repeated measures) ANOVA was carried out followed by 
Tukey or Bonferroni post-hoc tests to compare every column mean with every other 
column mean or to control mean. Hatch-rate was analysed by Chi Squared analysis 
of proportions by calculating the degree of difference between the observed data and 
the null hypothesis (based on the control data). A Bland-Altman plot was produced 
for ejection fraction to determine the assay accuracy. This analysis was carried out 
on one sample group where observer 1 determined the ejection fraction, multiple 
times on separate occasions (intra-observer variation), the same population sample 
was analysed by observer 2 multiple times on separate occasions (inter-observer 
variation). The data are plotted as the difference between the two measurements on 
the Y axis, and the average of the two measurements on the X axis (Figure 2.10). 
Statistical significance throughout was accepted as p<0.05 (*p=0.05, **p≤0.001, *** 
p≤0.0001). 
 
Figure 2.10 Bland-Altman analysis for embryonic ejection fraction.  
This statistical analysis was applied to assess intra-observer (A) and inter-observer (B) 
variation in the measurement of area with ImageJ. The differences between the measures are 
plotted against the mean for the two tests. The dotted line represents the 95% limits of 













3 Characterisation of the zebrafish glucocorticoid system 
3.1  Introduction 
As described in chapter 1, GC biosynthesis is a tonically active process (with a 
circadian diurnal pattern). However, a well-documented increase in GC biosynthesis 
occurs in response to stressful stimuli where, along with catecholamine signalling 
pathways, GCs enable the body to deal with and respond to the stressor by increasing 
essential and decreasing non-essential bodily functions. This increase in GC levels is 
an evolutionary conserved, physiological homeostatic mechanism common amongst 
most species (Steenbergen et al, 2011). GC are also used therapeutically for 
conditions such as asthma, rheumatoid arthritis and inflammatory bowel disease 
(Wei et al, 2004) and have often been shown to produce similar therapeutic effects in 
animals as observed in humans (Miller, 1999). 
GC levels are regulated by negative feedback of the HPA axis and tissue specific 
local enzyme inactivation. Short-term increases in circulating GC are advantageous 
but chronic increases, due to impaired regulatory mechanisms, can be detrimental 
(Chapman & Seckl, 2008) and lead to side-effects such as elevated blood pressure 
(Dixon & Bansback, 2012; Schacke et al, 2002)). As highlighted in chapter 1, 
understanding better the cellular and molecular actions of GC will allow greater 
knowledge of the physiological and pathophysiological roles of these hormones. Few 
animal models have been widely accepted for investigation of GC physiology; while 
the mouse model is the most commonly used it is not without problems. 
The teleost fish has been suggested as a complementary model for GC research (Hsu 
et al, 2006; Pikulkaew et al, 2010; Steenbergen et al, 2011). Previous studies in adult 
zebrafish have shown that their corticosteroid system has many similarities with the 
human system at a molecular and cellular levels (Steenbergen et al, 2011; Veldman 
& Lin, 2008). The GC synthesis pathway in the adult zebrafish is believed to be 
virtually identical to that found in mammals (Leatherland et al, 2010; Lohr & 
Hammerschmidt, 2011; Schaaf et al, 2009; Schoonheim et al, 2010; Steenbergen et 
al, 2011; Tokarz et al, 2013). Furthermore the zebrafish embryo allows relatively 
easy observation of cellular and organ specific development which is particularly 
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important for determining physiological function. In addition, these developmental 
processes can be readily manipulated by altered pharmacological and environmental 
conditions (Zon & Peterson, 2005). 
While these features support the utility of the zebrafish as a model for GC research, a 
limited number of published studies have fully assessed the functional roles of the 
GC system during embryonic development. For example, a number of issues remain 
unanswered in relation to the biochemical, anatomical, organisational and 
mechanistic control of GC biosynthesis in zebrafish embryos. A comprehensive 
review of the importance of this pathway in zebrafish development is particularly 
lacking. While cortisol is a known indicator of stress in the adult zebrafish it is 
unclear whether the machinery is in place to mediate such a response in the embryo 
and, if so, when. While it has previously been shown that cortisol is present in the 
zebrafish embryo (Alsop & Vijayan, 2008) the physiological relevance during 
development has never been investigated. 
3.2 Hypothesis and aims 
The zebrafish embryo has a physiologically functional GC system which is 
responsive to physiological or environmental stimulus. 
Data presented here aimed to address the following questions: 
1) Are the key components for GC biosynthesis present in the zebrafish? 
2) When does de novo GC biosynthesis occur in the zebrafish embryo? 
3) Is there endogenous production of GC in response to stress? 






3.3.1 Embryonic glucocorticoid modulation 
Modulation of GC activity in zebrafish embryos was carried out as described 
(Section 2.4.4). Briefly all modulations were carried out at the 2 cell stage (approx. 
1h after egg collection) until 120 hpf in accordance with Home Office regulations. 
Embryos were housed in standard husbandry conditions as described in a 10cm Petri 
dish at a density of 1 embryo/mL. 
3.3.1.1 Pharmacological manipulation 
Pharmacological manipulation was performed by bathing embryos in various 
concentrations of the following drugs: Doxy, Met and Dex. All drugs were dissolved 
in EtOH (0.1%) (optimisation in Appendix 1) and diluted to final concentration in 
systems water. Embryonic survival, phenotype scoring, and drug replacement were 
performed daily over the 120h study. 
3.3.1.2 Genetic manipulation 
Genetic manipulation was by Mo targeted to the cyp11b1 gene, which is responsible 
for encoding the catalytic enzyme 11β-hydroxylase responsible for the conversion of 
11-deoxycortisol to cortisol (Figure 3.1). Mo design, sequence and dosage 
optimisation are described in Appendix 1. Successful genetic manipulation was 
determined by a significant reduction in cyp11b1 mRNA gene abundance in ss-Mo 
(ss-Cyp Mo) injected embryos compared to mm-Mo (mm-Cyp Mo (Figure 3.2)). A 
wide dose ranging study demonstrated that the concentration of ss-Cyp Mo that 
produced a significant (30%) knockdown of cyp11b1 mRNA, without altering 
survival or phenotype, was 6 ng/nL. This concentration was found to also produce 
comparable survival and phenotype data for the translational blocking (atg-Mo) 
targeted for cyp11b1 knockdown (atg-Cyp Mo) and mm-Cyp Mo. As a result a 
concentration of 6 ng/nL was used for all. As previously highlighted, unless stated 
otherwise, data shown from here on in will be for translational blocking atg-Mo, and 
will be referred to as Cyp Mo throughout (Chapter 2).  
As for pharmacological manipulations embryos were stored in systems water which 
was replenished daily over the 120 h study whilst scoring survival and phenotype 
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occurred daily. Confirmation of embryonic Mo uptake was achieved by the 
cytoplasmic presence of the fluorescent fluorescein 5’ Mo modification (Section 
2.4.4).  
3.3.1.3 Embryonic experimental controls 
For all pharmacological manipulations carried out in this chapter controls are vehicle 
only controls (0.1% EtOH as determined in appendix 1). For molecular manipulation 











Figure 3.1 Schematic of the mature zebrafish glucocorticoid system. 
Summary of key reactions, enzymes and components of the mature zebrafish GC systems. 
This schematic shows corticotrophin releasing factor (crf), adrenocorticotropic hormone 
(acth), steroidogenic acute regulatory protein (star), cholesterol side-chain cleavage enzyme 
(cyp11a1), 17α-hydroxylase (cyp 17), 3β-hydroxysteroid dehydrogenase (3βhsd), 11β-





Figure 3.2 Confirmation of cyp11b1 knockdown by Cyp Mo 
Gene abundance analyses for cyp11b1 mRNA at 72 hours post fertilisation (hpf) in control 
(mism-Mo-injected) whole embryo homogenate compared to those which had been injected 
with 6 ng/nL cyp11b1 splice site specific morpholino (Cyp Mo). N=3 expts (10 embryos per 
group). Gene abundance is given as an arbitrary concentration (AU) and normalised to 
house-keeping gene. Columns represent mean ± SEM. Comparisons were made using 
Student’s t-test, ** p<0.001. 
3.3.2 Maternal glucocorticoid manipulation 
To determine whether the early detectable GC in the embryo was maternally-derived 
a maternal GC modulation experiment was carried out using Dex. Two forms of 
modulation were investigated, maternal bathing and injection. 
For bathing modulation adult female WIK zebrafish were placed in a stand-alone 1 L 
tank containing distilled water at a density of 6 fish per L. To this Dex was added to 
give a final tank concentration of 10 µM Dex. The drug was replaced every second 
day (after pH, chlorine and salt levels were assessed and found to be comparable to 
un-altered distilled water).  
For the injection experiment, intraperitoneal (IP) injection of Dex was carried out 
using an adapted protocol of Kinkel and colleagues, (Kinkel et al, 2010). Following 
anaesthesia fish were placed ventral side upwards in a slotted, moistened sponge and 
a 5 µL bolus of 1 nM Dex was injected.  
3.3.2.1 Maternal experimental controls 
Controls for mothers bathed in Dex were mothers bathed in vehicle only (0.1% 
EtOH). Vehicle was replaced every second day. Controls for maternal Dex injections 
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were injected with a 5 µL vehicle (0.1% EtOH) only bolus. Injections of vehicle 
occurred twice weekly. Experiment was repeated in triplicate (6 adult fish per tank) 
3.3.2.2 Maternal manipulation offspring  
After 35 days of treatment the manipulated mothers were placed in pair-mating tanks 
with un-manipulated WIK male fish (1:1 ratio). Embryo production was assessed 
daily with fecundity and survival recorded. Embryos were collected for assessment 
of cortisol concentration at 8, 24 and 120 hpf. 
3.3.3 Gene abundance study 
Gene abundance analysis was performed for a range of GC genes of interest in whole 
embryo homogenates over the course of 120 h. Embryonic genes investigated were 
cyp11b1, cyp11a1, gr, mr, 11βhsd2, 20βhsd, star and crf as these have been 
highlighted in mammalian models as key indicators of active GC production (the 
primer sequences for these genes are shown in Table 3.1). Gene abundance was 
analysed throughout the course of development over a range of time points - 8, 24, 
48, 72, 96 and 120 hpf (n=5 samples per time point (10 embryos per sample)). All 
embryonic time-course studies were normalised to ef1α and 18s. Adult gene 
abundance was measured in isolated kidney, heart, brain and liver for gr, mr, 
11βhsd2 and cyp11b1. 
Table 3.1 mRNA gene abundance primer sequences.  
Glucocorticoid genes of interest with forward and reverse primer sequence used for qRT-
PCR 
Gene Forward Primer Reverse Primer 
cyp11b gcagacacagcaaaggagtct gacagacgaggacaccatca 
cyp11a1 ggatataaaggccagtgtcacc tcataaagcgtccacagcag 
gr ttctcaagcagcccctattc tctttccaccagctgacgat 
mr cctgcagagtacgcaagtgt cccaacttcttcgacttcc 
11βhsd2 gggggtcaaagtttccactat gtactctgcgttactgctctgc 
star cctggagctagcacttggat agcactggtcagcttcactg 
crf tccaaggatttaccaattacgc tcatacggcggtggaaag 
20βhsd2 aatggttgaaagggggaaag ttatgggtcatgttcgtgga 
3.3.4 Cortisol enzyme-linked immunosorbent assay (ELISA) 
Whole embryo cortisol was extracted and analysed from homogenates as described 
(section 2.9). Adult cortisol excretion was determined by analysing swim water. 
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Cortisol levels either in tissue homogenates or in the swim water were calculated by 
interpolation from cortisol standard curve in the range of 1000-10 ng/µL, using 
AssayZap, assay calculating software (BioSoft).  
3.3.4.1 Embryonic cortisol: time-course 
To determine the expression profile of cortisol in the embryo a time-course study 
over 120 hpf was performed using whole embryo homogenates. The time points 
investigated here were 8, 18, 24, 36, 48, 72, 96 and 120 hpf (n=5 samples, (n=10 
embryos per sample)). Embryos were collected at the time-points of interest and 
processed as described (section 2.9).  
3.3.4.2 Embryonic cortisol: stress 
For embryonic stress experiments, unless stated otherwise, all embryos were sampled 
at the same time of day (between 14.00-15.00h) under standard light: dark cycle 
conditions to control for the possible influence of diurnal circadian cortisol 
production (Dekens et al, 2003; Dickmeis, 2009; Lohr & Hammerschmidt, 2011). 
Stressed embryos were stored in an incubator for 1 h after stressor (at the time-point 
of interest) prior to euthanizing and homogenisation. This allows for induction of the 
stress response as the release of cortisol in teleostean and other bony fishes is 
delayed relative to catecholamine release (Barton, 2002) with cortisol synthesis and 
release from interrenal cells being shown to have a lag time of several min after 
stressor (Iguchi et al, 2003). Cortisol was extracted from whole embryo homogenates 
as described (section 2.9). Controls are described in section 3.3.6. Experiment was 
repeated in triplicate (10 embryos pooled). 
3.3.4.3 Embryonic cortisol: drug treatment 
To determine whether drug incubation had any influence on cortisol levels, embryos 
which had been continuously incubated in drug (from the 2-cell stage) were 
thoroughly rinsed through a series of system water prior to cortisol extraction as 
described in section 2.9.1. For drug data ELISA, the concentrations determined were 
normalised to an embryo free drug solution (containing the equivalent dose of drug) 
to determine whether background levels of cortisol are measured as a result of drug 
presence. Experiment was repeated in triplicate (10 embryos pooled). 
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3.3.4.4 Adult cortisol: drug treatment 
For determination of the maternal cortisol influence on embryonic cortisol levels, 
adult fish were treated with Dex (section 3.3.2). Water was collected at two time 
points during Dex treatment (24h after initial exposure and 24h after final drug 
exposure). All samples were collected at 2pm on sampling day then cortisol 
extraction and ELISA were carried out as per adult swim water cortisol (described in 
Section 2.9.2). Experiment was repeated in triplicate (6 adult fish per tank). 
3.3.5 Cortisol radioimmunoassay (RIA) 
The cortisol was further determined over the time-course study using an appropriate 
radioimmunoassay (RIA). The RIA was only used here to confirm the ELISA data 
and was not used for any other study as the ELISA was felt to be faster, cheaper, 
more reproducible and safer (no radio conjugate is required for ELISA). The same 
homogenisation/ cortisol extraction method was used as for the ELISA (Section 
2.9.1). However after the samples were dried down under N2, they were reconstituted 
with 100µl of borate buffer (0.133 M boric acid, 67.5 mM NaOH and adujusted to 
pH7.4 with 1M HCl containing 0.5% bovine serum albumin, 1% methanol and 
0.01% ethylene glycol). For the RIA 25 µL of either sample extract or standards 
(0.31-320 nM cortisol) were incubated with 25 µL of cortisol sheep antibody 
(MicroPharm, 1:3000), 25 µL of anti-sheep SPA scintillation beads (GE healthcare) 
and 25 µL of 
125
I labelled cortisol (MP, Biomedicals), in 96-well plates. Plates were 
covered with transparent film, shaken and left to incubate at room temperature for 6 
h for the reaction to reach equilibrium. The γ-emission of bound 
125
I was measured 
by counting each well for 5 min in a Gamma scintillation counter (Wallac, 
PerkinElmer, Cambridge, UK). Sample concentrations were determined by 
interpolation from the standard curve using AssayZap assay quantification software 
(BioSoft). Experiment was repeated in triplicate (10 embryos pooled). 
3.3.6 Embryo stressor 
A number of “stressors” were assessed for activation of HPI activity. HPI activity 
was determined by a rise in cortisol concentrations (determined by ELISA; section 
2.9) following stress, compared with un-stressed controls. Experiment was repeated 
in triplicate (10 embryos pooled). 
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3.3.6.1 Embryonic hypoxia 
To assess hypoxia as an environmental stressor, embryos (24, 72 and 120hpf) in 
30mL Petri dishes containing systems water (10 embryos/group; 3 h) were placed in 
a hypoxic chamber (Coy cabinet) in the following conditions: 1% oxygen, 5% carbon 
dioxide, 94% nitrogen at 28.5
º
C and a relative humidity of 45%. 
3.3.6.2 Embryonic kinetic stress 
Two forms of kinetic stressors were investigated for their impact on cortisol 
production. 10 embryos were placed in 30 mL Petri dishes containing systems water 
at 28.5
º
C. For constant movement stressor, the Petri dish was placed on a horizontal 
shaker at 30rpm for 1h. For brief kinetic stressors embryos were placed on a 
horizontal shaker for 100 rpm for 1min. 
3.3.6.3 Embryonic electrical stress 
Direct electrical current pulse (DCP)-induced stress was induced by placing 10 
embryos in a 30 mL Petri dish and passing a 2 mA electrical current (10 m/s 
duration, 3 times per h) through the bathing water over a 2h period. 
3.3.6.4 Determination of stress cortisol 
For all methods of stress induction embryos were left in an incubator (28.5
o
C) for 1 h 
after exposure to the stressor to allow for induction of stress-induced cortisol 
production. Embryonic cortisol was then measured by extraction followed by 
ELISA, as described (section 2.9). Controls were treated the same as controls, i.e. 
were taken out of incubator for the duration of experiment and kept on a bench near 
stressor protocol thus received all same handling, lighting, temperature apart from 
stressor. 
3.3.7 Experimental controls 
In the following experiments data were obtained primarily in the un-manipulated 
zebrafish (embryo and adult). These results are displayed in the open (colourless) 
columns. Where a manipulation (pharmacological or molecular) was carried out 
controls (red column) were either vehicle only (0.1% EtOH for drug studies) or mm-
Mo (for Mo studies). Adult drug studies were carried out by treating adults with Dex 
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(black columns) the controls were treated with vehicle only (0.1% EtOH - red 
columns). For embryonic stress experiments temporal controls were used. 
3.4 Results 
3.4.1  Aim 1 
Are the key components for GC biosynthesis present in the zebrafish? 
3.4.1.1 Important GC genes are found in isolated adult tissue 
To confirm previously reported adult zebrafish data the abundance of gr, mr, 
cyp11b1 and 11βhsd2 was detected in isolated adult tissues. gr and mr mRNA were 
both detected at varying levels in all tissues investigated (brain, kidney, heart and 
liver), with gr mRNA abundance highest in the brain. 11βhsd2 was found in the 
brain and at lower levels in the heart and kidney, there was virtually no 11βhsd2 in 
the liver. cyp11b1 was found in the kidney with levels in other tissues negligible 
(Figure 3.3). 
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Figure 3.3 Relative abundance of glucocorticoid genes in adult zebrafish 
Relative mRNA abundance of key glucocorticoid genes in isolated adult zebrafish tissue. A) 
gr mRNA, B) mr mRNA, C) 11βhsd2 mRNA and D) cyp11b1mRNA. All gene abundance is 
n=3 (5-10 pooled organs) mean ± SEM. Gene abundance is quantified through standard 
curve production and normalisation to the housekeeping genes ef1a and βactin Data are 
presented as arbitrary units (AU). 
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3.4.1.2 Important GC genes are found throughout development in embryos 
A number of key genes important for GC biosynthesis, metabolism and action were 
investigated in the developing embryo (8-120hpf). Changing patterns of relative 
abundance were shown for mRNA of all of the factors associated with GC system 
over the 120 hpf time-course of the study (Figure 3.5). 
gr mRNA (Figure 3.5A) abundance increased significantly (p≤0.0001) by 48 hpf 
(0.96 ± 0.09AU) compared with 24 hpf (0.38± 0.04AU). This higher level was 
sustained until 120 hpf (p≤ 0.0001 vs. 24 hpf). Similar to gr mRNA relative 
abundance, Gr protein abundance in whole embryo homogenates (n=3, 5 embryos 
per sample) was found to increase significantly at 48 hpf compared to 24 hpf, with 
levels thereafter sustained until 120 hpf at which point a rise in protein levels was 
observed (Figure 3.4). 
Unlike gr, the mRNA levels of mr remained constant over the first 48 hpf (0.33 ± 
0.07 and 0.39 ± 0.06 AU for 24 and 48 hpf, respectively) then increased significantly 
by 72 hpf (p≤ 0.0001). This level of relative abundance was maintained for 96 and 
120 hpf (Figure 3.5B). A similar temporal pattern of abundance was observed for the 
Mr regulatory enzyme 11βhsd2, with no difference in levels between 24 and 48 hpf 
but with a significant increase noted at 72 hpf compared to 24 hpf (p<0.001(Figure 
3.5C)). Another regulatory enzyme investigated was the novel 20βhsd2 enzyme 
which is found in teleost fish and is proposed to be an important enzymes in cortisol 
catabolism in zebrafish where it is responsible for converting cortisone into 20β-
hydroxycortisone, providing a route for cortisol catabolism (Tokarz et al, 2012). 
When the abundance profile was investigated it was found to be a similar to 11βhsd2, 
that is, expressed at low levels in the first 48 hpf but significantly increased 
significantly at 72hpf; a feature which was sustained over the remaining 24h until 
120 hpf (Figure 3.5H). 
The temporal abundance pattern of crf mRNA, the main mediator of stress-induced 
GC biosynthesis showed low levels initially with a significant increase from 72 hpf, 
with the levels detected at 96 (p<0.001) and 120 hpf (p<0.05) significantly higher 
than those detected at 24 hpf (Figure 3.5D)). 
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star, the gene responsible for cholesterol transportation in steroidogenesis, displayed 
higher levels at 72 compared to 24 hpf (p<0.05). However the levels detected at all 
other time points were comparable to the 24 hpf level (Figure 3.5E). The levels of 
cyp11a1 mRNA remained constant during the course of development with no 
significant alteration with time (Figure 3.5F). In contrast cyp11b1 mRNA relative 
abundance showed a biphasic pattern, initially lowest at 24 hpf, rising significantly at 
48 hpf compared to 24 hpf (p≤0.0001), and then falling again at 72 hpf. Higher levels 
were then detected at 96 and 120 hpf (p≤0.0001). 
 
Figure 3.4 Glucocorticoid receptor protein levels in whole zebrafish embryos 
Embryonic zebrafish glucocorticoid receptor protein (Gr) abundance studied over 120 hours 
post fertilisation (hpf). Gr is presented as percentage (%) relative abundance as determined 
by band density normalised to the house-keeping protein α-tubulin, determined using ImageJ 
image analysis software with band density plugin. Data are mean ± SEM (n=3 blots (n=8 
embryos <72hpf; n=5 embryos >72hpf)) analysed by 1-way ANOVA and Dunnett’s post hoc 



























































































































































































































Figure 3.5 Relative abundance of genes regulating glucocorticoid biosynthesis 
Relative mRNA abundance of glucocorticoid related genes over the course of the first 120 
hours post fertilisation (hpf). A) gr, B) mr, C) 11βhsd2, D) crf, E) star, F) cyp11a1, G) 
cyp11b1 and H) 20βhsd2. In all cases columns represent mean ± SEM (n=6 (10 embryos 
per time pooled)). Gene abundance is presented as arbitrary units (AU) after standard 
curve production and normalisation to ef1a and 18s. Data were analysed by 1-way 




3.4.1.3 Embryonic zebrafish cortisol levels show a biphasic pattern  
Following demonstration of components of the GC system in the zebrafish embryo, 
investigations were performed to determine whether cortisol levels were actively 
regulated in the embryo. Cortisol was detected at all time-points investigated. Levels 
were found to decrease from initial levels at 8hpf (2.2 ± 0.29 ng/embryo) until 36 hpf 
(0.4 ± 0.42 ng/embryo; p=0.01). Thereafter, the levels increased steadily from 48 hpf 
onwards reaching 3.39 ± 0.44 ng/embryo at 120 hpf; more than 1 ng/embryo greater 
than the initial detectable levels at 8 hpf (Figure 3.6A). To confirm these data and 
ELISA specificity further a RIA method was used for cortisol detection. A similar 
cortisol profile was observed as for the cortisol ELISA, supporting ELISA specificity 






3.4.2 Aim 2 
When does de novo GC biosynthesis begin in the zebrafish embryo? 
3.4.2.1 Embryonic cortisol pharmacological manipulation 
Incubation of embryos over 120 hpf with the 11β-hydroxylase substrate Doxy [1µM] 
resulted in a significant increase in embryo cortisol levels compared to vehicle only 
controls (5.43 ± 0.01 vs. 3.68 ± 0.02 ng/embryo (p=0.05(Figure 3.7A)). In embryos 
incubated with increasing concentrations of Met there was a concentration-dependent 
Embryonic cortisol (ELISA)


















































Figure 3.6 Zebrafish whole embryo cortisol levels 
Cortisol concentration over the course of 120 hours post fertilisation (hpf) in whole 
embryo homogenate. Cortisol levels were determined by two methods. A) Cortisol 
ELISA (n=6 (10 embryos per sample)). B) Cortisol radioimmunoassay (n=3 (10 
embryos per sample)). Data are mean ± SEM and were analysed by 1-way ANOVA 
and Dunnett’s post hoc test. ** p ≤ 0.001 vs 8 hpf levels.. 
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decrease in cortisol levels compared to controls at 120hpf, with a 15% reduction 
noted for 0.1μM Met, 47% reduction for 1μM Met and a 66% reduction at the 
highest concentration (10µM Met) (Figure 3.7C). Conversely an ELISA specific for 
Doxy demonstrated a concentration-dependent increase in the levels of substrate, 
Doxy, with the highest detectable level of Doxy observed for the highest 
concentration of Met investigated (10 μM (Figure 3.7 D)). 
Co-incubation of Met with 0.5µM Doxy impaired the increase in cortisol production 
observed with Doxy alone, a concentration-dependent reduction in cortisol levels 
was observed with increasing concentrations of Met. Incubation in a further 11β-
hydroxylase substrate Doc [0.5µM], as expected had no influence on the forward 
reaction and produced comparable data to controls with increasing concentrations of 
Met (Figure 3.7 E). 
A further pharmacological manipulation which was carried out to determine HPI axis 
activity was Dex treatment, following continuous exposure from the 2-cell stage. 
Whole embryonic cortisol levels were reduced by ~25% at 120 hpf (p<0.05) (Figure 
3.7 B).  
Continuous incubation in 1µM Met resulted in a significant reduction in whole 
embryo cortisol by 120 hpf, at time points prior to this (24 and 72 hpf) however, the 
effects of Met on cortisol were not significantly different from controls (Figure 3.8).  
Furthermore, the Cyp Mo treated embryos (30% reduction in cyp11b1 mRNA at 72 
hpf) displayed a significant (~45%) reduction in cortisol levels at 120 hpf (p<0.01). 
Similar to the observations for Met there was no difference between this group and 
the controls at 24 or at 72 hpf (p>0.05 (Figure 3.8A)). 
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Figure 3.7 Embryonic cortisol levels following pharmacological manipulation 
Whole embryo steroid levels in embryos 120 hours post fertilisation (hpf) as determined by 
ELISA following various forms of pharmacological manipulation. A) Whole embryo cortisol 
data for embryos incubated in 1µM deoxycortisol (Doxy) for 4 hours prior to cortisol 
sampling vs. controls (vehicle only). B) Cortisol levels in embryos treated continuously with 
dexamethasone (Dex) from the 2 cell stage vs. controls. C) Cortisol levels following 
continuous incubation in 0.1, 1 and 10µM metyrapone (Met) from 2 cell stage vs. control. D) 
whole embryo Doxy levels following continuous incubation in 0.1, 1 and 10µM Met from 2 
cell stage vs. controls. E) cortisol data for embryos continuously incubated with Met at 0.1, 1 
and 10µM, co-incubated with 0.5 µM Doxy or 0.5 µM deoxycorticosterone for 4 h prior to 
sample preparation. All data are mean ± SEM (n=3 (10 embryos per group)), A and B were 
analysed by Student’s t-test, C-E by 1-way ANOVA and Dunnett’s post hoc analysis); 










3.4.2.2 Pharmacological manipulation of cortisol in adults 
As part of the experiment to manipulate maternally-derived cortisol in zebrafish 
embryos, adult female zebrafish, were treated with the synthetic GR agonist Dex for 
35 days. This duration of treatment was chosen to reflect the time period of 
gametogenesis in the fish (Carnevali et al, 2010).  
Two routes of administration were investigated, 1) Dex in the bathing water (Dex-B) 
and 2) IP injection (Dex-Inj). Each Dex administration group had an appropriate 
vehicle control group (C-B or C-Inj). As part of the experiment, cortisol was 
measured in the swim water (the water surrounding the fish) over the course of the 
35 day study. On occasion cortisol was measured in an adaption of a human Dex 
suppression test in which Dex is used to assess the functionality of the patient’s HPA 
axis. Dex should produce a negative feedback on the pituitary gland to supress the 
production of Acth and Crh, and thus reduce cortisol production. In adult fish cortisol 
water was collected 24h after the first treatment (either injection or bathing) to assess 
the negative feedback regulation of cortisol production (Figure 3.9). It was observed 
that Dex Inj produced a reduction in cortisol levels. 
 



















































Figure 3.8 Embryonic cortisol levels following 11β-hydroxylase manipulation 
Whole embryo cortisol levels at 24, 72 and 120 hours post fertilisation (hpf) following 
manipulation of 11β-hydroxylase activity by A) cyp11b1 targeted morpholino (Cyp Mo) 
injected at the two cell stage, or B) 10µM metyrapone (Met) compared in both cases to 
control data (mismatch morpholino for Cyp Mo and vehicle only for Met). Data are mean ± 
SEM (n=3 (10 embryos per group)) and were analysed by 2-way ANOVA and Bonferroni 
post hoc analysis.**p ≤ 0.01 compared with control. 
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When cortisol levels were measured at a later stage (35 days) of the experiment -24h 
after final Dex treatment- a more pronounced alteration was observed between the 
groups. Dex-Inj fish had significantly lower cortisol than C-Inj similarly Dex-B fish 
also displayed a reduction in cortisol levels compared to the C-B. Overall, the trend 
for Dex–Inj and Dex-B adults was similar, with both displaying reduced cortisol 
level in the swim water suggesting Dex suppression of endogenous cortisol 





3.4.3 Aim 3 
Is there endogenous production of GC in response to stress? 
3.4.3.1 Cortisol is produced in response to stressful stimuli 
A number of stressors were assessed including kinetic agitation (both brief and 
prolonged exposure), 3 h of hypoxia (1% O2) and Direct Current electrical impulse 
passed through the bathing water. Changes in cortisol were assessed using these three 
stressors at 3 developmental time points 24, 72 and 120 hpf (Figure 3.10). At 24 hpf 
none of the stressors caused an increase in cortisol compared to controls (Figure 
3.10A). A stress response (as determined by a significant rise in cortisol levels) was 
detected at 72 hpf. At this time-point, hypoxia, prolonged kinetic agitation and DCP 
24h Dex supression Test




















35 day Dex supression Test






















Figure 3.9 Adult zebrafish swim water cortisol after dexamethasone treatment 
Measurement of cortisol in swim water from tanks containing adult zebrafish for 24 h. 
Zebrafish were pre-treated with with dexamethasone (Dex) or vehicle only controls (C). 
Exposure to Dex was achieved either by injection (Dex-Inj or C-inj) or by administration to 
the swim water (Dex-B or C-B). Data displayed are of sample collections at A) 24 hour after 
initial treatment or B) 24h after final treatment (35 days after the first treatment). Cortisol 
levels were quantified by ELISA and concentrations determined through standard curve 
intrapolation. Data are mean ± SEM (n=3 (6 adult fish per tank) analysed by Student’s t-test. 
*p≤0.05, ** p≤0.001 vs respective controls. 
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all significantly increased cortisol (p<0.001). No significant increase in cortisol was 
observed for brief kinetic agitation compared to controls (0.77 ± 0.06 ng/embryo, 
p=0.57 (Figure 3.10B)). At 120 hpf brief kinetic agitation and hypoxia did not alter 
the levels of cortisol compared to controls (p>0.05). A significant increase in cortisol 






















































































Figure 3.10 Embryonic cortisol levels after stress  
The impact of hypoxia (Hyp), brief or prolonged kinetic stressor, or direct electrical 
current pulses (DCP) were investigated on embryos aged 24, 72 or 120 hours post 
fertilisation (hpf). Stimuli were investigated for activation of stress response by measuring 
increases in whole embryo cortisol levels by ELISA. Data shown are following stressor at 
A) 24 hpf B) 72 hpf and C) 120hpf. Data are mean ± SEM ( n=3 (10 embryos per 
experiment)) and were analysed by 1-way ANOVA and Tukey’s post hoc test. ** p≤0.01, 
***p≤0.001 compared to age- matched controls. 
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3.4.3.2 Embryonic stress induced cortisol production is controlled by HPI axis 
While a marked increase in cortisol levels was associated with prolonged kinetic 
agitation at 120 hpf in Figure 3.10 this was found to be abolished in embryos that had 
been treated with either Met or Cyp Mo from the 2 cell stage (Figure 3.11) (Met + 
prolonged kinetic stress 0.89 ± 0.08 vs. prolonged kinetic stress 5.80 ± 0.80 
ng/embryo (p<0.001) and (Cyp Mo + prolonged kinetic stress 1.10 ± 0.15 v 
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Figure 3.11 Embryonic cortisol levels after stress and 11β-hydroxylase manipulation 
A stressor stimulus (kinetic agitation) was investigated 24 and 120 hours post fertilisation 
(hpf) for activation of the stress response with or without 11β-hydroxylase inhibition using 
metyrapone (Met) [10µM] or by targeting the cyp11b1 gene using Cyp Mo. Data are mean ± 
SEM (n=3 (10 embryos per group)) and were analysed by 1-way ANOVA and Tukey’s post 




3.4.4 Aim 4 
Does maternal stress impact on embryonic cortisol levels? 
3.4.4.1 Adult cortisol manipulation alters whole embryo cortisol levels  
As can be noted from the embryonic time-course data, whole embryo cortisol 
appears to be high in the early stages of embryogenesis (8hpf), reducing over the 
next few h reaching a minimum around 48hpf. From this point a steady and 
progressive rise in cortisol develops until 120hpf. The initial decrease may be 
attributed to a maternal component within the developing embryo yolk sac which is 
depleted over time as the embryo requires the particular gene or protein. If this is the 
case for cortisol it may be that maternal cortisol levels have a direct effect on the 
levels in the embryo prior to the inflection point. As described (section 3.4.2) adult 
females exposed to Dex both by bathing and by IP injection display altered swim 
water cortisol.  
When the offspring of these mothers were investigated for cortisol production it was 
found that only those embryos from the mothers injected with Dex had an altered 
whole embryo cortisol compared to the control basal data (Figure 3.12A). Whole 
embryo cortisol in this group was found to be greater at the initial time point of 8 hpf 
compared to controls (p<0.05). Cortisol levels in this group then fell at 24 hpf 
following the trend of the controls (0.72 ± 0.16 v 1.50 ± 0.30 ng/embryo p=0.059). 
At 120 hpf there was no difference between the Dex-inj offspring and the controls 
(5.7 ± 0.98 v 3.285 ± 0.3 p= 0.06). All other groups investigated showed no 







































































































Figure 3.12 Influence of maternal dexamethasone treatment on offspring cortisol  
Whole embryo homogenate cortisol levels (time-course over 8, 18, 24, 36, 48, 72, 96 and 120 hours post fertilisation (hpf)). 
Each graph shows data of offspring from maternal dexamethasone (Dex) or vehicle overlaid at 8, 24 and 120 hpf to compare 
with controls (untreated embryos). A) Dex injected (Dex inject) B) dex bathed (Dex bath) C) vehicle injected, and D) vehicle 
bathed (Vehicle Bath). Data are mean ± SEM (n=4 experiments (10 embryos per experiment)) analysed by Student’s t-test *p ≤ 




This chapter set out to investigate the hypothesis that the zebrafish GC system is 
functional. On the basis of the limited evidence available on the zebrafish GC system 
and current understanding of the mammalian system the following hypothesis was 
produced. The zebrafish embryo has a physiologically functional GC system, 
responsive to physiological or environmental stimulus. 
Data presented here aimed to answer the following questions 
1) Are the key components for GC biosynthesis present in the zebrafish? 
2) When does de novo GC biosynthesis occur in the zebrafish embryo? 
3) Is there endogenous production of GC in response to stress? 
4) Does maternal stress impact on embryonic cortisol levels? 
 
Data presented here clearly shows that the zebrafish embryo has many of the key 
components critical for a functional GC system from 24 to 48 hpf. Using 
pharmacological and genetic manipulations it has been shown that endogenous GC 
biosynthesis is active from 48 hpf onwards. It has also been shown for the first time, 
using stress experiments, that the HPI axis becomes functional and responsive in the 
zebrafish embryo at 72 hpf. With the stress induced rise in cortisol at 120 hpf 
abolished by pharmacological and genetic inhibition of 11β-hydroxylase. 
Furthermore it has been shown for the first time that maternally derived embryonic 
cortisol can be influenced by maternal exposure to the synthetic GC Dex.  
3.5.1 Aim 1 
Are the key components for GC biosynthesis present in the zebrafish? 
It has been shown previously that there is maternal deposition of a number of 
endocrine components, such as oestrogen, in the zebrafish embryonic yolk sac which 
progressively deplete during embryogenesis (Alsop & Vijayan, 2008); in accordance 
with this data presented here shows a biphasic pattern of whole embryo cortisol 
levels during early development. This pattern suggests that cortisol detected from 48 
hpf onwards is newly synthesised by the embryo itself. Endogenous embryonic 
biosynthesis of GC is further supported by my data showing an increase in mRNA of 
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key genes required for cortisol biosynthesis crf, star, cyp11a1 and cyp11b1 from 48-
72hpf. These genes each play a critical role in HPI axis activity as highlighted in 
Figure 3.1. Star and Cyp11a1 proteins are important in the conversion of cholesterol 
into steroid hormones. Their pattern of gene relative abundance during development, 
in conjunction with observed changes in the gene responsible for the final rate 
limiting phase of cortisol production cyp11b1 (Hagen et al, 2006), would strongly 
support de novo embryonic cortisol biosynthesis as primarily responsible for the 
secondary rise in cortisol levels between 72 and 120 hpf. CRF in mammals plays a 
central role in the response to stressors through regulation of the activity of the HPA 
axis (Smith & Vale, 2006). In the experiments described here a rise in the crf mRNA 
relative abundance was detected from 72 hpf which strongly supports the acquisition 
of a functional HPI axis at this developmental time-point. 
The data presented clearly display a rise in gr mRNA and Gr protein relative 
abundance increase significantly at 48 hpf. This increase continues until 120 hpf 
confirming a key functional role during this period of rapid growth and development 
of the embryo, consistent with other vertebrate models (Cole et al, 1995; Liggins, 
1994; Murphy et al, 2006; Smith & Shearman, 1974) and other fish species 
(Hillegass et al, 2007; LaLone et al, 2012; Nesan et al, 2012). The mr is another 
receptor for GCs, particularly in the fish in which the classical mammalian MR 
ligand aldosterone is not present. mr relative abundance also increased 4 fold 
between 24 and 120hpf. However the increase in abundance appears to double at 72 
hpf suggesting that the action of GCs on Mr may not be important until later phases 
of development while their actions via Gr may be more important during earlier 
stages of development. This has been previously highlighted in rodent and human 
studies where a role for MR has been implicated in lung maturation, electrolyte and 
fluid dynamics in the developing foetus (Hirasawa et al, 1999; Keller-Wood et al, 
2005).  
Although the role of Mr in fish remains uncertain, since there appears to be no 
aldosterone-like molecule, studies have suggested that Mr plays a similar role in fluid 
homeostasis in fish as it does in mammals (Colombe et al, 2000; Gilmour, 2005; 
Pippal et al, 2011). It also appears to play a further fish specific role in salt water 
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adaptation (Gilmour, 2005; Strum et al, 2005). The lack of aldosterone in fish 
suggests that these roles are primarily activated by cortisol but recent work has 
suggested that 11-deoxycorticosterone (a cyp11b1 substrate) may act as a ligand for 
MR in fish (Kiilerich et al, 2011; Strum et al, 2005). These findings do not exclude 
the possibility that Mr plays an important role in the developing embryo. Indeed, the 
late rise in levels of abundance of 11βhsd2 further support a possible role of Mr in 
development since this enzyme confers specificity on the Mr through the conversion 
of biologically active GCs to inactive 11-keto metabolites (Hirasawa et al, 1999; 
Mommsen et al, 1999; Tokarz et al, 2013b). Other work has suggested that, through 
increased exposure to cortisol, the abundance level of the 11βhsd2 is increased as a 
compensation mechanism in order to reduce circulating levels of GCs (Tokarz et al, 
2012). Another GC catabolic enzyme 20βhsd2 has also been implicated in GC 
regulation in the zebrafish (Tokarz et al, 2013b). A rise in 20βhsd2 mRNA 
abundance was also detected from 72hpf. These data support the hypothesis that the 
increase in 11βhsd2 and 20βhsd2 abundance coincides with the cortisol surge at 
around 72 hpf in order to regulate GC activity and to prevent over activation of both 
zebrafish Gr and Mr. 
Numerous studies to date have described gene abundance patterns for steriodogenic 
enzymes and pathways in the adult zebrafish but these abundance profiles have 
largely focused on the steriodogenic tissues such as the interrenal cells, the gonads, 
ovaries and brain (Diotel et al, 2011; Goldstone et al, 2010; Sakamoto et al, 2001) or 
have assumed that expression will be in accordance to mammalian systems due to the 
striking conservation of the systems (Tokarz et al, 2013a). Work here was carried out 
to confirm the expression of the two main receptors for GC function, Gr and Mr, a 
key gene required for local synthesis (cyp11b1), and 11βhsd2 which is required for 
local GC catabolism. In accordance with animal studies, gr and mr were both found 
in all of the tissues investigated, suggesting that these receptors may have similar 
functions in adult zebrafish as in other mammals. The abundance of mr but lack of 
classic ligand (aldosterone) are intriguing and may offer a mean of characterizing the 
cortisol mediated Mr effects. Growing evidence in mammals suggests that the roles 
of GCs in target tissues are critically determined by the abundance of not only the 
receptors (GR and MR) but also by the presence of 11βHSDs. The data here also 
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suggest a varying expression profile for 11βhsd2 in different tissues. cyp11b1 mRNA 
abundance was only found at quantifiable levels in the kidney, suggesting that local 
GC generation does not occur in the other tissues investigated here, although this 
does not eliminate the possibility in other tissue types. The interrenal tissue of 
teleostian fish is found in close proximity to, or embedded in, the head-kidney; 
therefore it is likely that the cyp11b1 mRNA abundance found in the kidney tissue 
here is as a result of interrenal tissue presence. 
3.5.2 Aim 2 
When does de novo GC biosynthesis begin in the zebrafish embryo? 
Taking the cyp11b1 gene abundance data and the developmental cortisol profile into 
consideration, steps were taken to confirm the hypothesis that cortisol detected after 
36 hpf is not derived from the mother but synthesised by the embryo. To do this Mo 
technology was used to target the enzyme 11β-hydroxylase, which catalyses the final 
rate-limiting step in cortisol production. In keeping with the presence of a functional 
enzyme at this developmental time-point an increase in cortisol following incubation 
in 11-deoxycorticosteroid substrates was observed. Doxy incubation increased 
cortisol levels by around 35% consistent with Doxy acting as the immediate 
precursor for cortisol biosynthesis confirming the likelihood of de novo GC 
synthesis. To further explore the action of this enzyme in the zebrafish, embryos 
were incubated in the known inhibitor of 11β-hydroxylase activity, Met. With 
increasing concentrations of Met a dose-dependent reduction in whole embryo 
cortisol was observed at 120hpf. Similar observations have been made in adult fish 
of other teleost species (Doyon et al, 2006; McConnachie et al, 2012; Milligan, 
2003). Further to this when Doxy was co-incubated with Met a reduction in cortisol 
was observed consistent with inhibition of the forward reaction of doxy to cortisol. 
Additionally Met-induced inhibition of 11β-hydroxylase activity was confirmed by 
an increase in Doxy levels determined by ELISA for this steroid. The possibility of 
molecular suppression of cortisol by Mo knockdown of the cyp11b1 gene was also 
investigated and showed that with a modest mRNA reduction of ~30% there was a 
significant decrease in cortisol at 120hpf; however this genetic manipulation was 
found to not significantly alter cortisol at earlier time points investigated (24 and 
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72hpf). These data clearly indicate that the zebrafish embryo has the machinery in 
place to control its own production of cortisol at least by 120hpf.  
3.5.3 Aim 3 
Is there endogenous production of GC in response to stress? 
This work confirms that at 120hpf, zebrafish respond to a variety of stressors with an 
increase in cortisol (Alsop & Vijayan, 2008; Pikulkaew et al, 2010; Steenbergen et 
al, 2011). Hypoxia and prolonged stirring both increased whole embryo cortisol 
more than twofold. Varying the intensity of stress altered the level of response: a 
shorter period of stirring caused a 1.5 fold increase whereas electrical stimulation 
caused a 2.5 fold increase. Lesser degrees of stress and assay sensitivity may explain 
why other studies failed to show significant cortisol changes in larval fish (Barry et 
al, 1995; Long et al, 2012). The ontogeny of the stress response was investigated by 
comparing stress-induced cortisol changes at different stages of development. No 
response to stress at 24 hpf was determined indicating that detectable cortisol at this 
stage is most likely due to residual maternal cortisol in the yolk-sac since at this early 
stage the embryo lacks the elements required for de novo cortisol biosynthesis.  
A marked response to stress at 72 hpf was noted however, at a time when crf, star 
and cyp11b1 are clearly active. Taken together these data suggest that once all of the 
elements of the embryonic HPI axis are in place then endogenous cortisol production 
becomes stress-responsive. Indeed, it is significant that inhibition of 11β-hydroxylase 
or Mo knockdown of cyp11b1 both abrogated the stress response at 72 and 120 hpf. 
Interestingly, at 72 hpf, 11β-hydroxylase blockade lowered stressed cortisol levels to 
unstressed control levels but at 120 hpf, levels were reduced even further, below 
unstressed controls. This implies that some unstressed cortisol at 72 hpf may still be 
maternally-derived and not susceptible to 11β-hydroxylase inhibition.  
Data presented also shows that a main cortisol catabolism gene, 11βhsd2, is present 
at a significant level from 48 hpf onwards. The enzyme encoded by this genes 
catalyses the local inactivation of cortisol to cortisone, the activity of this gene along 
with 11β-hydroxylase activity is therefore important for regulating cortisol levels 
(Tokarz et al, 2013b). This is an apparent conserved homeostatic regulatory response 
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found in mammals and other species. However, unlike mammals the opposing 
reaction (cortisol production from cortisone by 11βhsd1)- does not occur (Tokarz et 
al, 2013a). The presence of key genes for homeostatic regulation of cortisol in the 
developing embryo from 48 hpf onwards lends further support for a functional HPI 
axis and an active stress response. 
3.5.4 Aim 4 
Does maternal stress impact on embryonic cortisol levels? 
It has previously been shown that progeny can be influenced by non-genetic factors 
derived from the mothers environmental/physiological status during gametogenesis, 
possibly by affecting the mother-to-embryo transfer of proteins or other factors 
(McCormick, 1998). In this way, maternal environmental conditions may influence 
oogenesis and, thus, influence the next generation (Li & Leatherland, 2012). On the 
basis of this the ability of the mother to influence the embryonic cortisol levels was 
investigated by altering the environmental conditions experienced by the mother 
during gametogenesis. 
Maternal exposure to the synthetic GC Dex clearly influences maternal cortisol 
production. Chronic exposure to Dex suppresses basal cortisol production in treated 
adult females. This finding mirrors the phenomenon seen in the diagnosis of 
Cushing’s disease (al-Saadi et al, 1998), the Dex suppression test. Where Dex is 
acting as a GR agonist on the cortisol biosynthesis pathway; activating a negative 
feedback loop resulting in suppression of endogenous cortisol production. 
Subsequently the offspring of mothers injected with Dex displayed a significant 
increase in whole embryo cortisol levels at the earliest time point investigated (8hpf). 
Previous studies have shown that prenatal Dex treatment mimics the effect of 
maternal stress and in rat studies offspring of mothers treated in late gestation with 
Dex have increased plasma corticosterone (the primary GC produced by rodents) 
(Levitt et al, 1996). Reduced birth weight (an indicator of maternal stress, GC 
exposure) has also been associated with increased plasma cortisol levels in humans 
(Phillips et al, 2005; Phillips et al, 2000).  
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Importantly no significant effect on cortisol levels was observed on the offspring of 
maternal Dex treatment at later time points confirming that by these later stages of 
development the endogenous production of cortisol by the embryo is the main 
contributor to cortisol. These data clearly suggest that cortisol detected in the embryo 
in the first 36 hpf is maternally-derived and that by altering the environmental/ 
physiological status in the mother, using injected Dex, we can influence the cortisol 
composition of the egg.  
3.6 Conclusion 
This chapter has detailed a comprehensive investigation of the temporal abundance 
of a number of key components of the GC system, highlighting their activity during 
early development in the zebrafish embryo. The corticosteroid biosynthesis pathway 
becomes physiologically active and relevant from 72hpf, with positive and negative 
HPI axis control from 72hpf. It also supports the suitability of the zebrafish embryo 
as a model system to study physiological and pathophysiological consequences of 
corticosteroid excess and deficiency. While this chapter has confirmed the presence 
of the GC system in the zebrafish embryo it does not determine the role that this 
system plays during embryogenesis and whether manipulating this system will result 
in long term consequences in the adult. Chapter 4 will address the short and long-
term effects on development, HPI axis function and behaviour while chapter 5 will 
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4 Embryonic developmental programming 
4.1 Introduction 
Maternal-foetal signalling and the in utero environment are known to influence foetal 
development. Exposure to adverse in utero environmental factors can result in 
altered foetal cellular and molecular development (Cottrell & Ozanne, 2008) which 
can have long-lasting, and possibly permanent, physiological and pathophysiological 
effects; this is called foetal programming. 
Numerous studies, observational in humans and experimental in other mammals, 
have highlighted a number of abnormalities as a consequence of foetal environmental 
alterations such as reduced birth weight, raised blood pressure, increased adult body 
mass index, glucose intolerance, insulin resistance and dyslipidaemia (Seckl & 
Meaney, 2004). Foetal exposure to GCs can lead to permanent modification of HPA 
function (Kapoor et al, 2006; Kapoor et al, 2008) with evidence of an association 
with increased anxiety and depressive behavioural traits in adult life (Hack, 2006) 
including increased incidence of disruptive behavioural disorders (Latimer et al, 
2012).  
As highlighted in chapter 1, GCs have been suggested as a primary candidate for 
programming. It is clear that GCs ordinarily play a role in growth and tissue 
development, by acting as nutritional and maturational signals (Fowden & Forhead, 
2004), as a rise in GC exposure coincides with a reduction in growth rate, in 
preparation for birth (Fowden & Forhead, 2004). GCs are also given to mothers at 
risk of preterm delivery to assist development and maturation (Stocker et al, 2005).  
Animal models of programming have been developed in order to further evaluate and 
characterise features and mechanisms involved following GC exposure. Pregnant rats 
treated with excess GCs in the mid-trimester, produce fewer, lighter pups per litter. 
These pups show alterations in glucose handling and in liver glycolytic pathways in 
adulthood (Nyirenda et al, 2006; Nyirenda et al, 1998). 
Current models of GC-induced programming have, however, limitations which can 
affect the interpretation of experimental studies. For example, environmental 
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manipulation and follow-up investigation can introduce confounding maternal stress 
(Steenbergen et al, 2011). In mammalian models the placenta adds further 
complexity, firstly due to the high level of abundance of the GC catabolising enzyme 
11βHSD2 (Burton & Waddell, 1999) protecting the foetus from GC over-exposure. 
Secondly, there are conflicting and controversial views as to whether changes in the 
foetus are directly caused by GCs or whether are secondary to maternal or placental 
effects (Barker & Thornburg, 2013; Braun et al, 2013). A further limitation of 
mammalian in utero embryogenesis is that real-time observation of organogenesis is 
challenging (Hsu et al, 2006) and often invasive. 
Zebrafish could provide a solution as they develop externally, removing a direct 
maternal influence and also allowing ease of environmental and non-invasive 
observation of growth and development. The concept of maternal programming has 
previously been looked at in a number of salmonoids, including zebrafish (Aluru & 
Vijayan, 2009; Cai et al, 2012; Cole et al, 2012; Mommer & Bell, 2013; Zhang et al, 
2006). The concept of GC modulation in the zebrafish has generated considerable 
interest recently (De Marco et al, 2013; Nesan et al, 2012; Pikulkaew et al, 2011). 
However, investigation has largely focused on the profound effects of global 
abolition of GCs on morphology rather than subtle adaptive effects on tissues which 
may underpin reprogramming events. 
4.2 Experimental hypothesis and aims 
Manipulation of GC activity in the embryonic zebrafish during the first 5 days post 
fertilisation will result in developmental abnormalities in the embryo leading to 
longer term changes in the adult. 
Data presented here aimed to answer the following questions: 
1) Does embryonic GC manipulation impact on embryonic and adult growth and 
development? (Aim 1) 
2) Does embryonic GC manipulation impact on embryonic and adult HPI axis 
function? (Aim 2) 
3) Does embryonic GC manipulation alter embryonic and adult swim 
behaviour? (Aim 3)  
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4.3  Methods 
4.3.1 Embryonic glucocorticoid modulation 
Modulation of GC activity was performed in zebrafish embryos at the 2 cell stage 
(approx. 1h after egg collection), as described (Appendix 1). Embryos were housed 
under standard conditions (section 2.2) in a 10cm Petri dish at a density of 1 
embryo/mL.  
4.3.1.1 Pharmacological manipulation 
Pharmacological manipulation (Appendix 1) was achieved by bathing embryos in: 
Dex [100 µM], RU486 [10 µM], Met [10 µM] or spironolactone [0.1 µM]. Controls 
for all drug bathing studies in this chapter were embryonic bathing in vehicle only 
(0.1% EtOH). Experiment was repeated in triplicate (10 embryos pooled). 
Pharmacological manipulation in a small cohort was achieved by injection (section 
2.4) of a small bolus (2 ng/mL) of drug dissolved EtOH then diluted in systems 
water. 
4.3.1.2 Genetic manipulation 
Genetic manipulation was achieved by injection of targeted Mo for knockdown of 
two key zebrafish genes (gr and cyp11b1). Design, dosage and injection is 
summarised in Appendix 1. Unless stated otherwise, data shown subsequently will be 
for atg-Mo and will be referred throughout as either GR Mo or Cyp Mo. Controls for 
each of the Mo is injection of respective mm-Mo for each of the genes of interest. 
Experiment was repeated in triplicate (10 embryos pooled). 
4.3.1.3 Embryonic developmental assessments 
Embryonic development was undertaken by daily measurement of total body length, 
head-trunk angle, eye size/length, self-hatch rate and swim bladder inflation 
throughout 120 hpf (section 2.4.5). All experiments were n=3 (20 embryos per 
group) apart from self-hatch which was n=3 (20-60embryos per group). 
4.3.2 Embryo to adult programming study 
To assess the long term effects of embryonic GC manipulation, three groups were 
allowed to grow to adulthood after manipulation had ceased at 120 hpf (un-
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manipulated from 120 hpf -120 dpf). The adult fish are referred to as embryonic 
modification (Emmod). The experimental plan is summarised in Figure 4.1. Two of 
these groups were pharmacological; exposure to Dex [100 µM] (EmmodDex), or 
exposure to RU486 [10 µM] (EmmodRU486) for the first 120 hpf and then left un-
manipulated under normal fish husbandry conditions (section 2.2). The third 
manipulation group investigated was the genetic knockdown of gr (EmmodGR Mo) 
at the 2 cell stage, for the first 120 hpf and then left un-manipulated under normal 
fish husbandry (section 2.2). In each of these manipulations treated embryos and 
adults were compared with age-matched controls. For pharmacological manipulation 
the control was a “vehicle only” group, whilst for the GR Mo it was injection of mm-
Mo. All control groups are referred to as “Control” in figures. However, where two-











Figure 4.1 Embryo to adult programming experimental plan 
Schematic (images not to scale) highlighting the protocol for investigating longitudinal 
effects of embryonic cortisol manipulation on adult phenotype. Embryonic manipulations 
were exposure to dexamethasone (Dex), or RU486, or targeted glucocorticoid receptor 
morpholino (GR Mo) from the 2-cell stage. Manipulation lasted from ~2 hours post 
fertilisation (hpf) until 120 hpf during the course of which embryonic assessments were 
performed. From 120 hpf until 120 days post fertilisation (dpf) embryos/larvae were allowed 
to develop under normal husbandry conditions. At 120 dpf a number of phenotypic 
characteristics were assessed in adults. 
4.3.2.1 Adult developmental assessments 
Adult phenotype and growth were assessed throughout the course of development as 
described (in section 2.5). Length and weight were measured in all fish at 10, 20, 40, 
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60, 90 and 120 dpf. A condition factor (K) was derived for each fish from length 
(mm) and weight (mg) measurements. The formula is given in section 2.5.3. Adult 
zebrafish male/female ratio confirmed by dissection post mortem. 
4.3.3 Gene abundance analysis 
Abundance analysis was performed for several genes, during embryogenesis (whole 
embryo homogenate) or in adulthood (isolated tissue). Whole embryo homogenate or 
adult isolated tissue were processed, RNA extracted, cDNA synthesised and qRT-
PCR performed as described (section 2.6).  
Abundance analysis was performed on a gene previously associated with zebrafish 
development, insulin-like growth factor-1 (igf1) (White et al, 2009) and two genes 
which have been previously suggested to be mediated by GC activity, FK506 binding 
protein 5 (fkbp5) (Mathew et al, 2007) and matrix metallopeptidase 13 (mmp13) 
(Hillegass et al, 2007; Hillegass et al, 2008)). mRNA relative abundance analysis 
was carried out on three genes key genes associated with downstream GC activity gr, 
mr and 11bhsd2. Gene selection is summarised in Appendix 2. 
4.3.4 Measurement of cortisol levels 
Whole embryo homogenate and adult swim water cortisol were measured using a 
sensitive and specific in-house ELISA (section 2.9). This method has previously 
been validated and applied extensively within our laboratory for buffer-reconstituted 
urine, saliva and cell cultures (Al-Dujaili et al, 2011; Al-Dujaili et al, 2009; Moore et 
al, 2011).  
4.3.4.1 Basal whole embryo cortisol 
Whole embryo cortisol was determined from pooled homogenates of 20 embryos 
(section 2.9) following pharmacological or genetic manipulation. 
4.3.4.2 Optimisation of measurement of cortisol in stressed adult fish. 
A series of techniques were assessed to determine a suitable protocol by which to 
adequately and humanely stress adult zebrafish. To determine whether the stress 
response was altered in Emmod adults the following protocol was employed. Briefly, 
five fish were placed in a 1 L tank. For each set of fish (EmmodDex, EmmodRU486 
129 
 
or EmmodGR Mo, and their respective controls) 3 groups of 5 fish were assigned as 
basal (unstressed) controls and 3 groups of 5 adult fish were assigned as stressed 
(n=3 (5 fish per tank)). Stress was induced using netting protocol. Protocol began 
with a 24 h baseline familiarisation period, followed by a 24 h stressed period 
(consisting of 5h of repeated stressor - netting every 30 min for 5 h) then a 24 h 
recovery period. 
4.3.5 Behavioural assessments 
Behavioural characteristics (swim/movements) were determined in embryos and 
adults which had undergone pharmacological or genetic manipulation of the GC 
system at the 2-cell stage. 
4.3.5.1 Embryonic behaviour 
Briefly, a single embryo was placed in a 5cm Petri dish containing 3 mL fresh 
systems water. Embryo movement was recorded from above using a digital CCTV 
camera (Baxall, AD group, UK). Twitch response was counted manually and 
swim/movement data were analysed by commercially available software (Limelight 
Ltd, UK).  
4.3.5.2 Adult swim behaviour 
Adult fish swim behaviour was assessed as described (section 2.5.6). These studies 
included an open field assay, a novel object assay and a forced swim/dive assay. 
Movement of the fish over a given period was recorded using a digital CCTV camera 
(Baxall, AD group, UK) connected to a PC. Swim behaviour were then analysed by 
commercially available software (Limelight Ltd, UK). 
4.3.6 Experimental controls 
In the following experiments data were obtained both in embryos and in adult 
zebrafish. For embryonic pharmacological manipulations controls are vehicle only 
(0.1% EtOH). For embryonic Mo manipulation control data are for injected control 
Mo. For data where embryonic pharmacological and molecular manipulation are 
represented together (e.g. gene abundance) control data are a mean of vehicle only 
and control Mo together (Student’s t-test shows no significance between groups) to 
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ease graphical representation and interpretation. For adult investigations, control data 
for EmmodDex and EmmodRU486 are adult fish which were treated with vehicle 
only during embryogenesis. EmmodGR Mo controls are adults which were injected 
with control Mo during embryogenesis.  
4.4 Results  
4.4.1 Aim 1 
Does embryonic GC manipulation alter embryonic and adult growth and 
development? 
4.4.1.1 Embryonic growth and development 
4.4.1.1.1 Total body length 
None of the embryos which were treated with Dex, Met or Cyp Mo had any 
difference in total body length when compared to controls at any of the time-points 
investigated (Figure 4.2). However targeting the GR receptor (RU486 and GR Mo) 
delayed growth/total body length such that by 48 hpf embryos treated with RU486 
were shorter than controls (p<0.001). This significant difference was lost by 120 hpf 
in embryos incubated with RU486 (Figure. 4.2A). Similarly GR Mo embryos were 
also shorter than controls at 48 hpf (p <0.05), this significant reduction in length was 
maintained at 72 hpf (<0.05), however there was no significant difference between 
GR Mo and controls at 96 and 120 hpf (Figure 4.2 B).  
4.4.1.1.2 Embryonic Growth rate 
RU486 and GR Mo displayed significantly reduced growth rate (the length (µm) 
grown in 1 h) in the early stages of the study with comparable growth rate to controls 
by 120 hpf (Figure 4.4 (A and B)). There was no reduction or enhancement in growth 
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Figure 4.2 Embryonic body length following glucocorticoid modulation 
Total body length (mm) throughout development up to 120 hours post fertilisation (hpf) in 
zebrafish embryos A) treated with 10µM RU486, B) injected with gr-targeted morpholino 
(GR Mo), C) treated with 10µM metyrapone (Met), D) injected with cyp11b1-targeted 
morpholino (Cyp Mo), or E) treated with 100µM dexamethasone (Dex). All data from 
treated fish were compared with appropriate controls (vehicle only for drugs and mismatch 
morpholino injection for morpholino treated- red line on each graph). Data are mean ± SEM 
for n=3 (20 embryos per group). Data were analysed by 2-way ANOVA and Bonferroni post 
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Figure 4.3 Embryonic growth rate following glucocorticoid modulation 
Growth rate (mm grown/ h) over the course of 120 hours post fertilisation (hpf) for embryos: 
A) treated with 10µM RU486, B) injected with gr-targeted morpholino (GR Mo), C) treated 
with 10µM metyrapone (Met), D) injected with cyp11b1-targeted morpholino (Cyp Mo), or 
E) treated with 100µM dexamethasone (Dex). All data from treated fish were compared with 
appropriate controls (vehicle only for drugs and mismatch morpholino injection for 
morpholinos - red line on each graph). Data are mean ± SEM for n=3 (20 embryos per 
group). Data were analysed by 2-way ANOVA and Bonferroni post hoc test; *p ≤ 0.05, *p < 
0.05, **p<0.001.  
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4.4.1.1.3 Head-trunk angle 
When visual observation of embryos was carried out it was noted that embryos 
treated with RU486 and GR Mo appeared to have a delay in reaching straight body 
axis compared to controls, this is an indicator of embryogenesis in developmental 
biology and is quantified by head-trunk angle. The reduced head trunk angle in the 
GR Mo group was equivalent to a 6h developmental delay (in accordance with 
Kimmel (Kimmel et al, 1995) delay shown in Figure. 4.4). Embryos treated with 
RU486 had a significantly reduced head-trunk angle compared to controls at all time-
points. Likewise embryos treated with GR Mo showed changes in head-trunk angle 
at all time-points (p<0.001; Figure 4.5 B). Embryos treated with Met and Cyp Mo 
did not show significantly impaired head-trunk angle at any of the time-points 
(Figure 4.5 C and D). Dex treatment accelerated development with more advanced 
changes in head trunk angle over the time-points studied compared to controls, 









Figure 4.4 Body axis in glucocorticoid receptor morpholino embryos 
Body development at 18 and 30 hours post fertilisation (hpf) in control embryos and those 
which had been injected with an oligonucleotide morpholino sequence specific for the 
glucocorticoid receptor (GR Mo) producing a transient 40% knockdown in gr mRNA (Figure 
4.2). Images show developmental delay of 8h in those embryos treated with morpholino 


































































































































































Figure 4.5 Embryonic head-trunk angle following glucocorticoid modulation 
Head trunk angle over the course of 120 hours post fertilisation(hpf) for embryos: A) treated 
with 10µM RU486, B) injected with gr morpholino (GR Mo), C) treated with 10µM 
metyrapone (Met), D) injected with cyp11b1 morpholino (Cyp11b1 Mo), or E) treated with 
100µM dexamethasone (Dex). All data from treated fish were compared with appropriate 
controls (vehicle only for drugs, for morpholino these were mismatch morpholino - red line 
on each graph). Data are mean ± SEM for n=3 (20 embryos per group). Data were analysed 




4.4.1.1.4 Abundance of key growth, maturation and regeneration genes 
mRNA relative abundance was measured at 72 and 120 hpf in GC modulated 
embryos for three genes previously highlighted as having a role in growth (igf2) or 
GC activity (fkbp5 and mmp13)(Figure 4.6(A-C)). 
Embryos treated with GR Mo had lower igf2 mRNA levels than control injected 
embryos at 72 and 120 hpf (p<0.001). Lower igf2 mRNA abundance was also 
observed at 120 hpf for embryos treated with RU486 compared to vehicle exposed 
embryos (p<0.001) but not at 72 hpf. No other treatments altered igf2 mRNA 
abundance at either time point (Figure 4.6A).  
There was an increase in fkbp5 mRNA abundance in Dex treated embryos at 72 and 
120 hpf (both p<0.05). In contrast, a decrease in fkbp5 mRNA was observed at 120 
hpf in embryos treated with the GR Mo (p<0.05). No other treatment altered fkbp5 
abundance (Figure 4.6 B). 
Abundance of mmp13 mRNA has previously been shown to be altered following GC 
treatment (Matthews et al, 2004) however was found here to be similar at 72 and 120 
hpf in all of the treatment groups investigated (Figure 4.6 C). 
Insulin-like growth factor ( igf)















































































Figure 4.6 Gene relative abundance following glucocorticoid modulation 
Gene mRNA relative abundance in whole zebrafish embryos at 72 and 120 hours post 
fertilisation (hpf). Embryos had previously been treated from the 2-cell stage with 100µM 
dexamethasone (Dex-black bars), 10 µM RU486 (blue bars), glucocorticoid receptor targeted 
morpholino (GR Mo-green bars), metyrapone (Met-orange bars) or targeted cyp11b1 
morpholino (Cyp Mo-purple bars) compared to controls (red bars) as detailed in section 
4.3.6. Abundance data are mean ±SEM for n=3 (10 pooled embryos each time) for A) igf2 
mRNA B) fkbp5 mRNA, and C) mmp13 mRNA. Gene abundance is presented as arbitrary 
units (AU) after standard curve production and normalisation to ef1a and 18s as described 
(section 2.5). Data are mean ± SEM and were analysed by 2-way ANOVA and Bonferroni 
post hoc test; *p < 0.05, **p<0.001. 
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4.4.1.1.5 Eye length and area 
Embryos treated with Met and the Cyp Mo had similar eye length and similar eye 
area to their controls (p>0.05). Embryos treated with Dex, RU486, or GR Mo 
however all showed reduced eye length compared to controls (Dex 0.79 ± 0.02mm, 
RU486 0.78 ± 0.01mm, GR Mo 0.78 ± 0.02mm vs controls 0.91 ± 0.01 mm, p≤ 0.05) 
resulting in a smaller eye area (p≤0.001 (Table 4.1)). 
4.4.1.1.6 Chorion hatch-rate 
The number and proportion (%) of embryos spontaneously hatching from the chorion 
(hatch-rate) was carefully documented over 120 hpf in each of the treatment groups 
(Figure 4.7). Dex incubation increased the percentage hatched by 48 hpf (43 ± 3% v 
controls 16.5 ± 3.5 % p<0.05). Injecting the embryos with a bolus of 2 ng/nL Dex 
increased the proportion of embryos hatched by 48hpf, (97.5 ± 0.5 % vs controls 
16.5 ± 3.5 % p=<0.0001) (Figure 4.7B).  
In embryos treated with RU486 there was a reduction in the proportion of embryos 
hatched by 48 hpf (p<0.05), this difference was sustained at 72 hpf (67.5 ±2.5 v 99 
±1 % p<0.05) but lost by 96 hpf (Figure 4.7C). A more profound delay in self-
hatching was observed in embryos injected with RU486 where hatch rate remained 
lower at all the time-points studied up to 120 hpf at which time a substantial 
proportion of embryos (~34% of those injected) remained un-hatched (Figure 4.7D).  
Similar findings were observed for embryos injected with GR Mo. There was a 
reduction in the number/proportion of self-hatched embryos compared to controls at 
all time-points 48 hpf (p<0.001). As with RU486, a many (~85%) of the GR-Mo 
injected embryos remained un-hatched by 120 hpf. No significant difference in 
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Figure 4.7 Embryonic hatch rate following glucocorticoid modulation 
Proportion of embryos with spontaneous chorion hatching during development vs controls 
(red lines). A) Effects of 100µM dexamethasone (Dex -black line), B) Dex injection (black 
dashed line), C) 10µM RU486 (blue line), D) RU486 injection (blue dashed line), E) 10µM 
metyrapone (Met -orange line), F) Met injection (orange dashed line), G) glucocorticoid 
receptor targeted morpholino (GR Mo-green line), F) cyp11b1 targeted morpholino (Cyp 
Mo-purple line). Values are mean ± SEM for n=3 experiments (20-60 embryos per 
experiment). Effects were compared to vehicle/injected control using Chi squared probability 
test (*p≤0.05, **p≤0.001, ***p≤0.0001).   
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4.4.1.1.7 Gross developmental phenotype and morphology 
Careful phenotype observations were undertaken for dose optimisation (Section 2.4) 
of both the pharmacological and genetic manipulations. The final selection of doses 
for Dex, RU486 and Cyp Mo used in this study did not significantly alter the gross 
phenotype characteristics assessed using a 6 point scoring system (section 2.4.3). GR 
Mo embryos were found to be significantly different at 96 hpf compared to age 
matched controls (p<0.05), the difference in phenotype score at this point is due to 
reduced head trunk angle, a feature which was not apparent at 120 hpf when the 
phenotype score was comparable to controls. Embryos treated with Met displayed 
different phenotype scores are 96 and 120 hpf, (both p≤ 0.01) which was mainly due 
to an excess of pericardial oedema in Met treated embryos. No GC manipulations in 
this work resulted in a mean phenotype score of less than 4, indicating that they 
caused only mild to moderate alterations in gross developmental phenotype (Figure 
4.8).  
Histological examination of treated embryos showed no significant differences in the 
cellular architecture and the structure of non-cardiovascular organs at 120 hpf 
(Figure 4.10), with many of the key anatomical features present (in consultation from 
a departmental vet pathologist). However a common observation noted by 120 hpf in 
embryos where GR activity was suppressed (RU486 and GR Mo) was an alteration 
in swim bladder inflation (recorded as the percentage of the total treatment group 
which had an inflated swim bladder at 120 hpf).  
Embryos incubated in RU486 or treated with GR Mo were less likely to have an 
inflated swim bladder at 120 hpf compared to controls (RU486 7.3 ± 1.3 % vs 99.4 
±0.2 %, respectively, p<0.001) with similar findings in the GR Mo embryos (25.4 ± 
3.4 % vs 99.4 ± 0.2 % p<0.001). Examples of a lack of swim bladder inflation in the 
RU486 group are shown in Figure 4.9. Treatment of embryos with Dex, Met or Cyp 
Mo had no significant impact on swim bladder inflation (Table 4.1). 
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Figure 4.8 Embryonic phenotype score following glucocorticoid modulation 
Mean phenotype score for groups of embryos treated either pharmacologically or genetically 
to manipulate the effect of glucocorticoids. A) 10µM RU486 B) glucocorticoid receptor-
targeted morpholino (GR Mo), C) 10 µM metyrapone (Met), D) cyp11b1-targeted 
morpholino (Cyp Mo), and E) 100 µM dexamethasone (Dex) all vs control (vehicle alone 0.1 
% EtOH or mismatched morpholino) over 120 hours post fertilisation (hpf). Scoring system 
is as follows 6 (Normal), 4-5 (Mild), 2-3 (Moderate), 1 (Severe) and 0 (dead). Data are mean 
± SEM (n=3, duplicated results of 35-40 embryos per experiment) and analysed by 2-way 
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Figure 4.9 Effects of glucocorticoid modulation on swim bladder inflation 
Images depicting swim bladder inflation in embryos at 120 hour post fertilisation (hpf) in 
controls and in those which had been treated with 100µM dexamethasone (Dex); 10µM 
metyrapone (Met) or 10µM RU486. Arrow in control image depicts location of inflated 
swim bladder. Arrow in RU486 image shows absence of inflated swim bladder. Calibration 





Figure 4.10 Embryonic histology following glucocorticoid modulation 
Typical sagittal-sectioned embryos at 96 hours post fertilisation (hpf) in untreated controls or those which had been continuously pharmacologically 
or molecularly manipulated to modulate the activity of the GC system using the drugs dexamethasone (Dex), RU486 (a GR antagonist), metyrapone 
(Met) or morpholinos targeted towards gr (GR Mo) or cyp11b1 (Cyp Mo). Sections were stained with haematoxylin (H) and eosin (E). H stains 
nuclei blue/indigo while E stains eosinophilic structures (proteins etc.) shades of red, pink and orange. Images shown may have planar differences 
and are only used to highlight anatomical features; histological images have not been used for quantitative analyses. Features highlighted are: somite 




Table 4.1 Embryonic phenotype observations 
Summary of eye length (72 hours post fertilisation (hpf)), eye area (72hpf) and swim bladder inflation (120 hpf) in zebrafish embryos which had 
undergone glucocorticoid (GC) manipulation from the 2-cell stage by using dexamethasone (Dex), RU486, glucocorticoid receptor morpholino (GR 
Mo), metyrapone (Met), or cyp11b1 targeted morpholino (Cyp Mo). Data are mean ± SEM for n=3 (12 per group for eye data/50 per group for swim 
bladder inflation). Eye data were compared with controls using 1-way ANOVA, swim bladder inflation was analysed by chi-square analysis.  
 
 Control Dex P value RU486 P valued GR Mo P value Met P value Cyp Mo P value 
Eye length @72 hpf (mm) 0.91± 0.01 0.79±0.02 p<0.0001 0.78±0.01 p<0.05 0.78±0.02 p<0.05 0.89±0.02 NS 0.87± 0.02 NS 
Eye area @72 hpf (mm2) 0.51±0.01 0.39±0.02 p<0.0001 0.38±0.02 p<0.0001 0.42±0.02 p<0.001 0.49±0.02 NS 0.46±0.03 NS 




4.4.1.2  Adult growth and development 
4.4.1.2.1 Embryo to adult Survival 
No differences were observed in terms of group survival over the course of the study 
with comparable numbers surviving until 120 dpf. These data include fish that died 
spontaneously and those that were humanely disposed of due to major structural 
abnormalities in accordance with Home Office regulations. The majority of deaths in 
all groups occurred between 10 dpf and 20 dpf (EmmodDex, 24% dead vs control, 
14% dead, p<0.05; EmmodRU486, 17% dead vs control, 21% dead; and EmmodGR, 





Figure 4.11 Adult survival following embryonic glucocorticoid modulation 
Adult survival from 10-120 days post fertilisation (dpf) following embryonic glucocorticoid 
system manipulation with either A) 100µM dexamethasone (EmmodDex), B) 10µM RU486 
(EmmodRU486) or C) glucocorticoid receptor morpholino (EmmodGR Mo). In each 
treatment data mean± SEM (60-80 fish per group) and compared with a control (red 
symbol); for A) and B) the control is embryonic exposure to vehicle (0.1% EtOH) and C) is 
a mismatched glucocorticoid receptor morpholino.  
4.4.1.2.2 Juvenile swimming behaviour 
Beyond 120 hpf it was noted that a high percentage of juveniles treated with RU486 
(EmmodRU486) were not free swimming at 10 dpf compared to the controls 
(p<0.04). By 20 dpf, however, most fish in this group were able to swim freely 
(p>0.05). Similarly, fewer EmmodGR Mo fish were able to swim freely at 10 dpf 
compared to controls (p<0.05); again this was not observed at 20 dpf when all 
surviving fish in these groups were able to swim freely (Table 4.2).  
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Table 4.2 Adult development 
Data presented in this table are a summary of male: female ratio, total body length at 90 days post fertilisation (dpf) and 120 dpf, weight at 90 dpf 
and 120 dpf in adult zebrafish which had been treated with glucocorticoid manipulating compounds during embryogenesis. Data are for those treated 
during embryogenesis with dexamethasone (EmmodDex), RU486 (EmmodRU486) or with glucocorticoid receptor morpholino (EmmodGR Mo). 























21.5± 0.9 18.9± 0.9 0.05 22.5 ± 0.9 19.4 ± 0.8 0.02 19.4 ± 0.9 17.1 ± 0.8 0.154 
Total body 
length @ 120 
dpf (mm) 
26.1 ± 0.3 23.8 ± 0.3 <0.001 27.5 ± 0.3 25.0 ± 0.3 
<0.00
01 
23.1 ± 0.7 22.1 ± 0.6 0.105 
Total body 
weight @ 90 
dpf (g) 
198.0±9.0 225.3±15.0 0.13 189.2±11.0 195.4±10.1 0.68 196.2±6 192.4±8.8 0.71 
Total body 
weight @ 120 
dpf (g) 
532.0 ± 22.1 340.6 ± 15.6 
 
<0.001 
495.0 ± 20.0 387.1 ± 19.0 0.002 257.6 ± 26.1 345.5 ± 36.0 0.055 
Condition 
factor 
1.42 ± 0.06 0.84 ± 0.04 <0.001 1.33 ± 0.07 1.02 ± 0.06 0.002 0.58 ± 0.07 0.82± 0.09 0.008 
145 
 
4.4.1.2.3 Total body length 
Body length was recorded at 20-30 day intervals over the course of 120 dpf. 
EmmodDex adults showed no difference in length up to 60 dpf. However, by 90 dpf 
they were longer than their controls (p<0.05. This difference was maintained until 
120 dpf (p<0.001 Figure 4.12A)). EmmodRU486 adults were of similar length to 
controls until 60 dpf after which they were longer (EmmodRU486 22.5 ±0.9mm vs 
Controls 19.4± 0.8mm, p=0.02). This difference was maintained until 120 dpf 
(p<0.05 (Figure 4.12B)). EmmodGR Mo adults showed no significant difference in 
body length at any point throughout the course of the experiment (p>0.05 (Figure 
4.12C)). 
4.4.1.2.4 Body weight 
EmmodDex showed a weight-gain trajectory similar to controls up to 90 dpf. 
However, by 120 dpf these fish were significantly heavier than controls (p<0.01 
(Figure 4.12D)). No sex difference was observed (Table 4.2)). EmmodRU486 adults 
showed no difference in body weight compared with controls until 120 dpf by which 
point they were heavier (495 ± 20 mg vs. 387 ± 19 mg, p=0.002 (Figure 4.12E)). 
There was also no detectable difference between the sexes within each group (Table 
4.2)). EmmodGR Mo adults had a similar weight gain trajectory as controls 
throughout the 120 day time-course of the study. However, a trend towards 
significance was observed at the end of the experiment at 120 dpf, when the GR Mo 
were slightly smaller than the controls (258 ± 26 mg vs. 346 ±36 g, p=0.056 (Figure 
4.12F)) increasing the group number here may determine the importance of this 
result.  
4.4.1.2.5 Condition factor (fish girth) 
EmmodDex adults had a greater condition factor than controls at 120 dpf (1.42 ± 
0.06 k vs. 0.84 ± 0.04 k, p<0.0001). EmmodRU486 also displayed a greater 
condition factor compared to controls (1.327 ± 0.07k vs 1.023 ± 0.06 k, p<0.05, 
whereas EmmodGR Mo displayed a significantly lower condition factor compared 





































































































































Figure 4.12 Adult growth following embryonic glucocorticoid modulation 
Growth (length and weight trajectories) of adults derived from embryos which underwent glucocorticoid manipulation during embryogenesis. 
Data presented here are from 10 days post fertilisation (dpf) until 120 dpf. Adults are from the groups treated during embryogenesis with: A) 
and D) dexamethasone (EmmodDex-black line), B) and E) RU486 (EmmodRU486-blue line), or C) and F) glucocorticoid receptor-targeted 
morpholino (EmmodGR Mo-green line). All data are compared with their own specific controls (for drugs this was vehicle only (0.1% EtOH) 
for morpholino this was mismatched morpholino - red line). A-C) is for total body length and D-F) is for total body weight. Data shown are 





4.4.2 Aim 2:  
Does embryonic GC manipulation alter embryonic and adult HPI axis function? 
To investigate whether GC manipulation altered HPI axis activity cortisol levels 
were monitored using cortisol ELISA, and the abundance of key GC genes was 
determined using qRT-PCR. 
4.4.2.1 Embryonic HPI axis activity 
4.4.2.1.1 Embryonic Basal cortisol 
Changes in cortisol levels were determined by ELISA of whole embryo homogenates 
at 72 and 120 hpf following pharmacological or genetic modulation of the GC 
system. There were no differences in cortisol for any of these modulations at 72 hpf 
compared to controls (p>0.05 (Figure 4.13(A)). However, by 120 hpf, all embryos 
treated with drugs or Mo displayed reduced cortisol levels compared to controls Dex, 
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Figure 4.13 Embryonic cortisol after glucocorticoid modulation 
Whole embryo cortisol in embryos exposed to dexamethasone (Dex) [100µm], RU486 
[10µm], metyrapone (Met) [10µm] or morpholino targeted towards cyp11b1 (Cyp Mo)  
or glucocorticoid receptor (GR Mo) from 1 hour post fertilisation (hpf) until 72 hpf (A) 
and 120 hpf (B) Data shown are mean ± SEM for n=3 (10 embryos). Data were analysed 





4.4.2.1.2 Embryonic gene relative abundance after glucocorticoid manipulation  
Incubation in Dex or Met had no effect on abundance of gr mRNA relative 
abundance at 72 or at 120 hpf. Incubation in RU486 had no effect on detectable gr 
levels at 72 hpf (p>0.05) but increased abundance of gr mRNA at 120 hpf (p<0.001). 
Embryos treated with Cyp Mo showed a reduction in gr mRNA at 72 hpf (p<0.05) 
but not at 120 hpf (0.88 ± 0.10 vs. controls 0.97 ± 0.01 AU, p>0.05). Meanwhile for 
GR Mo embryos a reduction in gr mRNA was noted at 72 hpf (P<0.0001) the 
detectable levels at 120 hpf were found to be significantly lower than controls but the 
difference here was less extreme (p<0.05 (Figure 4.14 A)). 
mr mRNA abundance was also assessed at 72 and 120 hpf following continuous 
incubation with drug (from 1 hpf) or treatment with Mo (Figure 4.14 B). Neither of 
the Mo gene knockdown treatments altered mr mRNA levels significantly compared 
to controls at 72 hpf (both p>0.05) or at 120 hpf (both p>0.05). Likewise no 
difference in mr mRNA was detected in embryos which had been constantly 
incubated in RU486 at 72 hpf or at 120 hpf (p>0.05). Met incubation did, however, 
result in increased levels of mr mRNA at 120 hpf (1.23 ± 0.02 vs. control 0.75 ± 
0.02, p<0.0001), but not at 72 hpf (p>0.05). Following Dex incubation there was an 
obvious increase in mr mRNA at 72and at 120 hpf (p<0.001 (Figure 4.14B)).  
hsd11b2 mRNA relative abundance was also assessed (Figure 4.14C). RU486 
treatment did not alter abundance of this gene at 72 or 120 hpf (p>0.05). Met 
incubation and treatment with the Cyp Mo showed similar findings at 120 hpf where 
both of these groups displayed and increase in hsd11b2 mRNA relative abundance 
compared to the controls (p<0.01). Embryos treated with GR Mo showed higher 
mRNA levels of hsd11b2 at 120 hpf (p>0.001), however, there was no difference at 
72 hpf (0.99 ± 0.1 vs. control 0.91 ± 0.03AU.). Constant incubation in Dex resulted 








































































































Figure 4.14 Embryonic gene abundance after glucocorticoid modulation 
Gene mRNA relative abundance in whole zebrafish embryos at 72 and 120 hours post 
fertilisation (hpf). Embryos had previously been treated from the 2-cell stage with 
dexamethasone (Dex-black bars), RU486 (blue bars), morpholino targeted towards 
glucocorticoid receptor (GR Mo-green bars)), metyrapone (Met-orange bars) or a 
morpholino targeted towards cyp11b1 (Cyp Mo-purple bars) compared to control embryos 
(red bars) as detailed in section 4.3.6. Relative mRNA abundance is shown for A) gr, B) mr, 
and C) 11βhsd2. Data are mean ± SEM for n=3 (10 embryos per time pooled), presented as 
arbitrary units (AU) after standard curve production and normalisation to ef1a and 18s. Data 
were analysed by 1-way ANOVA and Dunnett’s post hoc test, compared to controls at each 





4.4.2.2 Adult HPI axis activity 
4.4.2.2.1 Adult basal and stressed cortisol 
To determine the long-term effects of embryonic GC manipulation on adult HPI axis 
function 24h cortisol was measured in the bathing water of Emmod-adults. Basal 
cortisol levels were determined as the cumulative concentration achieved in the 
bathing water of a 5L tank containing 5 adult fish over a 24 h period prior to stress, 
followed by the same measurement in the 24h following the stressful stimulus.  
EmmodDex adults had a similar basal 24h cortisol level to controls (EmmodDex 
8.15 ± 0.35 ng/fish/ L vs. control 6.87 ± 0.50 ng/fish/ L, p=0.09 (Figure 4.15A). 
Following netting stress, however, EmmodDex showed a higher 24h tank cortisol 
level compared to controls (EmmodDex 19.80 ± 0.60 ng/fish/ L vs. control 15.10 ± 
0.46 ng/fish/ L, p=0.008 (Figure 4.15 B). 
EmmodRU486 adults showed no difference in 24h tank cortisol levels compared to 
controls both basally (10.37 ± 1.89 vs. 9.45 ± 0.97 ng/fish/ L, p >0.05) and following 
stress, (p>0.05(Figure 4.16A and B)). EmmodGR MO showed no detectable 
difference in basal tank cortisol levels compared to controls (p>0.05), however did 






Figure 4.15 Embryonic dexamethasone exposure and adult cortisol 
Tank Cortisol levels in 24 h collection pre (basal) and post (stressed) net/restraint stressor 
protocol for adult fish treated with dexamethasone during embryogenesis (EmmodDex) vs. 
vehicle only controls. Data are mean ± SEM for n=3 (5 fish per L) expressed as mean 
cortisol levels in ng/fish/ L and analysed using Student’s t-test (**p≤0.01). 
 
























































Figure 4.16 Embryonic RU486 exposure and adult cortisol 
Tank Cortisol levels in 24 h collection pre (basal) and post (stressed) net/restraint stressor 
protocol for adults which had been treated with RU486 during embryogenesis 
(EmmodRU486) vs vehicle only controls. Data are mean ± SEM for n=3 (5 fish per L) 





Figure 4.17 Embryonic glucocorticoid receptor knock down and adult cortisol 
Tank Cortisol levels in 24 h collection pre (basal) and post (stressed) net/restraint stressor 
protocol for adults which had been treated with glucocorticoid receptor targeted morpholino 
during embryogenesis (EmmodGR Mo) vs. injected mismatch controls. Data are mean ± 
SEM for n=3 (5 fish) expressed as the mean cortisol levels in ng/fish/ L, analysed using 
Student’s t-test (** p≤0.001). 
  





























































































4.4.2.3 Adult mRNA abundance of key Glucocorticoid genes 
Abundance of GC function genes was determined in various isolated adult tissues 
following embryonic manipulation (Tables 4.3 and 4.4). EmmodDex increased gr 
mRNA relative abundance in the kidney (P<0.001) and in the liver (p<0.05). No 
other tissues investigated (including brain and smooth muscle) showed altered gr 
mRNA levels. In EmmodDex mr mRNA abundance was unaltered in all of tissue-
types studied. 
EmmodRU486 adults, showed lower gr mRNA gene abundance in isolated liver 
compared to controls (p<0.05) with no differences in other isolated tissues (kidney, 
brain, smooth muscle). mr mRNA levels were higher in isolated brain tissue 
compared to controls (11.21 ± 0.52 vs. 7.55 ± 0.31 AU, p<0.001), with abundance of 
mr mRNA comparable to controls all other tissues investigated. 
EmmodGR Mo adults, showed lower gr mRNA in isolated liver preparations 
compared to controls (p<0.01) with no differences in other isolated tissues (kidney, 
brain, smooth muscle). mr mRNA abundance levels in EmmodGR Mo were higher 
in brain than for controls (p<0.01) but unaltered in all other tissues investigated. 
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Table 4.3 Glucocorticoid receptor (gr) mRNA abundance  
gr gene relative abundance as determined using qRT-PCR following embryonic treatment with dexamethasone (EmmodDex), RU486 
(EmmodRU486) or morpholino targeted towards glucocorticoid receptor (EmmodGR Mo), versus their respective controls. Gene abundance is 
quantified as relative concentration in arbitrary units derived from a standard concentration curve and normalised to the house keeping genes ef1α 
and gapdh. Data are mean ± SEM of n=3 (5 organs pooled) analysed by Student’s t-test. 
 
gr mRNA abundance EmmodDex Control P value EmmodRu486 control P value EmmodGR Mo Control P value 
Liver 0.47±0.03 0.34±0.05 0.056 0.29±0.02 0.35±0.02 0.03 0.21±0.02 0.37±0.03 0.01 
Kidney 2.03±0.07 1.17±0.17 0.0007 1.22±0.21 1.15±0.16 0.80 1.45±0.09 1.20±0.26 0.41 
Brain 7.23±0.85 6.35±0.59 0.44 7.35±0.21 6.89±0.15 0.15 6.74±0.14 7.01±0.65 0.71 
Muscle 2.34±0.04 2.48±0.09 0.22 1.85±0.04 1.98±0.17 0.09 2.10±0.12 2.01±0.23 0.75 
 
Table 4.4 Mineralocorticoid receptor (mr) mRNA abundance 
mr gene relative abundance as determined using qRT-PCR following embryonic treatment with dexamethasone (EmmodDex), RU486 
(EmmodRU486) or morpholino targeted towards glucocorticoid receptor (EmmodGR Mo), versus their respective controls. Gene abundance is 
quantified as relative concentration in arbitrary units derived from a standard concentration curve and normalised to the house keeping genes ef1α 
and gapdh. Data are mean ± SEM. of n=3 (5 organs pooled) analysed by Student’s t-test. 
 
mr mRNA abundance EmmodDex Control P value EmmodRu486 control P value EmmodGR Mo Control P value 
Liver 0.68±0.03 0.62±0.02 0.17 0.56±0.03 0.68±0.08 0.24 0.62±0.08 0.71±0.07 0.44 
Kidney 1.12±0.05 1.20±0.09 0.48 1.32±0.08 1.29±0.05 0.76 1.28±0.05 1.32±0.06 0.71 
Brain 11.7±0.06 10.05±0.63 0.10 11.21±0.57 7.55±0.31 0.001 10.33±0.42 9.35±0.31 0.01 
Muscle 0.89±0.23 0.85±0.65 0.95 0.91±0.05 0.92±0.12 0.94 0.87±0.03 0.91±0.02 0.31 
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4.4.3 Aim 3:  
Does embryonic glucocorticoid manipulation alter embryonic and adult swim 
behaviour? 
4.4.3.1 Embryonic swim/movement behaviour 
4.4.3.1.1 Spontaneous twitch behaviour 
The first locomotor behaviour observed in zebrafish embryos is in the form of 
spontaneous movement, whereby the embryos repeatedly perform slow, alternating 
twitch like movements (Selderslaghs et al, 2013). The influence of GC manipulation 
on locomotor development was observed in all treatment groups at 18hpf. Embryos 
which were continuously incubated in Dex and Met or injected with Cyp Mo 
displayed no difference in spontaneous twitches compared to controls. However, 
embryos which had been treated with RU486 or GR Mo showed fewer twitches 
compared to controls (p<0.001 Figure 4.18A). 
4.4.3.1.2 Response to touch stimulus 
Coordinated muscular movements in response to touch stimulus were observed in 
embryos which were continuously incubated in drugs or following treatment with 
morpholino. Dex, Met or Cyp Mo embryos showed no alteration in the response to 
the gentle touch of a forcep tip. RU486 and GR Mo embryos did, however, display 
muted responses to this stimulus, with a lower percentage responding than in controls 
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Figure 4.18 Embryonic movement after glucocorticoid modulation 
Embryonic movement following either pharmacological or molecular glucocorticoid 
modulation. Pharmacological manipulations include: dexamethasone (Dex), RU486 and 
metyrapone (Met). Molecular manipulations include: morpholino targeted towards 
glucocorticoid receptor (GR Mo) or cyp11b1 (Cyp Mo). Shown are A) mean twitches per min, 
the spontaneous uncoordinated movements observed in embryos at 18 hours post fertilisation 
(hpf)(n=20 embryos per group). B) The response to gentle touch stimulus given as a percentage 
of the total study group (n=5, 10 embryos per test). Data are mean ± SEM, analysed by 1-way 
ANOVA and Dunnett’s post hoc test; *p≤0.05, ***p≤0.001. 
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4.4.3.1.3 Distance travelled 
Velocity of movement was observed at 72 and 120 hpf in embryos continuously 
treated with drug, or after Mo treatment. Treatments did not impair velocity of 
movement at 72hpf, when embryos are not actively exploring their environment 
(Figure 4.19A). However, by 120hpf, some treatments altered embryonic velocity. 
All treatments which suppress the activity of GC resulted in a reduced velocity 
compared to controls (p<0.001). Embryos which were treated with Dex had 
comparable velocity to controls (Figure 4.19 B). Locomotor activity of embryos was 
compared between treatment groups at 120 hpf over a standardised 5 min time 
period. Embryos treated with Dex showed no difference from controls in distance 
travelled (p>0.05) while treatment with either RU486 or GR Mo resulted in less 
distance travelled compared to controls (p<0.05). Embryos treated with Met or Cyp 
Mo also showed lower locomotor activity compared to controls (p<0.001 ((Figure 
4.19 C)).  
At 72 hpf control embryos spend a large proportion of their time in the mid region of 
the Petri dish with typically 73.25 ± 1.93% of their time spent in this region 
compared to only 12.75 ± 1.37 % of the time in the outer region. Met, RU486, Cyp 
Mo and GR Mo-treated embryos mirrored this pattern of swim behaviour (Table 
4.5). In contrast, Dex treated embryos spent less time in the central region 
(p<0.0001) with more time spent in the outer region (p<0.0001 (Table 4.5)). At 120 
hpf control embryos spent 20.05 ± 3.20% of their time in the outer region, this was 
similar to the time spent by, Met and Cyp Mo (p>0.05). Less time was spent in this 
zone by RU486 and GR Mo embryos compared to controls (p<0.05). These embryos 
spent longer in the mid region (entry region) of the Petri dish than any other group, 
significantly more than the un-manipulated controls (p<0.001). Conversely, embryos 
which were treated with Dex spent much longer in the outer region of the dish 
(p<0.001), with very little of their time spent in the mid or inner regions (p<0.001) 
and (p<0.001) of the time, respectively (Table 4.3)). These findings are clear in the 





Figure 4.19 Embryonic swim activity after glucocorticoid modulation  
Locomotive/swim activities in embryos following various treatments with drugs and morpholinos. Drugs investigated include: dexamethasone (Dex-
black bars), RU486 (blue bars) and metyrapone (Met-orange bars). Morpholinos were targeted towards the glucocorticoid receptor (GR Mo) or cyp11b1 
(Cyp Mo). Data shown are A) Speed of 72 hours post fertilisation (hpf) embryos (n=3 (8 embryos per expt.)), B) Speed of 120 hpf embryos, after 
constant incubation in drug or treatment with drug n=3 (8 embryos per expt), C) Distance travelled (mm/min) of 120 hpf embryos (n=3 (8 embryos per 
group)). Data are mean ± SEM, analysed by 1-ANOVA compared to controls and analysed with Dunnett’s post hoc test (*p≤0.05, **p≤0.001, 
***p≤0.0001). D-E) Typical heat maps and traces of embryo movement at 72 and 120hpf. LimeLight video analysis software was used to digitally 
delineate the Petri dish into 3 concentric regions. Shown are traces of a single embryo’s movement over a 5 min period (blue line on black background) 
with corresponding graded heat map with areas of high activity indicated by the warmer colours (red) in a downward gradient towards cooler colours 
(blue) for less activity. 

































































Table 4.5 Embryonic zone preferences after glucocorticoid manipulation 
Embryonic zone preference at 72 and 120 hours post fertilisation. Zone preference refers to 
the time spent in a particular delineated region of a Petri dish. Three concentric regions were 
marked, the inner, mid and outer. The time spent in each zone was given as a percentage of 
the total study time. Data are mean ± SEM (n=12 embryos). Statistical analysis was carried 
out by 1-way ANOVA of variance, p values displayed with those highlighted deemed 
statistically significant; p≤0.05.  
 
72hpf Inner P value Mid P value Outer P value 
Control 1.20 ±2.15 / 73.25±1.93 / 12.75± 1.37 / 
Dex 0.75±1.85 0.88 20.25± 0.95 0.0001 68.25±1.54 0.0001 
RU486 1.75±1.63 0.84 79.00 ± 1.08 0.22 9.25±1.10 0.06 
GR Mo 0.75±2.86 0.90 67.75± 2.98 0.14 12.50±0.65 0.87 
Cyp Mo 3.75±2.16 0.42 76.25± 3.09 0.42 16.00±0.82 0.06 
Met 9.25±3.19 0.05 75.50 ± 2.84 0.52 15.25±1.03 0.15 
120hpf Inner P value Mid P value Outer P value 
Control 18.80±2.15 / 40.32±1.56 / 20.05± 3.20 / 
Dex 4.75±1.06 0.0001 10.25± 1.25 0.0001 59.53±3.02 0.0001 
RU486 2.75±0.52 0.0001 59.00 ± 3.06 0.0001 6.20±5.01 0.03 
GR Mo 5.75±2.86 0.001 72.75± 1.68 0.0001 8.50±1.05 0.002 
Cyp Mo 11.75±2.86 0.06 36.25± 2.07 0.13 17.0±0.82 0.37 
Met 16.25±5.19 0.08 42.50 ± 1.64 0.35 18.50±1.23 0.66 
 
4.4.3.2 Adult swim behaviour 
4.4.3.2.1 Forced swim/dive assay 
This assay exploits the zebrafish natural tendency to initially dive to the bottom of a 
novel or unfamiliar tank after which vertical activity should gradually increase. The 
time used for this assay was four min during which it was apparent that control fish 
spent longer in the lower region of the tank (on average 86% of time) with an 
average of only 14% of total time spent in the upper region of the tank.  
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There was no difference between EmmodRU486 and controls in the time spent in the 
upper region of the tank or, consequently, in the time spent in the lower region of the 
tank (p>0.05; Figure 4.21). Likewise the EmmodGR Mo adults spent a similar 
proportion of their time in the upper region and the lower regions as controls (p>0.05 
Figure 4.22. A difference however was noted in the EmmodDex adults which spent 
longer in the upper region of the tank compared to controls (36.5 ±8.9 vs. 14.2 ± 6.4 
%, p=0.05), and, consequently, less time in the lower region of the tank (53.3 ± 8.9 












Figure 4.20 Adult dive tank/forced swim assay after embryonic modulation 
Forced swim/dive tank region preference (either upper or lower region of tank) in adult fish 
embryonically manipulated by: A) dexamethasone (EmmodDex-black bars), B) RU486 
(EmmodRU486-blue bars), or C) glucocorticoid receptor targeted-morpholino (EmmodGR 
Mo –green bars). Data are mean ± SEM (n=12 fish) and were compared with respective 
controls (red bars) by Student’s t-test (*p≤0.05). 













































































































4.4.3.2.2 Open field assay 
An open field test was used to assess adult swim behaviour. This assessment 
measures the number of zones that the fish crosses in a 3 min period using a 9-square 
grid template to track fish movements using LimeLight software. The percentage of 
time spent in the central zone (a feature of “boldness”) and the speed at which the 
fish travels whilst exploring the tank are documented and analysed by the tracking 
software. EmmodRU486 and EmmodGR Mo displayed no difference in zone 
crossing or the time spent in the central zone compared to their controls. There was, 
however a difference in the time spent in the central region by the EmmodDex 
groups compared to controls (p<0.05, Figure 4.21A). The speed at which adults 
explored the open field area was also calculated. No group showed any difference in 

















































































































































































Figure 4.21 Adult open-field assay after embryonic manipulation 
Open field quantitative analysis of adults which had glucocorticoid modulation during 
embryogenesis. Manipulation was achieved using: dexamethasone (EmmodDex-black), 
RU486 (EmmodRU486-blue), or targeted glucocorticoid receptor morpholino (EmmodGR 
Mo-green). All group data are versus respective control (red). A-C) Percentage of total time 
in the open field arena which was spent in the central square of a nine square grid open field 
arena, and D-F) Mean velocity (cm/s) of adults in an open field arena. Data are mean ± SEM 
for n=12 fish. Data were analysed by Student’s t-test vs controls (* p≤0.05). 
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4.4.3.2.3 Novel object assay 
The aim of this assay is to measure “boldness” by recording the amount of time a 
single fish spends close to a foreign object, representing a predator, in the testing 
arena. The average number of times the fish crossed into the novel object zone was 
recorded over a 2 min period. EmmodRU486 adults showed very similar behaviour 
to controls (p>0.05, Figure 4.22B)). EmmodGR Mo displayed an apparent reduction 
in the number of crosses into the novel region but this did not reach statistical 
significant (EmmodGR Mo 2.2 ± 0.6 vs. 4.0 ± 0.9 crosses/2min, p=0.09. In contrast, 
EmmodDex showed increased time spent in the novel object zone compared to 






























































































Figure 4.22 Adult object avoidance after embryonic glucocorticoid manipulation 
Total number of crosses into the novel object region by adult zebrafish which were 
manipulated during embryogenesis. Data shown are for adults treated during embryogenesis 
with: A) dexamethasone (EmmodDex-black), B) RU486 (EmmodRU486-blue), or C) 
injected with a targeted glucocorticoid receptor morpholino (EmmodGR Mo). Data are mean 




This chapter has carefully explored and documented whether pharmacological or 
genetic manipulation of the GC system during early embryonic development alter 
development and growth, HPI axis function and swim behaviour in the developing 
zebrafish embryo, and whether long-term disruption of these processes is 
“programmed” in the adult. 
4.5.1 Aim 1:  
Does embryonic GC manipulation alter embryonic and adult growth and 
development? 
GCs play a crucial role in mammalian foetal maturation during the late phases of 
gestation which is why they are used clinically to accelerate lung maturation in 
preterm infants (Hewitt et al, 2006). However, this pre-natal GC exposure reduces 
birth-weight, possibly as a result of decreasing cell proliferation and increasing tissue 
differentiation (Cottrell & Seckl, 2009; Seckl, 2004). The underlying cellular and 
molecular events are poorly characterised. To assess the suitability of the zebrafish as 
a model of GC programming model, the effects of manipulating the GC system on 
growth and development were assessed by both inhibiting and activating GC-related 
pathways.  
Despite differences in growth observed in the early stages of development, by 120 
hpf none of the pharmacological treatments investigated altered the length of the 
embryos. There was, however, a clear lag in development/embryogenesis with a 
reduced growth rate and head-trunk angle during the first 72 hpf for embryos in 
which the GC activity pathway was impaired. This lag was not sustained, however, 
as a return to normal developmental rate and head-trunk angle was observed by 
120hpf. Exposure to GC, using Dex incubation, did not cause an increase in growth 
by 120hpf, in contrast to the low birth weight observations in GC over-exposure 
mammals (Reynolds, 2013). Similar investigations using Damselfish (McCormick & 
Nechaev, 2002), however, were consistent with the findings shown in the current 
work. McCormick and colleagues suggested that, as growth is pulsatile in teleost 
fish, there are periods of faster growth followed by longer periods of no growth. By 
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introduction of cortisol global effects on growth may appear more dilute, resulting in 
a highly variable cortisol effect as observed here. However, by exploring growth 
through numerous time-points and assessing numerous features (i.e. head-trunk 
angle) it is evident that GC exposure does have a direct effect on specific periods of 
growth and development, particularly in the early phases of development (less than 
72hpf).  
While an impairment of growth is observed here the effects are less profound than in 
animal models where the foetus and offspring are known to be smaller, a possible 
explanation for this is the likely direct placental effects of GC administration. Whilst 
it is always difficult to extrapolate directly from fish to mammals, the unexpected 
growth shown here could suggest that the placenta plays a key role in the Dex 
influence on growth, possibly potentiating the effects of GC on growth, i.e. a subtle 
growth inhibition is noted in the developing tissue however the gross effect on size is 
as a result of the placenta. Support for this is given from rodent studies where the 
impact of Dex on placental growth has been found to be greater than on growth 
(Hewitt et al, 2006). In the zebrafish, therefore, we may be seeing the true direct 
impact of GCs on growth rather than a combination of direct and indirect effects on 
the foetus via the placenta. 
The most profound effects of GR inhibition on growth were observed in the first 24-
72hpf. As previous data confirmed that GR is present (Chapter 3), this would suggest 
a GR role in early cell growth, even before the endogenous GC system has become 
fully active. Indeed the very early inhibition of GR expression by RU486 suggests 
that the maternal cortisol (identified in Chapter 3) signalling through GR must be 
contributing to some extent to somatic growth. This is in accordance with previous 
research which suggests that GR signalling is essential for mesoderm formation and 
is required for growth and patterning of the neural tube and somites (Reshef et al, 
1998). The delay observed with GR inhibition in the current studies represents a 6-8h 
developmental delay (staged according to Kimmel et al, 1995), since defined somite 
patterning was not observed at 18hpf. The reduction in spontaneous twitching, an 
early marker of somatic muscle innervation, is consistent with these findings. Eye 
size may also be indicative of development as the eye is one of the first detectable 
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features in the embryo. The reduction in eye length and area in the RU486 and GR 
Mo embryos, suggests a global developmental delay. However, interestingly, 
embryos which were incubated in Dex also had a smaller eye. These embryos had no 
other detectable impairment in growth and, thus, it might be that Dex treatment at 
this stage interrupts critical proliferative steps in the formation of the eye. While 
retinal formation data in GC over-exposure studies is limited previous studies in GR 
over-expressing mice have indicated that GR activity may be important for normal 
retinal formation and gene expression analysis of GR morphant zebrafish embryos 
suggests altered expression of critical genes involved in eye formation (Nesan et al, 
2012).  
Chorion hatch-rate, which normally occurs between 48 and 72 hpf (Kimmel et al, 
1995), was delayed in embryos incubated in RU486 and in embryos treated with GR 
Mo. These data also suggest global developmental delay, possibly related to changes 
in the chorion itself or changes in the developing skeletal muscle of the embryo 
(rendering it less capable of mechanically breaking through the chorion). In contrast, 
Dex incubation increased the rate of spontaneous-hatching. This could be due to 
softening of the chorion (Kim et al, 2006). To try to address this, Dex was injected 
directly into the embryo at the 2-cell stage. This produced an even greater increase in 
early hatching, suggesting that this process is initiated predominantly from within the 
embryo itself, as a GR-mediated process. There are at least two possible explanations 
for these findings. Firstly, it is possible that GR promotes hatching-gland maturation 
and subsequent production of proteolytic enzymes that induce softening of the 
chorion (Hagenmaier, 1974). Secondly, Dex has been shown to reduce embryonic 
energy stores within the yolk sac resulting in the need for embryos to hatch earlier to 
seek alternative energy sources (McCormick & Nechaev, 2002). Met incubation and 
Cyp Mo, both influencing endogenous GC biosynthesis pathways, had no significant 
effect on hatch-rate in early development suggesting that endogenous synthesis of 
GC has limited functional role in hatching before 72 hpf and, therefore, hatching is a 
feature of maternal cortisol and functional embryonic GR. 
As mentioned, mammals prenatally exposed to excess GC show reduced birth 
weight. This, in turn, is associated with metabolic alterations and abnormal feeding 
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behaviour (Cottrell et al, 2012). These models typically result in delayed growth with 
subsequent catch-up in growth later in development (Coupe et al, 2012). Catch-up 
growth is known to occur following removal of the mediator of growth restriction 
which results in a steeper trajectory of growth (Wit & Boersma, 2002). 
Developmental regulation, and the underlying cellular mechanisms responsible for 
catch-up, growth are poorly understood with two suggested mechanisms 1) a 
neuroendocrine mechanism, as a result of mis-match in growth between the 
organism’s target size and its actual size; resulting in alteration in the production of 
growth factors, neuroendocrine factors, hormones, and other signal molecules to 
adjust the growth rate accordingly to the degree of the mismatch. 2) the senescence 
model, in which cell senescence is delayed following GC exposure (Coupe et al, 
2012). The findings shown here clearly show that EmmodDex are longer and heavier 
than controls from around 90 dpf. Using length and weight data to calculate the 
condition factor (the fish girth) confirmed that these fish were indeed larger than 
controls. In contrast for EmmodGR Mo adults there was a trend towards smaller and 
lighter adult fish with a clearly reduced condition factor (girth) than their controls.  
In the “senescence hypothesis” exposure to GCs delays cell senescence (in the form 
of cell division), thus delaying proliferation and preserving the proliferative capacity 
of the cells (Coupe et al, 2012). When cessation of treatment occurs, the proliferative 
capacity is reinstated and the cells are capable of proliferating like younger cells. 
This results in an increased rate of proliferation and, as such, an increase in growth 
velocity (Chagin et al, 2010). This senescence hypothesis is very complex to 
investigate in vitro with numerous cell types thought to be contributing to the 
phenomenon; the role of GC in growth plate stem cell proliferation, longitudal bone 
growth, and catch-up growth has been described in detail (Baron et al, 1994). While 
investigation of cellular proliferation may confirm the senescence model, the 
favourable regenerative capacity held by the fish may make investigation of this 
problematic. 
To date there has been little convincing data to suggest that an increase in growth 
hormone signalling is present in catch-up growth. However, there are numerous cell 
culture studies which show a relationship between GCs, IGF expression and cellular 
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growth (Fowden, 2003; Fowden & Forhead, 2004). The data presented here further 
suggest a neuroendocrine mechanism may be causative in altered adult growth 
trajectory as there is a reduction in the expression of igf mRNA in the zebrafish 
embryo when GC activity is reduced. The adults derived from these embryos are 
smaller than controls. These findings are contradictory to previously published data 
generated using GR Mo knockdown in the zebrafish embryo which showed no 
detectable reduction in igf mRNA (Nesan et al, 2012). However, Nesan et al. 
investigated gene expression earlier in development (<36hpf) than the data shown 
here. It may be that GR-mediated igf signalling pathways are more critical in later 
stages of zebrafish development and earlier unchanged levels of igf detected by 
Nesan and colleagues are due to maternally-derived transcript. 
Somewhat contradictory to the data of EmmodDex and EmmodGR Mo, is an 
increase in length and weight in EmmodRU486. It has been previously been shown 
that RU486 treatment of rats increases their growth rate, possibly by antagonising the 
anti-proliferative actions of GC (Soro et al, 1995). However, as embryos were only 
exposed to GR antagonism for 5 days and the detectable difference between 
treatment groups and controls only became apparent at 90+ dpf, this may be unlikely. 
Another possible explanation is in RU486’s other role as a progesterone receptor 
(PR) antagonist (Cadepond et al, 1997). PR have been found in osteoclasts and 
osteoblasts, and the activity of these has been shown to have a direct action on bone 
mass, with PR knock-out mice showing greater bone mass than wild type littermates 
(Yao et al, 2010). It might be possible that in exposing embryos to RU486 during 
critical stages of linear bone growth the bone mass of these adults is greater. 
However, as no investigation of bone mass was carried out this is purely speculative. 
4.5.2 Aim 2:  
Does embryonic GC manipulation alter embryonic and adult HPI axis function? 
GCs are important for normal brain development, promoting myelination and 
terminal maturation (Huang, 2011; Lupien et al, 2009). The developing HPA axis 
has been shown, in many species, to exhibit a number of differences to the HPA axis 
at various postnatal life stages, with the hypothalamus, pituitary and adrenal glands 
all undergoing significant morphological and/or functional changes during 
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maturation (Tegethoff et al, 2009). Numerous animal studies have highlighted that 
maternal over-exposure to GCs can result in higher than normal levels crossing the 
placenta and exposing the foetal brain to elevated GC levels. In mammalian models 
this can affect development of the HPA axis (Kapoor et al, 2008) resulting in long-
term changes in neuroendocrine function that can persist throughout life (Kapoor et 
al, 2006; Kapoor et al, 2008). Epidemiological studies have shown that, in humans, 
low-birth weight babies have higher (basal and stress-induced) plasma cortisol levels 
throughout adult life, indicating life-long HPA axis programming (Seckl, 2004; 
Seckl & Meaney, 2004). 
As shown (Chapter 3), zebrafish GC biosynthesis, including an intact and functional 
HPI axis, is present in the embryo from 72hpf. The impact of embryonic GC 
manipulation on embryonic HPI axis activity was assessed by measuring cortisol at 
72 and 120hpf. In keeping with a functional HPI axis, it was shown that Met 
treatment and the Cyp Mo reduced cortisol levels at 72 and 120hpf, confirming that 
GC biosynthesis is an evolutionarily conserved process (Steenbergen et al, 2011) 
ultimately regulated by 11β-hydroxylase activity (as found in numerous species; 
chapter 3), this also abolished the stress-induced cortisol production. Interestingly 
reduced HPI axis activity (in the form of reduced whole embryo cortisol) was 
demonstrated in embryos treated with Dex. It is well known that the mature HPI axis 
is subject to negative feedback by GCs via corticosteroid receptors (Alderman et al, 
2012). Similar effects on basal GC following Dex-exposure have been made in 
guinea pigs (McCabe et al, 2001), human foetal cord blood (Ballard et al, 1975) and 
neonates 1 day after birth (Karlsson et al, 2000). At 72 hpf however, cortisol levels 
were unaffected by Dex incubation suggesting that residual maternal cortisol within 
the yolk sac remains important at this point. 
Interestingly, there was also an unexpected reduction in cortisol levels in RU486-
treated embryos which, as predicted by mammalian systems, would be expected to 
antagonise the negative pituitary feedback of either endogenous or exogenous GC, 
resulting in enhanced GC production. However, these data (combined with reduced 
head-trunk uncoiling, delayed hatching and impaired swim activity) are consistent 
with developmental delay, and it may be that in these embryos the HPA axis itself is 
167 
 
immature. Steps were taken to assess the functionality of the HPI axis in the RU486 
embryos by co-incubation with Met [5µM RU486 and 0.5µM Met]. However, the 
survival of these embryos was severely impaired with an almost 100% mortality 
noted by 72 hpf (data not shown) and severe developmental delay. While neither Met 
or RU486 treatment alone resulted in such high mortality, the effects observed may 
be GR independent or it may be highlighting the importance of not only GR but of de 
novo cortisol biosynthesis. 
During normal development, there was an increase in mr and 11βhsd2 mRNA 
abundance at both 72 and 120hpf. In mammals 11ΒHSD2 is responsible for the 
inactivation of cortisol to its 11-keto metabolites, conferring selectivity for 
aldosterone at MR (Chapman & Seckl, 2008). It has also been suggested that in the 
developing foetus 11ΒHSD2 is important for foetal growth and development by 
playing a protective role in regulation GR-mediated responses. However, since 
aldosterone, the classical MR agonist in many vertebrate species is not synthesised 
by teleosts it is possible that cortisol serves as a MR agonist in this setting. This 
possibility is supported by the demonstration of increased mr mRNA abundance at 
120 hpf in embryos treated with Met (reduced basal cortisol). Therefore, the 11βhsd2 
up-regulation seen in Dex-treated embryos may enable selective-prevention of 
cortisol access to MR binding sites, further controlling the levels of circulating 
cortisol by inactivation. 11βhsd2 is also minimally capable of metabolizing Dex 
(Tang et al, 2011), further suggesting that the up-regulation of this gene will reduce 
availability of GC and, hence, reduce activation of GR. 
Mammalian studies of chronic maternal Dex exposure suggest a trend for reduction 
in MR mRNA abundance (Vellucci et al, 2002) but this was not seem in the current 
investigation. As mentioned, this may be due to cortisol activity at fish MR. Studies 
of MR function in teleost fish are compromised by the lack of specific 
pharmacological antagonists. Recent studies suggest that both spironolactone and 
eplerenone (MR antagonists in mammalian species) are MR agonists in zebrafish 
(Fuller et al, 2012; Pippal et al, 2011). The use of spironolactone here supports that 
the effects of GC modulation on growth and development are GR-mediated. While it 
is unclear what role MR plays in zebrafish embryogenesis, the expression of this 
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receptor throughout embryonic development would suggest a functional role. Future 
work should be carried out on the physiological role of MR in zebrafish development 
including determination of whether effects are cortisol-mediated or whether other 
hitherto unrecognised ligands are responsible. 
It is well documented in mammals that GC over-exposure via maternal stress 
reprograms the developing HPA axis and stress-related behaviours, resulting in an 
altered ability to deal with a stressful environment (Jellyman et al, 2012; Kapoor et 
al, 2006; Kapoor et al, 2008; Seckl & Meaney, 2004; Tegethoff et al, 2009). The 
long term impact of embryonic GC manipulation (up to 120hpf) was examined by 
measuring the basal and stress-induced cortisol levels in the bath water of 
EmmodDex, EmmodRU486 or EmmodGR Mo. In accordance with data generated in 
other species (e.g. rhesus monkey; (Slobada et al, 2006; Uno et al, 1994)), cortisol 
levels were elevated in bathing water from EmmodDex adults, suggesting enhanced 
HPI axis responsiveness to an acute stressor with no change in basal cortisol levels 
(as has been shown by others). There were no alterations in either basal or stress-
induced cortisol in EmmodRU486 adults. However, there was a reduction in stress-
induced cortisol in EmmodGR Mo adults. This is not the first report showing that 
suppression of GC action during embryogenesis results in a markedly reduced stress 
response in the subsequent adult animals. Work by Ridder et al (Ridder et al, 2005) 
suggests that mice heterozygote for GR knockdown (GR-/+) have no alteration in 
basal corticosterone but have a reduced corticosterone stress response. Furthermore 
zebrafish with abnormal negative feedback due to abolished transcriptional activity 
of GR display higher than normal cortisol levels (Ziv et al, 2013). 
4.5.3 Aim 3: 
Does embryonic glucocorticoid manipulation alter embryonic and adult swim 
behaviour? 
The stress response is important in a number of physiological roles. Of particular 
interest here is the role of arousal and emotional salience in allowing the organism to 
adapt and respond to this detrimental stressor and, thus, increasing the chance of 
survival. However, when the HPA axis is chronically activated or is in a state of 
deregulation this can increase the susceptibility to behavioural abnormalities (Kolber 
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et al, 2008). Early life stress alters the neuroendocrine stress response, particularly 
the HPA axis. This has been associated with psychiatric, cognitive and behavioural 
disorder (Bolten et al, 2013; Paschetta et al, 2013; Starkman, 2013). To determine 
whether modulation in GC activity had any impact on zebrafish behaviour, 
swimming and locomotor activity were observed in the embryo and in the adult 
following embryonic GC manipulation. 
RU486 and Met treatment reduced swim speed and swim distances indicating a role 
for embryonic rather than maternal GC signalling through GR. It has previously been 
shown that swim movements increase as a fish grows and changes shape during early 
development, particularly between 72 and 120 hpf (Muller & van Leeuwen, 2004). 
This allows a more active exploration of their environment - mainly to forage for 
food (Brustein et al, 2003; Thirumalai & Cline, 2008). Our findings confirm these 
reports and show that inhibiting GC synthesis and its actions alters normal swim 
activity. This could be a consequence of delayed development of the skeletomotor 
system, although detailed phenotype scoring of all treated and control embryos failed 
to detect any significant structural differences (other than a lack of swim bladder 
inflation) in the majority of RU486 treated embryos. Swim bladder inflation usually 
occurs at 72 hpf and assists buoyancy. It has previously been shown that “swim-up” 
to the surface behaviour is critical in the larval zebrafish for swim bladder inflation 
(Lindsey et al, 2010) and it has been suggested that swim bladder development is a 
corollary of early mammalian lung development (Winata et al, 2009) which is well 
known to be modified by GC administration. It is likely therefore that the lack of 
swim bladder inflation simply reflects the delayed development of normal swim 
behaviour. Increased time spent in the centre of the Petri dish was observed in 
embryos treated with Met or RU486 and is once again likely to be related to the 
impact of GCs on development and maturation.  
Swimming activity in fish is linked to defined behavioural characteristics such as 
escape and avoidance. Zebrafish larvae have been shown to be thigmotactic from 
96hpf, i.e. they spend longer in the periphery of a tank or open-field area, than in the 
centre; an evolutionary response to avoid predation (Colwill & Creton, 2011). As 
Dex embryos spend longer in the periphery of the test area, this again suggests a 
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more mature phenotype compared to the other groups investigated, further 
supporting an important developmental role for GCs in adaptive responses linked to 
survival and feeding. 
The adult zebrafish is gaining more support as a model of complex behaviours such 
as learning and memory, anxiety, reward and aggression (as reviewed by Norton & 
Bally-Cuif, 2010). Much of the zebrafish behavioural assessments determine fish 
“boldness”. Boldness is mostly assessed by monitoring individual zebrafish 
behaviour in: (1) an unfamiliar open-field environment, (2) the same environment 
with and unfamiliar/novel object, (3) forced swim in a narrow novel tank. The 
alterations observed in embryonic swim behaviour following GC manipulation, plus 
the altered adult cortisol profile following embryonic GC manipulation, suggested 
there would be a similar effect on swim behaviour in the adult. 
The open field test was used to assess novelty exploration, a feature which has been 
shown to be evolutionarily conserved (Stewart et al, 2012) with similar observations 
noted in rodent and zebrafish. Generally, due to the averse environment, adult 
zebrafish show limited exploration and increased thigmotaxis (wall hugging 
(Steenbergen et al, 2011)). In this investigation, EmmodDex showed a reduced 
thigmotaxis compared to controls, with significantly more time spent in the central 
region of the open field arena. This behaviour is referred to as “exploratory 
boldness” (Wisenden et al, 2011). No other treatment groups showed changes in 
thigmotaxis or boldness. Introduction of a novel object into the tank demonstrated a 
further boldness characteristic in the EmmodDex-approaching the possible predator. 
Again, no other group showed this characteristic. The dive tank test was used to 
exploit the zebrafish’s natural tendency to dive to the bottom of a novel tank 
followed, with time, by a gradual increase its vertical activity with increasing 
familiarity with the tank. The proportion of time that the fish spends at the bottom of 
the tank has been interpreted as an index of anxiety (Subbiah & Kar, 2013). A clear 
difference was seen in EmmodDex adults, which showed a bolder swim pattern with 
significantly less time spent at the lower region of the tank. These findings are 
interesting since these “bold” fish also showed similar basal cortisol levels but raised 
cortisol levels following stress. This suggests that there is no direct relationship 
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between boldness and stress-responsiveness, i.e. the bold behaviour is not a result of 
increased basal cortisol. While these findings differ slightly than in mammalian 
models it may be that in fish behavioural programming differs from mammalian 
models.  
4.6 Conclusion 
GCs play important maturational effects at early stages of development in the 
zebrafish embryo, with suppression of GC activity (RU486 or GR Mo) resulting in 
delayed growth rate, reduced head-trunk angle and decreased hatch-rate. 
Phenotypically these embryos are normal with a low mortality; the only observable 
feature is an absent, or poorly-inflated, swim bladder which may be a consequence of 
decreased swim activity in these embryos. Increased GR activation, in the form of 
Dex treatment, results in enhanced growth rate with more mature swim behaviour. 
The enhanced growth rate here appears to alter growth trajectory of these fish post 10 
dpf, as by adulthood (120 dpf) they are heavier and more robust than their control 
counterparts. Not only are these fish heavier but they display a bolder behavioural 
phenotype than un-manipulated fish. Alteration in behaviour may be a consequence 


















Chapter 5: Early-life glucocorticoid 




5 Early-life manipulations and cardiovascular 
developmental programming 
5.1 Introduction 
In many animal species, including humans, GCs become crucially important towards 
the end of gestation where a dramatic peak in circulating levels is obvious (Fowden 
& Forhead, 2004). GR is also detected in most tissues; in the mouse from as early as 
E9.5, with gene abundance rising throughout gestation (Harris & Seckl, 2011). The 
peak in circulating GC and GR expression corresponds to a period of accelerated 
maturation of tissues and organs in preparation for birth (Roberts & Dalziel, 2006; 
Smith & Shearman, 1974), suggesting a developmental role for GCs. 
The key role of GCs in organ development was first highlighted in the global GR 
knockdown mouse (GR
-/-
) which has a 100% perinatal mortality rate as a result of 
multi-organ failure (Cole et al, 1995; Opherk et al, 2004). Furthermore, organ 
specific GR manipulation has suggested that GR are important for maturation of 
many systems (including the gastrointestinal tract (Babyatsky, 2004), skin, liver and 
kidney (Liggins, 1994)) and in the process of erythropoiesis (Tang et al, 2011). More 
recently convincing evidence has emerged to indicate a possible role for GR in early 
heart development and maturation (Rog-Zielinska et al, 2012). 
Although there is fairly strong evidence to allow us to describe an association 
between GC exposure and alterations in the mature cardiovascular system (such as 
cardiac and vessel remodelling, structural alterations (Christy et al, 2003; Katz et al, 
1988) and increased disease risk factors (Girod & Brotman, 2004; Ng & Celermajer, 
2004; Stewart & Petersenn, 2009; Trayhurn & Beattie, 2001)) there is less evidence 
to support a direct and specific action of GCs (whether exogenous and/or 
endogenous) on the developing cardiovascular system (Sainte-Marie et al, 2007). It 
is also unclear whether abnormalities in GC signalling during critical stages of 
development can alter cardiovascular structure and function. 
As highlighted in chapter 4, exposure to raised GC levels during gestation can have 
life-long detrimental effects on health (Seckl & Meaney, 2004), such as increased 
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risk of cardio-metabolic disease in later life (Seckl, 2004). Synthetic GC 
administration in rodent models causes myocardial hypertrophy and increased 
neonatal systolic blood pressure (Dodic et al, 2002; Langley-Evans, 1997; Oritz et al, 
2003). While these cardiovascular abnormalities may be a result of the systemic 
effects of GC, the work here will investigate whether the long-term effects of GC on 
cardiovascular programming may be due to direct cardiovascular actions during 
development. 
While there are clear anatomical differences between fish and mammalian 
cardiovascular systems there are sufficient similarities to allow relevant experimental 
observations of heart and blood vessel growth to be made. The vertebrate embryo 
heart, for example, is the first organ to form and function in all species (Glickman & 
Yelon, 2002). In its earliest incarnation the mammalian heart is a tube shaped 
structure with two basic chambers -atrium and ventricle, thus the zebrafish heart is a 
relevant model of early mammalian heart development (Glickman & Yelon, 2002; 
Yelon, 2001). These near identical heart developmental processes coupled with 
embryonic transparency and the ability to survive many days without functional 
cardiac or circulatory systems (Glickman & Yelon, 2002), allow investigation of 
manipulations, modifications and mutations which would otherwise result in 






5.2 Experimental hypothesis and aims 
The work described in this chapter directly assesses the effects of early life GC 
manipulations, constituting both excess and diminished GC levels, on development 
of the heart and vasculature in the zebrafish, from embryonic stages through to 
adulthood. The hypothesis which will be investigated is that modulation of GC 
activity during embryogenesis will impair normal embryonic heart and blood vessel 
development and function resulting in life-long alterations in the adult cardiovascular 
system. 
Data presented here aimed to answer the following questions: 
1) Does manipulation of the GC system alter early embryonic vascular 
development? 
2) What are the long term effects of early life GC manipulations on the adult 
vascular system? 
3) Does manipulation of the GC system alter embryonic heart development? 
4) What are the long term effects of early life GC manipulations on the adult 
heart? 
5) Is the embryonic phenotype caused by GR Mo rescued by capped gr mRNA 
The above chapter aims will be addressed in three parts: 
Part 1: The influence of embryonic GC manipulation on the embryonic and adult 
vasculature (aims 1 and 2).  
Part 2: The influence of embryonic GC manipulation on the embryonic and adult 
heart (aims 3 and 4). 
Part 3: Genetic manipulation of GC activity, can GR Mo be rescued? (aim 5).  
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5.3 Materials and methods 
5.3.1 Embryonic glucocorticoid modulation 
A number of zebrafish embryonic GC modulations were performed as described 
(Chapters 2 and 4). Briefly, all embryonic modulations were performed at the 2 cell 
stage (approx. 1h after egg collection). Embryos were housed under standard 
husbandry conditions (section 2.3.1) in a 10cm Petri dish at a density of 1 
embryo/mL.  
5.3.1.1 Pharmacological manipulation 
Pharmacological manipulation was performed as described (section 2.3.4) by bathing 
embryos in the following: Dex [100 µM], RU486 [10 µM], Met [10 µM], or 
spironolactone [0.1 µM]. All drugs were dissolved in EtOH (0.1%) and diluted to 
final concentration in systems water. Embryonic survival, phenotype scoring and 
drug replacement occurred daily over the 120h of the study.  
5.3.1.2 Genetic manipulation 
Genetic manipulation was achieved as described (Chapters 2 and 3) by the injection 
of targeted Mo knockdown of two key genes, gr and cyp11b1 (referred to as GR Mo 
and Cyp Mo, respectively). Appropriate mm-Mo was used as controls. The design, 
sequence and dosage optimisation are described in section 2.3.5. Embryos were 
stored in systems water which was replenished daily over the 120h study whilst 
scoring survival and phenotype and drug replacement occurred daily. 
5.3.2 Embryo to adult longitudinal study 
In keeping with the experimental hypothesis underpinning this work, embryos 
undergoing pharmacological and genetic GC manipulations during the first 120 hpf 
were then maintained under standard fish husbandry conditions (un-manipulated) 
from 120 hpf until adulthood (120 dpf) to determine programming. The embryo to 
adult programming study was carried out as described (section 4.3.2). Briefly, three 
groups were assessed until adulthood, EmmodDex, EmmodRU486 and EmmodGR 
Mo. For each of these adult groups a contemporaneous age-matched group acted as 
the control. For pharmacological manipulation this was a vehicle only (0.1% EtOH) 
group and for the GR Mo this was mm-Mo. All control groups are referred to in 
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graphs as “Control” except in instances where confusion may arise (e.g. two-way 
ANOVA) when they are referred to as treatment group and control, for example 
EmmodDex Control. 
5.3.3 Gene abundance analysis 
Gene abundance analysis was carried out on a number of key cardiovascular, 
structural, angiogenic and maturational genes in the embryo and the adult using qRT-
PCR.  
vegfaa, il-8 and flk mRNA abundance were determined in whole embryos and in 
adult caudal tail fins to elucidate signalling in angiogenesis. In both embryonic and 
adult isolated myocardial tissue mef2c, vmhc, gata4, igf, gr, mr and 11βhsd2 mRNA 
abundance were assessed. Gene selection is summarised in Appendix 2. 
All adult tissue or whole embryo homogenate samples were processed, RNA 
extracted, cDNA synthesised and qRT-PCR carried out as described (section 2.5). 
5.3.4 Protein abundance analysis 
Protein abundance of Gr was carried out by Western blot analysis as described 
(section 2.7). Samples were prepared from pooled tissue: 100 embryonic hearts or 5 
adult hearts. 
5.3.5 Embryonic vascular assessment  
Embryonic vascular assessments performed as described (section 2.4.6) using 
tg(FLi1: EGFP) zebrafish embryos. Briefly, after manipulation the number of ISV 
were determined in a given region of the embryonic tail. Vascularisation index was 
also calculated (as in section 2.4.6.2). 
5.3.6 Adult vascular assessment 
Adult zebrafish of the tg(FLi1: EGFP) strain were used to observe tail vasculature, as 
described (section 2.5.7). The pattern of tail blood vessels was observed under 
fluorescent microscopy and still-frame images recorded using Leica software. 
Images were analysed using ImageJ software to determine caudal ray vessel 
179 
 
patterning including the number of vessel-crosses between rays and the number of 
visible angiogenic sprouts present post-tail-fin resection (Section 2.5.7). 
5.3.7 Adult tail fin regeneration 
To determine whether embryonic GC manipulation altered the angiogenic properties 
of the adult zebrafish a tail-fin regeneration model was adapted (Azevedo et al, 
2011) as described fully in section 2.5.7. 
5.3.8 Embryonic cardiac assessments 
A number of structural and functional embryonic cardiac assessments were carried 
out as described (section 2.4.7) using tg(CMLC2:GFP) embryos. Structural 
assessments included ventricle length, inflow/outflow distance, pericardial area and 
heart area. Functional assessments included heart rate, ventricular ejection fraction, 
stroke volume and cardiac output (as in section 2.4.7.3). 
5.3.9 Adult cardiac assessment 
Adult hearts were isolated as described (section 2.5.4). After isolation, hearts were 
weighed and bright-field microscope images taken to determine ventricle length. 
Heart weight was normalised to body weight, and heart length was normalised to 
body length. Further cardiac assessments involved histology which was performed as 
in section 2.8 with H&E or Masson’s trichrome staining. Inter-trabecular space was 
measured from theses stained sections. For this hearts were imaged as previously 
described (Section 2.3), these images were then analysed using ImageJ software, 
ventricle size was calculated by tracing around the outer ventricular wall using the 
free-hand tool, inter-trabecular space was then determined by tracing around areas of 
free-space (unstained with no apparent tissue) within this ventricle. The regions of 
empty space were then totalled to give the free area within the section. This inter-
trabecular space was then subtracted from the total ventricular area and the total 
percentage of inter-trabecular was thus given as a percent.  
5.3.10  Messenger ribonucleic acid (mRNA) morpholino rescue 
To determine proof of specificity of GR Mo an mRNA rescue experiment was 
performed by co-administration of Mo with mRNA encoding the gene of interest 
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(GR). The rescue mRNA was constructed with an altered 5’ UTR (capped) and thus 
no GR Mo target (the five prime un-translated region).  
Rescue of GR Mo was deemed successful if the associated GR Mo phenotype 
observed after administration was not detected or was significantly attenuated in the 
rescue mRNA embryos, indicating that the observed Mo phenotype is due to 
knocking down the target gene and not due to an unexpected interaction with an off-
target RNA. 
5.3.10.1 DNA linearization 
Template DNA was purchased in the form of IMAGE clone (Source Bioscience, 
Cambridge), in plasmid Miniprep form, meaning it is a purified plasmid. The GR 
gene was cloned into the pDNR-LIB clone (Figure 5.1) with the insert being found 
between Sfil (77) and (298) sites. The plasmid was then linearized with XhoI 
restriction enzyme (Applied Biosystems) with cleavage sites downstream of the 
insert. Confirmation that this restriction enzyme cuts the vector at one site only and 
does not cleave the DNA sequence of interest was carried out using SerialCloner 
software mapping the pDNR-LIB donor vector (vector shown in Figure 5.1). 
A typical linearization reaction was as follows: to a 2 mL Eppendorf tube on ice were 
added 500 ng DNA, 10X NEB Buffer, BSA, ddH20 and the XhoI restriction enzyme. 
This was then warmed to 37
o
C for 1 h to activate the enzyme, and the reaction then 
stopped by the addition of 1/20th volume 0.5 M EDTA, 1/10th volume 5 M sodium 
acetate and 2 volumes ethanol. The sample was then chilled at -20
o
C for 30 min. The 
tube was then centrifuged at 10,000 g at 4
o
C for 15 min to pellet the DNA, 
supernatant was removed and discarded and the pellet was reconstituted in TE buffer 
at a concentration of 500 ng/µL. Confirmation of completed cleavage was carried out 




Figure 5.1 Restriction map and multiple cloning site of pDNR-LIB vector.  
Multiple cloning sites (MCS) A and B are highlighted to the left and right of the stuffer 
sequence. MCS A is shown in frame with the loxP site. T7 promoter location is also 
highlighted. The “stuffer” fragment shown here is replaced by the cDNA insert of interest, in 
our case with the zebrafish GR sequence. This image was produced using SnapGene 
software (from GSL Biotech; available at snapgene.com). 
 
 
Figure 5.2 Multiple cloning site of pDNR-LIB vector.  
Unique restriction sites are shown in bold. MCS A is shown in frame with the loxP site with 
the last four nucleotide bases of the loxP highlighted at the left hand side of MCS A in bold. 
The “stuffer” fragment shown here would be replaced by the cDNA insert of interest, in our 





5.3.10.2 Proteinase K treatment 
After linearization, the template DNA was treated with proteinase K (100 µg/mL) 
and 0.5% SDS for 30 min at 50
o
C to eliminate for RNase or other transcription 
inhibitors to prevent suboptimal transcription. 
5.3.10.3 Phenol/chloroform extraction and ethanol precipitation 
Proteinase K treatment was followed by phenol/chloroform extraction using a well-
documented protocol. Briefly, 1 volume of phenol was added to the DNA, this was 
mixed and then centrifuged for 2 min at 15, 000 g at 4
o
C. The resulting supernatant 
was removed into a clean tube and an equal volume of chloroform was added 
followed by vortexing. The resulting solution was then centrifuged for 2 min at 
15,000 g at 4
o
C. The supernatant was transferred to a fresh tube where 0.1 volume of 
sodium acetate and 2.5 volumes of 100 % ethanol were added. This was then allowed 
to precipitate at -20
o
C overnight. Following precipitation, the tube was spun at 
15,000 g for 20 min at 4
o
C. The resulting supernatant was removed and 1 mL of 70% 
ethanol was added to wash out any salts, following a final 10 min centrifugation at 
15,000 g at 4
o
C. Liquid was removed and the pellet was allowed to air dry after 
which it was reconstituted in TE buffer. 
5.3.10.4 Capped transcription reaction 
Capped transcription reaction was carried out using the mMessage mMachine Kit 
(Ambion) according to manufacturer’s instruction. Briefly, 500 ng/µL linearized 
DNA was added to a chilled Eppendorf tube. To this 2x NTP/CAP solution was 
added along with 10X reaction buffer and T7 enzyme mix. The volume of the tube 
was then made up to 20 µL by addition of ddH2O. The tube was then gently mixed 
and incubated at 37
o
C for 1.5 h. After the incubation, 1 µL TURBO DNase 
(Ambion) was then added to the tube and incubated at 37
o
C for 15 min. This step 
removes any residual template DNA. 
5.3.10.5 RNA recovery and quantification 
Lithium chloride was used as an effective way to remove unincorporated nucleotides 
and proteins. This step follows directly from the previous protocol (Capped 
transcription reaction). The reaction was stopped by the addition of 30 µL nuclease 
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free ddH2O and 30µL lithium chloride. The tube content was then mixed gently and 
chilled for 1 h at -20
o
C. After chilling, samples were centrifuged at 4
o
C for 15 min at 
15,000 g. The supernatant was then carefully removed and the remaining pellet was 
washed once with 1 mL of 70% ethanol and then centrifuged again as before. The 
supernatant was then removed and the pellet was reconstituted in 20 µL DEPC 
treated water. The final concentration of RNA was determined using a nanodrop 




5.3.10.6 Injection titration 
It has been documented that incorporation of rescue RNA may result in teratogenic 
effects. It was, therefore, important to carry out titration reactions, similar to those 
carried out for Mo dosage determination. Here, 4 nL boli of various diluted 
concentrations of rescue RNA were injected into developing zebrafish embryos, at 
the 2-cell stage. The embryos were then assessed and scored using the 6 point 
phenotype scoring system as described (section 2.4.3). The final concentration of 
rescue RNA which was found to not significantly alter gross morphology was 3 
ng/nL. The effects of rescue success were determined by assessing global and 
cardiovascular development and will be described further part 3. 
5.3.11 Experimental controls 
In the following experiments data were obtained both in embryos and in adult 
zebrafish. For embryonic pharmacological manipulations controls are vehicle only 
(0.1% EtOH). For embryonic Mo manipulation control data are for injected control 
Mo. For data where embryonic pharmacological and molecular manipulation are 
represented together (e.g. gene abundance) control data are a mean of vehicle only 
and control Mo together (Student’s t-test shows no significance between groups) to 
ease graphical representation and interpretation. For adult investigation control data 
for EmmodDex and EmmodRU486 were obtained in adult fish which were treated 
with vehicle only during embryogenesis. EmmodGR Mo controls are adults which 




5.4 Part 1 
The influence of embryonic glucocorticoid manipulation on the embryonic and 
adult vasculature. 
The following section will address the impact which GC manipulation has on 
vascular development in the zebrafish embryo, and the long-term impact that this 
embryonic GC manipulation has on adult vasculature. 
5.4.1 Part 1: Results 
5.4.1.1 Aim 1:  
Does manipulation of the glucocorticoid system alter embryonic vascular 
development? 
tg(FLi1: EGFP) zebrafish were used to determine whether manipulation of the GC 
system altered the formation of the embryonic vasculature. As mentioned previously 
(section 2.4.6) the fli1 promoter is a known endothelial marker in mouse models and 
known to be expressed during vascular formation, haematopoietic cell types and the 
jaw mesenchyme (Lawson 2002) making it an ideal gene for vasculature. This EGFP 
expression enables visualisation of the vasculature for qualitative and quantitative 
assessment of blood vessel formation and function (Figure 5.3). 
5.4.1.1.1 Intersegmental vessel formation 
In the first instance the number of ISV expressing EGFP which crossed completely 
between the aorta and the DLAV following the tail somite patterning were counted 
throughout the length of the tail, referred to here as “normal ISV”.  
Pharmacological and genetic manipulations that reduced production of active cortisol 
(Chapter 3), namely incubation of embryos in the drug Met or injection with the Cyp 
Mo, had no effect on the number or patterning of these normal ISV expressing EGFP 
at any of the time-points investigated (Figure 5.4 C and D). 
Incubation of embryos in (the GR agonist) Dex (100µM), reduced the number of ISV 
expressing GFP compared to controls at all time-points investigated (p<0.0001 
(Figure 5.4 E)). Embryos incubated in Dex typically showed an incomplete EGFP 
signal throughout the length of the somite, making the ISV appear truncated, dense 
or in some instance absent along the length of the tail (Figure 5.3). 
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Incubation of embryos with (the GR antagonist) RU486 altered ISV EGFP  
expression reduced the number of “normal” ISV at all time-points investigated 
(p<0.0001(Figure 5.4A)). Embryos incubated with RU486 showed increased 
expression of GFP in branching appenditures from the ISV with many forming a “Y” 
shape which typically did not follow the normal somatic patterning arrangement 
observed in controls (Figure 5.3). 
Similarly, embryos treated with GR Mo showed a change in ISV patterning 
compared to mm-Mo (controls) at several time points during early development 
(p<0.0001). No quantifiable ISVs expressing EGFP were detected in this group at 48 
hpf (data for GR Mo begins at 72 hpf on Figure 5.4B) possibly as a consequence of 
severe retardation in vessel sprouting (Figure 5.5). EGFP expressing ISV detected in 
the later developmental stages were largely found towards the yolk sac of the embryo 
with very few “normal” ISV observed further along the length of the tail. 
In order to try to ascertain whether these observations were mediated by GR or MR 
(GCs may have MR agonist activity in fish), ISV patterning was also examined in 
embryos which had been incubated in a known teleost MR agonist
*
 spironolactone 
(Pippal et al, 2011) [1uM]. Spironolactone was found to have no effect on the 
number of complete EGFP expressing ISVs compared to the controls at any of the 
time-points investigated (Figure 5.4 F). 
  
                                                          
*
 Spironolactone has classical MR antagonistic properties in most mammalian systems and although it 
has been used as an antagonist previously in zebrafish studies it has more recently been shown to have 

















Figure 5.3 Typical intersegmental vessel (ISV) appearance 
ISV appearance in 96 hours post fertilisation (hpf) tg(FLi1:GFP) zebrafish tail mid-
sections which were either (untreated) controls or had been treated with Dex 
[100uM], RU486 [10uM] or targeted morpholino knockdown of the GR (GR Mo). 
The dorsal longitudinal anastomotic vessel (DA), aorta (A) are marked with the 
location of the yolk sac (YS) highlighted for orientation. Normal ISV are observed in 
the control fish, GFP expression is present in vessels following the normal somite 
patterning of the tail connecting the A and the DLAV. Low expression of GFP is 
detected in ISV of Dex and GR Mo embryos, with ISV appearing missing or 
incomplete. RU486 embryos display increased GFP expression with expression 
observed in many branched appenditures. Scale bars represent 100µm. 
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Figure 5.4 Number of complete inter-segmental vessels (ISV) 
ISV within a given range of the tail, between yolk sac extension and last detectable ISV on 
the tail tip. The number of complete ISV is shown after: A) RU486 (blue) [10µM], B) 
targeted glucocorticoid receptor morpholino (GR Mo-green), C) metyrapone (Met-orange) 
[10µM], D) targeted cyp11b1 morpholino (Cyp Mo-purple), E) dexamethasone (Dex-blue) 
[100µM], or F) spironolactone (grey), treatment from the 2-cell stage. At 48hpf; there were 
no quantifiable ISV for GR Mo at this point. Data are mean ± SEM for n=5 (5 fish per 





Figure 5.5 Typical vessel appearance in glucocorticoid receptor morpholino embryos 
Shown are embryos which were either (untreated) controls or had been treated with targeted knockdown of the glucocorticoid receptor (gr). Images 
shown are for two concentrations of Mo (5ng/nL (GR Mo) and 10ng/nL (2x GR Mo)) to show concentration-dependent effects. Each row shows 
images of the same fish throughout the first 24 h of development (6-24 hours post fertilisation (hpf)) from embryo collection under white light and 
also under UV fluorescence. The green vasculature is imaged by fluorescent imaging of the EGFP expressed in the tg(FLi1: EGFP) line. High 
magnification images are shown of 24 hpf embryos on the right hand side. Sprouting ISV in control and GR Mo are highlighted by arrows.
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5.4.1.1.2 Intersegmental vascularisation index 
While it was apparent that the GC manipulation was altering vessel EGFP expression 
it was also clear that the manipulations were have differing effects. To better 
quantify the level of variation in vascular patterning, a scoring system was devised 
(referred to here as the Vascularisation Index (VI)) for a given region of the tail at 
96hpf. This was determined using a scheme which assessed the number of EGFP 
expressing vessel intersections by three perpendicular lines in a defined region of the 
tail (Figure 5.6).  
Embryos treated continuously with Met or Cyp Mo from fertilisation showed no 
difference in VI compared to control (un-manipulated). Those treated with RU486 
however showed a higher VI (p<0.05) at 96 hpf as a result of a greater number of 
line intersections by ISV (Figure 5.6 A). In contrast, embryos treated with GR Mo 
showed an opposite effect at 96 hpf with a reduction in the number of grid-line 
intersections (p<0.001 (Figure 5.6 B)). 
A similar reduction in the number of vascular intersections was observed in embryos 
treated with the GR agonist Dex, (p<0.001 (Figure 5.6 E)). The typical abnormal 
appearance of ISV in Dex-treated embryos is shown in Figure 5.7, with the mid-
region (the area used to determine VI), marked to show absent or truncated vessels. 
To determine whether this was a GR or MR mediated effect, again embryos were 















5.4.1.1.3 Embryonic vasculature specific gene abundance  
flk1/kdr is a prominent receptor in vegf signalling in zebrafish (Bussmann et al, 
2008). To determine whether alteration in abundance of this gene may be associated 
with abnormal ISV appearance, its abundance was measured at 120 hpf in whole 
embryo homogenates for each treatment group and respective controls. Continuous 
incubation in GC modifying drugs or GR Mo had no detectable effect on gene 


































































































































































































































Figure 5.6 Embryonic vascularisation index (VI) 
VI of 5 somite mid-tail section from cloaca towards the head in 96 hours post fertilisation (hpf) 
Fli1: GFP zebrafish embryos which had been continuously incubated in drug or treated with 
morpholino from 2-cell stage (~1hpf). All data show control (red) versus A) RU486 (blue) B) 
targeted glucocorticoid receptor morpholino (GR Mo-green), C) metyrapone (Met-orange), D) 
morpholino targeted towards cyp11b1 (Cyp Mo-purple) E) dexamethasone (Dex-black) and F) 
spironolactone. Data are mean ± SEM n=3 (5 embryos per n), analysed by Student’s t-test,  
* P≤0.05, *** p≤0.001.  
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VEGF A is a key determinant of normal vascular formation in mammals, and is 
recognised as a key angiogenic factor (Bussmann et al, 2008). Previous studies have 
highlighted alterations in abundance pattern of the zebrafish form (vegfaa) associated 
with altered vascular developmental in the zebrafish (Gore et al, 2012). Here, 
embryos treated with Dex showed a lower abundance of vegfaa mRNA than controls 
at 120 hpf (p<0.05). Conversely embryos treated with RU486 showed increased 
abundance of vegfaa mRNA (p<0.05 (Figure 5.7B). No other treatment altered 
vegfaa mRNA abundance. 
IL-8, a member of the chemokine signalling family, is a key pro-angiogenic and pro-
metastatic factor (Li et al, 2003; Stoll et al, 2011) The expression profile of the gene 
encoding this protein was examined at 120 hpf in GC manipulated embryo-
homogenates. There was a lower level of abundance in embryos treated with Dex 
compared to controls (p<0.001), while RU486 incubation increased the abundance of 
il-8 mRNA when compared to controls (p<0.05) at this time point however GR Mo 
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Figure 5.7 Gene abundance analyses in zebrafish embryos 
Relative mRNA abundance in embryos which had been treated with the glucocorticoid 
modulating pharmacological agents dexamethasone (Dex-black bars), RU486 (blue bars) or 
metyrapone (Met-orange bars), or genetically using morpholinos directed against 
glucocorticoid receptor (GR Mo-green bars) or cyp11b1 (Cyp Mo-purple bars). Data shown 
are mRNA abundance of key vascular angiogenic genes flk (A), vegfaa (B) and il-8 (C) 
quantified by standard curve production and normalised to the housekeeping gene ef1α. All 
data are mean± SEM presented as AU, n=4 (10 embryos per group). Data were analysed by 1-
way ANOVA and Dunnett’s post hoc test; * p≤0.05, **p≤0.01 compared with control. 
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5.4.1.2 Aim 2: 
What are the long term effects of embryonic GC manipulation on the adult 
vascular system? 
To determine the long term impact of embryonic GC manipulation on adult vascular 
phenotype, the caudal fins of anaesthetised adult tg(FLi1:GFP) zebrafish were 
assessed under fluorescent microscopy at 120 dpf. While it appeared that GC 
manipulated embryos had varying levels of branching, as indicated by altered GFP 
expression, steps were taken to investigate whether there was a similar effect on the 
fine capillary like appenditures between caudal ray vessels (red arrows Figure. 5.8) 
in the adult. However, measuring the interconnections between these vessels which 
expressed GFP proved challenging due to: the wide branching/meshing (blue arrows 
Figure 5.8) both in treated and in control adult fish; the plane of observation; and 








5.4.1.2.1 Ray fin vessel crosses 
In an adaptation of the ISV quantification the number of complete vessels connecting 
rays in a given region of the caudal fin was determined. The defined region was two 
caudal rays on the left hand side (LHS) of the central caudal ray (CCR) and two 
Figure 5.8 High magnification image of adult zebrafish caudal fin vasculature. 
Highlighted features include the central caudal ray (CCR) in yellow, ray to ray vessel 
crossing as highlighted by red arrows, complex meshing of vessels between rays (blue 
arrows) and around the main ray vessels (white ellipse). 
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caudal rays on the right hand side (RHS) of the CCR (so 4 inter-ray spaces). The 
total number of connections between the rays was then counted, as for ISV. Only 
those which completely joined the rays and were un-branched were counted 
throughout the length of each of the inter-ray spaces. With this method no 
differences in fin ray vascular patterning was observed in any of the treatment groups 
(p>0.05 (Figure 5.9)). In determining the number of ray fin vessel crosses there 
appeared to be a greater number of fine vessels connecting rays towards the tip of the 
homocercal tail in EmmodDex adults compared to the other groups investigated 
(Figure 5.9). Measuring these subtle differences was problematic with varying caudal 
fin length and non-uniform tail appearance not allowing an accurate method of 
quantification. Caudal fin patterning is, however, highlighted in Figure 5.9 for 
qualitative assessments. To investigate whether this apparent increase in fine vessels 
in the EmmodDex group conferred an increase in blood vessel perfusion, Dextran 
injections were carried out. Many of the fine vessels (which were thought to be in 
greater abundance in the EmmodDex group) did not have active blood flow as 
indicated by lack of red fluorescence following injection of 70kDa dextran 
tetramethylrhodamine (Dextran-rhodamine). This was also noted in control fish so 
was not as a result of treatment. This dye was chosen as it is comparable in 
particulate size to the mononucleated blood cells found in the circulation (Bayliss et 
al, 2006). Typical images 5 min after intra-ocular dextran are shown in Figure. 5.11 
These data suggest that these fine vessels towards the end of the tail in the 
EmmodDex adults are not functional. 
 
 




































































































Figure 5.9 Adult fin ray vascularisation index (VI) 
Total number of vessel crosses between the central caudal fin rays of the adult zebrafish tail in a 
5 ray section. Data show adults treated during embryogenesis with A) dexamethasone 
(EmmodDex-Black bars) B) RU486 (EmmodRU486-Blue) or C) glucocorticoid receptor targeted 
morpholino (EmmodGR Mo-green bars). All data are versus respective controls (red). Data are 









Figure 5.10 Typical caudal fin vascular patterning in adult tg(FLi1:GFP) zebrafish 
Typical caudal fin appearance in adults which had been treated with dexamethasone 
(Dex), RU486, targeted glucocorticoid receptor morpholino (GR Mo) or vehicle control 
for the first 120 hours post fertilisation (hpf) and then left to develop un-manipulated until 
120 days post fertilisation (dpf). Low magnification images are shown to highlight the 
area of interest. High magnification images show the central caudal ray (CCR), denoted by 





Figure 5.11 Adult caudal fin patency 
Images of a caudal fin of an adult zebrafish treated with dexamethasone (Dex) as an embryo 
(EmmodDex). Upper panel images show control caudal fin vasculature under fluorescent 
microscopy, lower panels show EmmodDex adult caudal fin vasculature. Images on the left 
hand side show GFP expression in the tg(FLi1:GFP) line highlighting the vasculature, 
central panels show 70kDA Dextran-rhodamine expression in circulation following 10 min 
of cardiac cycles. The right hand side panels show the green and red channels merged to 
show the level of blood flow within the vasculature. 
5.4.1.2.2 Caudal fin angiogenesis model 
To determine whether the intrinsic angiogenic capacity of the adult zebrafish vessels 
had been reprogrammed by embryonic environmental GC manipulation, a classical 
zebrafish regenerative model was adapted to examine angiogenic blood vessel 
formation and patterning following caudal fin resection. Before the angiogenic 
capacity was investigated basic assessments of tail regenerative capacity were carried 
out. 
There was no gross difference in the appearance of regenerated fins in adults that had 
undergone GC manipulations during embryonic development compared to respective 
controls. Adults from all treatment groups showed a classical homocercal tail 









5.4.1.2.3 Tail regenerative capacity 
The regenerative capacity of EmmodDex, quantified as rate of fin regrowth, was 
found to be similar to controls (p>0.05). EmmodGR Mo showed similar fin regrowth 
as controls, likewise there was no difference in fin regrowth in the EmmodRU486 
group either (Figure 5.13 A-C). 
5.4.1.2.4 Angiogenic gene abundance in tail fin regenerates.  
After tail re-growth was investigated, the total area of fin regrowth was assessed for 
the abundance of pro-angiogenic genes, vegfaa and il-8, mRNA abundance, were 
assessed in the adult by qRT-PCR. il-8 mRNA abundance in tail fin regenerates was 
found to be unaffected by embryonic GC manipulation with none of the adult groups 
displaying any differences in il-8 mRNA abundance. Similar observations were 
noted for vegfaa mRNA abundance in the EmmodRU486 and EmmodGR Mo 
groups, with neither group showing a detectable difference in vegfaa mRNA 
abundance. However, a reduction in vegfaa mRNA abundance was detected for the 
EmmodDex group (p<0.05).  
Figure 5.12 Typical caudal fin regrowth 21days post amputation (dpa). 
Caudal fin regrowth in adult tg(FLi1:GFP) zebrafish which had been exposed to 
dexamethasone (Dex), RU486 or a morpholino targeted towards the glucocorticoid receptor  
(GR Mo) during embryogenesis. Images show tail appearance and site of initial amputation 















































































































































































































































Figure 5.13 Caudal fin regrowth assessments 
Data shown are from adults which had been manipulated during embryogenesis with 
dexamethasone (EmmodDex-black bars), RU486 (EmmodRU486-blue bars), or a morpholino 
targeted towards the glucocorticoid receptor (EmmodGR Mo-green bars); all versus their 
respective controls (red bars). (A-C) data shown are the mean length (mm) of three regions of the 
homocercal tail (central ray, left hand side lateral ray, and right hand side lateral ray) per fish 
displayed as the mean ± SEM (n=10 adult fish per group). Data were analysed by Student’s t-test. 
(D-F) Data shown for vegfaa mRNA abundance in tail regrowth. (G-I) Data shown for il-8 mRNA 
abundance in tail regrowth. mRNA abundance data were quantified through standard curve 
production and normalisation to house-keeping gene ef1α. Data are given as mean ±SEM (AU), 




5.4.1.2.5 Angiogenic vessel sprouting in tail regenerates  
While there was no clear difference in vascular patterning between treatment groups 
and controls 21dpa (data not shown) a difference was observed at 3dpa in 
EmmodDex vs. their controls (Figure. 5.15). In 64% of control fish vessel sprouting 
from the regenerate wound site occurred earlier than in EmmodDex fish, with vessel 
sprouts being detected by 3dpa (Figure. 5.15). There was no observable difference 
detected for EmmodRU486 and EmmodGR Mo fish when compared to their 
controls. 
Quantification of these sprouting vessels in the caudal fin rays indicated that 
EmmodDex-treated fish did indeed have fewer sprouts at 3dpa compared to the 














































































































Figure 5.14 Quantification of angiogenic sprouts at 3 days post amputation (dpa) 
Data are of caudal tail fin angiogenic sprouts in adult zebrafish 3 dpa which had been subjected to 
glucocorticoid manipulation during embryogenesis. Data are shown for adults treated as embryos 
with (A) dexamethasone (EmmodDex-black bars), (B) RU486 (EmmodRU486-blue bars), or (C) 
morpholino targeted towards glucocorticoid receptor (EmmodGR Mo) and their respective 
controls (red bars). Angiogenic sprouts were recorded as the number of caudal rays which display 
an angiogenic sprout in relation to the total number of caudal rays (percentage). Data are mean± 






Figure 5.15 Adult zebrafish angiogenic sprouts 3 days post amputation (dpa) 
Vessel sprouting in the caudal fin of adult tg (Fl1: GFP) zebrafish tails 3 days post 
amputation (3dpa), in adults which had been treated during embryogenesis with 
dexamethasone (EmmodDex) compared to controls. Low magnification images 
show location of tail amputation (red dashed line). A higher magnification image is 
shown highlighting vessel-sprouting (blue arrows) from the injury site (red dashed 
line). For orientation, the high magnification image has the central caudal ray (CCR) 
highlighted (yellow arrow).  
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5.4.2  Part 1: Discussion 
This section of work has focused on the direct and specific actions of GC modulation 
on the developing embryonic zebrafish vasculature and the long-term effects this has 
in the adult.  
5.4.2.1 Short-term effects of embryonic GC manipulation on the vasculature  
Hypertension is widely believed to be a programmable cardiovascular risk factor but 
the mechanism underpinning this remains uncertain (Alexander, 2006). Many years 
of hypertension research have suggested that changes in peripheral vascular 
resistance may be linked to endothelial dysfunction, structural changes in the vessel 
wall, and micro vascular rarefaction (Pladys et al, 2005). However, the association 
with hypertension and a direct causative role has been difficult to establish (Nuyt, 
2008). While this work has not looked at blood pressure, we have been able to assess 
whether specific manipulations of the GC system result in short- and longer-term 
changes in vascular structure and associated molecular signalling by virtue of the 
transparency of the embryo and the ability to readily observe angiogenesis as part of 
the regeneration of the caudal fin in the tg (FLi1: EGFP) zebrafish line. 
It is well established that the molecular and cellular pathways controlling vascular 
anatomy are conserved amongst vertebrate models (Kamei et al, 2006) which makes 
it possible to assign homologies between distinct blood vessels and to directly 
compare the formation of these vessels in different vertebrate species. During the 
processes of vertebrate embryogenesis the first blood vessels to form are the large 
midline artery and vein. The formation of these vessels is through the process of 
vasculogenesis - the migration, differentiation and coalescence of angioblasts 
(Ellertsdottir et al, 2010). When these vessels are established the trunk vessels then 
form, by the migration of endothelial cells from those midline vessels, through a 
process referred to as sprouting angiogenesis. It is apparent that the formation of 
vessels by angiogenesis is as a result of highly-regulated signalling events to 
coordinate cell migration, rearrangement and proliferation. However, the underlying 
cellular and molecular events are not yet fully characterised. A number of important 
signalling molecules and pathways have, however, been identified in the regulation 
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vasculogenesis and angiogenesis: for example, VEGFs, ephrins, angiopoietins, 
netrins, chemokines, and their receptors, (Stoll et al, 2011). 
The zebrafish has been previously used as a model of angiogenesis, with many of the 
major molecular pathways regulating angiogenesis in mammalian systems found to 
be conserved in this species (Hasso & Chan, 2011). Indeed, treatment of zebrafish 
embryos with known mammalian anti-angiogenic compounds has been shown to 
inhibit angiogenesis (Evensen et al, 2010). The success of this model is in part due to 
the availability of transgenic strains which allow easy visualisation of blood vessels, 
such as the transgenic line used in this chapter tg(FLi1:EGFP). 
In the work presented in this chapter manipulation of GCs in the embryo resulted in 
marked changes in the formation of the embryonic zebrafish vasculature, with a 
strong association with ISV formation in the first 120hpf. This was clear from simple 
counts of complete ISV or calculation of VI. Often the vessels were completely 
missing (as observed by somite patterning but no EGFP expression) or were 
truncated and denser in appearance, suggesting abnormalities in the migration and/or 
differentiation of endothelial cells.  
The primary axial vessels were formed similarly in all groups investigated, 
suggesting that the formation of these vessels by vasculogenesis is unaffected by GC 
manipulation. However, it may be that subtle effects did occur which were not 
detected by the methodology used and future work could focus on the origin and 
specificity of endothelial cells, the formation of the dorsal aorta and caudal vein, the 
anterior and posterior differences in artery formation and the processes of lumen 
formation for these primary vessels (Ellertsdottir et al, 2010) which may be affected.  
To enhance our understanding of angiogenesis numerous vessel networks have been 
assessed in the zebrafish; for example the sub-intestinal vessels, a vascular network 
ventral to the gut (Serbedzija et al, 1999). However, one well documented zebrafish 
model of angiogenesis is the formation of the ISV network in the tail of the 
developing embryo (Cannon et al, 2010; Childs et al, 2002; Gore et al, 2012). The 
formation of the ISV in the trunk of the zebrafish embryo has previously been used 
as a model of endothelial tube formation in vivo (Blum et al, 2008).  
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ISVs sprout from the dorsal aorta at around the 24 somite stage (Kimmel et al, 1995) 
and extend and connect to the dorsal longitudinal anastomotic vessel (DLAV). Cell 
lineage labelling experiments indicate that ISVs form when a tip-cell embedded in 
the dorsal aorta carrying a dorsally sprouting filopodia-like appendage this grows 
dorsally along vertical somite boundaries, leaving elongated cells behind (Gore et al, 
2012). The migration of these cells is a very fast and dynamic process. As the tip-cell 
reaches the neural tube the cells branch rostrally and caudally to form a T-shaped cell 
in the DLAV (Childs et al, 2002). Cellular rearrangement and division occurs, 
allowing the interconnected cells to become lumenised. These tube structures have 
been shown, through time-lapse microscopy, to develop as a result of the formation 
of endothelial vacuoles which then undergo intracellular and intercellular fusion 
(Kamei et al, 2006). 
In the current work, it is clearly demonstrated that alteration in GC activity impairs 
the formation of the ISV, with both Dex and RU486 treatment resulting in abnormal 
ISV EGFP expression. Manipulation of cortisol biosynthesis, using Met or Cyp Mo, 
did not affect ISV number suggesting that the effects of GC on ISV formation are 
receptor mediated rather than reliant on embryonic cortisol biosynthesis which, as 
shown in chapter 3, is present from 48hpf. GR and MR are both present very early in 
development (8hpf) (Chapter 3) suggesting a possible physiological role for GC in 
early formation of the vascular tree. 
Both GR and MR have been associated with mammalian angiogenic effects. 
Decreased MR receptor expression is associated with angiogenesis and increased 
microvasculature density, with the converse observed with increased MR activity 
(Tiberio et al, 2013). Reduced GR activation has been associated with increased 
angiogenesis (Small et al, 2005). Spironolactone (used here as an MR agonist (Pippal 
et al, 2011)) incubation during embryogenesis had no effect on ISV number or 
appearance while GR Mo treated embryos (and the selective GR agonist Dex) had 
reduced numbers of ISVs, suggesting that these effects are mediated by GR rather 
than MR. However, it is possible that, by altering GR expression and/or activity, we 
are also indirectly altering MR activation. Genetic MR knockdown, through targeted 
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MR Mo, may provide a more specific way to assess and define MR mediated effects 
in the zebrafish model.  
vegfaa is important in the formation of ISV, and is known to be produced and 
secreted by the somites between which the sprouting ISV cells migrate (Cleaver & 
Krieg, 2001; Liang et al, 2001a). Furthermore it has been documented that 
suppression of activity of its receptor, inhibits the formation of ISV (Habeck et al, 
2002). In addition, drugs which promote angiogenesis have been shown to increase 
expression of vegfaa in zebrafish (Tian et al, 2012). Interestingly the Dex-treated 
embryos displayed both reduced angiogenic phenotype and a reduced level of vegfaa 
mRNA, suggesting a possible interaction between increased GC levels and 
suppression of angiogenesis through reduction in vegfaa signalling. These findings 
are in keeping with similar work in mammalian placenta (Hewitt et al, 2006), human 
chrondocytes (Koedam et al, 2002) and in angiogenesis linked to prostate cancer 
(Yano et al, 2006a). 
Unlike previous studies, however, no alteration in the expression of vegf (flk/kdr) 
receptor mRNA was observed, suggesting that the reduction in ISV formation is as a 
result of reduced ligand-dependent (vegfaa) receptor activation rather than the 
unavailability of receptor. This may explain the sporadic appearance of vessels 
observed here rather than a complete absence of ISV as previously observed with 
(flk/kdr) receptor antagonism (Zhang et al, 2011).  
While the findings presented here may also suggest that the vascular abnormalities 
following GC manipulation may be independent of vegfaa signalling. Further support 
for a role of GR in Vegfaa signalling is that it has previously been shown that Vegfaa 
is not required for the establishment of the axial vasculature patterning i.e. midline 
vessel development. In contrast, the development of ISV by angiogenesis is strongly 
dependent on vegfaa signalling (Nasevicius et al, 2000). The data presented here is in 
accordance with this, as reduced ISV was accompanied with apparently normal 
vasculogenesis. 
A reduction in il-8 abundance in embryos treated with Dex was also observed. The 
most widely recognized role of IL-8 in mammals is in the inflammatory system 
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where it promotes release of neutrophil granular enzymes (de Oliveira et al, 2013; 
Rahman et al, 1999). Similar observations have been noted in fish (Renshaw et al, 
2006). However, IL-8 is also recognized as an important regulator of angiogenesis in 
mammals with suppression of IL-8 activity known to have anti-angiogenic effects 
(Yano et al, 2006a). Not only has IL-8 been associated with angiogenesis but has 
also been linked with the GC system; impaired local regeneration of GC in the 
11βHSD1
-/-
 mouse increased IL-8 activity, which was suggested as the mechanism 
for increased angiogenesis in vitro and in vivo within sponges, wounds, and infarcted 
myocardium (McSweeney et al, 2010; Small et al, 2005) in these mice.  
In contrast to these data, embryos which were treated with the GR antagonist RU486 
had a higher level of il-8 associated with an increased VI (consistent with increased 
branching or sprouting). The observed sprouting and branching out-with the somite 
boundaries may also be due to altered Vegfaa signalling of the tip cells as the data 
presented here shows in contrast to embryos incubated in Dex, those which were 
treated with RU486 displayed raised vegfaa mRNA levels. However, as for Dex 
treatment there was no alteration in the levels of the vegfa receptor mRNA.  
The data shown here for Dex and RU486 suggest that GR modulation could 
influence zebrafish angiogenesis by altering the expression of key angiogenic factors 
vegfaa and il-8 while this may suggest a mechanism for the alteration in the 
embryonic vasculature there are numerous other angiogenic factors which could be 
investigated further. The data here is particular interesting as mammalian studies 
have highlighted a signalling pathway common to VEGF and IL-8 (amongst other 
chemokines), the mitogen activated protein kinase (MAPK) pathway, in which 
mRNA expression of these pro-inflammatory factors is negatively regulated by the 
activity of GR through the p38MAPK subgroup (Holehouse et al, 2012; Imasato et 
al, 2002), again suggesting a possible route for further investigation.  
GR Mo embryos also displayed an altered vascular phenotype with missing ISV 
throughout the length of the tail during the course of the first 120 hpf. It has been 
established that ISV form dorsally as the embryo grows and this treatment caused 
impaired sprouting of vessels with many found to be truncated in appearance. While 
no alteration in the mRNA abundance profile of the angiogenic factors was observed 
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in this group a reduction in the VI was noted. This suggests that the developmental 
rate of angiogenesis is likely to be impaired. The initial sprouting delay observed at 
24 hpf, may result from an overall developmental delay, (as highlighted in chapter 4 
there is an 8-12h delay in formation of somites accompanied by delayed vessel 
sprouting in the GR Mo embryos). Interestingly, a clear return of global 
developmental milestones was observed in these embryos by 120 hpf (chapter 4) 
meanwhile ISV number and VI remained reduced compared to controls. As these 
embryos maintain a reduced gr mRNA at this time point, data presented here 
suggests that GR signalling is important for ISV angiogenesis in the developing 
zebrafish. 
While the data presented here indicates that Dex treatment reduced the number of 
ISV with detectable EGFP expression, it is also apparent that the patency of ISV 
does not appear to be affected by Dex treatment during embryogenesis, suggesting 
that while the endothelial EGFP expressing component of the vasculature appears to 
be reduced the lumenisation of these vessels was not impaired. GCs have previously 
been shown to directly inhibit tube formation in cultured endothelial cells in human 
umbilical vein endothelial cells (HUVECs) and human aortic endothelial cells 
(HAoECs) treated with cortisol (Logie et al, 2010). This inhibition of tube structure 
formation was proposed to be the result of a GR-mediated effect on cellular 
morphology rather than impaired migration, differentiation and cellular viability 
(Logie et al, 2010). It should, however, be noted that Logie et al., used cultured 
endothelial cells, whereas the current observations in the zebrafish may offer new 
opportunities to investigate the mechanism of GC mediated inhibition of tube 
structure formation which currently remain unclear. While there is detectable 
Dextran within the somite boundaries this is however not a direct indication of blood 
cell flow, and although care was taken to select a Dextran of molecular weight as 
close to red blood cells as possible there are obvious differences between this and the 
properties of blood such as adherence and movement. 
5.4.2.2 Long-term effects of embryonic GC manipulation on vasculature  
Hypertension is characterized by an increase in peripheral vascular resistance and 
micro-vascular abnormalities (Noon et al, 1997; Wong et al, 2001). It is well 
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established that the appearance of these abnormalities often precedes alterations in 
blood pressure. The association with later-life hypertension and /embryonic 
reprogramming is well established from numerous observational studies in humans 
and in a number of animal models, including rodents (Barker, 1997). While 
endothelial dysfunction and artery remodelling are common observations in both 
animal and human studies of programming (Nuyt, 2008; Nuyt & Alexander, 2009) it 
is only more recently that negative changes in small vessel form and function have 
been investigated as an early indicator of cardiovascular risk in adult life (Ciuffetti et 
al, 2003; Noon et al, 1997). 
Early pathogenesis of hypertension is thought to result from direct structural effects 
on the artery and on the capillary bed (Ligi et al, 2010) with reduction in capillary 
density (rarefaction) observed in the offspring of rats following maternal nutrient 
restriction (Nuyt & Alexander, 2009). These offspring also have reduced angiogenic 
capacity accompanied by reduced in Vegf expression (Goligorsky, 2010; Pladys et 
al, 2005). In humans vascular rarefaction, which may elevate peripheral vascular 
resistance, has been detected in capillary beds of young men with hypertension risk 
and those who had low birth weight (Irving et al, 2004). Furthermore it has also been 
documented that suboptimal maternal nutrition and growth can result in reduced 
microvascular perfusion and functional dilator capacity, reduced expression of 
VEGF proteins, decreased angiogenic potential, shorter cultured neo-vessel 
formation and increased levels of cellular apoptosis (Khorram et al, 2007a; Pladys et 
al, 2005). These changes in small vessel molecular composition, structure and 
function can often be observed long before the onset of cardiovascular and metabolic 
abnormalities (Goligorsky, 2010; Pladys et al, 2005). It is therefore highly likely that 
altered vascular pathophysiology is as a result of some direct alteration in vascular 
phenotype. 
Small vessels (those less than 150µm in diameter) are particularly important 
physiologically in the regulation of solute transfer, a process which is largely 
controlled by the number of vessels and by the local flow of blood (Clough & 
Norman, 2011). Therefore, alterations in microvasculature structure and flow can 
have a profound impact on functional integrity, with reduced surface area resulting in 
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suboptimal tissue perfusion and failure to meet the metabolic demand (Clough & 
Norman, 2011). These vessels are also important in the maintenance of overall 
peripheral resistance, with reduced capillary density found to increase peripheral 
resistance (Gregório et al, 2007). 
Given this apparent association of microvasculature structure with programming, the 
primary aim here was to investigate whether the alterations in embryonic blood 
vessel appearance can impair adult vasculature. To do this a caudal fin ray 
vasculature assessment was performed in adult fish that had undergone embryonic 
GC manipulation. The adult caudal fin vasculature is an interconnected tubular 
multi-tissue structure which allows the transportation of blood throughout the caudal 
fin, similar to fine capillary networks. An increase in tail fin vascularisation has been 
observed in some fish models of exercise training (Sanger & Stoiber, 2001) 
suggesting that capillarisation, a feature which allows increased oxygen supply to 
working muscle, may be an adaptable feature for increased energy demand. This fin 
is commonly used as a relatively accessible model for studying regenerative 
processes in the adult zebrafish following amputation (Bayliss et al, 2006) and was 
adapted here to assess whether capillary density and angiogenesis could be altered in 
the adult fish of GC-manipulated embryos. 
In the work presented no significant alteration in the number of vessels joining 
caudal rays was observed, suggesting that the features which alter embryonic ISV 
formation do not result in long-term alteration in these fine adult vessels, at least in 
terms of inter-ray connections. This is in contrast to mammalian studies in which 
developmental programming altered neonatal capillary number or length⁄volume 
density in key organs (such as skeletal muscle, pancreas, brain, and kidney (Clough 
& Norman, 2011)). Vascularisation in the heart has also been effected with reduced 
intra-myocardial vascularisation in male rat offspring of low protein diet mothers 
(Gregório et al, 2007). However, whether these adaptations for short-term survival 
are sustained through the life course in these models remains unclear. 
While the data presented here do not highlight any differences in microvasculature 
structure, it does not mean that differences in capillary density do not occur in other 
tissue capillary beds, such as skeletal muscle. It may be that decreased capillary 
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density allows redistribution of blood and nutrients to central tissues at the expense 
of peripheral tissues, therefore to fully understand vessel effects other capillary 
networks should be investigated in the adult fish. In keeping with the energy 
demands, the highly vascularised gills may offer a more suitable model.  
Altered angiogenesis in embryos treated with Dex also resulted in long term 
alteration in angiogenic capacity of EmmodDex adults which manifests as a 
reduction in angiogenic sprouting in the amputated tailfin at 3dpa. These data are 
consistent with data published by Pladys and colleagues, (Pladys et al, 2005) where a 
decrease in cultured aortic ring angiogenesis was observed from offspring of 
maternal low protein diet rats. Interestingly, the EmmodDex impaired angiogenesis 
was not accompanied by reduced tail tissue regrowth suggesting that the tissue 
regeneration pathways are not altered by embryonic GC manipulation and also 
showing that impaired angiogenesis is not a result of impaired tail regrowth. By 
21dpa there were no obvious differences in tail morphology or in blood vessel 
appearance, in any of the groups investigated, suggesting that the angiogenesis 
processes are only temporally delayed and not completely impaired.  
5.5 Part 2  
The influence of embryonic glucocorticoid manipulation on the embryonic and 
adult heart 
5.5.1 Part 2: Results 
5.5.1.1 Aim 3: 
Does manipulation of the glucocorticoid system alter embryonic cardiac 
development? 
5.5.1.1.1 Cardiac functional assessments following embryonic GC manipulation 
tg (CMLC2: GFP) zebrafish were used to investigate the structure and function of the 
developing heart in the zebrafish embryo following pharmacological and genetic 
manipulation of the GC system (Figure 5.16(A-D)). 
Reduced heart rate was observed at 120 hpf in embryos where treatment resulted in 
reduced GR activity i.e. the RU486 or GR Mo groups (p<0.001). Ejection fraction 
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was also lower in these groups (RU486 p<0.01 and GR Mo p<0.001) when 
compared to controls. None of the other treatment groups investigated (Met, Cyp Mo 
or Dex) altered these parameters at 120 hpf (Figure 5.16(A and B)). 
Dex incubation increased stroke volume by 120 hpf (0.14± 0.03 µl
3
 vs 0.08± 0.03 µl
3
 
Figure 5.16 (C)). This resulted in an increase in cardiac output (p<0.05(Figure 5.16 
(D)). Conversely a reduction in cardiac output was observed in embryos treated with 
GR Mo by 120 hpf (15.7± 3.0 µl
3
/min vs controls 11.3 ± 0.7 µl
3
/min, p<0.05) 
although no difference in stroke volume was noted. No other treatment altered stroke 



























































































Figure 5.16 Embryonic cardiac assessments 
Cardiac assessments at 120 hours post fertilisation (hpf) in zebrafish embryos continuously 
incubated in 100µM dexamethasone (Dex - black bars), 10µM RU486 (blue), morpholino 
targeted towards glucocorticoid receptor (GR Mo-green), 10µM metyrapone (Met-orange) or 
morpholino targeted towards cyp11b1 (Cyp Mo-purple). Data shown are A) heart rate, B) 
embryonic ejection fraction, C) embryonic stroke volume and D) embryonic cardiac output. 
Data are mean± SEM (n=21 hearts/group; maximum to minimum for (A)) and analysed by 




5.5.1.1.2 Cardiac structural assessments following embryonic GC manipulation 
In order to quantify the effect of GC manipulation on embryonic zebrafish heart 
morphology, the distance between the junction of the heart with the inflow tract at 
the sinus venosus (SV) and the junction with the outflow tract at the region of the 
bulbus arteriosus (BA) (an indicator of heart looping) was determined. This 
parameter was unaffected by Dex or Met treatment but increased in RU486 (0.83 ± 
and GR Mo (P<0.0001). 
While the gross phenotype of embryos was unaffected by drug treatments at the 
selected concentrations, mild pericardial oedema was detected in some embryos 
(Figure 5.17). This can often be associated with cardiac dysfunction/enlargement as a 
result of impaired circulation and pooling of erythrocytes. As the cardiac function 
and heart looping had already been assessed, the pericardial area was calculated to 
determine whether there was any correlation with abnormal cardiac function and the 
observed oedema. Unlike the heart looping investigation and ejection fraction data, 
RU486 or GR Mo treatment did not alter pericardial area (neither did Dex treatment). 
However, embryos treated with Met or Cyp Mo (P<0.001) showed increases in area 
compared to controls.  
Reduction in cardiac function (for example in GR Mo and RU486 embryos) is often 
associated with a fall in blood flow which would be expected to reduce filtration at 
the developing pronephros (Rider et al, 2012). As a result of the alteration in 
filtration activity an increase in fluid volume would be expected which would 
ultimately lead to oedema. To determine whether alteration in pericardial area was a 
result of increased fluid accumulation, the distance between the heart wall and the 
pericardial wall was investigated. This distance was greater in embryos treated with 






Figure 5.17 Heart morphology after glucocorticoid modulation 
Quantitative assessments of embryonic heart morphology in zebrafish embryos at 72 hours 
post fertilisation (hpf) in controls or in those which had been treated continuously with 
dexamethasone (Dex-black bars), RU486 (blue), morpholino targeted towards glucocorticoid 
receptor (GR Mo-green), metyrapone (Met-orange) or morpholino targeted towards cyp11b1 
(Cyp Mo-purple). Data shown are for A) blood inflow/outflow distance of the heart, B) the 
pericardial area (area between head and yolk sack), and C) the heart wall/pericardial wall 
distance. Data are mean ± SEM (n=21 embryos/group), analysed by 1-way ANOVA and 
Dunnett’s post hoc test; **p≤0.01, *** p≤ 0.001 D) Typical images of 72 hpf zebrafish 
embryos treated continuously from the 2-cell stage with the glucocorticoid-manipulating 









Embryonic heart size was assessed in situ throughout the course of development 
(Figure.5.18). At 72 hpf ventricle length was unchanged following Dex; Met or Cyp 
Mo treatment compared to controls (controls 82.9 ± 2.3 µm; Dex 85.6 ± 2.6 µm; Met 
89.4 ± 1.0 and Cyp Mo 88.7 ± 2.9 µm).  
Embryos with reduced GR activity, resulting from treatment with RU486 or the GR 
Mo, showed a reduction in ventricle length compared to controls at 72 hpf and at 120 
hpf. In contrast, hearts from embryos continuously incubated in Dex displayed an 
increase in ventricle length at 72 hpf (p<0.001). Embryos which had been incubated 
with Met or treated with Cyp Mo were of similar length to controls. The differing 



































 Figure 5.18 Embryonic ventricular length after glucocorticoid modulation 
Ventricle long axis length during maximum diastole. Data shown are for 72 and 120 hours post 
fertilisation (hpf) for control untreated embryos and embryos which had been continuously 
incubated with dexamethasone (Dex), Ru486 or metyrapone (Met), or treated with morpholino 
targeted towards glucocorticoid receptor (GR Mo) or cyp11b1 (Cyp Mo) from the 2 cell stage. 
Data are mean ± SEM (n= 10 embryos per group where,. each n represents the mean of three 
cardiac cycles). Data were analysed by 2- way ANOVA and Bonferroni post hoc analysis; 





















Figure 5.19 Isolated embryonic hearts following glucocorticoid modulation 
Representative images of isolated tg(cmlc2:GFP) hearts 120 hours post fertilisation 
(hpf) co-stained with nuclear stain following exposure to dexamethasone (Dex), 
metyrapone (Met), or RU486, or to morpholinos targeted towards the glucocorticoid 
receptor (GR Mo) or cy11b1 (Cyp Mo). Features annotated are ventricle (V, and 
dotted ellipse), atrium (A), and bulbous arteriosus (BA). Yellow arrows show 




5.5.1.1.3 Isolated embryonic heart cardiomyocyte number 
Total ventricular cardiomyocyte number was assessed in 120 hpf embryonic hearts. 
Following treatment, hearts from tg(CMLC2:GFP) fish were surgically isolated and 
stained with DAPI, ventricular cardiomyocyte nuclei were distinguished from other 
cell types by the close association of the DAPI-stained nuclei to the GFP expression 
and counted (Figure 5.20 (B)). Treatments which reduced cortisol production, 
namely incubation with the drug Met or treatment with Cyp Mo (2.04 ± 0.15 cells 
per heart) caused no change in cardiomyocyte number compared with controls 
(p>0.05). However, treatments that reduced GC activity, RU486 or GR Mo 
(p≤0.001) reduced the mean ventricular cardiomyocyte number compared with 
controls. When this was normalised to total ventricle length, the difference was 
maintained (both p<0.001). Although no reduction in mean cardiomyocyte number 
was detected for hearts of embryos treated with Dex (187.5± 11.35 cells per heart vs 
controls 194.6± 11.8 cells per heart), when this number was normalised by the 
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Figure 5.20 Cardiomyocyte number in isolated embryonic zebrafish hearts 
Cardiomyocyte number in hearts isolated 120 hours post fertilisation (hpf) following continuous 
treatment with glucocorticoid modulators dexamethasone (Dex-black), RU486 (blue), targeted 
glucocorticoid receptor morpholino (GR Mo-green), metyrapone (Met-orange) or targeted 
cyp11b1 morpholino (Cyp Mo (purple). A) Shown is the mean ventricular cardiomyocyte 
number of isolated hearts and B) following normalisation to the ventricular length (µm). Data are 
mean± SEM (n=12 hearts). Data were analysed by 1-way ANOVA and Dunnett’s post hoc 
analysis; *p ≤ 0.05, ** p ≤ 0.01 compared with controls. 
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5.5.1.1.4 Glucocorticoid gene abundance in isolated embryonic hearts 
Three key genes of GC activity were determined in the isolated 120hpf embryonic 
heart. Constant incubation in either Dex or RU486 had no effect on relative 
abundance of gr, 11hsd2 and mr genes. No alteration in mr or 11hsd2 mRNA 
abundance was observed in isolated hearts from GR Mo embryos, however in 
accordance with gene knock down data (chapter 3) a 39% reduction in gr mRNA 
was observed in isolated hearts (p≤0.05) (Figure 5.21 (C)).  
5.5.1.1.5 Cardiac gene abundance in isolated embryonic heart  
The abundance of four key cardiac genes was determined in isolated embryonic 
hearts at 120 hpf following continuous incubation in drug (Figure 5.22). For gene 
abundance studies, due to challenges in isolation and extraction of RNA from these 
very small hearts only 3 treatment groups were chosen for investigation. These were: 
Dex, RU486 and GR Mo which were found to have the greatest impact on 
cardiovascular structure and function in the embryo (Sections 5.5.1.1.1 to 5.5.1.1.4). 
Myocyte enhancer factor-2c (Mef2c) through its role as a transcription factor can 
regulate skeletal and cardiac muscle-specific genes during development, influencing 
cellular differentiation and consequently playing a critical role in cardiac 
development (Xin et al, 2013). The abundance profile of this gene in isolated 
embryonic hearts was unaffected (p>0.05) by treatment with Dex or RU486. Isolated 
hearts from embryos treated with GR Mo however showed a reduction (P<0.001) in 
mef2c abundance compared with controls (Figure. 5.22(A)). 
Gata 4 is involved in the development of numerous zebrafish organs (Holtzinger & 
Evans, 2005). It has an important influence on cardiac development and 
cardiomyocyte proliferation (Singh et al, 2010), a role which appears to be conserved 
in zebrafish and rodent models (Holtzinger & Evans, 2005). In isolated embryonic 
hearts there was no difference in the abundance levels gata 4 compared with controls 
for any of the treatments investigated (all p<0.05) (Figure 5.22(B)). 
Ventricular myosin heavy chain (vhmc) is a gene homologue to the human MYH7 
gene which is responsible for the production of myosin heavy chain beta (Miyata et 
al, 2000). Vmhc therefore, required for the normal contractile activity of the heart 
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and is particularly important in the later stage of cardiac development. There was a 
rise in vmhc abundance in hearts treated with Dex (p<0.05). Conversely, embryos 
treated with RU486 or GR Mo showed a reduction (p<0.0001) in abundance 
compared with controls (Figure 5.22(C)). 
Insulin-like growth factor 1 (IGF1) is important for cardiomyocyte proliferation 
during cardiac development (Li et al, 2011). Following incubation of embryos in 
Dex or RU486 for 120 hpf there were no differences in the abundance of igf1 levels 
p>0.05). A significant reduction in igf1 abundance was however detected in isolated 
hearts from embryos treated with GR Mo, (p<0.05) (Figure 5.22(D)). 
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Figure 5.21 Glucocorticoid gene abundance analyses in isolated embryonic heart  
Relative mRNA abundance in isolated embryonic hearts at 120 hours post fertilisation (hpf) 
Data shown are for hearts isolated from embryos constantly incubated in the drugs 
dexamethasone (Dex-black) or RU486 (blue), or treated with targeted glucocorticoid 
receptor morpholino (GR Mo-green). Abundance data are for A) gr mRNA B) mr mRNA 
and C) hsd2 mRNA. Data shown are quantified by normalisation to the house-keeping genes 
ef1α and gapdh. Abundance is presented as arbitrary units (AU). Data are mean ± SEM (n=3 
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Figure 5.22 Cardiac gene abundance in isolated embryonic heart.  
Cardiac mRNA abundance in embryonic zebrafish hearts isolated 120 hours post fertilisation 
(hpf). Data shown are for hearts constantly incubated in the drugs dexamethasone (Dex-
black bars) or RU486 (blue) or treated with morpholino targeted towards glucocorticoid 
receptor (GR Mo-green), versus un-manipulated controls (red). Abundance data are for: A) 
mef2, B) gata4, C) vmhc and D) igf mRNA. Data shown are quantified by normalisation to 
the house-keeping genes ef1α and gapdh. Abundance is presented as arbitrary units (AU). 
Data are mean ± SEM (n=3 (100 hearts per group)) and were analysed by 1-way ANOVA 






What are the long term effects of embryonic manipulation of the GC system on the 
adult heart? 
5.5.1.1.6 Isolated adult hearts 
Hearts were isolated from adult zebrafish that had undergone GC manipulation 
during the first 120 hpf (embryogenesis) and been allowed to develop un-
manipulated until 120 dpf (as described in section 5.3.2). A number of parameters 
and features were investigated in the isolated hearts from each of the 3 treatment 










Figure 5.23 Isolated adult hearts after embryonic glucocorticoid modulation  
Light microscopy images of typical hearts isolated from adult (120 days post fertilisation 
(dpf)) zebrafish. Images shown are excised hearts from those treated during embryogenesis 
with: A) dexamethasone (EmmodDex) – shown with controls, B) RU486 (EmmodRU486) – 
and controls, and C) injected with a targeted gr morpholino (EmmodGR Mo) – shown with 
controls. Highlighted on images are: bulbus arteriosus (BA) - blood outflow from heart, 
atrium (A) – in some instances only partial atrium is shown (B and C), and ventricle (V). 
Images in A) were taken using a microscope to which access was no longer available at the 
time required for images B and C. Images shown are purely representative and have not 
been used for quantification of any feature. 
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5.5.1.1.7 Cardiac size and weight 
The wet weight of isolated hearts (the weight of the hearts directly after removal) 
was normalised to each individual adult fish body weight. Hearts from EmmodDex 
adults were heavier than controls (p<0.001) Figure 5.24 (A)). Hearts derived from 
the EmmodRU486 group were found to be no different in weight from their controls 
p >0.05(Figure 5.24 (B)). EmmodGR Mo group were found to be similar in weight 
to those of the control fish (p=0.05) (Figure 5.24 (C)). Normalised ventricular length 
was no different for EmmodDex or EmmodRU486 treatments compared to their 
controls (p>0.05). A difference was however noted for the EmmodGR Mo adult 








Figure 5.24 Isolated adult heart weight and length 
Isolated hearts from adult zebrafish which were embryonically glucocorticoid manipulated 
with dexamethasone (EmmodDex - black bars), RU486 (EmmodRU486 - blue bars) or 
targeted glucocorticoid receptor morpholino (EmmodGR Mo - green bars), compared with 
their corresponding controls (red bars). Data shown A-C) are normalised heart weight/body 
weight for isolated wet hearts; D-F) are ventricular length normalised to total body length. 

















































































































































































































5.5.1.2 Heart histology 
Detailed histological assessment was carried out in conjunction with a trained 
Veterinary pathologist. In EmmodDex fish the cardiac anatomy was grossly normal 
although some of these hearts did display features of cardiac enlargement with mild 
thickening of the compact myocardium but otherwise normal trabecular of the 
spongy myocardium (Figure 5.25). Staining with Masson’s trichrome, a stain used to 
differentiate between collagen and smooth muscle cells, failed to show interstitial or 
sub-endocardial fibrosis which often suggests cardiac hypertrophy (Data not shown). 
There was no apparent difference in inter-trabecular space between the EmmodDex 
and control hearts (13.86 ± 0.68 % ventricular area vs controls 12.06 ± 1.04 % 
ventricular area). 
EmmodRU486 also showed normal cardiac architecture including shape and size of 
bulbous, ventricle and atria; valve morphology; cardiomyocyte size and arrangement; 
sarcoplasmic integrity (cross striation, fragmentation, vacuolation); endocardial 
morphology and epicardial morphology (Figure 5.26). As for EmmodDex fish, there 
were no obvious differences in the interstitial collagen component of these hearts 
(Data not shown) and there was no obvious difference in the inter-trabecular space 
(12.42± 1.07  % ventricular area vs 12.24 ±1.07 % ventricular area). 
In contrast, at least 70% of the hearts removed from the EmmodGR Mo adults 
displayed changes in the ventricle affecting both compact and spongy muscle layers. 
In these hearts spongy trabecular were reduced in number and thickness. An increase 
in the inter-trabecular space was also apparent (20.32 ± 1.24 % ventricular area vs 
11.89 ± 1.22 % ventricular area) reducing the thickness of the compact myocardium 
along the full circumference in these hearts when compared to the control hearts 












Figure 5.26 Embryonic dexamethasone exposure: adult heart morphology 
Heart histology from adult fish at 120 days post fertilisation (dpf) following  
manipulation with dexamethasone [100µM] during embryogenesis (EmmodDex), and 
the respective control (EmmodDex Controls). Images shown are low power(4x) and high 
power (20x) magnification images. The magnified region is highlighted. Images show 
near identical trabeculae with mild cardiac enlargement in EmmodDex hearts. 
Figure 5.25 Embryonic RU486 exposure: adult heart morphology 
Heart histology from adult fish (at 120 days post fertilisation (dpf)) manipulated with 
RU486 [10µM] during embryogenesis (EmmodRU486), and the respective control 
(EmmodRU486 Control). Images shown are low power (4x) and high power (20x) 
magnification images. The magnified region is highlighted. Images are of the near identical 











5.5.1.2.1 Adult heart GC gene abundance analysis  
In EmmodDex adults gr mRNA abundance was higher than in controls (p<0.05). In 
EmmodRU486 adult hearts there was no difference in gr mRNA levels when 
compared to controls. Similarly no difference was detected in EmmodGR Mo 
(Figure 5.28 (A-C)). mr mRNA relative abundance was found to be unaffected in all 
of the groups investigated (Figure 5.28 (E-G)). 11βhsd2 mRNA abundance was 
significantly raised in EmmodDex (p<0.05). A reduction in levels in 11βhsd2 was 
observed in EmmodGR Mo isolated hearts (p<0.04) but no difference was detected 
in hearts from EmmodRU486 (1.82 ± 0.26 AU vs controls 1.74 ± 0.16AU). 
5.5.1.2.2 Adult heart cardiac gene abundance analysis 
Isolated EmmodDex hearts had lower (p=0.003) mef2c mRNA abundance than 
controls (Figure 5.29 (A)). In contrast, hearts obtained from EmmodGR Mo adults 
Figure 5.27 Embryonic glucocorticoid receptor knockdown: adult heart 
morphology 
Heart histology from adult fish (at 120 days post fertilisation (dpf)) manipulated with GR 
Mo during embryogenesis (EmmodGR Mo), and the respective control (EmmodGR Mo 
Controls). Images shown are low power magnification (4x) and high power (20x) 
magnification images. The magnified region is highlighted. Images show the 
substantially reduced compact myocardium along with the increase in the inter-trabecular 
space noted in 70% of the GR Mo hearts. The control hearts for this treatment did not 




displayed raised mef2c mRNA levels compared to controls (p<0.05). No difference 
was detected in mef2c mRNA relative abundance in EmmodRU486 hearts 
(p>0.05(Figure 5.29(B))). gata4 mRNA was decreased in EmmodGR Mo adult 
hearts compared to their controls (p<0.05) but was unaffected in both EmmodDex 
and EmmodRU486 groups. Similarly, EmmodDex and EmmodRU486 groups 
showed no alteration in vmhc relative abundance either. However, in EmmodGR Mo 
hearts there was a notable decrease in vmhc mRNA levels (p<0.01). None of the 








































































































































































































Figure 5.28 Glucocorticoid gene abundance in adult hearts  
Glucocorticoid gene mRNA abundance analyses in adult zebrafish hearts isolated 120 days 
post fertilisation (dpf). Data shown are for hearts constantly incubated in the drugs during 
embryogenesis and allowed to develop normally until adulthood. Embryonic treatments were 
with dexamethasone (EmmodDex - black bars) or RU486 (EmmodRU486 - blue bars) or 
targeted morpholino towards the glucocorticoid receptor (EmmodGR Mo - green bars), 
versus their respective un-manipulated controls (red bars). mRNA abundance data for A-C) 
gr, D-F) mr and G-I) 11βhsd2. Gene abundance data shown were quantified by 
normalisation to the house-keeping gene ef1α, and expression is presented as AU. Data are 








































































































































































































































































































Figure 5.29 Cardiac gene abundance in adult heart  
Cardiac gene abundance mRNA analyses in adult zebrafish hearts isolated 120 days post 
fertilisation (dpf). Data shown are for hearts constantly incubated in the drugs during 
embryogenesis and allowed to develop normally until adulthood. Embryonic treatments were 
with dexamethasone (EmmodDex - black bars) or RU486 (EmmodRU486 - blue bars) or 
treated with a targeted glucocorticoid receptor morpholino (EmmodGR Mo - green bars) 
versus their respective un-manipulated controls (red bars). Abundance data are for A-C) 
mef2c mRNA abundance, D-F) gata 4 mRNA abundance, G-I) vmhc abundance and J-L) 
nkx2.5 mRNA abundance. Gene abundance data shown are quantified by standard curve 
construction and normalisation to house-keeping gene data and are presented as arbitrary 





5.5.2 Part 2: Discussion 
This section of work has focused on the direct and specific action of GC modulation 
on the developing embryonic zebrafish heart and the long-term effects this has in the 
adult. 
5.5.2.1 Short-term effects of embryonic GC manipulation on the heart 
Corticosteroids such as GCs produce both protective and adverse effects on the heart 
(Hadoke et al, 2009). In addition to their effects on cardiovascular risk factors, the 
relative abundance of GC receptors in adult cardiac tissue suggests that they can 
directly influence both physiological and pathophysiological processes in the heart 
(Greenwood et al, 2003). The role of GCs on the developing heart however is less 
clear. Conditional knockdown of MR in the mouse produces severe heart failure and 
cardiac fibrosis, which can be fully reversed with the addition of MR antisense 
mRNA (Beggah et al, 2002). Furthermore in mice conditional overexpression of MR 
triggers cardiac arrhythmias with a high death rate. Again this phenotype can be 
mitigated using MR antagonist (Ouvrard-Pascaud et al, 2005). 
In MC target tissues, MR specificity for aldosterone is conferred by the activity of 
the enzyme 11βHSD2 which, by inactivating GCs (converting cortisol and 
corticosterone to cortisone and 11-dehydrocorticosterone, respectively), protects MR 
from inappropriate activation by GCs (Chapman et al, 2013). Human and rodent 
studies have highlighted that MR expression is largely restricted to MC target tissues, 
but it is also expressed in the heart without 11β-HSD2 co-localisation. Thus, in the 
heart, MR can bind endogenous cortisol/corticosterone and some actions of MR 
antagonist drugs may be derived from their ability to prevent action of GCs at 
cardiac MR. Overexpression of GR induces atrio-ventricular (AV) block (Sainte-
Marie et al, 2007). Global GR knockout (GR
-/-
) mice die shortly after birth with 
multiple organ defects and widespread somatic oedema. Notably the heart is smaller 
with abnormal cardiomyocyte architecture and impaired contractile function (Rog-
Zielinska et al, 2012). Taken together these data confirm a key role for GCs acting 
directly on the heart via GR, and possibly MR, in rodents. Similar published data 
from lower vertebrates, including the zebrafish, is sparse. 
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The heart is one of the earliest functioning organs in the zebrafish and data generated 
in this investigation indicate that supressed GC action via inhibition of GR activity, 
either by Mo knockdown of GR or pharmacological antagonism at GR using RU486, 
results in early impairment of cardiac function (reduced heart rate, ejection fraction 
and cardiac output). This is consistent with findings in GR
-/-
 mouse embryos which 
display severely impaired Doppler-derived indices of myocardial performance by 
ultrasound assessment (Rog-Zielinska et al, 2012). In addition to impaired function 
of the zebrafish embryonic heart, the ventricle (corrected for total body size) is also 
smaller. As shown (Chapter 4), these embryos have impaired growth rate and 
reduced head-trunk angle in early stages of development, suggesting an initial 
developmental delay. However by 120hpf, there is no apparent difference in 
development rate, suggesting that GC have a less critical role in later stages of 
development, and that developmental catch-up is occurring. Interestingly, although 
there is a somatic catch-up, cardiac development remains impaired, as indicated by 
small ventricular size, in embryos where GR activity was reduced either 
pharmacologically or with Mo. It is well documented that GCs have a profound 
effect on cell proliferation and differentiation and a smaller ventricle indicates that 
GCs play a key developmental role in the heart. Indeed in the mouse GR knockouts, 
hearts are smaller. In addition to smaller sized ventricles, these hearts also displayed 
an increased inflow/outflow distance at 72 hpf suggesting a delay in cardiac looping, 
consistent with delayed cardiac development. 
Embryos exposed to GR supressing treatments also displayed reduced expression of 
key cardiac maturational genes (including igf and vmhc) which also indicates that the 
hearts are developmentally immature and may at least partly explain some of 
observed functional abnormalities. Reduced cardiac function, in these embryos may 
also be the result of a loss of the direct ionotropic effects of GCs which has been 
described in rodent models (Rao & Narayanan, 2000; Rossier et al, 2008; Sainte-
Marie et al, 2007) although until now such observations have not been detected in 
the zebrafish. The findings reported here provide the first evidence for a direct effect 
of GCs on contractile function in the developing zebrafish heart.  
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There is some evidence that corticosteroid treatment of preterm infants is associated 
with post-natal adverse cardiovascular effects (Katz et al, 1988; Kelly et al, 2012) 
although some studies have suggested that this is not the case (Mildenhall et al, 
2009). When the rat foetus is exposed to a high cortisol preterm, increases in 
ventricular cardiomyocyte size are observed (Bal et al, 2009). In the work presented 
here, zebrafish embryos treated with Dex showed contrasting effects to those treated 
with GR Mo at 120hpf, with an increase in ventricular length and an increased 
cardiac output associated with normal heart rate. These hearts also displayed greater 
levels of vmhc mRNA, suggesting greater maturity and which could at least partly 
explain the observed increase in ejection fraction /stroke volume. 
When embryonic hearts treated with Dex were isolated at 120 hpf it was found that 
they contained the same total cardiomyocyte numbers as control hearts. However, 
after normalising for the larger ventricle these hearts appear to have fewer 
cardiomyocytes than controls. While this may need confirmation using volumetric 
analysis it suggests that the cardiomyocytes of the Dex treated embryos were larger 
than controls, pointing towards possible cardiac hypertrophy. A number of rodent 
and cell culture studies have demonstrated GC-induced cardiac hypertrophy (Ohtani 
et al, 2009), similarly early postnatal treatment with Dex in rats has been linked to a 
hypertrophic heart and increased MHC mRNA abundance (Muangmingsuk et al, 
2000) supporting the observations documented in the work presented here. 
Microscopic examination of the isolated embryonic Dex hearts showed them to be 
structurally more mature than those treated with GR Mo showing a well-defined 
muscle striation pattern. These hearts also displayed a normal cardiac morphology, 
with a normal folding pattern and normal trabeculation of the ventricle. 
Histologically there was no significant alteration in cellular morphology of these 
hearts in although hearts were significantly larger than controls. Further work is 
needed to establish whether these hearts had altered gene abundance consistent with 
cardiac hypertrophy, however, decreased cardiomyocyte number, increased vmhc 
mRNA abundance and increased heart size following Dex treatment would support a 
direct and dynamic role for GCs and GR signaling in the developing zebrafish heart. 
Further supporting this is the striking structural and functional abnormalities 
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resulting from a 39% reduction in cardiac GR mRNA during early development (GR 
Mo). 
Two further groups of GC manipulation which were investigated here were those 
treated with Met and Cyp Mo. As previously described, these treatments caused a 
significant reduction in cortisol levels in the embryo (chapter 3). This reduction in 
cortisol, while detrimental in stress-induced HPI axis activity appears to have had 
little or no effect on heart formation in the developing zebrafish embryo. This 
suggests that the role of GCs in early zebrafish cardiac development is largely 
attributable to maternally-derived cortisol rather than de novo synthesis within the 
embryo. While no morphological alterations were observed in the developing heart 
in these groups, an increase in pericardial edema was observed, which could be 
indicative of cardiac dysfunction. This does not appear to be the case here, as 
ventricular ejection fraction in these embryos was similar to controls. An alternative 
explanation for the pericardial edema is activation of MR via 11-deoxycortisol (a 
proposed Cyp11b1 substrate) ligand activity (Strum et al, 2005) resulting in excess 
sodium and water retention (Flynn et al, 1994).  
5.5.2.2 Long-term effects of embryonic GC manipulation on the heart 
Before the long-term cardiac effects of GC manipulation are discussed, it should be 
emphasised that all embryos, larvae and adults which were used in the longitudinal 
studies had stringent phenotypic/morphological assessments and were monitored for 
health and welfare throughout. The long-term survival of all embryos into adulthood 
was similar amongst all treatment groups with no increase in mortality observed 
following any of the embryonic manipulations.  
When embryonic fish that had undergone 5 days of GC manipulation were then 
allowed to mature in a normal environment, adult hearts displayed a number of 
structural, molecular and histological abnormalities. These long-term effects 
resulting from embryonic GC manipulation are consistent with the phenomenon of 
GC-induced early life programming (Barker, 1995). The most convincing evidence 
of a programming-like long-term alteration in the heart was in EmmodDex adults in 
which activity of GR was up-regulated in the embryo for the first 120h of 
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development (enhanced GR), and in EmmodGR Mo in which GR activity was down-
regulated for at least 120h (reduced GR). 
It has been fairly well established in humans that prolonged GC exposure in the adult 
can result in cardiac remodelling and cardiac dysfunction (Scheuer & Mifflin, 1998). 
Cardiac remodelling is characterised by myocyte hypertrophy and apoptosis, 
accompanied by hyperplasia and hypertrophy of non-muscular cells, with alterations 
to the extracellular matrix, inflammation and fibroblast function (Swynghedauw, 
1999). The teleost heart has a high level of plasticity, both anatomically and 
physiologically, in response to environmental changes, and ventricular growth can 
occur by hypertrophic (growth of cardiomyocytes) or hyperplasic (proliferation of 
cardiomyocytes) processes (Gamperl and Farrell, 2004). The association between 
stress, environment and cardiac remodelling has recently been investigated in 
salmonoid fish, with cardiac enlargement observed in high stress groups (Johansen et 
al, 2011): a feature seen here in the hearts of the enhanced GR adults. These hearts 
were larger and heavier than controls, in accordance with embryonic data (ventricles 
were larger than controls), and suggestive of cardiac hypertrophy. The classical 
histological markers of hypertrophy such as sarcomere reorganisation, increased 
vascularisation (to satisfy increased metabolic demand of hypertrophic cells) and 
increased fibrosis were absent from the EmmodDex zebrafish hearts. 
Cardiac hypertrophy in adult mammals is typically associated with alterations in 
genetic and molecular signals in the cardiomyocytes. This results in a switch to a 
pattern of gene expression (or re-expression) normally observed during early cardiac 
development. Alterations in the pattern of gene abundance associated with cardiac 
hypertrophy is less well defined in teleost fish with only a limited number of genes 
affected. This is mainly due to the lack of fish models which mimic mammalian 
models such as aortic banding or models of hypertension for example. However, 
some of the changes seen in mammals have been reported in fish (Chen et al, 2013). 
One such gene is vmhc (homologous to mammalian β-MHC). In the current 
investigation a similar increase in vmhc abundance was not observed in the 
EmmodDex group. Furthermore, a reduction in mef2 levels was observed. This is 
interesting as, Mef2c and GR act cooperatively in controlling gene transcription, with 
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GR influencing Mef2 activity (Speksnijder et al, 2012). The Mef 2 transcription 
factor family is important in early cardiac development and hypertrophy, and 
contributes to regulation of cardiac energy metabolism (such as cardiac fatty acid 
oxidation regulation and maintenance of mitochondrial function (Czubryt & Olson, 
2004)). This raises the question as to why mef2 abundance is low in this setting. It 
may be that manipulation of GC results in perturbations in various regulatory 
mechanisms in the heart via modification of Mef2c.  
Further investigation of additional molecular markers of hypertrophy, such as slow 
myosin light chain (smlc2) and muscle LIM protein (mlp) is clearly required. For 
example Mef2 synergistically regulates the transcription of several cardiac genes 
along with transcription factor Gata4.  
Numerous rodent studies have highlighted the importance of GATA4 in cardiac 
morphogenesis, with Gata4 -/- mice displaying embryonic lethality and a poorly 
formed heart tube (Kuo et al, 1997). The role of GATA4 in cardiac morphogenesis 
isn’t surprising given its role as a transcription factor regulating a number of cardiac 
specific genes (such as αMHC and atrial natriuretic peptide (anp)) in rodents. 
Furthermore, GATA4 is important in instances of hypertrophy and subsequent 
inducible expression of hypertrophic genes, with overexpression of GATA4 resulting 
in hypertrophy of cultured cardiomyocytes (Liang et al, 2001a; Liang et al, 2001b). 
The transcriptional activity of GATA4 is thought to be regulated by interaction with 
a number of cofactors, including nkx2.5. GATA4 is also activated through direct 
serine phosphorylation by the p38 MAPK pathway may be mechanism by which 
GCs can influence the vasculature. While EmmodDex adults did not show an up-
regulation of gata4 mRNA relative abundance as may have been expected, 
EmmodGR Mo hearts display a reduction in gata4 relative abundance associated 
with quite marked changes in in cardiac structure. These data suggest that GC 
modulation may alter cardiac and vascular morphogenesis via common pathways. 
While this is not particularly ground-breaking considering numerous compounds 
produce signal transduction through this GATA4 signalling pathway, it does offer a 
means of explaining the multiple actions of GCs on target tissues.  
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As the classical cellular and molecular features of cardiac hypertrophy were not 
observed in the EmmodDex hearts, future work should focus on exploring further the 
underlying molecular and cellular characteristics causing cardiac enlargement in this 
model. An increase in size could be as a result of cardiomyocyte hyperplasia. Since 
fish hearts have been shown to regenerate using this process, cell proliferation may 
contribute to cardiac alterations observed. However, no apparent increase in the 
number of nuclei was observed in the histological sections of the adult hearts. 
Further investigation of cellular proliferation could be assessed using carried out 
using proliferating cell nuclear antigen (PCNA). While histological examination did 
not identify structural abnormalities, some EmmodDex hearts displayed thickening 
of the compact myocardium. It is unlikely that this has much influence on overall 
cardiac size but further investigation of cardiac cellular composition could be 
completed to determine whether there is any alteration in the expression of cardiac 
fibroblasts, myocytes, endothelial cells, or vascular smooth muscle cells. 
Not only did the EmmodGR Mo alter abundance of some key cardiac genes 
(reduction of Gata4), there was clear evidence of altered cardiac morphology. The 
heart of salmonoid fish is composed of an inner spongy myocardium, which is 
supplied with oxygen from venous blood returning to the heart, and an outer more 
compacted myocardium (Pieperhoff et al., 2009). The ventricular wall in the adult 
zebrafish ordinarily has a thin compact layer with extensive elongated and thickened 
trabeculae. In EmmodGR Mo adult hearts there were long-lasting effects of GC 
manipulation on the gross anatomical structure of the heart muscle, with a reduction 
in spongy trabeculated myocardium muscle accompanied by an increase in inter-
trabecular space and an apparent reduction in compact myocardium. Normally the 
long thin appenditures of the trabeculae form a mesh like structure with intra-
trabecular spaces. Cardiac trabeculae are thought to enhance cardiac contractility and 
intra-ventricular conduction. The ventricular trabeculae of the adult zebrafish heart 
resemble those of the chick, where the arrangement of the trabeculae, ventricular 
shape and size are critical for ventricular contraction (Pieperhoff et al., 2009). The 
organization of the adult zebrafish myocardium is, in part, determined by the 
haemodynamic forces which occur during ventricular wall development. As embryos 
the EmmodGR Mo group displayed reduced ejection fraction and decreased heart 
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rate so this may explain why these hearts appear immature and not formed as normal. 
While it is unclear whether the hearts of these adult fish are functionally alike the 
controls or not it has been shown previously that the trabecular folds are vital for 
ventricular stability during contraction, suggesting that the EmmodGR Mo hearts 
may have impaired function. 
While it is clear that future work needs to be carried out on the adult heart of GC 
modulated embryos to understand the underlying cellular and molecular mechanisms 
involved, it is apparent that altered embryonic cardiac development can result in 
long-term alterations in the structure and genetic composition of the heart, i.e. 
programming. While it is unclear as to the functional impact of these abnormal hearts 
in this model, normal mortality rate, gross phenotype and normal motility would 
suggest that cardiac performance is not altered significantly enough to impair 
survival under normal conditions. However, these alterations may impair the ability 
of the cardiovascular system of these individuals to react to altered environmental, 
behavioural or mechanical stress. 
5.6 Part 3:  
Is the embryonic phenotype caused GR Mo be rescued by capped gr mRNA 
While the data presented in this chapter suggest that manipulation of GC activity 
through the GR can impact on cardiovascular development, phenotypic rescue would 
provide further support that the observations are the direct result of manipulation of 
Gr actions and not a secondary or non-specific effect. While pharmacological rescue 
is possible and has been investigated previously, rescue of the GR Mo phenotype 
was performed to avoid possible drug toxicity.  
5.6.1  Part 3: Results 
5.6.1.1 Aim 5  
5.6.1.1.1 Glucocorticoid receptor mRNA and protein abundance: GR Mo rescue 
To assess whether cardiovascular phenotypes resulting from GC manipulation were 
associated with altered gr mRNA abundance, gr mRNA abundance was confirmed in 
both the zebrafish embryonic and adult heart (Figure 5.30 A). Furthermore, Gr 
protein was also found both in embryonic and adult zebrafish hearts, using a custom-
233 
 
designed zebrafish Gr antibody (a kind gift from Professor M. Vijayan, University of 
Waterloo, Ontario, Canada) (Figure 5.30 B). Indeed, immunohistochemistry suggests 
that Gr is located in the DAPI: GFP positive mono-nucleated cardiomyocytes (Figure 
5.30.D). Further optimisation of this technique and enhanced imaging would be 
required, however, to quantify the abundance and determine whether localisation is 
cytoplasmic or nuclear. 
As previously shown (Chapter 4 and 5 previously), gr mRNA and protein signals 
were reduced in whole embryos following GR Mo treatment, with a clear reduction 
in both gr mRNA and Gr protein 72hpf. Embryos treated with GR Mo (splice) had a 
41.5 ± 6.3 % reduction in GR mRNA compared to age matched controls 
(representing 100%), p=0.004 (Figure. 5.30 E) and a 28.7 ± 5.4 % reduction in GR 




Figure 5.30 Confirmation of glucocorticoid receptor presence in zebrafish heart 
A) gr mRNA abundance in isolated embryonic and adult zebrafish heart tissue as determined 
by qRT-PCR normalised to house-keeping gene βactin. B) Gr protein abundance in isolated 
embryonic and adult hearts as determined by Western blot analysis and densitometry with α-
tubulin house-keeping protein. C) Representative immunohistochemistry of isolated 
embryonic zebrafish heart expressing GFP under the cmlc2 promoter (green) stained with an 
anti-Gr antibody (Alexa 555 conjugated secondary-red) and co-stained with the nuclear stain 
DAPI (blue). D) Higher magnification image to allow observation of weakly-expressed anti-
GR antibody. Arrows indicate possible abundance and cytoplasmic localisation within the 
mononucleated cardiomyocytes. Image capture was with Leica SP5 confocal microscope. E) 
qRT-PCR. GR Mo gene knockdown as a percentage of control gr mRNA abundance at 72 
hours post fertilisation (hpf). N=3 (10 embryos per group). F) Western blot densitometry 
data of GR Mo protein relative knockdown as a percentage of control Gr protein abundance 
at 72hpf. N=3 (5 embryos per group). Data are mean ± SEM, statistical analysis by Student’s 




5.6.1.1.2 Rescue experiment for GR Morpholino on cardiac phenotype 
To determine the specificity of the GR Mo, an mRNA rescue experiment was carried 
out as described (Section 5.3.10). Capped mRNA encoding GR was co-injected into 
embryos treated with the GR Mo. To determine whether successful rescue was 
achieved a number of parameters were investigated (Figure 5.31) based on features 
which could be assessed easily in the embryo and were observed to be altered by GR 
Mo; for example, ventricle length, cardiomyocyte number, head-trunk angle and 
blood vessel patterning. 
While ventricle length was reduced in GR Mo (<0.001) compared to controls, an 
increase was detected after rescue (p<0.05 vs GR Mo). However, the rescue group 
still had smaller hearts than controls (p<0.05) (Figure. 5.31 (A) and Figure. 5.32). 
Cardiomyocyte number remained lower in rescued, compared to control untreated, 
hearts (1.76 ± 0.09 cardiomyocytes/µm vs 2.18 ±0.13 cardiomyocytes/µm, 
respectively; p<0.05), although cardiomyocyte number was higher in rescued hearts 
than in those from embryos treated with GR Mo alone ((p<0.05) (Figure 5.31 (B)). 
It previously was shown (chapter 4) that GR Mo treatment resulted in developmental 
delay which manifested as impaired head-trunk angle. Co-injection of rescue 
significantly attenuated the effect of GR Mo on head-trunk angle at all time-points 
investigated (24hpf, rescue 58.87 ± 1.22
 O
 vs GR Mo 46.30 ± 3.87 
O
, p<0.05; 48 hpf 
rescue 116.43 ± 2.86 
O
 vs GR Mo 104.15 ± 2.47
 O
, p<0.001; 72 hpf rescue 140.35 ± 
1.02
 O
 vs GR Mo 127.09 ± 3.57
 O
, p< 0.001). No difference was observed in head 





Blood vessel patterning was also assessed in the rescue embryos. As reported 
previously (Section 5.4.1.1), a reduction in ISV number was observed in GR Mo 
(P<0.001), while rescued embryos had fewer ISV than mismatch controls. The mean 
number of ISV in rescued embryos was greater than in GR Mo-treated embryos (p 
<0.01) indicating a partial rescue of the blood vessel phenotype (Figure 5.31(D)).
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Figure 5.31 Glucocorticoid receptor morpholino phenotype rescue analysis  
Features known to be altered in zebrafish embryos by gr morpholino (GR Mo) treatment 
were assessed in embryos following co-injection of rescue gr mRNA with GR Mo. Data 
shown are for embryos treated with GR Mo (green bars), GR Mo co-injected with gr rescue 
(dashed green bars), and controls (mm-Mo – red bars). Features investigated were A) 
ventricle length at 120hpf, B) cardiomyocyte number at 120 hours post fertilisation (hpf), C) 
head-trunk angle 24-72 hpf and, D) intersegmental vessel number at 120hpf. Data are mean 
± SEM (n=3 (6 embryos per group)). A, B and D) were analysed by 1-way ANOVA and 
Dunnett’s post hoc test; C) was analysed by 2-way ANOVA and Bonferroni post hoc test; 









Figure 5.32 Isolated embryonic hearts from zebrafish embryos 
Representative images of hearts excised from embryos 120 hours post fertilisation (hpf). Examples shown are of a control (untreated) heart, one 
which was treated with targeted glucocorticoid receptor morpholino (GR Mo) at the 2-cell stage, and one which was co-injected with capped gr 
mRNA with GR Mo. Features annotated on images include ventricle (V), atrium (A - where applicable) and bulbus arteriosus (BA). Yellow 
arrowhead depicts blood outflow from ventricle through bulbus arteriosus.  
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5.6.2  Part 3: Discussion 
The mRNA rescue experiment of the GR Mo demonstrated a partial rescue of the 
structural phenotype in the heart. Specific notable features, compared with GR Mo 
embryos, included increased heart ventricle length, increased ventricular 
cardiomyocyte number and accelerated development (as shown by head-trunk angle). 
These findings provide support for a direct role for GR on the cardiovascular 
phenotype observed with GR Mo. While the effects of GR Mo may be partly related 
to developmental delay a direct impact on maturation and development of the 
cardiovascular system is also likely. 
Evidence of altered cardiomyocyte architecture, was also observed in GR Mo which 
was partly rescued by gr mRNA. While these findings may be attributable to altered 
cardiac gene abundance, they may also partly explain the finding of impaired cardiac 
function. In addition to being structurally immature the ventricles of GR-suppressed 
hearts also contained fewer cardiomyocytes than controls. Again, this lends support 
for a key role played by GC in cardiomyocyte proliferation. Indeed, cortisol triggers 
isolated cardiomyocytes to enter the cell cycle (Giraud et al, 2006). Further 
examination of the cellular microscopic structure and gene/protein abundance may 
allow a more complete understanding of the processes underlying the reduced 
cardiac size and function resulting from GR suppression and its rescue by capped GR 
mRNA.  
5.7 Conclusion 
GCs have both direct and indirect effects on the adult mammalian cardiovascular 
system as a consequence of the abundant expression of GR and MR in the 
vasculature and in the heart (Walker, 2007). Direct effects of GC include alterations 
to vascular function and cardiac and vascular remodelling (Hadoke et al, 2009). It is 
also fairly well established that foetal exposure to excess GC can alter embryonic 
development and increase the risk of developing cardiovascular disorders in later 
adult life (Seckl & Meaney, 2004). In this chapter, the effects of up- and down-
regulation of GC activity on the embryonic cardiovascular system were assessed 
during embryogenesis and the effects of this modulation on the longer term structure 
and molecular signalling in the adult cardiovascular system were investigated. The 
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zebrafish has provided a unique opportunity to achieve the main aims of this chapter 
within a relatively short period of time, highlighting its utility for this type of 
experiment. The use of organ-specific GFP-expressing transgenic fish and the ability 
to readily manipulate GC activity in parallel experiments and then allow the embryos 
to develop into adults represents a unique and highly efficient research approach. 
The main findings of this chapter are: 1) GC signalling through the GR is important 
for embryonic angiogenesis, with enhanced embryonic GR activity appearing to have 
long-term effects on regenerative angiogenesis in the adult caudal fin. 2) Enhanced 
embryonic GC activity through GR increases cardiac maturational events during 
embryogenesis; this enhanced early cardiac growth manifests in adulthood as a larger 
heart. 3) Genetic suppression of the embryonic zebrafish GR results in impaired 
cardiac maturation with resulting structural and functional abnormalities; leading on 
to similar abnormalities in adulthood. 
While these findings alone are interesting it is unclear what the wider implications 
may be. When the activity of GR is enhanced (exposure to excess GC in the form of 
Dex) in the embryo a reduced number of ISV was observed, however this did not 
prevent or impede the normal growth and development of these embryos by 120 hpf 
or into adulthood (120 dpf). In the adults there was evidence of reduced angiogenic 
response to injury in the caudal fin. Furthermore a reduction in key molecular 
contributors to pro-angiogenic signalling was also observed. These data could 
represent a diminished capacity to repair injured tissue and could be the first 
evidence of altered regenerative capacity in the zebrafish resulting from an early-life 
programming intervention with GC. This finding, along with published data on GC 
inhibition of angiogenesis (Khorram et al, 2013) suggest that documented 
programmed vascular dysfunction in adulthood (such as hypertension) may be as a 
result of reduced angiogenic capacity. Enhanced GR activity in the embryo also 
appeared to accelerate heart maturation resulting in enhanced cardiac performance at 
120hpf. Strikingly, in the adults this resulted in larger hearts with altered molecular 
signalling (e.g. increased vmhc mRNA abundance) this clearly highlighted a 
programmed effect of the early life GC exposure. While no functional data was 
observed in the adult hearts, survival data would suggest that normal functional 
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activity was maintained. However it is unclear whether this would affect long-term 
health. It may be that the plasticity of the heart which normally allows the heart to 
adapt in instances of increased workload may be finite and thus the observed rapid 
cardiac maturation following enhanced GR activity during embryogenesis may 
impair cardiac plasticity in later life.  
Reduced GR activity namely in the GR Mo group reduced cardiovascular 
development in the first 120 hpf by which point normal somatic development was 
observed clearly highlighting a developmental role of GC in the zebrafish 
cardiovascular system. Notably in the Gr Mo embryos hearts were smaller, 
structurally immature and subsequently had impaired cardiac function. By adulthood, 
long after the intervention was removed cardiac abnormalities persisted, as evident 
by the smaller hearts with increased intra trabecular space. Furthermore, molecular 
signalling in these hearts is also altered, with reduced vmhc abundance. While it is 
unclear as to the functional consequence of this in the adult it is likely that normal 














Chapter 6: General discussion 
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6 General Discussion 
6.1 Introduction 
Previous research has highlighted a clear association between environmental 
alterations and disease progression in later adult life, with cardiovascular disease and 
alteration in HPA axis function often displayed. This association, termed 
programming, is thought to be as a result of adaptive changes at an organ level 
occurring during critical stages of embryonic development. While the exact 
mechanism through which these adaptive changes result in adult onset disease is 
unclear, it is likely that alterations in tissue cellular and molecular composition may 
increase disease susceptibility. This disease risk can be further exacerbated by 
confounding features such as food abundance, environmental alterations or 
additional disease risk factors. 
Current models of programming do not allow the level of investigation required to 
determine the direct and subtle effects of programming on the system of interest. The 
zebrafish has many desirable features which make it suitable for this form of study. 
The work presented in this thesis investigates the impact of GC manipulation on 
zebrafish development. 
6.1.1 PhD hypothesis  
The overlying hypothesis which was investigated in this thesis was that modulation 
of embryonic GC system will result in direct effects on the structure and function of 
the developing cardiovascular system.  
6.1.2 PhD aims 
 To characterise the GC system in the embryonic and adult zebrafish to 
confirm the suitability of this species as a model of GC modulation. 
 To investigate programming in the zebrafish by assessing classical 
mammalian programmable features 1) development, 2) stress response, and 




 To investigate the long-term impact of early-life GC manipulations on 
cardiovascular developmental. 
6.2 Relevance of findings and future direction 
6.2.1 Physiological roles of glucocorticoids in embryonic development 
A number of studies have described the HPI axis in adult salmonoid fish, including 
the adult zebrafish, and have suggested that this system may be present in the embryo 
(Alderman et al, 2012; Alsop & Vijayan, 2008; Alsop & Vijayan, 2009; Mommsen 
et al, 1999; Nesan et al, 2012; Nesan & Vijayan, 2013). Few, however, have 
characterised whether the system is physiologically active in the zebrafish embryo 
(Tokarz et al, 2013a). 
This work clearly demonstrates a functional HPI axis in zebrafish embryos as 
indicated by the detection of key functional components of the system and receptors 
for cortisol from early in development (8hpf-fertilised oocyte). These findings are 
consistent with a number of factors: 1) GCs have well-documented developmental 
roles in the mammalian foetus (Brown & Seckl, 2005), with a correlation between 
increased basal circulating GC levels and maturational events in numerous organ 
systems (e.g. lung maturation, although the underlying cellular and molecular 
mechanisms are complex (Harris & Seckl, 2011); 2) the teleosteon HPI axis shares a 
high degree of homogeneity with the mammalian HPA axis in terms of composition, 
structural organisation and function (Steenbergen et al, 2011), and 3) the widespread 
expression pattern of GR and its ligand cortisol during very early zebrafish 
embryogenesis (Alderman et al, 2012; Nesan & Vijayan, 2013) would strongly 
support a developmental role. 
The data reported in this thesis support a key role for GCs in embryogenesis and 
development. Increased GR activation, resulting from Dex incubation, increased the 
rate of development (growth, hatching and swim bladder inflation) over the first 
72hpf. Conversely, diminished GR activity, using pharmacological (RU486) and 
genetic (GR Mo) manipulation, impaired these important developmental features. 
Two recent publications have also identified a role for GCs in zebrafish development 
(Nesan et al, 2012; Pikulkaew et al, 2011). These studies defined a role for GR in the 
formation of mesoderm structures, as GR Mo knockdown caused tail kinking and 
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malformed somites. While this supports a role for GC, it should be acknowledged 
that a relatively high concentration of Mo was used (10.3-20.6ng/embryo) and some 
of the features described can occur as off-target non-specific effects of Mo treatment. 
However, work by Pikulkaew (Pikulkaew et al, 2011) describes an mRNA rescue 
experiment similar to that described here, indicating that the effects seen are indeed 
due to a direct effect of greater GR knock-down. 
Capped GR mRNA rescue (Chapter 5) partially rescued the developmental delay by 
normalising the head trunk angle. A complete rescue was not observed, however, as 
higher concentrations of the capped mRNA alone caused phenotype abnormalities 
(pericardial oedema and craniofacial abnormalities). A possible explanation for this 
is over-expression of GR since exogenous RNA is not metabolised in the usual way 
and this over-expression could result in structural abnormalities (Summerton, 1999). 
The gold standard of mRNA rescue experiments, which was not carried out here but 
could be addressed on future work, would be the introduction of an mRNA from 
another species which has sufficient 5'-UTR sequence divergence but which can 
complement the missing protein's activity- thus rescuing the phenotype while 
minimising Mo RNA interactions (Summerton, 1999).  
The work presented here also demonstrates that maternally-derived cortisol within 
the embryo can be influenced, with the offspring of mothers injected with Dex 
displaying raised cortisol levels in the initial phase of development. This is the first 
(to date) documented alteration of maternally-derived cortisol in zebrafish. 
Consistent with a role of GC in hatching, a larger proportion of these offspring 
hatched earlier than controls (Data not shown). The significance of these findings 
would require further investigation but it may represent a form of natural selection, 
where individual embryos within this population have reproductive modifications or 




6.2.2 Embryonic glucocorticoid manipulation and adult development  
It is now widely recognised that small-for-gestational age, IUGR or pre-term infants 
have a greater risk of later onset cardio-metabolic disease (Boubred et al, 2013; 
Hales & Ozanne, 2003) and some neurological disorders (Phillips et al, 2000; 
Rugolo, 2005). There is emerging evidence that this risk is further amplified by rapid 
catch-up growth (Stein et al, 2013). The mechanisms involved are unclear and it is 
widely suspected that diseases in later life are more likely to result from this 
association of rapid catch-up growth postnatally rather than intrauterine growth 
restriction per se (Tedner et al, 2012). 
This phenomenon of catch-up or compensatory growth shows fairly wide variation 
around an optimal level in large populations (Stein et al, 2013). The trajectory of 
growth rate can increase, as seen in the EmmodDex fish reported here which, 
although not smaller at 120hpf, displayed increased growth rate between the juvenile 
and adulthood stages. Previous studies have suggested, however, that compensatory 
growth has a finite capacity (Tedner et al, 2012). This means that despite catch up 
growth, once there is cessation of cell proliferation, the final cell number may be 
lower than would have occurred under normal circumstances. This can result in 
irreversible alterations in organ cell number and size. Although cell number could 
not be determined in the isolated adult heart, cardiomyocyte number was reduced at 
embryonic stages of development when GR activity was inhibited by drugs or 
genetic manipulations.  
Abnormalities in organ size and or cellular structure have detrimental consequences 
on cellular and physiological activity with alterations in fat deposition, telomere 
abrasion, glucose tolerance, insulin resistance, obesity, risk of cardiovascular 
disorder and reduced lifespan shown in humans and other vertebrates (Metcalfe & 
Monaghan, 2001). It is, therefore, reasonable to suggest that the cellular 
abnormalities reported here could lead to alterations in function in later life in the 
zebrafish. However, the physiological consequences of such changes for the 




6.2.3 Embryonic glucocorticoid manipulation and embryonic stress response 
The data generated also suggest that, although the critical signalling and 
steriodogenic features of the stress response are present and functional from early in 
zebrafish development, the earliest detectable stress response does not occur until 
72hpf. The lag between functional activity of the system and stressor-induced 
cortisol biosynthesis has been reported in other teleost species, including the rainbow 
trout (Barry et al., 1995) and, more recently, the tilapia (Pepels and Balm, 2004). 
Although a delay in stress-induced activity is observed in other teleost species 
(Leatherland et al., 2010), its functional relevance remains unclear. It may suggest a 
further role of GCs as developmental regulators; the lag period being protective of 
key growth phases without which sudden surges in GCs may result in disruption of 
GC-sensitive developmental events. Indeed, this feature is observed following 
embryonic Dex exposure where there is an increase in growth rate and chorion 
hatching when the HPI axis stress response is absent. This is also referred to as the 
stress hyporesponsive (SHR) period in rodent models (Sapolsky & Meaney, 1986). 
Further support for a developmental role for GCs in the zebrafish embryo is the 
detection of significant levels of cortisol in the early oocyte. In zebrafish, as for other 
fish species, a number of developmental components are transferred from the mother 
into the yolk sac during gametogenesis. These hormones are thought to control 
developmental rate and are depleted as embryogenesis progresses prior to de novo 
synthesis (Gagliano & McCormick, 2009; McCormick & Nechaev, 2002). 
Furthermore, evidence suggests that there may be a direct link between maternal 
plasma hormonal levels and the eggs which are produced. Numerous maternal 
hormones are known to be transferred, such as those involved in growth (e.g. 
thyroxin (Brown et al, 1988)), reproduction (testosterone) and metabolism (cortisol). 
Maternally-derived cortisol is not thought to be important for stress response during 
this phase but, rather, it may play key functional interactive roles with a number of 
developmental hormones. These may include the suppression of reproductive activity 
and involvement in several aspects of gametogenesis and embryogenesis in fish 
(Schreck, 2010). As a consequence of this, raised oocyte cortisol levels can have a 
major impact on embryogenesis. In this work, embryonic GC incubation (Dex 
treatment) increased the abundance of a number of growth-related hormones, 
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including igf. This suggests that, increasing activity of GR at key developmental 
phases where GC levels are normally low (the SHR period), can produce a 
downstream effect on growth hormones and, subsequently, on tissue growth. 
The fall and rise in cortisol and in GC-related transcripts in this work showed a clear 
inflection point at, or near, 48hpf. This suggests that cortisol detected before this 
time-point was of maternal origin and subsequent increases represent de novo 
synthesis by the embryo itself. In mammals, maternal stress results in raised 
circulating cortisol levels and this subsequently influences mortality in the offspring. 
Similar observations have been detected in salmonoid fish, in which raised maternal 
plasma cortisol levels during the period of oocyte vitellogenesis can alter oocyte 
cortisol content (Leatherland et al, 2010; Veillette et al, 2007). Here to an increase in 
cortisol was also observed in the offspring of Dex injected mothers. The alteration of 
offspring cortisol in fish is said to represent evolution of reproductive strategies for 
generational life history and ecology progression (Burton et al, 2013; McCormick, 
1998). 
From published data on the environmental influences on fish reproductive function it 
is apparent that teasing apart the effects of cortisol on reproduction per se, versus the 
intrinsic survival mechanisms of the species under stressful conditions, is extremely 
difficult (Aluru & Vijayan, 2009; Segner, 2009). An important paper by Carl Schreck 
(Schreck, 2010), is one of a limited number which describe the impact of stress on 
the number and quality of surviving offspring, describing a reduction in egg 
production and viability following maternal stress. One other study reported that 
administration of cortisol to female tilapia (fish) by injection resulted in impaired 
oocyte growth and reduced adult offspring condition factor (Foo and Lam, 1993). 
These findings are particularly interesting as it may be an initial indication of 
adaptive programming of the embryo in fish species. 
6.2.4 Embryonic glucocorticoid manipulation and adult stress response 
As discussed, the function of the HPA or HPI axis is to provide an animal or 
organism with an adaptive response to environmental or physical stress to ensure 
homeostasis via production and release of GCs (cortisol in humans and cortisone in 
248 
 
rodents). This neuroendocrine system is present after the formation of the 
hypothalamus, pituitary brain structures and adrenal gland (found on the kidney), 
along with the presence of various catalytic cytochrome p450 enzymes and steroidal 
substrates. GCs released via this pathway act upon numerous target tissues which 
express either GR or, to a lesser extent, MR; the HPA/HPI axis itself also expresses 
these receptors creating auto-regulation or negative feedback of GC production 
(Chapman & Seckl, 2008). 
The ontogeny of this system, like many developing organ systems, is influenced by 
maternal GCs, with GC over-exposure during the perinatal period associated with 
programming of HPA axis function (Huang, 2011; Jellyman et al, 2012; Kapoor et 
al, 2006; Seckl & Holmes, 2007). GC over-exposure towards the end of gestation 
permanently increases basal and stress-induced plasma GC levels in rodents (Cottrell 
& Seckl, 2009). Consistent with these rodent studies, Dex treatment during zebrafish 
embryogenesis increased stress-induced cortisol in the adults. Furthermore, 
alterations in basal and stress-induced cortisol alters behaviour, resulting in increased 
incidence of anxiety-related behaviours (Welberg et al, 2000). This was 
demonstrated in EmmodDex adults who displayed differing behaviour in a number 
of assays; open-field, dive and response to a novel object in the tank. These data are 
of particular significance since, not only do they confirm a physiological role of the 
HPI axis in swim behaviour in zebrafish, but they also suggest that altered behaviour 
can be programmed in the zebrafish following embryonic GC exposure.  
Published data suggests that environmental modulation (such as GC over-exposure) 
can influence anxiety, learning, memory, and cognition in rodents (Cottrell et al, 
2012) and humans (Reynolds, 2013). The data presented here confirms behavioural 
alterations in the zebrafish model too following GC manipulation, not only 
confirming the suitability of the zebrafish as a behavioural model but also suggests 
that features such as learning and memory could be readily investigated using in 
zebrafish too. Indeed, Pavlovian learning (e.g. electric shock avoidance (Pradel et al, 
2000)) and operant conditioning (e.g. choosing between one arm of a maze and 
another (Colwill et al, 2005)) have been carried out successfully in zebrafish (Levin 
& Cerutti, 2009). 
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6.2.5 Embryonic glucocorticoid manipulation and vascular development 
Previous studies suggest an association between foetal GC exposure and increased 
cardiovascular abnormalities in adult animals (Wintour et al, 2003). GC inhibit the 
formation of vascular tubes by endothelial cells (Logie et al, 2010; Nicosia & 
Ottinetti, 1990) and prevent migration and proliferation of vascular smooth muscle 
cells (Longenecker et al, 1982), resulting in vascular remodelling and structural 
alterations (Christy et al, 2003; Katz et al, 1988) which is associated with an 
increased cardiovascular risk (Girod & Brotman, 2004; Ng & Celermajer, 2004; 
Stewart & Petersenn, 2009; Trayhurn & Beattie, 2001). However, less is known 
about the direct actions of GCs (whether exogenous and/or endogenous) on the 
growth and structure of the developing cardiovascular system (Sainte-Marie et al, 
2007).  
The work presented here not only confirms a role for GCs in global maturation and 
development of the zebrafish embryo but also suggests an important role in the 
development of the heart and blood vessels (Chapter 5). GCs have anti-angiogenic 
properties (Folkman et al, 1983) and here GC manipulation (either suppression or 
enhancement of receptor activity and not endogenous production) resulted in 
alteration of the process of angiogenesis but not vasculogenesis (the primary axial 
vessels are formed similarly in all groups investigated). This suggests that GC 
signalling plays no role in aggregation of angioblasts into blood vessels but does play 
an important role in the sprouting of vessels from existing vasculature. GC-induced 
abnormalities in the formation of embryonic ISV suggest that the migration and/or 
differentiation of endothelial cells are influenced by GC signalling. Increased GR 
activity (Dex treatment) results in reduced vessel/sprout formation with the converse 
observed for decreased activity (especially apparent in the increased branching in 
RU486). 
vegfaa mRNA abundance correlated with the observed alteration in ISV vessel 
formation. Reduced GR activity (Dex) reduced vegfaa abundance and also reduced 
il8 abundance. These data are consistent with cell culture data where GC 
overexposure resulted in reduced vegfaa and il8 abundance (Yano et al, 2006a). GCs 
are thought to produce a potent anti-angiogenic effect partly via their influence on 
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other growth and transcription factors, such as NFκB, resulting in the trans-
repression of inflammatory gene transcription (King et al, 2009). Activated GRs are 
also known to negatively regulate the MAPK subgroups JNK, ERK1, ERK2, and p38 
by inhibition of the phosphorylation step required for their activation (Figure 6.1). 
The defined molecular mechanisms of these GC-mediated effects have not been fully 
characterized and may be cell-type and stimulus specific (Stellato, 2004). However, 
similar observations in the zebrafish provide further support for future studies of this 
nature. This would permit greater understanding of the anti-angiogenic roles of GCs 
and could allow investigation of reduced vessel formation as a therapeutic strategy 
for cancer treatment. 
Hypertension is arguably the greatest risk factor for cardiovascular disease, a number 
of studies have highlighted that elevated blood pressure (basal and stress-induced) is 
programmed (O'Regan et al, 2008). Despite this, little is known about the underlying 
mechanism(s) that lead(s) from in-utero programming to hypertension later in life. 
Much of the work carried out to address this has focused on endothelial dysfunction 
and microvascular rarefaction when hypertension has already developed (Nuyt & 
Alexander, 2009) and it is unclear whether the observed changes are a cause or effect 
of the elevated blood pressure (Khorram et al, 2007a). 
Work carried out by Khorram et al (Khorram et al, 2013; Khorram et al, 2007a; 
Khorram et al, 2007b) characterised the vascular phenotype of IUGR offspring early 
in development, well before the hypertensive phenotype is apparent. The published 
work suggests that, in a rat model of maternal under-nutrition, there are marked 
vascular structural abnormalities such as extracellular matrix (ECM) remodelling and 
collagen deposition (Khorram et al, 2007b). These offspring were also found to have 
decreased vascular VEGF expression and a markedly reduced angiogenic capacity in 
microvascular endothelial cells (Khorram et al, 2007a). These data, taken together 
with what is known about GC ant-angiogenic actions both in complex systems 
(Hadoke et al, 2009) and in cell culture (Logie et al, 2010), leads to the hypothesis 
that increased foetal exposure to GCs results in adult onset hypertension by direct 
inhibition of embryonic vegfaa activity. 
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In the zebrafish, not only did enhanced GR activity (Dex) reduce blood vessel 
number, and abundance of key angiogenic factors in the embryo, but reduced 
angiogenic capacity in the adult as determined by reduced angiogenic sprouts 3 days 
following tailfin amputation. These data support a role for GC during embryogenesis 
on developing vasculature and also raises the possibility of a subtle life-long 
impairment of blood vessel angiogenesis. It may be that the observed alterations in 
vascular phenotype are subtle enough to permit normal growth and maturation and 
only result in pathophysiology when combined with further genomic, lifestyle or 
environmental risk factors such as diet, pollution or oxidative stress during the 
lifetime of the organism/animal. 
To conclude, enhanced GR activity (Dex) results in reduced ISV formation in the 
embryo and diminished capacity to repair blood vessels in the adult. To date this is 
the first documented study in the zebrafish to record programmed vascular 
dysfunction in the adult following embryonic GC exposure.  
 
Figure 6.1 Schematic summarising possible glucocorticoid vascular interactions 
Features shown are glucocorticoid receptor (GR), glucocorticoid responsive element (GRE), 
nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB), Interleukin 8 (IL-8), 
Tumour necrosis factor alpha (TNFα), inducible nitric oxide synthase (iNOS), nuclear factor 
of kappa light polypeptide gene enhancer in B-cells inhibitor, (IκB), c-Jun N-terminal 
kinases (JNK), Extracellular signal-regulated kinases 1 or 2 (ERK1/2) and P38 mitogen-
activated protein kinases (p38). Figure shows three possible methods of anti-angiogenic 
function: trans-repression (for example of inflammatory cytokines), gene transcription of 




6.2.5.1 Future studies of vasculature 
Further investigation of the vascular phenotypes is clearly required using these 
programming models. Extracellular matrix composition and collagen deposition 
could not be investigated fully during the course of this study although no significant 
alteration in mmp13 mRNA abundance was determined at 120 hpf in whole embryos 
(Chapter 4). However, it may be that alterations occur later in development or may 
occur in the composition of other ECM components. Initial histological assessment 
of collagen using Masson’s trichrome staining on microtome sections (Figure 6.2) 
did not show significant changes in collagen deposition in the Dex treated embryo. 
However, the GR Mo embryos did show a generalised increase in collagen staining.  
GCs have previously been shown to decrease Type I collagen synthesis in vivo and in 
fibroblast cell culture (Meisler et al, 1995). Since there was an increase in collagen 
staining in the GR Mo group but not in the Dex group, the effects observed may be 
mediated via MR. Furthermore, a developmental delay (which is apparent in the 
images shown in Figure 6.2) may also influence collagen deposition. The Masson’s 
trichrome staining used here was a qualitative assessment and more sophisticated 
quantitative assessment possibly using an alkaline phosphatase assay may provide 















6.2.6 Embryonic glucocorticoid manipulation and cardiac programming 
Exposure to GC during development may influence the maturation and development 
of a number of different organ systems. The effects of GC on cardiac development 
have not been fully investigated, although previous evidence has suggested that 
foetal exposure to excess GC can compromise cardiac growth (Torres et al, 1997). 
The work presented here indicates a clear impairment in cardiac growth and 
development during embryogenesis with reduced GR activity (GR Mo). These hearts 
were both structurally and functionally impaired compared to controls. These 
findings are similar to data published on GR
-/-
 and cardiac specific GR knockdown 
mice (Rog-Zielinska et al, 2012) in which GR suppression caused poor alignment of 
Figure 6.2 Embryonic Masson’s trichrome staining 
Typical sagittal sectioned embryos at 96 hours post fertilisation (hpf) in untreated 
controls or those which had been continuously treated pharmacologically with 
dexamethasone (Dex) or molecularly-manipulated using targeted gr morpholino (GR 
Mo) to modulate the activity of the GC system. Sections are stained with Masson’s 
Trichrome histological stain where connective tissue is stained blue, nuclei are stained 
dark red/purple, and cytoplasm is stained light red/pink. Images shown may have 
planar differences and are only used here to highlight anatomical features. Features 
shown are eye (E), brain (B), heart (H), gut (G) and swim bladder (SB). 
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cardiomyocytes and abnormal myocardial architecture. In adulthood GR Mo fish 
displayed smaller hearts, increased intra-trabecular area with abnormal myocardial 
architecture despite similar survival and gross phenotype to controls. This suggests 
that alterations in cardiac structure may be subtle enough to not influence baseline 
cardiac function under normal environmental circumstances. However, it may be that 
as in human programming counterparts (Barker et al, 1989), further confounding 
features such as adverse environment occur the stress, load and exposure to risk 
factors placed on the heart will have consequences that lead to disease or disorder. 
GR Mo treated embryos showed a significant reduction in GR mRNA this may 
suggest the suitability of the zebrafish GR Mo model for assessing the heart specific 
roles of GC during development. This would certainly overcome the poor survival 
observed in GR
-/-
 mice (Rog-Zielinska et al, 2013). While knockdown of GR mRNA 
produced an abnormal maturational phenotype in the heart, Dex exposure during 
embryogenesis also altered cardiac development with GR Mo impairing cardiac 
maturation and Dex enhancing it. These findings are consistent with the maturational 
role of Dex on other organ types such as the lungs. Indeed, the work of Torres and 
colleagues (Torres et al, 1997) also suggests that GCs can have a direct role in 
cardiac development, with prenatal treatment of rats altering development of the 
heart by restricting growth. These authors also describe an increase in cardiomyocyte 
cell volume, consistent with results reported in Chapter 5. This probably reflects a 
GC-mediated decline in the rate of cell division (withdrawal from the cell cycle) or 
influence on the actions of other growth factors.  
As GC treatment appears to have an influence on IGF (see chapter 4) further studies 
on the relationship between GCs and this growth factor and other maturational 
markers of cardiac development should be performed. GC may also exert cardiac 
effects on myocardial ECM, in a similar way to its effects on vascular ECM. Once 
again, maturational delay may be associated with a reduction in ECM as tissue which 
is actively proliferating would have less ECM (Gospodarowicz & Ill, 1980). While 
no changes in collagen content were detected in adult hearts (chapter 5) other 
workers have shown that chick hearts exposed to excess GCs have reduced collagen 
levels (Oikarinen et al, 1988): although this may be a transient effect during drug 
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exposure rather than a programming related alteration. Furthermore the alteration in 
chick heart ECM may be a result of delayed maturation rather than a true alteration 
in ECM composition. The changes in vmhc mRNA observed in the current 
investigations is interesting and has been seen in previous studies using animal 
models of excess GC exposure. It is linked to increased αMHC in rat models (Sheer 
& Morkin, 1984; Torres et al, 1997). Again opposing effects were noted in the 
adults, with vmhc abundance with enhanced Gr activity resulting in increased 
abundance and reduced Gr activity (GR Mo) reducing abundance.  
To conclude the cardiac data, supressing or enhancing GR activity in the developing 
zebrafish heart can have long-lasting effects on the adult heart structure and 
molecular composition long after the stimulus (Dex treatment or GR Mo) has been 
removed. Once again, while the effects of this change appear minimal under normal 
physiological conditions further work is needed to determine whether structural 
alterations and small change in vhmc abundance could have on cardiac function. The 
extent that these subtle cardiac alterations may have might not become apparent until 
the heart is placed under increased haemodynamic load or suffered acute injury. 
6.2.6.1 Future studies of the heart 
To truly understand the extent of these cardiac abnormalities, investigation into 
cardiac function should be carried out. While it was relatively easy to investigate 
various cardiac functional parameters in the embryo, investigation in the adult was 
more problematic. Initial pilot studies using ultrasound presented a number of 
problems, particularly the poor signal produced by the adult heart; the intra-
ventricular space is small and diffuse and, thus, accurate functional assessment is not 
possible. Further cardiac functional investigation could be carried out through 
respiratory assessments and exercise fatigue.  
6.3 Future work 
Strong evidence was generated in this thesis to show that early-life GC action in the 
zebrafish embryo has a direct influence on growth in later life. While this is an 
interesting observation, these data open up many further avenues of study to 
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investigate life- trajectory and potential long-term effects on the cardiovascular and 
other organ systems. 
6.3.1 Role of glucocorticoids in programming adult metabolic pathways 
Published data on GC exposure suggests a relationship between GC manipulation 
and altered cardio- metabolic profile in adulthood such as altered lipogenic capacity, 
insulin resistance and raised blood glucose (Fowden, 2003). A small associated study 
was carried out, during the course of this thesis, on the blood glucose profile of 
Emmod adults, data generated could be the basis for future investigation 
Blood glucose levels were determined using a commercially available blood glucose 
meter (Section 2.5.5) in a small cohort (n=8) of adult fish that had undergone GC 
manipulation as embryos (Figure 6.3). Higher blood glucose was observed in 
EmmodDex adults (p<0.01). Blood glucose in EmmodRU486 or EmmodGR Mo 
adults were the same as controls. This is similar to published work in rodents and 
humans showing a relationship between embryonic GC exposure, birth size, catch-up 
growth and disadvantageous insulin and glucose profiles in adulthood (De Blasio et 
al, 2007; Stocker et al, 2005). Further support for an altered metabolic status is 
provided by increased pepck mRNA abundance in the livers of EmmodDex adults 
(p<0.05 (Figure. 6.3 D). Pepck catalyses the rate-limiting step in gluconeogenesis 
and, therefore, is essential in glucose metabolism. In this pilot study transcription of 
pepck was enhanced by GC activity. These data are intriguing as in rats, maternal 
exposure to Dex in late pregnancy can programme permanent induction of hepatic 
PEPCK abundance, hyperglycaemia and insulin resistance in the adult (Nyirenda et 
al, 2001). The data generated support the hypothesis that GC elevation during 
development has a programming role in glucose metabolism leading to permanent 











6.3.2 Role of glucocorticoids in programming aging 
A further feature that could be explored in this GC-programming model using the 
zebrafish is the aging process and cell senescence. This is thought to be an important 
contributor to chronic disease progression and may be a link between catch-up 
growth and adult onset disease.  
Rat pups with IUGR display increased rate of kidney and heart senescence (Luyckx 
et al, 2009) and this is proposed as a mechanism to explain later life hypertension, 
chronic kidney disease, and cardiovascular disease. In the work presented here adult 
fish assessments were carried out at 120 dpf as this is when zebrafish are generally 
accepted to be sexually mature (Gerhard et al, 2002). However it may be important 
to look at later time-points to assess the influence of GC manipulation on the aging 
process. The zebrafish is thought to have a median lifespan of around 36 months 
(~1080 dpf) and can live for up to 66 months (~1980 dpf) (Gerhard et al, 2002). 











































































































































Figure 6.3 Impact of embryonic glucocorticoid modulation on adult blood glucose 
Blood glucose (mmol/L) and liver pepck mRNA expression. Data shown are blood 
glucose levels (mmol/L) for, A) EmmodDex, B) EmmodGR Mo, and C) EmmodRu486 
fish compared to their respective controls (n=12 per treatment). D-F data shown is for 
isolated liver pepck mRNA expression n=4 (4 pooled livers) from D) EmmodDex, E) 
EmmodGR Mo, and F) EmmodRu486 fish compared to their respective controls. All data 
are mean + SEM and were analysed by Student’s t-test (*p≤0.05, **p≤0.001, T=0.06). 
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disorders, it is surprising that aging is a relatively unexplored process in this species 
(Gerhard & Cheng, 2002). This may be as a result of the complexity of the aging 
process and its multifactorial nature in all species. However, in the quest to 
understand better the similarities between aging in zebrafish and mammals, work 
published by Kishi and colleagues over the last 10 years (Kishi, 2004; Kishi et al, 
2009) describes the gradual senescence process in the zebrafish, highlighting its 
suitability for the study of age-related alterations in musculoskeletal and eye 
morphology, endocrine factors, gene expression, circadian clock, sleep and cognitive 
functions (Kishi, 2004; Kishi et al, 2009). This group has further highlighted various 
pathological processes in aging zebrafish, coupled with age-dependent declines in 
their reproductive and regenerative capacity (Kishi et al, 2003). Kishi and colleagues 
also highlight the suitability of zebrafish for longevity studies, and their work 
supports the possibility of using it as a model of long-term programming. 
While it is not suggested that aging itself is a programmable feature, the long-term 
impact of programming remains poorly understood; and, as the zebrafish is well 
suited for the investigation of the basic processes implicated in aging (such as insulin 
signalling and oxidative stress) it may be used as a comparative model to species 
with widely divergent longevities (Gerhard, 2007). 
6.3.3 Role of glucocorticoids in multi-generational programming 
The experimental work and discussion in this thesis up until now has focused on the 
concept of embryonic exposure to an adverse environment resulting in altered 
developmental signals in that offspring (F1). However, it has also been suggested 
that these physiologically programmed changes, with or without a continuing 
environmental stressor, can result in a developmental signal being passed-on to the 
next generation (F2). This perpetuation of the alteration has been referred to as the 
cycle of inter-generational programming (Drake & Seckl, 2011; Drake & Walker, 
2004; Godfrey et al, 2010; Khulan & Drake, 2012; Roseboom & Watson, 2012).  
Work carried out in the rat suggests that alterations in birth-weight are sustained in 
the F2 generation of F1 offspring whose mothers were either calorie restricted or had 
altered exercise (both increased and sedentary life-style) (Drake and Walker, 2004). 
Abnormal glucose tolerance has also been demonstrated in F2 rats (Roseboom & 
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Watson, 2012) whilst studies in rabbits with surgically-induced hypertension 
displayed increased blood pressure in the F2 generation although this study 
suggested a sex-specific phenotype in the female F2 offspring (Drake and Walker, 
2004). Alterations in the HPA axis activity across generations has also been reported 
in these rodent models (Roseboom & Watson, 2012). From these data it would 
appear that programming of maternal physiology can persist through multiple 
generations and thus could form the basis of future work. 
6.4 Study limitations 
Whilst the work presented in this thesis strongly supports the suitability of the 
zebrafish as a programming model it is important to consider possible limitations. 
Much of the work presented in this thesis has focused on GR-mediated actions of 
GCs. Since GR modulation was the aim of this study one may assume that alterations 
in cardiovascular structure and physiology are as a direct effect of GR-mediated 
actions. However, as the ligand for MR has not been identified in the zebrafish and 
as there are limited 11βhsd2 mRNA found in the heart (Tokarz et al 2013); it is 
likely that GC stimulates both MR and GR in the zebrafish heart. Therefore, some of 
the observations may result from activation of MR. To understand the specific roles 
of the receptors, targeted Mr manipulation could be carried out concurrently with the 
Gr modulation as presented in mouse studies by Ren and colleagues (Ren et al 2012). 
Many investigations into the physiological influence of GC manipulation have 
focused on the genomic effects resulting from GC-GR interactions in the form of 
alterations in the relative abundance of mRNA for relevant genes. The genes 
included in this study were carefully selected to investigate the potential underlying 
mechanisms of programming. While a genome wide microarray analysis could have 
provided a greater insight into the potential positive and negative mediators of the 
observed alterations, the hypothesis-driven approach described in this thesis has 
provided important quantitative data for the genes concerned and highlighted 
potential downstream targets for future investigation. 
In various studies it has been demonstrated that classic steroid hormone receptors 
may be involved not only in genomic steroid action, but also in rapid non-genomic 
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steroid effects (Falkenstein et al 2000). As highlighted in drug optimisation studies 
(Appendix 1) the interpretation of the data presented here is based on the assumption 
that changes are mediated through activation of GR-dependent genomic effects 
rather than non-genomic effects. This interpretation is supported in part by the results 
obtained using GR Mo knockdown but, given that some of the non-genomic effects 
of GCs are mediated by GR in a non-nuclear location a more robust investigation of 
the genomic and non-genomic effects of GC would be required. Work could involve 
investigating the sensitivity of response in the presence of transcription and protein 
synthesis inhibitors. Genomic actions of GCs have been investigated by the treatment 
with actinomycin D (an inhibitor of transcription) or cycloheximide (an inhibitor of 
translation) (Lee et al 2012).  
The work presented in this thesis uses the zebrafish as a model for developmental 
programming of growth, behaviour, stress handling and cardiovascular function. 
While this model was chosen because of features which aid analysis (external 
fertilisation, embryonic transparency) there are clearly a number of limitations with 
regard to translation into human disease. Of particular importance in the 
cardiovascular programming chapter (Chapter 5, Part 2) are the anatomical 
differences between the zebrafish and the human heart. The zebrafish heart has many 
features that are similar to the foetal human heart, but the hearts of adult fish and 
adult humans have considerable differences; for example, zebrafish hearts lack 
septation and have fewer chambers (Glickman et al 2002). This should be taken into 
consideration when changes observed in zebrafish are translated to humans. 
While the current work (Chapter 5, Part 2) describes adult zebrafish cardiac structure 
and molecular composition it does not describe adult cardiac function. This was due 
to limited success with in vivo cardiac imaging in adult zebrafish. Despite the 
benefits of the zebrafish (compared with mammalian) embryos for in vivo imaging, 
real-time assessment of cardiac function remains challenging in the adult zebrafish. 
Pilot studies using cardiac Doppler ultrasound have identified a distinct pattern of 
filling and emptying of the ventricle, similar to mammals, although the actual images 
of the beating heart remain of relatively poor quality and would not have allowed 
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adequate assessment of cardiac structure and function. Further optimisation may 
produce better quality images..  
Because the analysis compared groups of equal sample size and because data were 
often found to meet classic homogeneity of variance assumptions, the likelihood of 
producing a type 1 error was considered to be low. However, increasing group size 
would have helped prevent the rejection of a true null hypothesis, particularly where 
data showed a trend towards significance. 
6.5 Concluding remarks 
The data presented here represent a comprehensive assessment of the use of the 
zebrafish as a model of foetal origins of adult disease and programming by 
modulating GCs during early development. The physiological roles of the GC system 
were assessed in the developing zebrafish embryo, through pharmacological and 
genetic manipulation. This highlighted various functions of the GC system in the 
zebrafish which have not previously been documented. Furthermore, it demonstrated 
that although these transient manipulations result in subtle alterations in 
development, organ structure and function, they are significant enough to alter the 
adult phenotype long after the manipulation has ceased. It is proposed that these 
alterations have indeed been “programmed” as a result of cellular and molecular 
alterations, in keeping with mammalian models of foetal programming. 
The data generated here, coupled with the desirable experimental features of the 
zebrafish (such as short generation time, ease of manipulation, ex utero fertilisation 
and low cost), could result in the zebrafish becoming a prominent model of foetal 
programming in the future. Indeed the possible embryonic manipulations that could 
be used with this model are extensive. The obvious anatomical (gills, fins, scales 
etc.) and physiological (osmoregulation) differences from mammals do, however, 
mean that the zebrafish may not provide evidence directly translatable to humans and 
the patient suffering from cardio-metabolic disorders. However, the data derived 
from this model, coupled with data from rodent (or other mammalian models) and 
cell culture studies, may provide complementary assessments of what appears to be a 
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8 Appendix 1: Pharmacological and molecular optimisation 
In the work presented in this thesis a number of pharmacological and molecular 
manipulations were carried out. To determine suitable concentrations for use in the 
relevant experimental chapters, comprehensive dose-ranging studies were performed 
and these are summarised here.  
8.1 Pharmacological optimisation 
The zebrafish embryo is widely recognised as a useful tool for pharmacological and 
novel-compound screening using a high-throughput approach (Brannen et al 2013). 
In the work described here the features which make the zebrafish embryo a suitable 
drug screening model (small size, high fecundity, rapid development and embryonic 
transparency) are utilised to determine viability, growth and other functional 
endpoints resulting from pharmacological manipulation of the glucocorticoid (GC) 
system. Before these functional endpoints could be investigated a series of model 
optimisation steps were carried out.  
When investigating any pharmacological manipulation assay it is important to 
consider whether the correct drug has been selected and whether the optimal dosage 
regimen has been established. This is particularly relevant when considering the 
translation of dose, exposure and subsequent response into human models 
(Gabrielssona et al 2010). 
8.1.1 Drug selection 
The primary aim of this work was to assess the developmental effects of GC receptor 
(GR) manipulation during embryogenesis in the zebrafish. A small group of drugs 
was selected which primarily alter GR activity and alter ligand availability by 
targeting the enzyme 11β-hydroxylase (which is responsible for the final step in 
cortisol biosynthesis). The following drugs were selected based on published 
pharmacological data from mammalian (and, where possible, teleostean fish) studies: 
the GR agonist dexamethasone (Dex), the GR (and progesterone receptor (PR)) 
antagonist RU486 (also known as mifepristone) and the 11β-hydroxylase inhibitor 
metyrapone (Met). Some experiments also included: the 11β-hydroxylase substrates 
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11-deoxycorticosterone (Doc) and 11-deoxycortisol (Doxy), and the zebrafish 
mineralocorticoid (MR) agonist spironolactone (Scott et al, 2005).  
8.1.2 Vehicle selection 
Work by Hillegass and colleagues (Hillegass et al., (2007); Hillegass et al., (2008)) 
highlighted the suitability of the zebrafish model for continuous drug exposure by 
dissolving drug in the bathing water in either dimethyl sulfoxide (DMSO) or an 
aqueous vehicle. Ethanol (EtOH) readily dissolves steroids but has detrimental 
effects of zebrafish development and survival at concentrations of more than 3% 
(Billotta et al 2004). It was, therefore, important to determine a concentration of 
EtOH which readily dissolved the drugs of interest but did not have a significant 
impact on development or survival (Figure 8.1). 
8.1.2.1 Vehicle concentration optimisation protocol 
It was found that concentrations of less than 1% EtOH had minimal impact on both 
survival and phenotype of embryos. Consequently, a concentration of 0.1% EtOH, 
which was sufficient for dissolving all the relevant compounds, was selected for all 
further drug solutions. For all experimentation where drug exposure occurred, a 










8.1.3 Drug concentration range selection 
As there were no previously published data on the effective doses (ED) and 
ligand/receptor activity of these drugs on zebrafish embryos, a typical drug 
optimisation screen was carried out. This consisted of treatment over a range of 
concentrations of the test compound and assessment of survival and phenotype 
throughout the course of exposure (120 h). The concentration ranges of drugs used 
were, where possible, based on previously published data. 
Dex was investigated over a range of 25-200 µM; while the upper limit may appear 
relatively high in comparison to mammalian studies, these concentrations were 
selected based on previous publications (Hillegass et al 2008; Schaaf et al 2009). 
These studies also use RU486 as a potential GR antagonist but used a lower 
concentration range (up to 1 µM) than described here. Park and colleagues (Park et 
al. 2012) used 12 µM RU486 without toxic effects. Since a number of concentrations 



































































Figure 8.1 Determination of concentration of ethanol used as a vehicle. 
A) influence of varying concentrations of ethanol (EtOH (%)) on survival over 120hours post 
fertilisation (hpf) B) influence of varying concentrations of EtOH (%) on phenotype score n=3 
experiments 30 embryos per group. Mean ±SEM, data analysed by 2-way ANOVA with 




have been used in published work, a concentration range up to 100µM was 
investigated in pilot studies.  
At the start of the current research no publications were available describing 
exposure of zebrafish embryos to Met; in the absence of data, a concentration range 
up to 100 µM was chosen. Subsequently, published work has shown that zebrafish 
can tolerate doses up to 45 µM Met without adverse effect (Liu et al 2013). 
Concentration optimisation for Doc, Doxy and Spironolactone was produced during 
work towards a Master of Science (MSc) dissertation (K Wilson 2009) and cannot be 
included here. However, the doses used for this study were Doc [1 µM], Doxy [0.1 
and 1 µM], and spironolactone [0.1 µM]. All drugs were dissolved completely in 
vehicle and diluted to their final concentrations in a 30 mL Petri dish. 
8.1.3.1 Drug exposure protocol 
A standard drug exposure protocol was used for optimisation of each drug of interest. 
Groups of 30 embryos were placed in Petri dishes containing 30 mL of drug solution 
at the desired concentration. Embryos were exposed continuously up to 120 hpf, with 
fresh drug added daily. Drug toxicity was monitored daily by assessing survival (as a 
percentage of the initial group size) and morphology (using a 6 point mean 
phenotype score-methods section 2.4.3). Optimisation for the drugs Dex, RU486 and 
Met are shown in Figures 8.2 and 8.3 and summarised in Table 8.1. 
8.1.3.2 Drug exposure concentration selection 
For Dex it was found that concentrations of 25, 50, and 100 µM did not significantly 
alter the survival or phenotype score of the embryos. 100 µM Dex was used for 
further studies as this was a concentration which was found to enhance a number of 
developmental features (Chapter 5) but did not significantly alter global morphology. 
Furthermore this concentration has been used previously in studies of GR activity in 
zebrafish (Schaaff et al 2009). For RU486, 10 µM was selected for further 
investigation as it did not impair survival or gross phenotype. In contrast, 50 and 100 
µM RU486 reduced survival and phenotype significantly. For Met concentrations of 
100 and 150 µM reduced survival and altered the phenotype the embryos whereas 
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concentrations of 0.1, 1 and 10 µM did not alter any of the features investigated. A 
summary of the drug concentrations used throughout the thesis is given in Table 8.1.  
 


































































































































Figure 8.2 Embryonic pharmacological survival curves 
Varying drug concentrations (µM) for optimisation of exposure to A) dexamethasone (Dex) 
B) Dex (reduced y axis for clearer interpretation). C) RU486 D) RU486 (reduced y axis for 
clearer interpretation) E) Metyrapone (Met) F) Met (reduced y axis for clearer 
interpretation). All data were for embryos compared to age matched vehicle 0.1% EtOH 
treated controls. Survival is shown as percentage of original embryo clutch; n=3 
experiments, 35-40 embryos per experiment. Mean ± SEM data analysed by 2-way ANOVA 
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Figure 8.3 Mean phenotypic score for pharmacological manipulation  
Concentration (μM) optimisation. A) dexamethasone (Dex) B) RU486 and C) metyrapone (Met) 
concentration determination vs. control (vehicle alone 0.1 % EtOH) over 120hpf. Scoring system 
is as follows 6 (Normal), 4-5 (Mild), 2-3 (Moderate), 1(Severe) and 0 (dead). n=3, duplicated 
results of 35-40 embryos per experiment, mean ± SEM Data are analysed by 2-way ANOVA and 
Bonferroni post hoc test *p≤0.05, **p≤0.01 and ***p≤0.001 
295 
 
Table 8.1 Concentrations (µM) of pharmacological agents-embryos 
Shown are drug concentrations which were selected for further investigation. Agents 
investigated were the glucocorticoid receptor (GR) agonist dexamethasone (Dex), the GR 
(and progesterone receptor -PR) antagonist RU486, the 11β-hydroxylase inhibitor 
metyrapone (Met), the 11β-hydroxylase substrates deoxycortisol (Doxy) and 
deoxycorticosterone (Doc) and the zebrafish mineralocorticoid (MR) agonist spironolactone. 
Concentrations shown are those used to bathe the embryos for the experimental chapters. 
The potential cross-reactivity is the amount of drug which would be present within the tissue 
homogenate assuming all drug is taken up into the embryo, the cross reactivity of cortisol 
ELISA is <0.01 % for interfering steroids so a greater potential cross-reactivity would 
suggest a greater likelihood of the drug interfering with cortisol concentration.  
8.1.4 Maternal glucocorticoid manipulation 
To determine whether the early detectable GC in the embryo was maternally-derived 
a maternal GC modulation experiment was carried out using Dex. Two forms of 
modulation were investigated, maternal bathing and injection. No previous 
investigation using maternal Dex treatment had been carried out so a maternal Dex 
exposure protocol was produced (Section 3.3.2). The potential cortisol ELISA cross-
reactivity of the doses used has been calculated and highlighted in Table 8.2. 
Table 8.2 Concentrations (µM) of pharmacological agents-adults 
Shown are drug concentrations which were selected for further investigation for maternal 
modulation of embryonic cortisol. The agents which was used for further investigation was 
the glucocorticoid receptor (GR) agonist dexamethasone Concentrations shown are those 
used to bathe the adult in or inject intraperitoneally. The potential assay read-out is the 
amount of drug which would be present within the swim water if all the injected bolus is 
present or the maximum amount of drug has been taken up by the adult fish.  
Pharmacological 
agent 
Concentration Potential assay read-out 
(ng/fish/litre) 
Dex Injected 5 nL of 10 uM stock 3.92 






Potential assay read-out 
(pg/fish) 
Dex 100 µM <897 
RU486 10 µM <128.70 
Met 0.1, 1 and 10 µM  <0.68-67.80 
Doxy 0.1 or 1 µM <1.05 
Doc 0.1 µM <0.99 
spironolactone 0.1 µM <1.25 
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8.1.5 Pharmacological manipulation-points to consider 
While the Dex concentration used here (100µM or 39 mg/30ml) may appear to be 
high in comparison to human therapeutic applications (orally 4-20 mg daily) (Bello 
et al 1999) or in rodent models (50 mg/kg) absorption and distribution should be 
taken into consideration. By bathing the embryo in the drug one would assume that 
absorption occurs through epithelial surface diffusion (skin) throughout the course of 
the study. However, pilot studies with a fluorescently-tagged Dex (Dexamethasone 
Fluorescein, Life Technologies, Paisley, UK) suggest that from 48 hpf onwards 
tagged Dex is detectable within the gut of the developing embryo. This suggests that 
Dex may be taken up orally as well as through skin, particularly in later stages of 
development. While both of these routes of administration are commonly used for 
GC therapy, it is unclear what the absorption and relative bioavailability of the drug 
is in this setting. Injection of a bolus of Dex (100 µM) directly into the developing 
embryo potentiated the physical effect observed following bathing in the drug, 
suggesting that a lower effective dose is experienced by embryos bathed in the drug. 
While tagged Dex did offer some information with regard to the uptake route, it did 
not fulfil its purpose in allowing quantification of Dex within the embryo. Steps were 
taken to determine the levels of Dex and its metabolite 11-dehydrodexamethasone 
using liquid chromatography–mass spectrometry (LC-MS) but there was insufficient 
time to develop this technique. Nevertheless this does offer a possible approach for 
future work. 
While absolute levels of Dex within the embryo remain uncertain it does appear clear 
that the concentration used throughout the thesis is having a functional effect in the 
embryo. Data in chapter 3 (Figure 3.8) suggest that this concentration of Dex 
suppresses endogenous cortisol in accordance to mammalian models; suggesting that 
enough Dex is being taken up by the embryo to suppress cortisol biosynthesis 
through negative feedback. Endogenous cortisol levels were determined using 
cortisol ELISA. Numerous steps were taken to optimise the ELISA in terms of 
calculating the cross reactivity of other steroids (endogenous and synthetic e.g. Dex) 
but it should be taken into consideration that (although the ELISA cross reactivity for 
Dex is low; <0.01 %) the relatively high concentration of drug used may interfere 
with the assay, providing an over-estimation of the cortisol concentration (a false 
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positive result). The maximum possible interference of each drug has been calculated 
for all drug doses used (Table 8.1). These calculations are based on the assumption 
that all drug present within the Petri dish is taken up by the embryos and thus any 
cross-reactivity would likely be lower than levels calculated here. Calculations are 
based on a zebrafish embryonic volume of 0.3 cm
3
 as determine by length, width and 
height measurements (3 mm x 1 mm x 1mm). For Dex the maximum interference for 
the assay was calculated as <897 pg/embryo. The ELISA data for this group of 
embryo embryos suggested cortisol levels were 2.18 ± 0.40 ng/embryo; therefore it is 
likely that the dose of Dex used is interfering with the ELISA. While this does 
suggest a degree of cross-reactivity it should be highlighted that Dex treatment 
resulted in a decrease the detected levels of cortisol, the risk of falsely showing an 
increase due to cross reactivity were therefore low, and Dex treatment may in fact 
have a more profound effect on cortisol than is shown here. The cross –reactivity is 
also highlighted for adults treated with Dex (Table 8.2). The data calculated for Dex 
injection is based on the injection of a bolus of 5 nLand the data for bathing is based 
on the assumption that all drug which the adult is exposed to is taken up (as for 
embryo this is calculated volumetrically (50 cm
3
)). Maximum cross-reactivity 
calculated are likely to interfere with the ELISA, as detected levels were found to be 
~5 ng/fish/litre for injection and ~6ng/fish/litre for bathing.  
As described in greater detail in chapter 1, GCs exert genomic effects by binding to, 
and activating, the transcription factors MR and GR. However, non-genomic effects 
have also been observed in mammals (Stellato et al 2004) and more recently in 
zebrafish (De Marco 2013). The mechanisms underlying the non-genomic effects are 
poorly understood and it is unclear whether non-genomic and genomic effects 
interact (De Marco 2013). It is likely that Dex, particularly at the higher 
concentration used here, is producing genomic and non-genomic effects as increased 
ligand concentration increases the likelihood of receptor saturation and thus more 
compound is available for non-receptor mediated non-genomic effects. The steroid-
binding characteristics of the receptors may also determine whether genomic or non-
genomic effects are responsible, with the calculated Dex dissociation constant (Kd) 
in trout gr being 5.5 ± 0.41nM (Strum et al 2005) (high degree of homogeneity to 
zebrafish gr). It is likely that some non-genomic effects are observed at the 
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concentration used throughout this study. While it is unclear whether the 
physiological effects observed following Dex exposure are as a result of genomic or 
non-genomic effects, steps were taken to address this, mainly through a non-
pharmacological approach (morpholino (MO) knocking down the zebrafish GR (gr) -
GR Mo), however, as non-genomic effects can also occur through GR this does not 
allow confirmation of genomic effects. To determine whether the observations 
described in this thesis are as a result of genomic or non-genomic GC-mediated 
effects transcription and protein synthesis inhibitors could be investigated (Lee et al 
2012). 
8.2 Molecular optimisation 
As a control for the pharmacological investigation, a molecular manipulation was 
carried out to reduce the abundance of gr mRNA in the zebrafish embryo using MO 
oligonucleotides. While this form of manipulation may appear to circumvent the 
issues associated with pharmacological manipulation, as with all other forms of anti-
sense gene knock-down, off-target effects may occur following Mo treatment. This 
can make it difficult to interpret whether the effects observed result from knock-
down of the gene of interest or of other genes (Eisen and Smith, 2008). To control 
for off-target effects and to confirm gene of interest function, a comprehensive 
scoring system was used for assessing the influence of Mo, this was the same as the 
pharmacological 6 point scoring system and allowed the grading of severity of Mo 
effects.  
8.2.1 Morpholino concentration optimisation protocol 
Molecular manipulation of embryos was carried out by Mo antisense gene knock-
down (Heasman, 2002; Summerton, 1999) targeted towards the genes encoding 
cyp11b1 and gr. Mo were purchased from GeneTools (Philomath, Oregon, USA) 
(http://www.gene-tools.com) designed specifically to the zebrafish cyp11b1 and gr 
gene sequence. MOs were injected as per section 2.4.4. This entailed injecting 
approximately a 5nl bolus of various concentration stock solutions 3-7 ng/nL as 
calculated in section 2.4.4. Data for the ATG Mo for each gene are shown for 
illustrative purposes (Figure 8.4). 
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8.2.1.1 Morpholino concentration selection 
An appropriate concentration was selected for both Cyp Mo and GR Mo by scoring 
for survival and gross morphology over the course of 120 h with concentrations of 5 
and 7 ng/nL GR Mo significantly reducing survival and morphology. After carrying 
out the dose ranging studies it was felt that a concentrations of 3 ng/nL would be 
used for the GR Mo groups (Mo, splice and mism) and a concentration of 6 ng/nL 
would be used for the Cyp11b1 Mo groups (Mo, splice and mism). For all data 
represented in this thesis the controls for the Mo and splice groups is the mism 
injection. Concentrations used throughout are summarised in Table 8.3. 
8.2.1.2 Molecular manipulation-points to consider 
The use of both atg-Mo and ss-Mo allows greater assessment of effects and 
confirmation of gene specificity. Titration studies where carried out for both ss-Mo 
and atg-Mo to determine suitable concentrations for this study (only atg-Mo are 
shown in Figure 8.4). Although atg-Mo offer a wider translational knockdown, this 
form of Mo does not confirm knock-down of gene of interest, ss-Mo therefore are 
used to quantify the efficiency of the Mo. Injection of Mo itself can be problematic 
with mechanical effects often resulting in phenotype alterations. Therefore a control 
base mispair mm-Mo was used here as this is the most similar to the Mo being 













Table 8.3 Morpholino sequences and concentrations 
Summary of morpholino (MO) concentrations used throughout this work unless stated 
otherwise in specific experimental chapters. 
Morpholino Sequence Concentration 
GR atg (GR Mo in text) CATTCTCCAGTCCTCCTTGATCCAT 3 ng/nL 
GR splice site GCCAGAGATATATGGAATACCTTCA 3 ng/nL 
GR mism CATTGTCCACTCCTGCTTCATCGAT 3 ng/nL 
Cyp11b1 atg (Cyp Mo in text) ATTTCCTCCTGAAATGAGCCCTCAT 6 ng/nL 
Cyp11b1 splice site CTCTCTTTGTGAGACTTTACATCAC 6 ng/nL 
Cyp11b1 mism CTCTCTTTGTGAGCTTTACATCAC 6 ng/nL 
 
8.3 Pharmacological and molecular optimisation conclusion 
The work described in this appendix details the steps which were taken in the 
concentration optimisation during GC pharmacological and molecular manipulation 
model set up. Concentrations used for further investigation are detailed along with 
concentrations which were found to detrimentally impact on survival or phenotype.  












































































































Figure 8.4 Optimisation of morpholino injection dose 
Embryonic survival curves of varying concentrations (ng/nL) of either A) glucocorticoid 
receptor (GR) targeted ATG morpholino (MO) knockdown and B) cyp11b1 targeted ATG 
MO knockdown. Mean phenotypic score for molecular manipulation concentrations by C) 
GR targeted knockdown and D) cyp11b1 targeted knockdown, scoring system is as follows 
6 (Normal), 4-5 (Mild), 2-3 (Moderate), 1(Severe) and 0 (dead). N=3 experiments, 30 
embryos per experiment, data are mean ± SEM*p≤0.05, **p≤0.01 and ***p≤0.001 
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Appendix 2: Gene selection 
Table 0.1 Gene of interest selection 
Summary of the reasons for selection of a number of genes investigated during the course of 
the work presented in this thesis. More detail is given within chapters 4, 5 and 6. Genes 
highlighted are the zebrafish transcript encoding insulin-like growth factor-1 (igf), FK506 
binding protein 5 (fkbp5), vascular growth factor (vegfaa), interleukin 8(il-8,) myocyte 
enhancer factor 2( mef2c), ventricular myosin heavy chain( vmhc) and GATA transcription 
factor 4 (gata4). 
 
 
Gene  Reason for investigation 
igf1 igf signalling is important for zebrafish development (White et al 
2009). 
Glucocorticoid treatment has been shown to reduce igf mRNA in many 
models and is important for cardiomyocyte proliferation during cardiac 
development (Li et al, 2011). 
fkbp5 FK506 binding protein is a co-chaperone for heat shock protein (hsp) 
51. fkbp5 mRNA has been found to increase after chronic stress or 
glucocorticoid exposure. 
Fkbp5 has been shown to be altered in zebrafish after glucocorticoid 
treatment (Mathew et al, 2007) 
vegfaa Vegfaa signalling has been shown to be involved in the formation of 
zebrafish intersegmental vessels (Nasevicius et al, 2000). 
Vegf concentration has been found to decreased following 
glucocorticoid exposure in tumours (Koedam et al, 2002). 
il-8 Glucocorticoids have been shown to reduce the expression of 
inflammatory cytokines (Yano et al, 2006a)  
Il8 has been associated with the formation of intersegmental vessels in 
the zebrafish 
flk flk1/kdr is a prominent receptor in vegf signalling in zebrafish 
(Bussmann et al, 2008). 
mef2c The Mef 2 transcription factor family is important in early cardiac 
development and hypertrophy (Czubryt & Olson, 2004). 
Mef2c and GR act cooperatively in controlling gene transcription, with 
GR influencing Mef2 activity (Speksnijder et al, 2012) 
vmhc Vmhc is required for the normal contractile activity of the heart and is 
particularly important in the later stage of cardiac development (Miyata 
et al, 2000) 
gata4 Gata 4 is involved in the development of numerous zebrafish organs 
(Holtzinger & Evans, 2005) and is an important influence on cardiac 
development and cardiomyocyte proliferation (Singh et al, 2010) 
 
 
